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ABSTRACT 
 
 
 
Epithelial  ovarian  cancer  (EOC)  is  the  most  common  form  of  gynaecological 
malignancy  in  the  developed  world.  Identifying  molecular  markers  of  disease  may 
provide novel approaches to screening and could enable targeted treatment and the 
design  of  novel  therapies.  In  previous  work,  141  primary  ovarian  tumours  were 
analysed using metaphase comparative genomic hybridization to identify complete or 
partial chromosome deletions that may harbour tumour and/or metastasis suppressor 
genes. Chromosome 18 (Ch18) was found to have deletions in 50% of the tumours. 
Microcell-mediated chromosome transfer (MMCT) of normal Ch18 material into EOC 
cell  lines  resulted  in  hybrids  that  displayed  significant  suppression  of  anchorage-
independent growth, invasiveness and reduced tumour growth in nude mice. 
 
The  major  aim  of  this  project  was  to  identify  protein  changes  associated  with  the 
tumour  suppression  observed  in  the  EOC  Ch18  MMCT  cell  models.  The  project 
involves a detailed quantitative proteomic comparison of two parental ovarian cancer 
cell  lines  (derived  from  primary  endometrioid  and  clear  cell  carcinomas)  and  their 
MMCT-derived Ch18 hybrid clones. The cellular, secreted and surface proteomes were 
probed  in  order  to  gain  comprehensive  coverage  and  to  improve  the  likelihood  of 
useful biomarker identification. 
   4 
A  combination  of  quantitative  two-dimensional  difference  gel  electrophoresis  (2D-
DIGE),  affinity  chromatography  and  two-dimensional-liquid  chromatography  and 
tandem  mass  spectrometry  (2D-LC-MS/MS)  have  been  employed  to  examine  the 
whole cell, secreted and cell surface proteomes of the parental and hybrid cell models 
to identify differentially expressed proteins as potential markers of tumour suppression. 
 
Proteins of interest have been validated using immune-based detection methods in the 
parental cell lines, Ch18 hybrids, revertant cell lines, a panel of cancer cell lines and 
normal ovarian surface epithelium cell lines and in serum from a set of ovarian cancer 
cases and healthy controls. 
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Chapter 1 Introduction 
1.1 Epithelial Ovarian Cancer 
Background 
Epithelial Ovarian cancer is the most lethal form of gynaecological malignancy in the 
western world and the ovary is the seventh most common site of cancer in women. 
Overall incidence rates of ovarian cancer are increasing although they show a high 
degree of variation geographically. In Europe, the USA and Canada, observed rates are 
highest whilst the lowest rates are observed in Asia, Africa and Latin America. Every 
year in the UK, nearly 7000 new cases of ovarian cancer are diagnosed and the disease 
accounts  for  more  than  4400  deaths  annually  (CRUK  2006 
http://info.cancerresearchuk.org/cancerstats/types/ovary/).  
 
Most  ovarian  cancers  occur  after  menopause  when  the  ovaries  have  little  or  no 
physiological role. As a consequence, abnormal ovarian function has few symptoms 
and combined with the anatomical location of the ovaries deep in the pelvis, ovarian 
cancer is usually diagnosed at an advanced stage. Patients with early stage ovarian 
cancer, in whom the disease is confined to one or both of the ovaries (stage I; Table 
2.1), have good prognoses (5 year survival rate >80%). Patients with advanced disease, 
in whom the tumour has spread within or beyond the abdominal cavity, (stage III and   16 
IV) have  a significantly poorer prognosis (20% of patients surviving 5  years). The 
overall survival rate is as low as 30%, mostly due to this late detection in presenting 
patients (Breedlove and Busenhart 2005).  
 
Most ovarian tumours are epithelial in origin (80-90%), the remaining tumours arise 
from  germ-cell  or  sex  cord/stromal  cells.  The  epithelial  tumours  are  grouped  into 
histological  sub-types  with  the  most  common  being  serous  adenocarcinoma  (42%), 
undifferentiated  carcinoma  (17%),  endometrioid  carcinoma  (15%),  mucinous 
cystadenocarcinoma (12%), and clear cell carcinoma (6%).  
 
Epithelial ovarian cancers are clonal neoplasms and it is thought that multiple genetic 
alterations must occur during their malignant transformation. Gene expression profiling 
or microarray analysis have enabled the measurement of thousands of genes in a single 
RNA sample. Despite its huge potential, gene expression profiling of EOC has been 
confounded by a lack of understanding of the cellular origin and pathways to EOC. The 
difficulty lies in the limited availability of early stage tumours, the heterogeneity, and 
the genetic instability of tumours, which makes it difficult to distinguish the occurrence 
of early or late stage mutations. In the literature it has been hypothesized that there 
maybe several cells of origin and precursor ovarian states, prior to transformation to 
malignancy.  It is believed  that  EOC  emerges via  transformation  of  the  cells  lining 
inclusion  cysts  or  directly  from  the  ovarian  surface  epithelium  (OSE)  (Auersperg, 
Maines-Bandiera et al. 1997; Auersperg, Edelson et al. 1998; Auersperg, Wong et al.   17 
2001)  or  other  epithelial  sources  such  as  the  fallopian  tubes,  endometrium,  or 
endoocervix  (Dubeau 1999).  
 
Surrounding the ovary is a single layer of phenotypically undifferentiated cells known 
as the OSE. The OSE, mesothelial lining of the peritoneal cavity and the reproductive 
tract tissues are all derived during development from the coelomic layer. However, the 
OSE develops from the epithelium overlying the gonadal ridge whilst the reproductive 
tract tissues originate from the mullerian ducts, arising from an invagination of the 
coelomic  epithelium  beside  the  coelomic  ridge.  It  has  been  observed  that  after 
metaplastic transformation, the OSE shares characteristics of mullerian duct-derived 
tissues  such  as  the  fallopian  tubes,  cervix  and  endometrium  (Auersperg,  Pan  et  al. 
1999). This aberrant differentiation forms the basis for ovarian cancer classification 
(Bell  2005).  An  additional  source  of  ovarian  epithelial  cells  is  the  rete  ovarii,  a 
reticulum of tubules thought to develop from the mesonephric tubules. Mesonephric 
cells migrate towards and into the undifferentiated gonad during ovarian development, 
resulting in an extension of mesonephric tubules through the mesovarian. 
 
It is known a significant fraction of ovarian cancer (10%) is hereditary. A few highly 
penetrant genes that contribute to genetic susceptibility have been identified. Women 
with germline mutations in the BRCA1 gene or BRCA2 gene and women harbouring 
such mutations are at a 20-60% risk of developing ovarian cancer in their lifetimes 
(Aunoble, Sanches et al. 2000; Welcsh, Owens et al. 2000; Welcsh, Lee et al. 2002). 
Mutations in the hereditary non-polyposis colorectal cancer genes, MSH2 and MLH1   18 
(Taylor, Charlton et al. 2003), also increase the risk of invasive EOC substantially, 
particularly of the endometrioid subtype (Ichikawa, Lemon et al. 1999). Association 
studies, considering the effect of common single nucleotide polymorphisms (SNPs) and 
risk  of  EOC,  suggest  that  other  lower  penetrance  mutations  exist  that  have  subtle 
effects  on  risk  of  EOC  (Ramus,  Vierkant  et  al.  2008;  Quaye,  Song  et  al.  2009). 
Furthermore, there are many reports that suggest the genetic and epigenetic changes 
that occur during ovarian tumourigenisis differ among the different subtypes of EOC 
(Duggan and Dubeau 1998). 
 
The genes that may contribute to the tumourigenesis of sporadic ovarian cancers fall 
into  two  categories:  oncogenes  and  tumour  suppressors.  Oncogenes  are  dominant 
transforming genes in that their activation occurs by the alteration of a single allele. 
Activation  of  oncogenes  occurs  through  a  variety  of  mechanisms  such  as  point 
mutation, gene amplification, deletion of a regulatory domain or gene fusion through 
chromosomal translocation. The normal counterparts of oncogenes, proto-oncogenes, 
are involved in controlling critical cellular events such as survival and cell proliferation 
(Aunoble,  Sanches  et  al.  2000;  Hanahan  and  Weinberg  2000).  Tumour  suppressor 
genes behave recessively. This involves the loss or inactivation of both copies of a 
tumour suppressor gene that normally confers constraints on cell proliferation, survival, 
DNA damage repair etc. Although oncogenes and tumour suppressors may influence 
ovarian cancer, little is known about their role in the transformation of ovarian surface 
epithelial cells and the relative contributions of multiple mutations. A few genes have 
been reported as frequently altered in sporadic epithelial ovarian cancers. For example   19 
the tumour suppressor gene p53, is mutated in approximately 50% of advanced stage 
cancers,  the  oncogene  K-RAS,  is  mutated  in  20-50%  of  borderline/low  malignant 
potential (LMP) tumours (Aunoble, Sanches et al. 2000; Liu, Yang et al. 2004), the 
oncogenic receptor tyrosine kinases HER2/ERBB2 and fms are overexpressed in 20-
50% of ovarian tumours (Auersperg, Maines-Bandiera et al. 1997; Auersperg, Edelson 
et al. 1998) and the tumour suppressor lipid phosphatase PTEN is frequently mutated in 
endometrioid type ovarian carcinomas (Kurose, Zhou et al. 2001).   
 
EOC risk increases with age with as much as 50% of all ovarian cancers being found in 
woman  over  the  age  of  63  (CRUK  2006 
http://info.cancerresearchuk.org/cancerstats/types/ovary/).  A  link  has  been  reported 
between the number of menstrual cycles in a woman’s reproductive lifetime and her 
risk of developing EOC (Parazzini, La Vecchia et al. 1989; Schildkraut, Bastos et al. 
1997; Purdie, Bain et al. 2003). This has been supported by evidence of a decrease in 
EOC  risk  with  decreased  lifetime  ovulation  number  through  pregnancy  or  oral 
contraceptive use (Tavani, Ricci et al. 2000). In addition, some studies suggest that the 
use  of estrogen  replacement  therapy  may  promote  EOC  in  women  who  have  been 
through the menopause (Folsom, Anderson et al. 2004; Rossing, Cushing-Haugen et al. 
2007), whilst, women who have never been pregnant because of infertility have a 40% 
higher  risk  of  developing  EOC  compared  to  women  who  have  never  attempted  to 
become pregnant. Moreover, the use of the progestin-only contraceptive pill has been 
shown to be even more protective against EOC than the combined contraceptive pill 
(Rodriguez 2003). Further studies have identified a protective effect of the high levels   20 
of  progesterone  during  pregnancy  (Mukherjee,  Syed  et  al.  2005).  The  role  of 
inflammation  during  ovulation  has  also  been  proposed  as  a  risk  factor  where  the 
associated cytokine release, influx of inflammatory cells and tissue reconstruction has 
been  postulated  to  stress  OSE  cells  such  that  they  become  predisposed  to  genetic 
damage and malignant transformation (Rae and Hillier 2005). Consistent with this are 
findings  that  patients  with  chronic  aspirin,  nonsteroidal  anti-inflammatory  drug  or 
acetaminophen use display decreased risk of EOC (Altinoz and Korkmaz 2004). 
1.1.2 Staging and Treatment 
All  ovarian  cancers  are  classified  according  to  the  terms  of  the  staging  scheme  (I 
through  IV)  developed  by  the  International  Federation  of  Gynaecological  and 
Obstetrics  (FIGO)  and  the  classification  system  developed  by  the  American  Joint 
Committee on Cancer (AJCC, TNM system), which indicate likely prognosis and help 
to define treatment (Table 1). 
 
  
  
  
 
 
 
 
 
Table  1.1.1  Ovarian  cancer  is  staged  using  the  AJCC  and  FIGO  system.  This 
system defines cancers by Roman numerals I through IV. The higher the number, the 
more the cancer has spread. The stages of cancer and their definitions are shown. 
The cancer has spread outside the pelvic region to distant sites such as inside the liver, the lungs, or other 
organs.
IV
The cancer is in one or both of the ovaries and has spread to the abdominal lining but can't be seen (IIIA) or 
small deposits observed (IIIB). Cancer has spread to the lymph nodes and deposits maybe visible in the 
abdomen (IIIC).
III
Cancer is one or both of the ovaries and has grown onto or into other pelvic organs. Cancer has spread onto or 
into the uterus or the fallopian tubes, or both (IIA). Cancer has spread onto or grown into the tissue within the 
pelvis (IIB). Cancer has spread to the uterus, fallopian tubes, or other tissues within the pelvis (IIC).
II
Cancer is in one (IA) or both of the ovaries (IB) and has not spread onto the outer surface of the ovary. Cancer 
is present in one or both of the ovaries and present on the outer surface of at least one of the ovaries or the 
tumour may have ruptured (IC). The disease has not spread to the abdomen or pelvis.
I
Description Stage
The cancer has spread outside the pelvic region to distant sites such as inside the liver, the lungs, or other 
organs.
IV
The cancer is in one or both of the ovaries and has spread to the abdominal lining but can't be seen (IIIA) or 
small deposits observed (IIIB). Cancer has spread to the lymph nodes and deposits maybe visible in the 
abdomen (IIIC).
III
Cancer is one or both of the ovaries and has grown onto or into other pelvic organs. Cancer has spread onto or 
into the uterus or the fallopian tubes, or both (IIA). Cancer has spread onto or grown into the tissue within the 
pelvis (IIB). Cancer has spread to the uterus, fallopian tubes, or other tissues within the pelvis (IIC).
II
Cancer is in one (IA) or both of the ovaries (IB) and has not spread onto the outer surface of the ovary. Cancer 
is present in one or both of the ovaries and present on the outer surface of at least one of the ovaries or the 
tumour may have ruptured (IC). The disease has not spread to the abdomen or pelvis.
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Almost all women with EOC will have some kind of surgery in the course of their 
treatment. The purpose of surgery is first to diagnose by pathological examination of 
ovarian and other tissues to define the nature of the tumour and its stage. Staging is 
performed  by  examining  histological  sections  of  tissue  samples  and  cytological 
assessment of fluid samples. EOC tumours display a spectrum of pathological changes.    
Tumours can be benign, borderline (low malignant potential or atypical proliferating 
lesions) or malignant. The success of treatment depends upon stage and grade of the 
disease, the histopathologic type and the patient’s age and overall health. Where early 
disease  is  detected  (confined  to  the ovaries)  in woman  who wish  to  preserve  their 
fertility, ‘conservative’ surgery that leaves tumour-free reproductive organs intact is 
considered. This is dependent on the tumour being confined to an ovary (usually not 
serous  or  endometrioid  sub-type,  which  tend  to  be  bilateral  tumours)  and  a  wedge 
biopsy of the opposite ovary shows no evidence of disease involvement. Conservative 
surgery  carries  an  increased  risk  of  relapse,  therefore  a  total  hysterectomy  and 
salpingo-oophorectomy is recommended immediately after child bearing is complete. 
The removal of the ovaries before the incidence of EOC reduces the risk to zero. The 
decision whether or not to proceed is often influenced by the fact that most women 
with increased risk of ovarian cancer are also at increased risk of breast cancer and 
there is clear evidence that oophorectomy reduces breast cancer risk in these cases. In 
advanced  cases  of  EOC,  where  disease  has  spread  beyond  the  ovaries,  treatment 
involves  surgery  and  chemotherapy.  A  total  hysterectomy  (removal  of  the  uterus), 
bilateral salpingo-opphorectomy (removal of fallopian tubes and ovaries on both sides), 
omentectomy (removal of the fatty tissues that covers the bowel), lymph adenectomy   22 
(removal of one or more lymph nodes) may be performed. Often with late stage cancers 
women will undergo debulking surgeries, which involves removing as much of the 
disease as possible. Sometimes patients will have their surgery performed after having 
3 cycles of chemotherapy. Ovarian cancer is a chemosensitive disease, and the use of 
immediate first line platinum-based chemotherapy improves prognosis for patients with 
advanced  disease.  The  platinum-based  drugs  cisplatin  and  carboplatin  are  equally 
effective in the treatment of EOC. Whilst ovarian tumours initially respond very well, 
eventually  between  70-80%  of  advanced  stage  ovarian  cancer  patients  develop  a 
resistance to these drugs. Indeed, ovarian cancer cells that have developed secondary 
mutations on the BRCA2 gene that restore the genes ability to repair DNA, confers a 
subsequent  resistance  to  chemotherapy    (Sakai,  Swisher  et  al.  2008).  Radiation 
treatment is also used in the treatment of EOC where high energy X-rays are used to 
kill cancer cells, ease the pain of metastases and stop tumours from bleeding. Patients 
are monitored for recurrence after treatment. Regular check-ups would continue from 
treatment  and  include  a  combination  of  bimanual  pelvic  examinations,  serial 
measurements of the serum cancer antigen CA125 and radiographic imaging.  
 
1.1.3 Screening for ovarian cancer 
Ovarian  cancer  is  often  described  as  a  silent  killer  because  the  symptoms  are  not 
specific and common to other diseases and disorders. Since most cases are diagnosed at 
late stage when treatment is less successful, there is an absolute necessity for early 
detection methods to reduce mortality.  At present however, there is no screening test   23 
that is reliable enough to use for ovarian cancer detection in the general population. 
The tumour marker, serum CA-125, is only approved for use in monitoring disease 
recurrence (Skates, Horick et al. 2004; Bast, Badgwell et al. 2005). 80% of women 
presenting  with  advanced  stage  disease  have  elevations  in  CA-125.  However,  it  is 
elevated in only 50-60% of women with early stage disease and can be elevated in 
other non-cancerous gynaecological complications such as benign ovarian neoplasms, 
endometriosis, pelvis inflammatory disease and liver disease. The glycoprotein, CA-
125  can  also  be  elevated  in  other  malignant  conditions  including  cancers  of  the 
pancreas,  breast,  lung  and  colon.  Despite  this,  a  large  randomised  trial  of  ovarian 
cancer screening in the general population is currently underway to evaluate the use of 
an  algorithm that  incorporates  the  rate  of  change  of CA-125  over  time  from  intial 
marker levels with estimated age adjusted ovarian cancer prevalence rates in order to 
increase sensitivity and specificity and includes an ultrasound modality (Jacobs, Skates 
et al. 1999; Menon, Gentry-Maharaj et al. 2008). There is preliminary evidence that 
such a screening technique will reduce the mortality from ovarian cancer (Neesham 
2007). 
 
Transabdominal ultrasound and transvaginal ultrasonography (TVS) have been studied 
as non-invasive screening tools. TVS is currently the preferred modality. However, the 
specificity of ultrasonography is not adequate for use as a single screening modality. 
Therefore, there is an urgent requirement for better early diagnostic markers of EOC.  
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1.2 Cell models of Disease 
Experimental cell models are of vital importance not only to understand the biological 
and genetic factors that influence the phenotypic characteristics of EOC, but also to 
develop robust early detection and intervention strategies. Cell models have remained a 
vital resource for understanding the underlying events that accompany oncogenesis. 
The use of cell lines carries a number of advantages including the purity of the research 
material, the ability to generate sufficient research material (DNA/RNA/protein) for 
numerous experiments and the ability to genetically manipulate cell lines allowing a 
wide range of in vitro and in vivo studies. The past 6 years has seen the development of 
ovarian surface epithelial cell models with inactivation/activation of different signalling 
pathways giving rise to transformed cells with different phenotypes (Davies, Steele et 
al. 2003; Liu, Yang et al. 2004; Mei, Young et al. 2005; Young, Mei et al. 2005). While 
these models offer the benefits of studying a simple and well-characterised system, the 
degree to which transformation of human cells in vitro represents the process in vivo 
remains unknown. 
 
Xenografting of human cancer cells into immune deficient mice has been essential for 
analysing the tumourigenicity of cells, the histology of the tumours they form and the 
evaluation of therapeutics (Han, Begemann et al. 1996; Hu, McCrea et al. 2000; Oktem 
and Oktay 2007). While xenograft models using human cancer cell lines may reveal the 
nature and behaviour of advanced human ovarian cancer, they do not allow study of the   25 
earlier steps in ovarian cancer development or provide meaningful information about 
human host-tumour interactions.  
 
The  use  of  mouse  ovarian  surface  epithelium  (MOSE)  creates  the  opportunity  for 
studying disease progression and therapeutic response in immune-competent animals 
(Fig 1.1.1). The  role of the immune system on tumour progression is  a factor that 
should  not  be  ignored.  Cancers  that  develop  in  immune  deficient  mice  are  very 
immunogenic when transplanted back into immune-competent mice, compared to the 
poor immunogenicity of spontaneous tumours arising directly in immune-competent 
mice. Immunosurveillance protects the host against tumour development and can shape 
the  immunogenic  phenotype  of  a  developing  tumour.  Despite  this,  chronic 
inflammation as a result of immune response has for a long time been associated with 
cancer development.  For example, macrophages produce many factors that promote 
growth and survival of tumours, angiogenesis, tissue invasion and metastases. A dual 
role  exists  for  immunosurveillance  in  protection  against  and  promotion  of  tumour 
development.  Retroviral  transduction  to  introduce  various  oncogenes  or  tumour 
suppressors  in  MOSE  can  lead  to  transgenic  models  in  which  tumours  initiate  and 
progress in situ (Roberts, Mottillo et al. 2005).  
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Figure 1.1.1 Summary of models used to characterize tumour development and 
progression. 
 
 
1.3 Expression profiling of EOC 
Traditionally,  tumours  have  been  categorised  on  the  basis  of  histology.  However, 
staining of cancer cells viewed under the microscope gives insufficient information on 
the underlying molecular events that drive the neoplastic process. The chromosomal 
abnormalities and alterations in cancerous cells, somatic and/or acquired, are distinct 
for unique tumour subtypes and may be targets of new treatments. There are multiple 
mechanisms by which genes or biological pathways can lead to the development of 
cancer. Most cancer-associated genes are altered at either the chromosome level (e.g. 
translocations, interstitial chromosome deletions and rearrangements and chromosome 
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ploidy),  the  base  level  (e.g.  coding  sequence  mutations,  genomic  deletions, 
rearrangements and amplifications), or at an expression level (e.g. splice site mutations 
or aberrant methylation of promoter regions). Identifying these molecular markers of 
disease may provide novel approaches to screening and could enable targeted treatment 
and/or lead to the design of novel therapies. However, the biological and molecular 
genetic basis of epithelial ovarian tumour development remains poorly understood.   
 
Comparative genomic hybridisation (CGH) and loss of heterozygosity (LOH) studies 
have identified multiple, common genomic alterations in cancers (Sakamoto, Sakamoto 
et  al.  1996;  Kudoh,  Takano  et  al.  2000;  Suehiro,  Sakamoto  et  al.  2000;  Bozzetti, 
Bortesi et al. 2004). CGH is a cytogenetic method of screening a tumour for genetic 
changes. In a typical CGH experiment, equal amounts of tumour DNA and normal 
reference DNA are labelled with fluorescent dyes. The samples are then pooled and 
allowed to competitively hybridise to target DNA, which for conventional CGH would 
be condensed metaphase chromosomes on a glass slide. The genomic differences are 
then viewed by microscopy. More recently, genomically mapped DNA fragments (i.e. 
BAC clones, cDNA, oligonucleotides) immobilized on to a glass slide serve as the 
target  DNA.  Laser  excitation  of  the  hybridized  targets  yields  emission  with 
characteristic spectra from each dye. The DNA copy number is determined by the ratio 
of the fluorescence of the test sample over the fluorescence of the reference sample 
(Fig 1.1.2). 
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Figure 1.1.2 Conventional and array CGH. An example of the co-hybridization of 
differentially-labelled  test  (tumor-  red  fluorochrome)  and  reference  (normal-  green 
fluorochrome) genomic DNA probes onto metaphase target chromosomes and a BAC 
array. 
 
 
In one study, metaphase CGH was used to characterize the deletions and amplifications 
in 141 ovarian tumours grouped with respect to BRCA1/2 status (Ramus, Pharoah et al. 
2003).  This  showed  multiple  frequently  occurring  somatic  alterations  (Fig  1.1.3). 
Chromosome deletions are thought to suggest the location of tumour suppressor genes 
involved in the pathogenesis of the disease and possibly reflect the genetic damage that 
occurs  during  tumour  progression.  Interestingly,  they  identified  molecular  genetic 
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differences  between  the  four  tumour  types  under  study,  indicating  different 
mechanisms  are  involved  in  tumour  development  which  may  impact  on  clinical 
outcome.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.3 Metaphase CGH analysis of 141 epithelial ovarian cancers. This graph 
shows the frequencies of chromosomal deletion identified for each chromosome arm in 
a  cohort  of  cancers  from  BRCA1  and  BRCA2  mutation  carriers,  individuals  with 
familial non-BRCA1/2 epithelial ovarian cancer, and women with non-familial ovarian 
cancer. 
 
 
CGH studies have revealed that the frequency of deletions increases with grade and 
stage of ovarian tumours and that low malignant potential/borderline tumours are more 
similar to benign ovarian cancers than they are to malignant tumours (Wolf, Abdul-
Karim et al. 1999). 
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With  the  improvements  in  microarray  technology,  simultaneous  interrogation  of 
thousands of genes in a high-throughput fashion offers unprecedented opportunities to 
obtain the molecular signatures of cell models or solid tumour samples (Haviv and 
Campbell 2002). The  advantage of  microarrays is that  you obtain a comprehensive 
parallel record of genes that are expressed together in a condition-dependent manner 
(Adib, Henderson et al. 2004).  
 
In a recent study, microcell-mediated chromosome transfer (MMCT) was employed to 
introduce normal chromosomes into recipient tumour cell lines to induce a suppressive 
effect on their tumourigenic phenotype. The extent of genomic transfer suspected to 
carry tumour suppressor genes was characterised by array CGH (Dafou, Ramus et al. 
2009).  MMCT  (Doherty  and  Fisher  2003)  comprises  a  donor  cell  (e.g.  murine 
fibroblasts) containing normal human chromosome material tagged with a selectable 
marker. After prolonged exposure to colcemid, the cell is held in metaphase and forms 
no functional spindle. The cell eventually leaves mitosis and the nuclear membrane 
reforms around single chromosomes to produce micronuclei which can be isolated and 
fused with a recipient cell (Fig 1.1.4).   31 
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Figure 1.1.4 MMCT. A donor cell containing a chromosome of interest tagged with a 
selectable marker is treated with colcemid for 48 hours to produce micronuclei. These 
are isolated and the microcells fused with a recipient tumour cell. The cells containing 
the chromosome of interest are then selected for. 
 
 
The study involved the transfer of a number of chromosomes previously identified to 
be  genetically  altered  in  ovarian  cancers  into  two  EOC  cell  lines.    Among  others, 
normal chromosome 18 material was transferred into two epithelial ovarian cancer cell 
lines,  TOV-112D  and  TOV-21G.  These  ovarian  cancer  cell  lines  were  originally 
derived from grade III malignant ovarian tumours. Each was derived from tumours 
with different histopathologies: a clear cell carcinoma (TOV-21G) and an endometrioid 
carcinoma (TOV-112D). The TOV-21G cell line grows as a monolayer in tissue culture 
plates, while the TOV-112D cell line is loosely adherent and the cells have a tendency 
to grow in compact colonies and form foci (Fig 1.1.5). 
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Figure 1.1.5 Morphology of cell lines TOV-112D and TOV-21G. Both cell lines 
have a rounded morphology characteristic of highly transformed cell lines.  
 
MMCT was used to generate hybrid clones that contained whole or partial chromosome 
incorporation. Microsatellite analysis, FISH and array CGH revealed a ~10 Mb region 
(18p11.21-18q11.2) had been transferred into the TOV-112D hybrid cell lines, while a 
full copy of chromosome 18 was transferred into the TOV-21G hybrid cell lines. In 
addition, deletion of chromosome 8q and partial deletion of chromosome 9q and 12q 
was observed in the TOV-112D hybrid cell lines (Fig 1.1.6). 
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Figure 1.1.6 Genomic analysis of four Chromosome 18 hybrid clones.  A) Array 
CGH analysis of the parental cell line TOV-112D and two hybrid clones, 18-D-22 and 
18-D-23 respectively; and the parental cell line TOV-21G and two hybrid clones, 18-
G-5  and  18-G-1.26  respectively.  CGH  profiles  are  displayed  across  increasing 
chromosome number, running from the telomere of the p-arm to the telomere of the q-
arm of each chromosome. Yellow spots indicate no change in copy number between 
the parental cell line and its hybrid clone. Green spots indicate an increase in DNA 
copy number in the hybrid clone and red spots indicate loss of DNA copy number in 
the hybrid clone. A red line indicates a threshold of copy number change at +1 and -1. 
B) Fluorescent in situ hybridization analysis for chromosome 18 in each hybrid clone. 
The  hybrid  clones  18-D-22  and  18-D-23  showed  only  partial  incorporation  of 
chromosome 18 (ringed in white), whereas the hybrid clones 18-G-5 and 18-G-1.26, 
have each received a full copy of chromosome 18.   
 
18-D-22/TOV-112D
18-D-23/TOV-112D
18-G-5/TOV-21G
18-G-1.26/TOV-21G
A. B.
18-D-22/TOV-112D
18-D-23/TOV-112D
18-G-5/TOV-21G
18-G-1.26/TOV-21G
18-D-22/TOV-112D
18-D-23/TOV-112D
18-G-5/TOV-21G
18-G-1.26/TOV-21G
A. B.  34 
The  hybrid  cell  lines  displayed  significantly  suppressed  tumourigenic  phenotype 
compared to their parental ovarian cancer cell counterparts in a number of assays. To 
characterise anchorage-independent growth of the ovarian cancer cell lines, their ability 
to  form  colonies  in  soft  agar  was  assessed.  The  parental  line  TOV-112D,  rapidly 
formed foci, while TOV-21G showed a more delayed formation of smaller foci. The 
hybrid clones displayed poor colony forming efficiency (CFE) compared to their parent 
cell line counterparts (Fig 1.1.7) 
 
 
 
 
 
Figure 1.1.7 The colony forming efficiency of ovarian cancer cell lines in soft agar. 
The parental cell lines, TOV-112D and TOV-21G, rapidly formed distinct foci in soft 
agar. Seven hybrid clones from each parental cell line examined displayed poor colony 
forming efficiency in soft agar.   35 
The ovarian cancer cell lines were also tested in in vivo assays. Injection of TOV-112D 
cells into nude mice resulted in the rapid appearance of tumours in four out of four 
animals tested, with tumours appearing between 2 and 5 weeks. The TOV-21G cell line 
also  produced  tumours  in  all  animals  although  tumours  appeared  later.  Notably, 
injection  of  the  TOV-21G  cell  line  also  resulted  in  the  formation  of  metastases, 
characterised by the presence of metastatic deposits in the lungs and ascito. The hybrid 
clones displayed significant suppression of tumour development in nude mice. In some 
hybrid clones, no tumours were detected for the duration of the experiment (Fig 1.1.8).  
 
 
Figure 1.1.8 Tumour growth in vivo of ovarian cancer cell lines. Each parental cell 
line and their chromosome 18 hybrid clones were injected interperitoneally into nude 
mice and the natural history of the mice recorded after 3 weeks and 12 weeks. The 
chromosome  18  hybrid  clones  display  significantly  reduced  tumour  development 
compared to their parental cell lines. 
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The  introduction  of  chromosome  18  into  two  primary  ovarian  carcinoma  cell  lines 
appears  to  suppress  the  in  vitro  and  in  vivo  neoplastic  phenotype  suggesting  that 
chromosome 18 harbours tumour suppressor genes for OC. Following on from this 
work,  Dafou  et  al.  employed  gene  expression  microarray  profiling  to  identify  21 
candidate tumour suppressor genes located on chromosome 18 that were significantly 
over-expressed in association with the suppression phenotype reported earlier. Further 
analysis identified a potential tumour suppressor gene (data not published). These cell 
models were chosen for proteomic analysis in this study.   
 
Despite the obvious potential of gene-expression profiling, there has been little overlap 
in the genes that have been identified in different studies as being important in ovarian 
cancer  development  or  as  clinically  useful  biomarkers.  The  heterogeneity  of  EOC, 
compared with other cancers, makes interpretation of the results extremely difficult and 
it is probable that multiple independent mechanisms may underlie the same phenotype 
in  different  cancer  cell  lines  and  tumour  samples.  In  addition,  the  mRNA  changes 
identified in these studies often do not reflect changes at the protein level, and protein 
analysis  techniques  may  be  more  relevant  for  studying  cancer  biology  and  for 
biomarker discovery (Hernandez, Rosenshein et al. 1984; Jochumsen, Tan et al. 2007; 
Khalique, Ayhan et al. 2007). 
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1.2 Proteomics 
Proteomics defines the study of the protein complement in a cell, tissue or organism, as 
genomics defines the DNA & RNA content. Proteomics includes the study of protein 
expression levels, activities, modifications, localization and the interaction of proteins 
within complexes and with other biomolecules. Developments in proteomic research 
have been made possible with the availability of complete sequence data from high-
throughput DNA sequencing efforts (Anderson and Anderson 1998; Naaby-Hansen, 
Waterfield  et  al.  2001;  Patterson  and  Aebersold  2003;  Tyers  and  Mann  2003). 
Biological  function  is  not  carried  out  by  the  static  genome,  but  by  the  dynamic 
population of proteins which is determined by the interplay between gene and protein 
regulation and is dependent on the organism’s environment and physiological state. It 
has been estimated that there are approximately 25 000 genes in the human genome. 
Taking into account RNA splice variants, post-translational modifications and other 
post-transcriptional processing events, these genes are estimated to produce between 
200 000 and 1 million distinct protein isoforms (Jensen 2004; Tress, Martelli et al. 
2007).  Proteins  encoded  by  these  genes  are  the  true  effector  molecules  and  the 
functional  manifestations  of  genetic  information  (Fig  1.2.1).  The  functions  of  the 
expressed  proteins  may  be  altered  by  co-translational  and  post-translational  events, 
biomolecule  binding  and  temporal  and  spatial  signalling  within  the  cell  and  local 
microenvironment. 
 
   38 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.2.1  An  overview  of  the  transfer  of  information  from  the  sequence  in 
genes to the functioning proteins of the cell.  A gene is transcribed (step 1) to pre-
mRNA, which can be under editing control (step 2), then processed to one mRNA or 
by  alternative  splicing  to  several  forms  of  mRNAs  (step  3).  The  mRNA  is  then 
transported (step 4) out of the nucleus into the cytosol. In the cytosol the mRNA can be 
degraded into inactive forms (step 5) or translated into protein (step 6). Proteins maybe 
synthesized in an active or inactive form. Control (step 7) by activation or deactivation 
in a reversible or irreversible manner regulates cellular processes. 
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1.2.1 Cancer Proteomics 
It  is  widely  accepted  that  tumour  development  is  a  multi-step  process  of  cellular 
transformation driven by somatic genetic alteration. For most cancer types, primary 
tumour  development  is  associated  with  an  accumulation  of  genetic  changes  in  the 
progenitor cell. Successive alterations affecting specific genes are thought to confer an 
increased  growth  advantage  allowing  tumours  to  develop  by  clonal  expansion  and 
progress from benign to cancerous lesions. Despite these genetic changes the proteins 
encoded by these genes are the true effector molecules that drive transformation and it 
is for this reason that proteomic technologies are developing to answer questions about 
protein expression and function particularly in relation to the changes associated with 
cancer (Wu, Hu et al. 2002; Hanash 2003; Check 2004; Boyce and Kohn 2005). 
 
The major difficulty in treating ovarian cancer is that it presents at a late clinical stage 
giving a dismal prognosis (section 1.1). For this reason, there is an urgent need for 
methods to aid in its successful treatment and for reducing mortality. Biomarkers are 
typically disease associated proteins that can be detected and quantitatively measured 
for  disease  diagnosis,  staging  and  prognosis  and  treatment  monitoring.  The 
development  of  disease  is  a  multi-step  process  involving  many  different  biological 
processes and many proteins will have altered expression or are modified during these 
processes. These proteins can be detected in tissue, blood, urine, or other body fluids 
and be used as markers of disease. It is highly desirable for protein markers for use in 
medical practice to be detected and measured in body fluids. These fluids are highly   40 
complex  mixtures  of  proteins  and  exhibit  a  very  broad  dynamic  range  of  protein 
abundances (up to 10 orders of magnitude). Because of this, it is believed that many 
potentially  useful  biomarkers  escape  detection  using  the  current  proteomics 
technologies. 
 
In 2002, a serum-based proteomic pattern diagnostic has been developed and applied 
for  differential  diagnosis  detection  in  ovarian  cancer  using  a  technique  known  as 
surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-
TOF MS) (Petricoin and Liotta 2004). SELDI generates protein ions from subsets of 
protein analytes desorbed from a chemically-modified surfaces or chips. These ‘chips’ 
have either a hydrophobic, cationic or anionic chromatographic support surface or are 
coated with affinity supports such as antibodies and purified proteins such as receptors 
or ligands. Treated tissue or body fluid can be directly applied to the ‘chip’ and after 
washing to remove unbound protein be analysed by TOF-MS. Generated ions extracted 
into a vacuum chamber migrate towards an oppositely charged detector. The mass-to-
charge (m/z) value of each ion can be determined from the time it takes for an ion to 
reach the detector. This is time of flight (TOF). The spectrum acquired in the TOF 
gives a signature of hundreds of protein ion features that can be used to build a pattern 
for disease recognition. Detection of potential markers is relatively quick, however, the 
protein peaks generated are not easily identified since the mass accuracy is relatively 
poor. Thus, the results cannot provide any information about the relationships and the 
roles of the proteins of interest to the underlying pathology. Petricoin et al. identified a 
protein pattern in the serum proteome from non-cancer controls and ovarian cancer   41 
patients (Petricoin, Ardekani et al. 2002). The spectra were used to train a classification 
algorithm which correctly classified 50/50 of the cancers and 47/50 of the normals in a 
validation set giving 100% sensitivity and  95% specificity respectively. Independent 
review  of  these  datasets  have  revealed  discrepancies  which  suggest  the  changes 
observed could be due to artifacts of sample processing, not the underlying biology of 
cancer. Since this landmark study, pre-analytical handling of samples has been shown 
to significantly affect protein profiles and the ability to differentiate between disease 
and control. The transition time, storage  conditions, temperature, clotting time,  and 
tube type can all affect serum profiles which is largely driven by proteolytic events and 
it  is  therefore  essential  to  handle  all  case  and  control  samples  identically  (Timms, 
Arslan-Low et al. 2007).  
 
The  protein  levels  of  most  body  fluids  have  substantial  intra  and  inter-individual 
variability. This distribution should be considered appropriately during experimental 
design. Clinical proteomics studies, with small sample numbers can be vulnerable to 
the misinterpretation of signals if not carefully designed and properly interpreted. As 
alluded to above the dynamic range of protein concentrations in body fluids is also an 
important concern. For example, 22 high-abundance proteins make up approximately 
99% of the total proteins in plasma. There are however approaches that can be used to 
reduce the dynamic range of protein abundance in body fluids for detection of lower 
abundance proteins, including affinity depletion and multiple fractionation methods. 
Care should also be taken to avoid loss of potentially important proteins/peptides that 
could  be  bound  to  high-abundance  proteins  such  as  albumin.  Indeed,  Liotta  et  al.   42 
proposed  that  carrier  proteins  like  albumin  may  accumulate  low  molecular  weight 
biomarkers and prolong their half-life (Liotta and Petricoin 2006). It is also believed 
that  disease-associated  protease  activity  can  result  in  altered  low  molecular  weight 
protein/peptide  profiles.  Villaneuva  et  al.  suggested  that  many  serum  peptides, 
including potential cancer biomarkers, are generated from clotting products ex vivo by 
unknown cancer-specific exoproteinases leaving a low molecular weight signature with 
diagnostic potential (Villanueva, Shaffer et al. 2006).  
 
Immuno-affinity  depletion  of  specific  high-abundance  proteins  through  the  use  of 
targeted  polyclonal  antibody  columns  and  spin  filters  has  recently  emerged  as  a 
promising tool for prefractionation. IgY12 columns from Genway use avian polyclonal 
IgY antibodies to allow highly specific removal of the top 12 highly abundant proteins 
in  human  serum/plasma  samples.  Similarly,  the  multiple  affinity  removal  system 
(MARS)  column  developed  by  Agilent  Technologies,  removes  the  7  most  highly 
abundant  proteins  from  serum/plasma  samples.  A  fractionation  technique  that  has 
become a promising alternative to SELDI, is the use of magnetic beads coated with 
hydrophobic or ionic resins as a purification step. Beads can be added to a sample to 
bind  protein/peptides  of  interest  before  thorough  washing  by  manipulation  with 
magnets.  This  approach  is  simple,  reproducible and offers  itself to  high-throughput 
analysis.  
 
Other  technologies  have  been  applied  for  biomarker  discovery,  including  two-
dimensional  (2DE)  gel-electrophoresis,  LC-MS,  and  protein-  and  antibody-based   43 
microarrays. 2DE provides information about proteins, such as expression volumes, 
actual  pIs  and  molecular  weights  and  can  typically  resolve  ~2000  protein  isoforms 
from a whole cell lysate. It also gives an insight into intact and fragmented protein 
species  and  information  regarding  post-translational  modifications  (PTMs). 
Downstream analysis of excised protein spots by mass spectrometry (MS) results in 
identification and additional information on PTMs. 2DE has for a long time been the 
primary tool for biomarker discovery in conventional proteomic analyses. It is uniquely 
suited for the direct comparisons of protein expression and for the identification of 
differentially expressed proteins between two or more conditions. For example, Gagne 
et al. investigated the differential protein expression profile between low malignant 
potential and highly proliferative human epithelial ovarian cancer cell lines derived 
from  malignant  tumours  (Gagne,  Ethier  et  al.  2007).  Ahmed  et  al.  examined  the 
expression  profiles  of  depleted  serum  from  ovarian  cancer  patients  compared  to  a 
control  group  of  healthy  women  (Ahmed,  Oliva  et  al.  2005).  Changes  in  serum 
expression of haptoglobin correlated with the change of CA-125 levels before and after 
chemotherapy. A comparison by 2DE of micro-dissected epithelial cells from two low 
malignant potential (LMP) ovarian tumours and three invasive cancers by Jones, et al. 
revealed  markers  of  invasiveness  including  RHOGD1,  glyoxalase-1  and  FK506BP 
(Jones, Krutzsch et al. 2002). 
 
As a technique for biomarker discovery, 2DE suffers from low sensitivity, low dynamic 
range, difficulties in resolving proteins with extreme masses or isoelectric points, and 
low-solubility  proteins.  Improvements  can  be  made,  for  example  the  use  of   44 
prefractionation techniques to reduce the complexity of the samples for analysis and the 
use of Cy dye labelling in differential gel-electrophoresis (2D-DIGE) has improved the 
sensitivity and quantitative performance of this approach.   
 
An emerging technology that requires a complex protein mixture to be digested with a 
specific protease before 2-dimensional liquid chromatographic separation is multiple 
dimension protein identification technology (MudPIT). Peptide fragments are separated 
initially  by  charge  then  by  hydrophobicity  before  eluting  directly  into  a  mass 
spectrometer  that  can  be  used  to  identify  peptides  as  they  elute.  Quantitative 
differences between two samples can be elucidated from the spectral intensity of the 
parent  ion  of  a  given  peptide  between  each  run,  or  each  sample  can  be  labelled 
differentially (in vivo using stable isotopes; or in vitro using mass tagging strategies 
such  as  ICAT/iTRAQ/TMT)  and  mixed  prior  to  chromatographic  separation  and 
quantification  determined  from  spectral  information.  This  technique  has  advantages 
over gel-based techniques in speed, sensitivity, and dynamic range. Limor Grotzak-
Uzan et al. examined ovarian cancer ascites in a MudPIT experiment resulting in the 
identification of over 2500 proteins of which 80 were suggested as potential biomarkers 
(Gortzak-Uzan, Ignatchenko et al. 2008). Yu et al. used the secreted proteins obtained 
from SILAC labelled human pancreatic cells as a standard to run with pooled sera of 
patients with early stage pancreatic cancer or controls using an IEF-2D-LC-MS/MS 
approach to identify low abundance proteins as biomarker candidates (Yu, Barry et al. 
2009).  A  study  by  Bouchal  et  al.  has  shown  the  ability  of  iTRAQ  combined  with 
MudPIT to define a protein signature in breast cancer tumour biopsies and to identify   45 
potential biomarkers of  metastasis (Bouchal, Roumeliotis et al. 2009).  Advances in 
chromatographic  separations  and  the  speed,  sensitivity  and  accuracy  of  mass 
spectrometers combined with innovative quantitative labelling strategies have allowed 
these ‘bottom up’ proteomic techniques to evolve into an important tool for biomarker 
discovery.   
 
In  recent  years,  protein  and  antibody  arrays  have  been  developed  to  allow  rapid 
interrogation of protein activity on a proteomic-wide scale. Recombinant proteins or 
reagents  that  interact  specifically  with  proteins  (e.g.  antibodies,  peptides  and  small 
molecules)  have  provided  a  platform  for  protein  arrays  (Nishizuka  2006;  Spurrier, 
Honkanen et al. 2008). High-throughput ELISA microarray technology offers promise 
for cancer biomarker validation. The advantages of protein microarrays include high 
sensitivity, good reproducibility, quantitative accuracy and the requirement for small 
sample volumes e.g. Gunawardana et al. performed parallel protein microarray analysis 
of  ascites  fluid,  pooled  from  30  ovarian  cancer  patients  and  a  control  pool  of  30 
samples  of  non-malignant  peritoneal  fluid  to  identify  tumour  associated  antigens 
(Gunawardana, Memari et al. 2009). However, ELISAs suffer from the nonspecificity 
of  protein−antibody  interactions,  which  could  result  in  “false  positives”.  Cell  and 
tissue-based arrays provide a further insight into functional activity (Ouellet, Guyot et 
al.  2006).  A  tissue  microarray  (TMA)  is  a  histological  section  in  which  tens  to 
hundreds  of  specimens  are  arrayed  for  analysis.  TMAs  enable  the  high-throughput 
analysis of a large number of tissue samples by immunohistochemical staining that 
have been  collected and archived as formalin  fixed paraffin embedded  blocks.  The   46 
most  popular  use  for  TMAs  is  for  the  validation  of  diagnostic  and  prognostic 
biomarkers  in  annotated  clinical  samples.  James  et  al.  have  performed 
immunohistochemical validation of marker proteins on panels of normal ovarian and 
tumour  tissues  (Bengtsson,  Krogh  et  al.  2007).  They  identified  statistically  valid 
markers  that  could  distinguish  between  normal,  benign,  borderline,  and  malignant 
tissue. 
 
Another emerging tool for biomarker validation is the application of peptide multiple 
reaction  monitoring  (MRM)-based  assays  for  targeted  quantitation  of  proteins  in 
clinical samples (Mills, Morris et al. 2005). The technology has been employed for 
over 15 years in the measurement of drugs and metabolites. This MS-based technique 
solves  the  challenges  to  preliminary  validation  of  putative  biomarkers  for  which 
immune-based  reagents  are  not  available  and  allows  detection  of  low-abundance 
proteins in complex tissue or biological fluids in addition to high-throughput, high-
precision quantification.  
 
A vast amount of research is being focussed on biomarker discovery and hundreds of 
putative biomarkers are being made available to the scientific community. Despite this, 
there are very few protein biomarkers in clinical use today and many of the identified 
biomarkers are abundant serum proteins or non-specific acute-phase proteins, and not 
proteins directly related to the disease process. Proteomics still has many challenges to 
overcome in the discovery of tumour biomarkers.    47 
1.3 Proteomic Technologies 
In the past, protein analysis was dominated by targeted approaches in which candidates 
derived  from  biological  knowledge  were  selectively  evaluated  for  correlation  with 
clinical conditions. However, the recent advances in proteomic tools has allowed for 
the  simultaneous  comparison  of  complex  protein  profiles  and  at  the  same  time 
identification of component proteins in a high throughput manner. 
 
The following sub-sections introduce and discuss the basis of the proteomic methods 
used in this study and how the combination of these approaches is used quantitatively 
to  characterise  proteomes.  The  two  main  methods  used  to  separate  proteins  and 
peptides were 2D-gel electrophoresis and liquid chromatography (LC). The separated 
proteins and peptides were then analysed by MS. 
 
3.3.1 Gel Electrophoresis 
Electrophoresis  describes  the  process  by  which  a  charged  molecule  migrates  in  an 
electric field. Molecules will separate at different velocities depending on their charge 
state, providing a basis for separation. Typically, electrophoresis of proteins is carried 
out in a polyacrylamide gel. Polycrylamide gels contain pores, the sizes of which are 
dependent on the concentration of acrylamide and bis-acrylamide cross-linker present 
in  the  gel.  A  common  form  of  electrophoresis  is  sodium  dodecyl  sulphate  (SDS) 
polyacrylamide gel electrophoresis (PAGE). Proteins are reduced and denatured in the   48 
presence of the anionic detergent SDS. SDS binds strongly to the amino acids of the 
reduced protein, as a result, the intrinsic charge of the protein is masked by the negative 
charges  of  the  SDS,  and  thus,  proteins of  similar  molecular  weight  have  the same 
apparent  charge.  Therefore,  separation  by  PAGE  is  mainly  related  to  the  size  or 
molecular weight of the protein as it passes through the pores present in the acrylamide 
gel. Smaller proteins are able to move more rapidly than larger ones through the gel 
pores as they migrate towards the anode (Chrambach and Rodbard 1971). 
 
Proteins  can  be  separated  by  another  form  of  electrophoresis,  namely  isoelectric 
focussing (IEF) (Bjellqvist, Ek et al. 1982; Choe and Lee 2000). Denatured proteins are 
separated by IEF in a pH gradient and focus when they acquire a net charge of zero at 
their  isoelectric point  (pI).  Gels  are  of  high  porosity  making  the  effects  of  sieving 
negligible. 
 
Two-dimensional gel electrophoresis (2DE) combines the two electrophoretic methods 
described above. In the first dimension, proteins denatured in urea and DTT/DTE to 
break disulphide bonds and are separated on the basis of their pI by IEF and in the 
second dimension by SDS-PAGE according to their molecular weight (Kenrick and 
Margolis  1970;  Rabilloud  1994).  The  reproducibility  of  2DE-based  separations  has 
improved with the introduction of gels with immobilized pH gradients (IPG) for the 
IEF dimension and optimisation of chaotropes (e.g. urea and thiourea) and neutral or 
zwitterionic detergents (e.g. CHAPS) which prevent precipitation of proteins when they 
reach their pI during focussing. In the region of 2000 distinct protein spots can be   49 
resolved on a single gel. However, these will largely be abundant proteins and multiple 
isoforms of the same gene products. Also basic proteins are often poorly resolved due 
to the inadequate buffering by ampholytes at basic pHs and also because of a loss of 
reductive capacity and a concentrating effect through electro endo-osmosis resulting in 
spurious  disulphide  bond  reformation  and  protein  precipitation  respectively. 
Hydrophobic  proteins  also  do  not  tend  to  resolve  well  on  2D  gels,  again  through 
aggregation,  whilst  large  (>200  kDa)  or  small  proteins  (<10  kDa)  are  also  under-
represented.  Despite  these  drawbacks,  2DE  is  still  the  most  widely  used  protein 
separation and relative quantitation method used in proteomics. Resolved protein spots 
can be picked directly from gels for MS-based identification. 
 
There exist a number of strategies for post-electrophoretic protein detection differing in 
their  sensitivities,  specificities,  linear  dynamic  ranges  and  compatibilities  with 
downstream identification by MS. Staining methods include:  
 
·  Cooomassie brilliant blue (Meyer and  Lamberts 1965; Neuhoff, Arold et al. 
1988; Neuhoff, Stamm et al. 1990), a rapid and convenient staining procedure 
with a detection range of 100-1000 ng and compatible with downstream MS.  
 
·  Colloidal Coomassie blue (G-250) (Meyer and Lamberts 1965; Neuhoff, Stamm 
et al. 1990; Candiano, Bruschi et al. 2004) is relatively simple to use without   50 
the need for destaining, has a detection range of 20-500 ng and is compatible 
with downstream MS. 
 
·  Silver staining (Eschenbruch and Burk 1982; Rabilloud 1990; Rabilloud 1992; 
Shevchenko, Wilm et al. 1996; Rabilloud 1999) provides excellent sensitivity 
(typically  1-10  ng)  using  simple  and  cheap  chemicals.  However,  classical 
silver-staining methods can be complex and are often incompatible with MS 
because of the aldehyde-based cross-linkers used in the sensitisation steps, and 
because silver ions can interfere with MS analysis. Non-linearity of the dynamic 
range of detection and preferential staining based on amino acid composition 
make it less desirable for quantitation of protein expression. 
 
·  Fluorescent stains (Patton 2000; Rabilloud, Strub et al. 2001) such as SYPRO 
Ruby, SYPRO Orange, Deep Purple and ruthenium II-tris bathophenantroline 
disulfonate (RUBP) bind directly to protein with a sensitivity comparable to 
silver staining (1 ng), but with a broader linear dynamic range and compatibility 
with downstream MS. The full potential of these stains can only be realised 
with a CCD camera or laser scanner-based fluorescence detection. As a result, 
these stains are not readily compatible with manual spot picking. To take full 
advantage, a robotic picking system is required.  
·  Radioactive  labelling  is  an  alternative  labelling  method  used  prior  to 
electrophoretic separation. This is performed by in vitro enzymatic labelling   51 
with radioactive metabolites, or by in vivo incorporation (Vuong, Weiss et al. 
2000). Radioactive labelling is very sensitive and provides the widest linear 
dynamic  range  of  any  detection  method.  Proteins  in-gel  can  be  detected  by 
exposure  to  film  (autoradiography)  or  phosphoimaging.  The  latter  is  more 
sensitive and has a wider dynamic range than autoradiography making it more 
desirable for quantitation. Radioactive labelling is however expensive and great 
care has to be taken due to its hazardous nature. 
 
·  Western blotting requires gel separated proteins to be transferred to a membrane 
(typically  PVDF  or  nitrocellulose)  where  they  are  probed  using  a  primary 
antibody  specific  to  the  target  protein.  Most  commonly,  a  horseradish 
peroxidase-linked secondary is used to cleave a chemiluminescent agent, and 
the reaction product produces proportional luminescence that can be detected by 
exposure to film. This method is highly specific however, is labour intensive 
and not high throughput. Specific reagents are not always available. 
 
1.3.2 2D-DIGE 
A covalent fluorescence labelling approach for differential protein expression analysis, 
known  as  difference  gel  electrophoresis  (DIGE)  allows  up  to  three  samples  to  be 
labelled and combined prior to electrophoretic separation (Unlu, Morgan et al. 1997; 
Gorg, Obermaier et al. 1999; Tonge, Shaw et al. 2001; Gharbi, Gaffney et al. 2002). 
Three spectrally distinct dye derivatives (NHS-Cy2/Cy3/Cy5) that are mass and charge   52 
matched are used to covalently label lysine residues (Fig 1.3.1). The ratio of dye to 
protein used has been optimised to ensure the dyes are limiting in the reaction such that 
only approximately 3-4% of each protein is labelled on an average of 1 lysine/protein 
molecule.  This  ‘minimal’  labelling  limits  the  generation  of  multiple  protein  forms 
which would separate on 2D gels, adding to the complexity of the sample. 
 
The differentially labelled samples are then mixed in equal amounts and resolved on 
2D  gels  (Fig  1.3.2).  Labelled  proteins  in  each  sample  are  then  detected  at  the 
appropriate  excitation  and  emission  wavelengths  using  a  multi-wavelength 
fluorescence  detection  device  and  the  signals  compared.  As  well  as  reducing  the 
number  of  gels  that  need  to  be  run,  differential  labelling  and  mixing  means  that 
samples are subjected to the same handling procedures and microenvironments during 
2D separation, raising the confidence with which protein spots can be matched and 
protein changes quantified. Since fluorescence detection also provides a superior linear 
dynamic range of detection and sensitivity to many methods, this technology is suited 
to  the  analysis  of  biological  samples  with  their  large  dynamic  ranges  of  protein 
abundance.  In  expression  profiling  experiments,  one  dye  is  often  used  to  label  an 
internal standard which is run on all gels against pairs of test samples labelled with the 
other  two  dyes.  This  allows  the  direct  comparison  of  ratios  of  expression  across 
multiple samples and gels, improving the ability to match protein spots and accurately 
distinguish true biological variation from  gel-to-gel variation.  In some respects, the 
advantages in applying 2D-DIGE can be limited by the method of post-staining for spot 
excision and subsequent identification. CyDyes offer great sensitivity, detecting as little   53 
as 125 pg of protein and giving a linear response to protein concentration of up to four 
orders of magnitude. In comparison, post-staining detects between 1–500 ng of protein 
with less than a hundred-fold linear dynamic range. However, it would be unwise to 
pick from gels using the Cy dye image since the combination of minimal labelling and 
addition of the Cydye moiety (~500 Da) means that the bulk of the protein does not 
exactly co-migrate with the labelled portion of the protein, particularly in the lower 
mass region of the gel. 
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Figure  1.3.1  The  chemistry  of  the  NHS-Cy  dyes.  A)  Cy2,  3-(4-
carboxymethyl)phenylmethyl)-3’-ethyloxacarbocyanine  halide  N-hydroxy-
succinimidyl  ester;  Cy3,  1-(5-carboxypentyl)-1’-propylindocarbocyanine  halide  N-
hydroxysuccinimidyl  ester;    and  Cy5,  1-(5-carboxypentyl)-1’-
methylindodicarbocyanine  halide  N-hydroxysuccinimidyl.  All  are  size  and  charge 
matched allowing co-separation of different Cy-Dye labelled proteins in the same gel, 
limiting experimental variation and ensuring accurate within-gel matching. B) Each 
Cy-dye is spectrally distinct, offering bright and intense colours with narrow excitation 
and emission band widths. C) The dyes have an N-hydroxysuccinimidyl ester reactive 
group that covalently interacts with the primary amine groups of lysine residues or the 
N-terminus of proteins. 
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Figure  1.3.2  2D-DIGE  work  flow  (adapted  from  www.gelifesciences.com,  GE 
Healthcare). Up to 3 labelled protein samples can be run simultaneously on a 2D gel. 
The internal standard is prepared by pooling aliquots of all biological samples in an 
experiment. This is run on all the gels in an experiment creating an intrinsic link that 
once normalised allows the ratio of relative expression of a given protein across all gels 
to be compared directly.   56 
1.3.3 Liquid chromatography (LC) 
Molecules  can  also  be  separated  on  the  basis  of  their  differential  partition  or 
distribution between two immiscible phases (Peng and Gygi 2001). In column LC, the 
two phases consist of chromatographic beads of distinct surface chemistry and a liquid 
phase  making  up  the  stationary  and  mobile  phases  respectively.  Molecules  are 
separated when their distribution coefficients (Kd) are different. Kd is defined as the 
concentration of a molecule in the stationary phase divided by its concentration in the 
mobile phase. In this study, high-performance LC (HPLC) was used with reversed-
phase (RP) and ion-exchange chromatography. The sample to be analysed is introduced 
in a small volume to the stream of mobile phase and is retarded by specific chemical or 
physical interactions with the stationary phase as it traverses the length of the column. 
The amount of retardation depends on the analyte, stationary phase and mobile phase 
composition. The time at which a specific analyte elutes is called the retention time and 
it is considered to be a unique identifying characteristic of the analyte. 
 
1.3.3.1 Reverse phase liquid chromatography (RP-LC) 
RP-LC separates proteins or peptides according to their hydrophobicity (Claessens and 
van Straten 2004).  The stationary phase is generally made of hydrophobic alkyl chains 
(-CH2-CH2-CH2-CH3)  that  interact  with  the  analyte  by  hydrophobic  and  van  der 
Waals interactions. There are three common chain lengths, C4, C8 and C18. C4 is 
generally  used  for  proteins  and  C18  is  generally  used to  capture  peptides  or  small   57 
molecules. Proteins and peptides are separated by running a linear gradient of organic 
solvent in the mobile phase. RP-LC is widely used for the analysis of proteins and 
peptides due to its high resolution and is often linked on-line to mass spectrometry-
based detection. 
 
1.3.3.2 Ion-exchange chromatography 
Ion-exchange  chromatography  retains  analyte  molecules  on  the  basis  of  ionic 
interactions. The stationary phase consists of charged functional groups and separation 
of molecular species occurs by virtue of their differences in charge. Protein molecules 
are eluted by adjusting the pH or the ionic concentration of the mobile phase. This type 
of chromatography is subdivided into two main types of ion exchangers, namely anion 
exchangers and cation exchangers. The form of ion exchange used in this study was 
strong cation exchange (SCX). Peptides interact with the negatively charged sulfonic 
groups linked to the stationary phase with affinities that are proportional to the overall 
number of positive charges on each peptide. Polypeptide samples were dissolved in a 
solvent of low pH and ionic strength so that all polypeptides have at least one positive 
charge. The peptides were eluted by using gradient of increasing salt concentration. 
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1.3.3.3 Multidimensional protein identification 
technology (MudPIT ) 
MudPIT is a non-gel approach for the identification of proteins from complex mixtures. 
The  technique  consists  of  two-dimensional  chromatographic  separation  of  peptides 
following tryptic digestion of protein samples and detection by electrospray-ionisation 
MS  (Liu,  Lin  et  al.  2002).  The  first  dimension  is  usually  strong-cation  exchange 
because  of  its  high  loading  capacity.  The  second  dimension  is  reverse-phase 
chromatography due to its compatibility with electrospray ionisation (ESI). In contrast 
to 2DE gel-based methods, liquid chromatography can resolve a wide range of proteins 
encompassing  high  and  low  molecular  weights  and  extreme  isoelectric  points.  In 
addition,  large  sample  volumes  can  be  applied  to  columns,  which  overcome  the 
problems of over-loading faced with 2DE gel approaches. This technique is capable of 
identifying in excess of 5000 proteins which can be increased further by combining 
with other fractionation strategies. Whilst this improved coverage is highly beneficial it 
comes at the cost of reduced throughput.  
 
1.4 Mass spectrometry 
Mass spectrometry is an analytical tool which allows the determination of the mass of a 
molecule  with  high  accuracy.  This  information  can  be  used  for  identification  and 
chemical  characterisation  (Gygi  and  Aebersold  2000;  Aebersold  and  Mann  2003). 
Mass spectrometers are composed of an ion source where the sample is applied and   59 
transferred as ions into the gas phase, a mass analyser that separates and measures the 
mass-to-charge  ratio  (m/z)  of  ionised  particles  and  a  detector  which  measures  the 
intensity  of  the  ions.  Mass  spectrometry  has  become  an  important  technique  in 
proteomics for the identification and quantification of proteins and to correlate protein 
and gene sequences. Genome sequence information has provided a powerful resource 
for  protein  identification  using  data  produced  by  matrix-assisted  laser  desorption 
ionization  time-of-flight  (MALDI-TOF)  and  electrospray  ionisation  (ESI)  mass 
spectrometry. These two methods differ in their mode of ionisation of the sample and 
are described in more detail in the following sections.  
 
1.4.1 Matrix –assisted laser desorption ionization 
MALDI generates ions from a solid phase using laser pulses (Hillenkamp and Karas 
1990; Hillenkamp, Karas et al. 1991; Griffin, Gygi et al. 2001). The sample is usually 
applied in a matrix that facilitates the ion formation by absorption of photon energy 
from the laser beam (Fig 1.4.1). The matrices used are typically acidic compounds with 
a maximal absorption in the region of the laser wavelength. For the most frequently 
used  laser  wavelengths  (377  and  355 nm),  the  most widely  used  matrices  are  2,5-
dihydroxybenzoic  acid  (DHB)  and  α-cyano-4-hydrocycinnamic  acid  (CHCA) 
(Hazama, Nagao et al. 2008). The analyte/matrix mixture is routinely spotted onto a 
metal surface to crystallise and introduced to a high vacuum and irradiated with the 
laser beam. DHB crystallises in a crystal rim around the centre of the spot. CHCA 
forms a homogenous shaped matrix spot, making it more suitable for automated data   60 
acquisition. Protonated analyte ions (MH
+) are formed whose m/z values can then be 
measured using a mass analyser. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.1 Ion formation by MALDI. The analyte is co-crystallised with the matrix 
(a) onto a target plate (b). A pulsed laser (c) is focused onto the target plate by optics. 
The mixture is desorbed into a plume (d). Protonated analyte ions are extracted by a 
high potential field (e) into the entrance of the mass spectrometer (f). 
 
1.4.2 Electrospray ionisation 
Electrospray  ionisation  (ESI)  creates  ions  through  the  application  of  a  potential 
difference placed between a capillary from which the sample is sprayed and the inlet to 
the mass spectrometer (Fenn, Mann et al. 1989). The sample is dissolved in an organic 
solvent,  typically  methanol or  acetonitrile,  containing  a small concentration  of  acid 
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(formic acid, 0.1-1%). The analyte/solvent mixture evaporates upon application of a 
high voltage and the charged particles enter into the gas phase. Dry gas and heating are 
used to evaporate solvent from the highly charged drops. As solvent evaporates from 
drops, the charge density increases until charge-charge repulsion is greater than the 
surface tension (Raleigh limit) and the drops divide. This process, known as coulomb 
fission,  continues  until  analyte  ions  free  of  solvent  are  formed.  In  addition,  ion 
evaporation occurs as charged analyte ions evaporate from the surface of small drops to 
reduce charge-charge repulsion.  
  
The introduction of the sample into the mass spectrometer can be carried out by a 
number of methods. In the simplest case, sample is directly infused through a syringe 
and a narrow transfer capillary. More commonly, it is achieved by the coupling of 
electrospray directly with reversed-phase  chromatography.  In this case  the capillary 
end of the chromatographic system is connected to a needle, with typical flow rates of 
200 to 500 nl min-1 (nanospray) used (Fig 1.4.2). A feature of ESI is the formation of 
multiply charged ions. This extends the mass range of  analysers  (see  below). Both 
ionisation methods can be performed in the positive as well as the negative ion mode 
but typically, for peptide mass analysis, ionisation scans are performed in the positive 
ion mode. 
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Figure 1.4.2 Electrospray ionization. This figure shows the delivery of sample to the 
mass spectrometer through  a needle  with a potential difference applied (a). Charge 
separation occurs at the tapered end of the needle (b) producing a Taylor cone. Droplets 
are formed with excess charge on their surface (c). Drops divide by coulomb fission 
(d). Ions free from solvent are produced by the combined effects of coulomb fission 
and  ion  evaporation  (e).  Multiply  charged  ions  are  directed  toward  the  mass 
spectrometer by an applied electric field (f).  
 
 
1.4.3 Mass analysers 
Mass analysers separate ions according to their mass-to-charge ratios. This is based on 
the  dynamics  of  charged  particles  in  electric  and  magnetic  fields  in  vacuum.  The 
preferred  analysers  used  for  investigation  of  biological  samples  are  time-of-flight 
(TOF), quadrupole (Q), ion trap (IT), fourier transform ion cyclotron resonance (FT-
ICR) and the orbitrap. 
a b
c
d
e f
High voltage
a b
c
d
e f
High voltage
+
+
+
+
+
+
+
+ +
+
+ + +
+ + -
- -
+
-
++
+
+
+ + +
+ +
High voltage 2-5 kV
ESI solution >
Mass spec >
a b
c
d
e f
High voltage
a b
c
d
e f
High voltage
+
+
+
+
+
+
+
+ +
+
+ + +
+ + -
- -
+
-
++
+
+
+ + +
+ +
a b
c
d
e f
High voltage
a b
c
d
e f
High voltage
+
+
+
+
+
+
+
+ +
+
+ + +
+ + -
- -
+
-
++
+
+
+ + +
+ +
a b
c
d
e f
High voltage
a b
c
d
e f
High voltage
+
+
+
+
+
+
+
+ +
+
+
a b
c
d
e f
High voltage
a b
c
d
e f
High voltage
+
+
+
+
+
+
+
+ +
+
+
a b
c
d
e f
High voltage
a b
c
d
e f
High voltage
a b
c
d
e f
High voltage
a b
c
d
e f
High voltage
+
+
+
+
+
+
+
+ +
+
+ +
+
+
+
+
+
+
+ +
+
+ + +
+ + -
- -
+
-
++
+
+
+ + +
+ + +
+ + -
- -
+
-
++
+
+
+ + +
+ +
High voltage 2-5 kV
ESI solution >
Mass spec >  63 
Whole protein analysis is primarily conducted on TOF and FT-ICR machines because 
of  their  high  mass  range  and,  in  the  case  of  the  FT-ICR,  its  high  mass  accuracy. 
Alternatively,  enzymatic  digestion  of  whole  proteins  into  smaller  peptides  with  a 
sequence-specific protease such as trypsin is widely used for peptide mass analysis 
with the quadrupole and ion trap analysers, which are better suited for the analysis of 
these lower mass analytes. In addition, peptides are more readily ionized than their 
larger protein precursors and knowledge of the protease cleavage sites is valuable in 
providing sequence information for identification. 
 
1.4.3.1 Quadrupole mass analysers 
A quadrupole mass analyser is the component of the instrument responsible for filtering 
sample ions based on their m/z ratio and is capable of transmitting only the ion of 
choice. In essence, a quadrupole mass analyser is composed of four parallel metal rods. 
Each opposing pair is connected together by direct current (DC) and radio frequency 
(RF) voltages. One pair of opposite rods has negative DC voltage, while the other pair 
has positive charge. The DC voltage is superimposed on the RF voltage and at specific 
voltage settings the trajectory of ions with a defined m/z value will be stable and only 
these reach the detector, while the trajectory of ions with other m/z values become 
unstable  and  are  diverted  to  the  rods.  A  mass  spectrum  is  obtained  by  a  scanning 
mechanism  that  alternates  the  voltages  such  that  ions  with  only  one  m/z  value  are 
transmitted at a time and the ion signals added together for the whole scan range. 
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1.4.3.2 Ion traps 
Ion  trap  mass  analysers  consist  of  a  ring  electrode  separating  two  hemispherical 
electrodes.  Ions  created  by  electron  impact  (EI),  electrospray  ionisation  (ESI)  or 
matrix-assisted laser desorption ionisation (MALDI) are focused using an electrostatic 
lensing system into the trap. An electrostatic gate pulses open (-V) and closed (+V) to 
inject ions into the ion trap (ionisation period). The ring electrode RF potential and AC 
potential  of  constant  frequency  but  variable  amplitude,  produces  a  3D  quadrupolar 
potential field within the trap. This traps the ions in a stable oscillating trajectory. The 
exact motion of the ions is dependent on the voltage applied and their individual m/z 
ratios. Structural information is obtained by the application of a low amplitude AC 
resonance  signal  across  the  endcap  electrodes  causing  the  ions  kinetic  energies  to 
increase and leads to ion dissociation due to many collisions with the helium gas in the 
trap, known as collision-induced dissociation (CID). This causes fragmentation along 
the peptide backbone and a spectrum is generated by sequentially ejecting fragment 
ions from low m/z to high m/z by choosing amplitudes of the ring electrode potential 
that sequentially make ion trajectories unstable. Ions are ejected through holes in the 
endcap electrodes and detected using an electron multiplier. The sequential detection of 
parent  ions  and  their  subsequent  fragmentation  to  produce  smaller  product  ions  to 
confer  sequence  information  is  known as  tandem  mass-spectrometry  (MS/MS)  (see 
below).   65 
1.4.3.3 Orbitrap 
The LTQ Orbitrap XL is a hybrid FT mass spectrometer that combines a linear ion trap 
and a orbitrap mass analyser. An orbitrap mass analyser is an iontrap, however, neither 
RF voltages or magnetic fields, as found in conventional traps and FT-ICR instruments 
respectively, hold ions inside. Instead, an electrostatic field is applied to trap moving 
ions. In an orbitrap mass analyser, ions are focused by two concentric electrodes. The 
electrostatic field which is generated, forces ions to move in complex spiral patterns 
around the central electrode. The axial component of these ion oscillations is measured 
by a Fourier Transform resulting in an accurate reading of their m/z. As a result the 
device has very high resolution and high mass accuracy (Hu, Noll et al. 2005; Olsen, de 
Godoy et al. 2005; Makarov, Denisov et al. 2006; Perry, Cooks et al. 2008).  
 
This  mass  spectrometer  features  a  secondary  collision  cell  to  provide  additional 
flexibility  to  MS/MS  experiments.  Ions  can  be  selected  in  the  linear  ion  trap  and 
fragmented either in the ion trap (CID) or in the secondary collision cell. The ions are 
accumulated  in  a  RF-only  quadrupole  called  a  C-trap  before  being  pulsed  into  the 
orbitrap.  The  C-trap  stores  ions  and  also  carries  out  higher-energy  collision-
dissociation (HCD) (Makarov, Denisov et al. 2006; Olsen, Macek et al. 2007). The 
HCD collision cell offers improved sensitivity, signal-to-noise ratio and fragmentation 
efficiency ideally suited to isotopic labelling experiments (see below).  
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1.4.3.4 Time-of-flight analyzers 
Ions are separated by TOF on the basis of the time that ions take to travel from the ion 
source to the detector through  a field-free  region. Ionised species starting from the 
same position at the same time, accelerating by means of a constant electric field, have 
velocities related to their mass-to-charge ratio and their times of arrival at a detector 
directly indicate their masses. TOF offers an unlimited mass range creating a complex 
mass spectrum for each ionisation event (Fig 1.4.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure  1.4.3  TOF  separation.  Ions  that  are  given  an  initial  kinetic  energy  by  an 
extraction pulse, drift along the field-free drift zone where they are separated according 
to their m/z ratios. 
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TOF mass analysers are commonly used in conjunction with MALDI because of the 
pulsed nature of its ionisation (Griffin, Gygi et al. 2001). Ions formed have a varied 
energy distribution arising from their differences in initial kinetic energies, and because 
of  their  spatial  and  temporal  distributions.  For  these  reasons,  devices  have  been 
incorporated into modern TOF instruments that correct for these energy distributions. 
Ions are first allowed to expand into a field-free region in the source and after a user 
defined delay, a voltage pulse is applied to extract ions from the source. This process is 
known as delayed extraction. In addition, reflectrons (ion mirrors) correct the energy 
dispersion  of  ions  leaving  the  source  that  have  the  same  m/z  values.  The  primary 
structure of peptides can also be obtained through a process called post source decay 
(PSD). In this mode, an increased internal energy is deposited to the analyte resulting in 
fragmentation in the field-free region of the TOF analyser. The fragmentation pattern 
can be used to elucidate the primary structure of the peptide in the same way as for 
tandem mass spectrometry (described below), however is not always effective.  
 
1.4.3.5 Tandem mass spectrometry (MS/MS) 
Tandem  mass  spectrometry  of  peptides  involves  the  selection  of  parent  ions  for 
fragmentation  to  generate  smaller  product  ions  with  loss  of  amino  acids.  Two 
approaches  are  commonly  used,  post-source  decay  (PSD)  in  a  MALDI-TOF-MS 
instrument,  and  collision  induced  dissociation  (CID)  in  an  ESI-MS/MS  hybrid 
instrument  such  as  a  Q-TOF.  Peptides  fragment  in  a  specific  manner,  that  is,  the 
protonated molecules fragment along the peptide backbone, but also show some side-  68 
chain fragmentation with certain instruments. There are three types of bonds that can 
fragment along the polypeptide backbone, the NH-CH, CH-CO, and CO-NH bonds. 
Each bond breakage gives rise to two species, one charged and one neutral, only the 
charged molecules are analysed in the mass spectrometer (Fig 1.4.4).  
 
 
 
 
 
 
 
 
Figure 1.4.4 Nomenclature for the product ions generated in the fragmentation of 
peptide molecules by tandem mass spectrometry. 
 
 
Fragment ions generated with the charge retained on their N-terminus are denoted ‘a’, 
‘b’, and ‘c’ ions and where the charge is retained on the C-terminal fragment, ‘x’, ‘y’, 
and ‘z’ ions. The mass difference between ions in an ion series is then indicative of a 
particular amino acid residue. Analysis of peptide sequence by PSD can be done post 
peptide mass mapping. A parent ion is selected and further analysed by induced laser 
energy forcing the peptide to fragment. The advantage of this method is that several 
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parent ions can be selected from the same aliquot of sample applied onto the target. 
However, the mass spectra are often harder to interpret due to the complex ion mixtures 
generated. 
 
The commonly used method for fragmentation in tandem mass spectrometry is by CID. 
This is carried out in an instrument that contains more than one analyser. Selected ions 
are introduced into a collision cell, into which an inert gas is admitted to collide with 
parent ions and bring about their fragmentation before separation and detection in the 
second mass analyser (Fig 1.4.5). The masses of the fragment ions are measured and 
then matched against a database of theoretical fragment ions using the parental ion 
mass as a guide. In addition to accurate information on the sequence of a peptide and 
thus the identification of a protein, tandem mass spectrometry is also an important tool 
for  the  analysis  of  post-translational  modifications,  such  as  glycosylation, 
phosphorylation and acetylation (Havilio and Wool 2007). 
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Figure 1.4.5 Tandem mass spectrometry by CID.  A tandem mass spectrometer has 
two mass  analysers  connected via a collision cell. In normal scan  mode, ions with 
different m/z values produced at the source flow through the MS/MS instrument and 
are separated according to their m/z values so that an MS spectrum is recorded. In 
MS/MS scan mode, the first mass analyser (e.g. quadrupole) isolates a single ion which 
is then fragmented in the collision cell. The fragmented ions are subsequently separated 
according to their m/z values in the second mass analyser and recorded by a detector. 
 
 
In  conventional  electrospray  mass  spectrometry,  peptide  mixtures  are  often  pre-
separated  by  high  performance  liquid  chromatography  (HPLC)  before  direct 
introduction into the mass spectrometer through an electrospray device. This method 
allows peptides to be resolved according to their retention time on the column during 
chromatography with subsequent mass analysis. Separation is commonly achieved by 
reverse-phase chromatography (RP-HPLC) or strong cation-exchange chromatography 
(SCX-HPLC).    These  separation  methods  can  also  be  combined  offline  to  greatly 
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reduce  sample  complexity  for  accurate,  efficient  and  high-coverage  protein 
identification by mass spectrometry. In addition, HPLC is also used to remove excess 
salts  or  detergents  that  can  affect  the  ionisation  process  and  interfere  with  mass 
analysis. 
 
1.5 Protein Identification 
Protein analysis by mass spectrometry can be carried out by peptide mass mapping or 
by MS/MS-based peptide fragmentation approaches to generate sequence information. 
Peptide  mass  mapping,  or  peptide  mass  fingerprinting  (PMF)  uses  the  masses  of 
proteolytic  peptides  obtained  from  a  mass  analyser  which  are  searched  against  a 
theoretical database of predicted masses that would arise from a digestion of all known 
proteins (James, Quadroni et al. 1993). Numerous databases can be used, which contain 
theoretical  protein  cleavages  according  to  the  enzyme  of  choice  and  possible  post-
translational modifications and known chemical modifications (Henzel, Billeci et al. 
1993;  Mann,  Hojrup  et  al.  1993).  A  list  of  potential  matches  is  given  and  ranked 
according to a scoring system depending on best probability of a match being real. 
Confidence in the identification then depends on the species studied, the mass and pI of 
the protein observed on a gel, the number of peptides matching a particular protein 
sequence, the mass accuracy of detection, the protein sequence coverage reached, the 
number  of  missed  cleavages  during  the  proteolysis  process  and  also  the  type  of 
modifications observed, which can reflect how the sample is processed.  
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Peptide  mass  fingerprinting  is  the  method  of  analysis  used  with  MALDI-TOF-MS 
instrumentation. The production of singly charged ions [M
+H]
+ creates mass spectra 
which are simpler to assign. Sample analysis is more tolerant to salts and detergents as 
the sample crystallisation with the matrix allows a degree of sample purification. 
 
1.5.1 MS-based Peptide & Protein Quantification 
Methods 
Mass  spectrometry  has  largely  been  used  to  qualitatively  characterise  proteins  in 
complex mixtures. The emergence of quantitative mass spectrometry methodologies 
serves  to  enhance  our  understanding  of  biological  processes  and  facilitating  the 
identification of diagnostic and prognostic markers of disease. 
 
In the past, quantitative proteomics was largely based around 2DE experiments where 
the  staining  intensities  of  matched  protein  spots  from  two  or  more  samples  were 
compared and ‘up’ and ‘down-regulated’ proteins picked from gels and identified by 
MS. Protein staining also provides an indication of the amount of protein in a sample. 
More  recently,  quantification  in  2D  gels  has  become  more  sophisticated  with  the 
development  of  fluorophores  that  are  covalently  attached  to  proteins  before 
electrophoretic  separation  (2D-DIGE).  These  spectrally  distinct  dye  derivatives  are 
mass  and  charge  matched  allowing  samples  to  be  combined  and run  together  on  a 
single  gel  and  direct  comparisons  of  ratios  of  expression  obtained.  As  described   73 
previously, 2DE has several limitations; membrane proteins, basic proteins and very 
large proteins are poorly resolved, the dynamic range of detection often only covers 2-3 
orders of magnitude and sensitivity is somewhat limited. Thus only the “well-behaved” 
and abundant proteins will be detected on gels.  
 
In  recent  years,  with  improvements  in  the  accuracy,  sensitivity  and  speed  of  mass 
spectrometers efforts have been made to extract quantitative data from mass spectra 
(Han, Aslanian et al. 2008). Mass spectrometry is not inherently quantitative because 
proteolytic peptides exhibit a wide range of physiochemical properties such as charge, 
size  and  hydrophobicity  which  lead  to  differences  in  mass  spectrometric  output. 
Successful  detection  and  identification  of  protein-specific  peptides  confirm  their 
presence  in  a  sample.  However,  failure  to  identify  or  detect  a  peptide  does  not 
necessarily confirm absence from a sample as it may be below the detection limits or 
overlooked by data-dependent acquisition. Database search algorithms score proteins 
based  on  numbers  of  matching  sequence  fragments  rather  than  their  absolute 
intensities.  Therefore,  database  identification  scores  are  not  a  reflection  of  protein 
abundance although spectral counting has been shown to correlate with abundance. 
However,  peptide  quantification  has  been  developed  upon  the  basis  that  in  a  MS 
experiment,  the  intensity  of  a  signal  given  by  a  peptide  as  it  elutes  from  a 
chromatographic column can be plotted over time. The area under the curve is known 
as the extracted ion current (XIC) and for a given peptide and experimental conditions, 
is  linearly  related  to  its  amount,  although  absolute  quantitation  will  depend  on 
ionization efficiency and ion stability as well. If the two proteomes to be compared   74 
have  been  processed  in  tandem  and  analysed  in  exactly  the  same  way  then  the 
intensities  of  peptides  can  be  compared  between  the  two  states  to  determine  their 
relative abundance. The obvious advantage of this label-free quantification approach is 
its versatility since it can be applied to any type of sample with reduced processing/ 
labelling steps and associated costs (Wang, Wu et al. 2006). 
 
The use of stable-isotope labelling in proteomics for quantification has been adopted 
widely and applications vary in the method of isotope incorporation. Stable isotope 
atoms impart a mass shift, allowing ‘heavy’ and ‘light’ peptides to be distinguished and 
quantitative  ratios  to  be  determined  from  their  signal  intensities.  This  approach 
eliminates quantification error introduced by experimental procedure because the exact 
same experimental conditions prevail for both peptide forms.  
 
The  chemical  synthesis  of  a  stable  isotope-labelled  peptide  analogue  and  a  known 
quantity ‘spiked’ into a sample serves as an internal standard in a MS experiment. This 
results in absolute quantification (AQUA), as the signal intensities are compared for the 
native peptide and ‘heavy’ analogue (Gerber, Kettenbach et al. 2007). AQUA has an 
important role in multiple reaction monitoring (MRM), where a predefined precursor 
ion and one of its fragments are selected by the two mass filters of a triple quadrupole 
instrument  and  monitored  over  time  for  precise  quantification  (Kuhn  et  al.  2004, 
Kirkpatrick et al. 2005). The AQUA strategy has also shown use for profiling protein 
post-translational modifications (Gerber, Rush et al. 2003).    75 
Stable isotopes for quantitation can be also introduced into peptides by the action of a 
protease.  If  the  digestion  is  performed  in  H2
18O  water,  two 
18O  atoms  will  be 
incorporated into the carboxy terminus of each new peptide. The incorporation results 
in a mass shift of 2 or 4 Da between ‘heavy’ and ‘light’ peptides allowing their signal 
intensities  to  be  differentiated  and  their  quantitative  ratios  determined  (Goshe  and 
Smith 2003). 
 
Another  approach  to  introduce  stable-isotope  labels  is  to  chemically  modify  two 
proteomes of interest with  ‘heavy’ and ‘light’ chemical labels. In the past, isotope-
coded affinity tags (ICAT) were developed consisting of a cysteine reactive moiety, a 
linker region with eight deuteriums, and a biotin group to facilitate recovery of labelled 
peptides. A typical ICAT experiment would involve the denaturing and reduction of the 
two extracted proteomes under study prior to labelling of cysteine residues with either 
the ‘heavy’ or ‘light’ reagent. The proteomes are then mixed, digested and labelled 
peptides enriched on a streptavidin column. The cysteine containing peptides are eluted 
from the column and subsequently analysed by MS (Bottari, Aebersold et al. 2004; Yi 
and Goodlett 2004). This can be advantageous where complex proteomes are being 
analysed. A disadvantage is the relative abundance of cysteine groups, some proteins 
contain no cysteine residues and others will have to be quantified on the basis of a 
single peptide. This approach has not generally been applied. 
 
More recently, the primary amines on peptides have been targeted for labelling.  By 
this  approach  it  should  be  possible  to  obtain  quantitative  data  on  every  peptide   76 
detected.  Isobaric  tags  for  relative  and  absolute  quantitation  (iTRAQ)  uses  N-
hydroxysuccinimide ester chemistry to add a tag which contains a balance group linked 
to a reporter group that is only revealed upon MS/MS fragmentation (Gagne, Gagne et 
al. 2005; Zhang, Wolf-Yadlin et al. 2005; Aggarwal, Choe et al. 2006; Unwin, Smith et 
al. 2006; Bantscheff, Boesche et al. 2008; Quaglia, Pritchard et al. 2008). Tags have 
been developed with different reporter ion masses, but through their carbonyl balance 
group have identical mass. Peptides from proteomes under comparison can be labelled 
with up to 8 different isobaric tags, combined and analysed by MS. Fragmentation of 
the tags attached to the peptides generates a low molecular mass reporter ion that is 
unique to the tag used to label each digested sample. Measurement of the intensity of 
these reporter ions enables relative quantitation of peptides in each digest and hence 
protein in the original sample. A major advantage of iTRAQ is multiplexing, allowing 
for up to 8 labelled pools of protein in a single analysis. Furthermore, it will allow 
identification of any type of protein, including high molecular weight proteins, acidic 
protein,  and  basic  proteins,  all  of  which  are  problematic  when  using  alternative 
methods  such  as  2D-DIGE.  Furthermore,  2D-DIGE  is  not  particularly  useful  for 
resolving  insoluble  proteins  such  as  membrane  proteins,  but  coupling  the  iTRAQ 
labelling system and MS can at least partially solve this problem.  
 
Recently,  Tandem  Mass  Tags  (TMT)  have  become  commercially  available,  taking 
advantage of the principle described above (Fig 1.5.1).  
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Figure 1.5.1 TMT quantitative protein expression profiling. A) Structural design of 
TMT  tags.  The  mass  reporter  is  released  from  the  cleavable  linker  under  MS/MS 
fragmentation conditions. Each  tag  has  a unique  mass normalizer  that balances  the 
mass reporter, ensuring the same overall mass for all tags in a set. The protein reactive 
group is an NHS ester that reacts with primary amino groups. B) Analysis of a TMT-6 
labelled peptide by HCD. MS/MS fragmentation spectra with reporter ions highlighted 
in red. C) Close-up of reporter ion region. Individual ion intensities for the 6 reporter 
ion masses.  
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Like iTRAQ, these are amino-group labelling isobaric tags and labelled peptides will 
co-migrate in chromatographic separations (Dayon, Hainard et al. 2008). These mass 
tags  are  currently  available  in  2,  4  and  6-plex  forms  and were  used  in  the  project 
described here.  
 
Tandem Mass Tags (TMT) comprise a ‘reactive group’ with a primary amine reactive 
N-hydroxysuccinimide ester (NHS-ester); a ‘mass normalization’ group that ensures 
that each tag shares the same overall mass and a fragmentation susceptible reporter 
group with a specific mass-to-charge ratio. Their chemical structure is composed of a 
combination of five heavy isotopes (
13C or 
15N) in the reporter group and five heavy 
isotopes (
13C or 
15N) in the mass normaliser group to produce 6 isobaric tags for the 
comparison of up to 6 different protein extracts in a single run. Quantification relies on 
CID/HCD to release the reporter ions from labelled peptides, which are detected in the 
low  mass  range  and  used  to  report  relative  peptide  expression  levels  following 
fragmentation. The 6-plex tags contain unique reporter ion masses in the range m/z 
126.1 to 131.1.  
 
To handle and interrogate the very large datasets produced during quantitative mass 
spectrometry-based experiments several software solutions are available. ThermoFisher 
offer Bioworks 3.3 to handle all the major quantitative labelling techniques including 
iTRAQ,  TMT,  SILAC  and  ICAT.  Relative  expression  ratios  are  reported  for  the 
peptides of a given protein. Bioworks uses the Sequest algorithm for identification of 
peptides  and  proteins.  More  recently,  ThermoFisher  has  developed  Proteome   79 
Discoverer  to  handle  iTRAQ  and  TMT  labelling  techniques  using  the  Sequest  and 
Mascot algorithms for peptide and protein identification. In addition it can determine 
false discovery rates for validation of protein identifications. Mascot 2.2 by  Matrix 
Science offers reporter, multiplex and exponentially modified protein abundance index 
(emPAI)  quantitative  methodologies.  Reporter  quantitation  is  based  on  the  relative 
intensities of fragment peaks at fixed m/z values within a MS/MS spectrum, e.g. 114 
and 115 for iTRAQ. Multiplex quantitation relies on the relative intensities of sequence 
ion fragment peaks within an MS/MS spectrum. EmPAI is a label-free quantitation 
method based on protein coverage by the peptide matches in a database search result. 
Peptide and protein identifications are assigned using the  Masocot  algorithm.  False 
discovery values are calculated for all database searches. 
 
Finally, a widely used method of stable-isotope incorporation is by metabolic labelling 
in vivo. A whole proteome can be stable-isotope labelled before an MS experiment. 
This is achieved by introducing isotopic metabolic precursors into the growth media of 
living cells. During cell growth and protein turnover the isotope labelled precursors are 
incorporated into all cellular proteins. Stable isotope labelling by amino acids in cell 
culture  (SILAC)  is  emerging  as  a  very  effective  approach  for  quantitative  MS 
experiments (Ong,  Blagoev  et  al.  2002;  Everley,  Krijgsveld  et  al.  2004;  Amanchy, 
Kalume et al. 2005; Uitto, Lance et al. 2007). The amino acids arginine and lysine in 
the labelling media contain 
13C to ensure that each tryptic cleavage product contains at 
least one heavy amino acid after tryptic cleavage that confers a mass shift to distinguish 
between the ‘heavy’ and ‘light’ labelled cell populations. Typically, after several cell   80 
population doublings, the cellular proteome will incorporate the ‘heavy’ amino acids to 
>90%. The two cell populations grown in either ‘heavy’ or ‘light’ media can then be 
combined at the earliest stage of any fractionation and digestion procedure for more 
accurate quantitative MS (Fig 1.5.2). 
 
   
  
  
  
  
  
  
  
  
  
  
 
Figure  1.5.2  SILAC  experimental  workflow.  Two  groups  of  cells  are  grown  in 
culture media that are identical except in one respect; one media contains the ‘light’ 
and the other a ‘heavy’ form of a particular amino acid e.g. leucine or lysine. Cell 
passaging results in the incorporation of > 90 % of the ‘heavy’ or ‘light’ form of the 
amino  acid.  The  cells  are  harvested,  mixed  and  digested  with  trypsin.  Quantitative 
information is extracted from the ‘heavy’ and ‘light’ parent ions for a given peptide.  
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 More recently, 
15N labelling of simple organisms through the use of 
15N-ammonium 
salts results in the complete labelling of amino acids within the cells. In turn, these 
micorooganisms such as 
15N-labelled algae can be fed to small mammals. Kruger M. et 
al. have fed mice with a 
13C6-lysine diet. No adverse effects have been observed on 
feeding and growth, fertility or activity, or development and physiology over several 
generations of SILAC labelling (Kruger, Moser et al. 2008). Stable-isotope labelled 
mice  have  been  produced  with  complete  incorporation.  The  limiting  factor  to  this 
approach is currently the high costs involved.   
 
 
 
 
 
 
 
 
 
 
 
 
   82 
1.6 Aims 
Epithelial ovarian cancer is the most lethal form of gynaecological malignancy in the 
western world. At present there is no reliable and specific method of early detection 
and robust biomarkers for the disease are urgently required. In addition, the molecular 
changes  associated  with  ovarian  cancer  development  and  progression  are  poorly 
understood.  The  major  aim  of  this  project  was  to  identify  the  protein  changes 
associated with suppression of the tumourigenic phenotype in epithelial ovarian cancer 
cell  models.  This  work  would  hopefully  not  only  identify  candidate  biomarkers  of 
ovarian cancer, but also increase our understanding of the protein changes associated 
with reconstitution of normal human chromosome 18  material that contain putative 
tumour suppressor genes.  
 
The  cellular,  secreted  and  surface  proteomes  will  be  probed  in  order  to  gain  a 
comprehensive  coverage  of  protein  changes.  Cell  surface  and  secreted  proteins  are 
important  not  only  in  normal  cell  physiology  (e.g.  cell-cell  signalling,  cellular 
adhesion, migration, morphogenesis and ionic conductance) but also in cancer (e.g. 
controlling many characteristics of malignancy including proliferation, angiogenesis, 
tissue invasion, and metastasis). These proteins may be important cancer biomarkers 
for  diagnostic  blood  screening  tests  and  targets  for  small  molecule  inhibitors  and 
monoclonal antibody therapies.  
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The  project  involves  a  detailed  quantitative  proteomic  comparison  of  two  parental 
ovarian cancer cell lines derived from primary endometrioid and clear cell carcinomas 
and their MMCT Ch18 hybrids (see section 1.3) (Dafou, Ramus et al. 2009). These cell 
lines have been well characterised with regards to their tumourigenic phenotype. The 
parental  cell  lines  displayed  the  characteristic  of  transformed  cell  lines whilst  their 
hybrid  clones  displayed  significant  suppression  of  this  phenotype  in  a  number  of 
assays.  Firstly, the cellular and secreted proteomes were examined by 2D-DIGE and 
differentially  expressed  proteins  identified  by  (MS)  directly  from  gels.  The  same 
fractions were also analysed using multiple dimensional LC combined with MS/MS 
and Tandem Mass Tagging (TMT) for quantification. TMT has only recently become 
commercially available and enables protein expression levels to be determined in up to 
6  samples  simultaneously  from  peptide-specific  reporter  ion  intensities  produced 
during fragmentation, as with the iTRAQ technology. The cell surface proteome was 
also examined by NHS-biotin surface labelling and streptavidin enrichment linked to 
1D-SDS-PAGE,  2D-LC  and  TMT-based  identification  and  quantitation.  For 
confirmation of changes and assessment of strategy, altered proteins will be analysed 
by western blotting and ELISA. To summarise, the aims of this research project are: 
 
·  To identify the protein changes associated with tumour suppression in epithelial 
ovarian cancer Chromosome 18 MMCT cell models. The cellular, secreted and 
surface proteomes were probed in order to gain a comprehensive coverage of 
the  protein  altered.  Enrichment  strategies  for  the  ‘secreted’  and  ‘surface’   84 
proteome were developed, optimized and coupled to a quantitative proteomic 
technique for protein expression profiling.   
 
·  To  evaluate  the  similarities  and  differences  between  the  different  proteomic 
technologies used within the context of the biological questions that the project 
aims to answer.  
 
·  To validate expression changes of proteins of interest by western blot analysis 
of the parental cell lines, and their Ch18 hybrids and revertant cell lines, where 
the selection conditions are no longer applied and transferred Ch18 material is 
lost from cells. To address the potential of candidates as biomarkers of ovarian 
cancer by examining expression in other ovarian cancer cell lines and normal 
ovarian surface epithelial cells and in serum from malignant and benign cases of 
ovarian cancer and healthy controls. 
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Chapter 2 Materials & Methods 
2.1 Cell Lines 
The ovarian cancer cell lines, TOV-112D and TOV-21G (American Tissue Culture 
Collection,  LGC  Standards,  Middlesex,  UK)  were  fused  with  monochromosome 
hybrids  (chromosome  18  tagged  with  hygromycin  phosphotransferase  selectable 
marker) in mouse A9 cells. Micronucleation was achieved by exposure to colcemid for 
48 hours. Post-fusion, hybrid clones were isolated and expanded in complete culture 
medium containing 400U/ml hygromycin B to maintain the transferred Ch18 material 
(Gynaecological  Cancer  Research  Laboratory,  IFWH,  UCL  (Dafou,  Ramus  et  al. 
2009)). Revertant cell lines were isolated by culturing hybrid clones in the presence of 
ganciclovir.  Ganciclovir-resistant  clones  with  the  loss  of  transferred  Ch18  were 
selected. A panel of ovarian cancer cell lines including Cov413b, PE014, Intov2, Jaue 
2, OvP1, OvcaX, Skov3, IgOV, Ovca3, Cov624, PxN94, 847AD, 41D, Cov318, LK2, 
OAW42M, 1847, Cov664, OAW41M and NOSE cell lines including NOSE4p5 and 
NOSE11p5  were  obtained  from  the  ATCC  and  cultured  under  recommended 
conditions. 
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2.2 Tissue Culture 
Parental ovarian cancer epithelial cell lines TOV-112D and TOV-21G were maintained 
in MCB105 and 199 media (Sigma, St Louis, MO) at 1:1 ratio containing 15% (v/v) 
foetal  calf  serum  (FCS),  supplemented  with  2  mM  L-glutamine,  100  mg/ml 
streptomycin and 100 unit/ml penicillin (Invitrogen, Paisley) in tissue culture dishes at 
37°C in a 5% CO2 humidified incubator. The hybrid cell lines, 18-G-5, 18-G-1-26, 18-
D-22 and 18-D-23 were cultured under the same conditions with an additional 400 
U/ml  of  hygromycin  to  maintain  clonal  selection.  Cells  were  passaged  when  they 
reached 70-80% confluence by trypsinisation according to standard procedures. Stocks 
of epithelial cells were stored in 10% DMSO and 90% FCS, frozen slowly overnight 
and submerged in liquid nitrogen for long-term storage.  
 
2.3 Extraction of total cell proteins 
Cells at 80% confluency were washed twice with phosphate buffered saline (PBS), 
drained well and cells lysed in 2D lysis buffer (4% (w/v) CHAPS, 0.5% NP40, 8 M 
urea, 2 M thiourea, 10 mM Tris-HCl (pH 8.3), 1 mM EDTA) and scraped. Samples 
were  homogenized  by  passage  through  a  25-gauge  needle  (4  times)  and  insoluble 
material removed by centrifugation (13,000 rpm/10 min/4°C). Protein concentrations 
were determined using a Bradford microtitre plate assay (Pierce). Standard curves were 
determined using dilutions of bovine serum albumin (BSA) and samples were assayed 
in triplicate.   87 
2.4 Preparation of secreted proteins 
For preparation of the secretome, cells at 80% confluence were washed twice in PBS 
and  further  incubated  for  24  hours  in  serum-free  medium.  The  medium  was  then 
replaced with 10 ml of fresh serum-free medium which was collected after a further 24 
hours  and  chilled  on  ice.  Floating  cells  and  cellular  debris  were  removed  by 
centrifugation (2000 g, 10 min). Protease inhibitors were added (100  g/ml AEBSF, 17 
 g/ml aprotinin, 1  g/ml leupeptin and 1  g/ml pepstatin) and the sample concentrated 
(25-fold)  and  desalted  by  ultrafiltration  through  centriplus  YM-3  filters  (MWCO 
3kDa). The samples were dried down in a speed vac and resuspended in 100  l of 2D 
lysis buffer. Protein concentrations were determined as above. 
 
2.5 Crude membrane preparation 
Cells were harvested in 1 ml of hypotonic buffer (10 mM HEPES pH 7.4, 5 mM KCl, 5 
mM MgCl2) prior to homogenisation with a Dounce homogeniser (at least 25 strokes). 
A crude nuclear fraction was prepared by centrifugation for 5 min at 800 g using a 
bench top centrifuge. The supernatant was centrifuged at 100,000 g using an Optima 
ultracentrifuge (Beckman Coulter, Inc., USA) for 60 min enabling the separation of a 
cytosolic supernatant fraction (S100) and a crude membrane fraction (P100). P100 was 
washed in hypotonic buffer and the final pellet was resuspended in 1 mL RIPA buffer 
(150  mM  NaCl,  10  mM  Tris  (pH  7.4),  0.1%  SDS,  1%  NP40,  0.5%  sodium 
deoxycholate,  5  mM  EDTA  with  protease  and  phosphatase  inhibitors  (100µg/mL   88 
AEBSF, 17µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 5µM BpVphen, 
5µM fenvalerate, 1 µM okadaic acid).  
 
2.6 Biotinylation of EOC Cell Surface Proteins 
Cells in four 15 cm tissue culture dishes at 80% confluency were washed twice in PBS 
and incubated for a further 24 hours in serum-free media. The media was removed and 
the  cells  washed  twice  with  PBS  before  labelling  with  0.3  mg/mL  Sulfo-NHS-SS-
Biotin  (Pierce)  in  PBS  for  30  minutes  on  ice.  Excess  label  was  removed  by  three 
washes in PBS. Cells were gently scraped into solution and washed in Tris buffered 
saline (TBS) 3 times to remove cellular material from damaged cells before a final 
centrifugation at 500 x g for 3 minutes. The cell pellet was lysed in 1 mL RIPA buffer 
(150  mM  NaCl,  10  mM  Tris  (pH  7.4),  0.1%  SDS,  1%  NP40,  0.5%  sodium 
deoxycholate,  5  mM  EDTA  with  protease  and  phosphatase  inhibitors  (100µg/mL 
AEBSF, 17µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 5µM BpVphen, 
5µM fenvalerate, 1 µM okadaic acid). Samples were homogenized by passage through 
a 25-gauge needle (4 times) and insoluble material removed by centrifugation (13,000 
rpm/10 min/4°C). Protein concentrations were determined with a BCA microtitre plate 
assay (Pierce) using BSA as a standard. Yields were less than expected because of cell 
loss during the washing stages. Streptavidin-agarose slurry (100 µL of 50% slurry) 
washed in RIPA buffer was incubated for 2 hours at 4ºC then washed 5 times with 
RIPA buffer and then twice with PBS. Captured proteins were eluted with Laemmli 
sample  buffer  (50  mM  Tris  pH  6.8,  10%  (v/v)  glycerol,  2%  SDS  (w/v),  2%  β-  89 
mercaptoethanol, 0.1% (w/v) bromophenol blue) by heating for 5 min at 100°C and the 
eluate  collected.  Elution  by  cleavage  with  DTT  of  the  disulphide  bond  linking  the 
biotin moiety and the protein with the cleavable reagent was investigated by 1D-gel 
analysis but found to result in poor yields compared to elution in Laemmli sample 
buffer.  
 
2.7 Protein labelling with Cy Dyes for 2D-DIGE 
Samples (typically 100  g protein) in 2D lysis buffer were labelled with NHS-Cyanine 
(Cy) dyes, at a dye to protein ratio of 4 pmol of dye/µg of protein on ice for 30 minutes 
in the dark (Cy2 dye was obtained from GE Healthcare, Cy3 and Cy5 were synthesized 
in-house, as outlined by Chan et al. 2005). A standard pool was prepared by mixing 
equal amounts of protein from each condition and labelled with Cy2. Reactions were 
quenched by adding a 20-fold molar excess of L-lysine to dye and incubating on ice for 
10 min in the dark. Equal protein amounts from pairs of differentially labelled samples 
and  Cy2  labelled  standard  were  mixed  appropriately  and  reduced  by  addition  of 
dithiothreitol  (DTT)  to  65  mM.  Carrier  ampholines  and  pharmalyte  mix  (1:1)  was 
added to a final concentration of 2% (v/v) and bromophenol blue to 0.001% (v/v). The 
final volume was made up to 450 µL with 2D lysis buffer plus DTT for rehydration of 
Immobiline (IPG) dry strip (IEF) gels (GE Healthcare).  
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2.8 Protein separation by 2D gel electrophoresis and 
gel imaging 
The  IPG  strips  (24  cm  Non  Linear  pH  3-10,  GE  Heathcare)  were  rehydrated  with 
labelled  samples  in  the  dark  overnight  according  to  the  manufacturer’s  guidelines. 
Isoelectric focussing was performed using a Multiphore II apparatus (GE Healthcare) 
for a total of 80 kVh at 16°C. Strips were equilibrated for 15 min in equilibration buffer 
(6 M urea, 30% (v/v) glycerol, 50 mM Tris-HCl pH 6.8, 2% (w/v) SDS) containing 65 
mM DTT and then for 15 min in the same buffer containing 240 mM iodoacetamide. 
Equilibrated strips were transferred to 12% uniform polyacrylamide gels cast between 
20  x  24  cm  low-fluorescence  glass  plates.  Gels  were  bonded  to  the  inner  plate  at 
casting using bind saline (PlusOne) according to the manufacturer’s guidelines. Strips 
were overlaid with 0.5% (w/v) low melting point agarose in running buffer containing 
bromophenol blue. Gels were run in an Ettan Dalt 12 gel tank at 16°C and 2.2 W until 
the dye front had run off the bottom of the gels. 
 
Gels were scanned on a Typhoon
TM 9400 multi-wavelength fluorescence imager (GE 
Healthcare). The photomultiplier tube voltage was adjusted on each channel (Cy2, 3 
and 5) for preliminary low resolution scans (1000 mm) to give maximum pixel values 
within 10% for each channel but below saturation level. A final high-resolution scan 
(100  mm)  was  performed  and  the  images  cropped  in  ImageQuant  software  and 
exported into DeCyder software for image analysis. 
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2.9 Image analysis 
Images  were  curated  and  analysed  using  Decyder  software  (GE  Healthcare).  This 
consists  of  two  modules,  the  differential  in  gel  analysis  (DIA)  module  and  the 
biological  variance  analysis  (BVA)  module.  DIA  performs  spot  detection  and 
calculates spot volumes/abundances for the three images (Cy2, 3 and 5) from a single 
gel and performs normalisation. In BVA, spots are manually matched between multiple 
samples across all the gel images in an experiment. This allows statistical analysis of 
changes  in  abundance  across  samples.  The internal  standard  was employed  here  to 
facilitate  spot  matching  and  allow  a  spot  by  spot  standardisation  for  improved 
reproducibility  and  accurate  quantitation  of  protein  abundance  changes  across  the 
samples.  A  student  t-test  was  performed  whereby  average  standardised  abundances 
from  replicate  samples  were  compared  across  the  different  conditions  being  tested. 
Spots displaying significant changes in abundance were then filtered by specifying a 
threshold of average-fold change with P values of <0.05. Pick lists for spots of interest 
were created from colloidal coomassie blue post-stained images of the same gels which 
were matched with the Cy Dye images in Decyder where peak lists were created and 
exported to an Ettan spot picking robot (GE Healthcare).  
 
2.10 Colloidal Coomassie Blue staining 
Bonded gels were fixed in 35% (v/v) ethanol with 2% (v/v) phosphoric acid overnight 
and then washed three times for 30 min in ddH2O. The gels were then incubated in 
34% (v/v) methanol with 17% (w/v) ammonium sulphate and 3% (v/v) phosphoric acid   92 
for 1 hour prior to the addition of 0.5g/L Coomassie G-250 (Merck), and left to stain 
for 2-3 days. Stained gels were scanned on the Typhoon 9400 scanner using the red 
laser with no emission filter. A similar procedure was followed for unbonded 1D gels, 
except that the washing and staining times were reduced. 
 
2.11 SYPRO Ruby fluorescence staining 
SYPRO  Ruby  fluorescent  protein  stain  (Molecular  Probes,  USA)  was  used  as  an 
alternative  post-staining  technique  with  2D-gels  for  its  increased  sensitivity  where 
protein loads were less. Following electrophoresis, gels were fixed for at least 3 hours 
in  fixing  solution  (30%  (v/v)  methanol,  7.5%  (v/v)  acetic  acid,  in  ddH2O).  Lower 
concentrations of methanol and acetic acid were used in order to avoid shrinkage and 
cracking  of  bonded  gels.  Gels  were  washed  twice  in  water  and  then  incubated  in 
SYPRO Ruby staining solution for a minimum of 3 hours in the dark. Gels were then 
washed  briefly  in  water  to  remove  excess  dye.  Gels  were  then  scanned  on  the 
Typhoon
TM 9400 scanner 
 
2.12 Spot Picking and Trypsin Digestion 
Spots were excised from gels using an Ettan spot picker (GE Healthcare) with a 2 mm 
picking head. For in-gel digestion, gel pieces were washed three times in 50% (v/v) 
acetonitrile (ACN), dried in a SpeedVac for 10 min, reduced in 10 mM dithiothreitol in 
5 mM ammonium bicarbonate (AmBic) pH 8.0 for 45 min at 50°C and then alkylated   93 
with 50 mM iodoacetamide in AmBic for 1 h at room temperature in the dark. Gel 
pieces were then washed twice in 50% ACN and vacuum dried. 50 ng of sequencing 
grade modified trypsin (Promega, Southampton, UK) in 5 mM AmBic was added to 
each dried gel piece and pieces were allowed to re-swell for 5 min. 5 mL of 5 mM 
AmBic was then overlaid onto the gel pieces and the samples incubated at 37°C for at 
least 18 hours. Tryptic peptides were then extracted three times with 50% (v/v) ACN 
plus  5%  (v/v)  trifluoroacetic  acid,  the  extracts  pooled  and  vacuum  centrifuged  to 
dryness. Peptides were  finally resuspended in 5 mL of 0.1% (v/v) formic acid and 
stored at –20°C prior to mass spectrometric analysis. 
 
2.13 MALDI-TOF MS and Peptide Mass Fingerprinting 
Routinely, 0.5 mL of tryptic digest was mixed with 1 µL of matrix solution (saturated 
aqueous 2,5-dihydroxybenzoic acid (DHB)) and spotted onto a target plate and left to 
dry. MALDI-TOF mass spectra were acquired using an Ultraflex mass spectrometer 
(Bruker Daltonik, Bremen, Germany) in the reflector mode. The mass spectrometer 
was calibrated with external standards using a standard mixture of peptides prior to 
aquisition.  Internal  calibration  was  carried  out  using  trypsin  autolysis  peaks  at  m/z 
842.51 and m/z 2211.10. Spectra were collected in the m/z range 500-4000 to generate 
a  peptide  mass  fingerprint.  Spectra  were  processed  using  FlexAnalysis  software 
(BrukerDaltronics). The  mass  lists  were  extracted  from  Ultraflex data  files  using  a 
Pearl  script  written  in-house,  UltraMass  List, 
(http://www.ludwig.ucl.ac.uk/bachem_html/software.html).  Mascot  search  engine,   94 
version  2.0.02  (Matrix  Science,  UK)  was  used  for  database  searching.  For  search 
criteria, carbamidomethylation of cysteines was selected as a fixed modification, while 
oxidation on methionine, N-acetylation and pyro-glutamate were selected as variable 
modifications.  A  positive  identification  was  accepted  when  ≥6  peptides  masses 
matched a particular protein (mass error of ±50 ppm, allowing 2 missed cleavage), 
sequence  coverage  was >25%,  MOWSE  scores  were  higher  than  a  threshold  value 
where p=0.05 and predicted protein mass matched the gel-based location.  
 
2.14 TMT labelling 
An equal amount of protein (25-100 µg) from each cell line was resuspended in 90 mM 
triethylammoniumbicarbonate  (TEAB)  and  then  reduced,  alkylated,  digested  and 
labelled according to the standard protocol supplied by the manufacturer (TMT 6plex 
Label Reagent, Thermo Scientific). Briefly, the protein sample was solubilised in 90 
mM TEAB and 0.5% SDS before reducing with 9.5 mM tris(2-carboxyethyl)phosphine 
(TCEP) for 1 hour at 55ºC and then alkylated with 17 mM iodoacetamide (IAM) for 30 
minutes in the dark. The sample was digested with trypsin (2.5 µg/100 µg protein) 
overnight at 37ºC. The TMT labels were reconstituted prior to labelling with 41 µl of 
ACN  and  added  to  the  appropriate  sample  for  labelling  over  1  hour  at  room 
temperature.  TMT  results  were  generated  from  the  analysis  of  isobaric  tag 
combinations. The parental cell line TOV-112D was labelled with reagent 126 and its 
hybrid  cell  lines,  18-D-22  and  18-D-23,  labelled  with  reagents  127  and  128 
respectively. The parental cell line TOV-21G was labelled with reagent 129 and its   95 
hybrid  cell  lines,  18-G-5  and  18-G-1.26,  labelled  with  reagents  130  and  131 
respectively. 
  
2.15 SCX Chromatography 
Tryptic peptides were fractionated by strong cation exchange (SCX).  TMT-labelled 
digests  were  combined  and  dried  down  in  a  Speedvac,  resuspended  in  buffer  A 
(95%/5%  water/ACN,  5  mM  NaH2PO4  buffer  pH=3)  and  acidified  (pH  2)  before 
injection (50 µg) onto a Polysulfoethyl column (1 mm  I.D x 15 cm, 5 µm, 300Å) 
(PolyLC, Columbia, MD) using an Ultimate 3000 LC system. The column was allowed 
to equilibrate for 25 min in buffer A before injection. A gradient was applied of 5-55 % 
B (mobile phase A + 1M NaCl) at 50 µl/min in 30 minutes using the loading pump and 
fractions of 150 µl were collected every 3 minutes.  
 
2.16 Sample clean-up using C18 pre-packed tips 
Samples were de-salted after SCX using the ‘ZipTip’ protocol. The clean-up is based 
on reverse phase LC using ZipTips (Millipore). The C18 packing material was wetted 3 
times with 10 µL of 50 % ACN using a standard 10 µL Gilson pipette. The C18 tip was 
then washed 3 times with 0.5 % TFA. The sample solution was then passed over the 
packing material a minimum of 10 times by aspirating and dispensing with care not to 
create air bubbles. The C18 tip was then washed 3 times with 0.5 % TFA. Finally, the   96 
sample was eluted from the packing material by aspirating and dispensing 10 µL of 
50% ACN/0.5% TFA 10 times before collection in a siliconised tube for drying down. 
 
2.17 Liquid Chromatography Tandem MS (LC-MS/MS) 
Tandem MS analyses of WCL proteins isolated from DIGE gels were performed by 
nanoflow  capillary  reversed-phase  liquid  chromatography  coupled  on-line  to 
electrospray  quadrupole  time-of-flight  tandem  mass  spectrometry  (ESI  Q-TOF 
MS/MS)  using  a  Q-Tof  (MicroMass,  Manchester,  UK)  or  a  QSTAR  (Applied 
Biosystems) instrument. Typically, 5 µl of sample was injected via a Famos system 
(Dionex) on to a 300 µm i.d x 5mm C18 PepMap guard column (5µm, 100A, LC 
Packings, Netherlands) and washed for 3 min with 95% solvent A (water + 0.1% FA) 
at a flow rate of 250 nl/min. Reversed-phase  chromatographic separation was carried 
out using an Ultimate system  (Dionex) on a  75mm i.d x 150mm column C18 PepMap 
Nano LC column (3µm, 100A, LC Packings, Netherlands) with a linear gradient of 5-
50% solvent B (water/ACN 20%:80% v/v + 0.1% FA). ESI MS/MS tandem spectra 
were recorded in the automated MS to MS/MS switching mode, with an m/z dependent 
set  of  collision  offset  values.  Singly  to  triply  charged  ions  were  selected  and 
fragmented,  with  argon  (Q-TOF)  or  a  second  reservoir  of  nitrogen  (Q-Star)  as  the 
collision gas. Acquired spectra were processed using ProteinLynx (Q-Tof) or Analyst 
QS (Q-Star) software and submitted to Mascot database search routines including +2 
and  +3  peptide  charge,  and  mass  tolerance  ±50ppm.  Positive  identifications  were   97 
accepted when at least two peptide sequences matched an entry with MOWSE scores 
above the p=0.05 threshold value.  
 
Tandem MS for 2D-LC with TMT labels work was performed on a Ultimate 3000 
system  linked  to  a  Orbitrap  XL  mass  spectrometer  (Thermo).  Reverse-phase 
chromatography  was  performed  under  the  conditions  described  above.  The  mass 
spectrometer was operated in the data-dependent mode to automatically switch between 
Orbitrap MS and MS/MS acquisition. Survey full scan  MS spectra (from m/z 400-
2000) were acquired in the Orbitrap with resolution r = 60,000 at m/z 400. The most 
intense ions (typically top 3-5 ions/scan) were sequentially isolated for fragmentation. 
Ions were selected in either the linear ion trap (LTQ) and fragmented by CID or in the 
collision cell and further measured in the Orbitrap mass analyser. Ions are passed to the 
collision cell through the C-trap for  Higher Energy Collisional Dissociation (HCD) 
fragmentation. 1 x 10
6 ions were accumulated in the C-trap for HCD spectra. HCD 
normalized collision energy was set to 40% and fragmentation ions were detected in 
the Orbitrap at a resolution r = 7500. Due to the higher ion accumulation and ion 
transfer  times  required  for  HCD  only,  up  to  three  of  the  most  intense  ions  were 
acquired following each full scan. Target ions that had been selected for MS
2 were 
dynamically excluded for 30 seconds. For accurate mass measurements the lock mass 
option was enabled. The polydimethylcyclosiloxane (PCM) ion m/z 455.120025 was 
used as an internal calibrant.  
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For peptide identification, data files were processed in Proteome Discoverer (Thermo 
Scientific)  and  Mascot  Daemon  using  the  IPI  human  database  and  the  following 
parameters  for  database  searching.  The  MS  tolerance  was  ±10  ppm  and  MS/MS 
tolerance 0.1 Da, one missed cleavage and carbamidomethylation of cysteines set as a 
fixed  modification.  Where  TMT-mass  tagging  was  used,  searches  were  carried  out 
using  carbamidomethylation  of  cysteine  residues  set  as  a  fixed  modification.  In 
addition, TMT modification of peptide N-termini and lysine residues were set as fixed 
modifications. Methionine oxidation and N-terminal acetylation were set as variable 
modifications.  Search  filters  were  selected  as  follows,  Mudpit  scoring,  Mascot 
significance threshold p>0.05, score > 20, requires bold red (matches that are red and 
bold  are  statistically  strongest  assignments)  and  quantitation  requires  at  least 
homology. Peptides with a ratio above 2 and below 0.5 are significantly different from 
the average to be considered as a potential change in protein expression. 
 
2.18 Western Blotting 
Cell  extracts  were  separated  by  1D  electrophoresis  and  electro-blotted  onto 
polyvinylidene  fluoride  (PVDF)  membrane  (Immobilon  P,  Millipore)  using  a  wet 
transfer tank in transfer buffer (195 mM glycine, 25 mM Tris, 20% (v/v) methanol). 
Membranes were blocked for 1h with 5% BSA (w/v) in Tris buffered saline with tween 
20 (TBS-T) (50 mM Tris pH 8, 150 mM NaCl, 0.1 % tween 20). Membranes were then 
incubated for a minimum of 1h in a primary antibody solution in TBS-T.   Membranes 
were  washed  in  TBS-T  (three  times  15  min)  and  then  probed  with the  appropriate   99 
horseradish  peroxidase  (HRP)-coupled  secondary  antibody  (Amersham  Biosciences, 
UK). After further washes in TBS-T, immunoprobed proteins were visualised using the 
enhanced chemiluminescence (ECL) method (NEN-Life Science Products, Inc., USA). 
All antibodies used in the present study are shown in Table 2.1. 
     
Antibody Company Mon/polyclonal Dilution
Actin beta (clone AC-15) Sigma mo mAb 1:25000
Akt Cell Signaling Technology rab pAb 1:2000
Akt anti-pSer473 Cell Signaling Technology rab pAb 1:2000
ErbB1/EGFR (1005)  Santa Cruz rab pAb 1:2000
ERK1/2 Promega rab pAb 1:5000
ERK1/2 activate (pT183/pY185-ERK2) Promega rab pAb 1:5000
Fascin1 Insight Biotech mo mAb 1:2000
PDLIM1  Abcam rab pAb 1:2000
Pigment derived epithelium-derived factor 
precursor (PEDF)
Abcam rab pAb 1:2000
PIG3 Santa Cruz goat pAb 1:2000
Prohibitin Lab Vision mo mAb 1:5000
PTEN Affinity Purified Ben Neel rab pAb 1:2000
Prolactin (M-19) Santa Cruz goat pAb 1:2000  
Table 2.1 List of antibodies used for western blotting in the present study 
 
2.19 ELISA 
The  MMP10  immunoassay  (Quantikine)  is  a  sandwich  enzyme  immunoassay 
technique. A monoclonal antibody specific for MMP10 is precoated onto the wells of a 
microplate. Standards and samples are pipetted into the wells and any MMP10 binds. 
Serum  samples  were  diluted  2-fold  with  calibrator  diluent  solution  and  standards 
prepared according to the manufacturer’s guidelines. After washing, an enzyme-linked 
monoclonal  antibody  specific  for  MMP10  is  added  to  the  wells.  After  repeated 
washing, a substrate solution is added and colour develops in proportion to the amount 
of total MMP10 bound in the initial step.   100 
 
Chapter 3 Proteomic profiling of Ch18 MMCT 
models of tumour suppression by 2D-DIGE 
Introduction 
The transfer of chromosome 18 by MMCT into two recipient tumour cell lines, TOV-
112D and TOV-21G, induced a suppressive effect on their tumourigenic phenotype. 
The  aim  of  this  project  was  to  identify  the  protein  changes  associated  with  this 
suppression  and  candidate biomarkers  of  ovarian  cancer.  To  investigate  the protein 
changes associated with tumour suppression in the Ch18 MMCT models, 2D-DIGE 
was  carried  out  and  the  identification  of  differentially  expressed  proteins  was 
performed by MALDI-TOF-MS and LC-MS/MS analysis. 
 
Firstly, 2D-DIGE was applied to compare the whole cell proteomes of each parental 
cell line and a pool of 5 hybrid clones derived from each. The hybrid clones were 
selected for their potency of suppression (Chapter 1). Pooling of a number of hybrid 
clones was chosen for this preliminary experiment to test the system and to reduce 
costs and facilitate the identification of common changes. However, the major caveat of 
this approach is that single clones may bias the results and clonal variation is thus 
masked  (see  later).  Whole  cell  lysates  from  each  parental  cell  line  and  five 
chromosome  18  MMCT  hybrids  from  each  were  prepared,  protein  concentrations 
equalised and the five clones pooled. Each parent and hybrid pool were labelled with   101 
Cy3  or  Cy5  in  triplicate.  A  pool  of  all  samples  was  also  prepared  as  an  internal 
standard and labelled with Cy2 to be run on all gels. Samples were mixed appropriately 
(Table  3.1)  and  proteins  separated  by  2D  electrophoresis  and  images  analysed  as 
described in Materials and Methods.  
 
 
 
 
 
  
 
 
 
 
 
 
Table  3.1 Experimental  strategy  for  the  2D-DIGE  comparison  of  two parental 
EOC cell lines and their pooled hybrid clones. Whole cell lysates from the parental 
cell lines and 5 chromosome 18 MMCT hybrids for each were harvested. The 5 clones 
were pooled. Total protein (150µg) for each parent and the hybrid pool was labelled 
appropriately in triplicate and separated on large format 2D gels prior to image analysis 
and differential protein expression analysis. A pool of equal amounts of the parent and 
hybrid pool lysates were labelled with Cy2 as an internal standard. 
 
Parental Hybrid Clone
21G 1
2
3
4
5
Pool B
Parental Hybrid Clone
112D 1
2
3
4
5
1
2
3
4
5
Pool A
Pool 112D-3 B-3 6
Pool A-3 21G-3 5
Pool B-2 21G-2 4
Pool 112D-2 A-2 3
Pool 21G-1 112D-1 2
Pool B-1 A-1 1
Cy2 Cy5 Cy3 Gel
Pool 112D-3 B-3 6
Pool A-3 21G-3 5
Pool B-2 21G-2 4
Pool 112D-2 A-2 3
Pool 21G-1 112D-1 2
Pool B-1 A-1 1
Cy2 Cy5 Cy3 Gel
Parental Hybrid Clone
21G 1
2
3
4
5
Pool B
Parental Hybrid Clone
112D 1
2
3
4
5
1
2
3
4
5
Pool A
Parental Hybrid Clone
21G 1
2
3
4
5
Pool B
Parental Hybrid Clone
112D 1
2
3
4
5
1
2
3
4
5
Pool A
Pool 112D-3 B-3 6
Pool A-3 21G-3 5
Pool B-2 21G-2 4
Pool 112D-2 A-2 3
Pool 21G-1 112D-1 2
Pool B-1 A-1 1
Cy2 Cy5 Cy3 Gel
Pool 112D-3 B-3 6
Pool A-3 21G-3 5
Pool B-2 21G-2 4
Pool 112D-2 A-2 3
Pool 21G-1 112D-1 2
Pool B-1 A-1 1
Cy2 Cy5 Cy3 Gel
Pool 112D-3 B-3 6
Pool A-3 21G-3 5
Pool B-2 21G-2 4
Pool 112D-2 A-2 3
Pool 21G-1 112D-1 2
Pool B-1 A-1 1
Cy2 Cy5 Cy3 Gel
Pool 112D-3 B-3 6
Pool A-3 21G-3 5
Pool B-2 21G-2 4
Pool 112D-2 A-2 3
Pool 21G-1 112D-1 2
Pool B-1 A-1 1
Cy2 Cy5 Cy3 Gel  102 
The 2D-DIGE comparison of parental and hybrid pools revealed a total of 318 spots 
displaying a change in average abundance of ≥ 2-fold where p≤ 0.05; this from gel 
images with around 1300 matched spots (Fig 3.1). Direct comparison of TOV-112D 
and its hybrid pool cell lysates revealed 118 spots displaying differential expression, of 
which 63 were up-regulated and 85 down-regulated. Comparison of TOV-21G and its 
hybrid pool cell lysates revealed a total of 255 spots showing differential expression, of 
which 157 were up-regulated and 98 down-regulated. 82 of these gel features were 
common in the two comparisons. Post-staining of the gels with colloidal coomassie 
blue and matching of the images to a master Cydye image (Gel 01; Cy2) resulted in 
143  well-defined,  coomassie-detectable  protein  spots  which  were  picked  for 
downstream  MS-based  identification.  The  lower  number  of  spots  for  picking  arose 
since fewer spots were detected by CCB staining verses Cydye differential labelling 
and because only well-resolved spots were chosen rather than spot shoulders or labelled 
areas between closely migrating spots. It is also unlikely that non-staining spots can be 
identified with confidence in some MS instuments due to their low abundance.  
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Figure 3.1 Merged 2D gel images of differential protein expression in the 112D cell 
line and its MMCT-derived hybrid pool. 150 g of total cell lysate from TOV-112D 
and its hybrid pool (Pool A) were labelled with Cy3 and Cy5 respectively, mixed and 
loaded  with  an  equal  amount  of  internal  standard  labelled  with  Cy2.  Differences 
between Cy3 and Cy5 labelled samples can be linked through the internal standard 
labelled with Cy2 as ratios Cy3/Cy2 compared to Cy5/Cy2 across all gels. This image, 
created in Adobe Photoshop, shows differentially expressed proteins in red and blue 
(up  and  down-regulated  in  Pool  A  vs.  TOV-112D  respectively).  A  total  of  2,327 
protein  features  were  defined  and  1300  spots  matched  using  the  DeCyder  image 
analysis software.   
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3.1.1 Identification of differentially expressed proteins  
All  143  spots  picked  from  CCB  stained  gels,  were  digested  and  in  some  cases 
identified largely by MALDI-TOF-MS peptide mass fingerprinting (see Chapters 1 & 
2).  Mass lists  generated from spectra were  compared  against theoretically expected 
tryptic  peptide  masses  in  the  NCBI  and  IPI  databases  searched  using  Mascot.  The 
identifications  were  scored  according  to  algorithms  that  take  into  account  mass 
accuracy and peptide coverage. The search criteria used allowed +/- 50 ppm mass error 
and up to 2 missed cleavages. The identified proteins were also verified by comparison 
of their theoretical molecular weights and pIs with gel position on the master gel.  
 
In total, 92 protein isoforms were identified with high  confidence (Table 3.2). The 
expression changes for some parent: hybrid pool protein spot comparisons were as high 
as 24-fold and a number of the identified proteins have been previously implicated as 
putative  markers  of  ovarian  cancer  in  the  literature.  Notably,  none  of  the  proteins 
identified were chromosome 18 gene products.  
 
Common changes detected included a significant up-regulation of cofilin in both the 
TOV-112D (3.1 fold) and TOV-21G hybrid pools (1.69 fold). A number of nuclear 
proteins were detected displaying the same expression profile in the hybrid pools. ATP-
dependent DNA helicase II was down-regulated in the TOV-112D (-7.93 fold) and 
TOV-21G hybrid pools (-5.05 fold). This nuclear protein plays a role in chromosome 
translocation.  Fizzy-related protein homolog displayed up-regulation in the TOV-112D   105 
(2.51 fold) and TOV-21G hybrid pools (2.91 fold). This protein regulates the ubiquitin 
ligase activity of the anaphase promoting complex/cyclosome (APC/C) and may confer 
substrate  specificity  upon  the  complex.  Exosome complex  exonuclease  RRP41  was 
significantly  down-regulated  in  the  TOV-112D  (-19.71  fold)  and  TOV-21G  hybrid 
pools (-10.13 fold).   
 
Despite these common changes there was little overlap between the two cell systems in 
terms of the proteins identified and surprisingly 38 of the common proteins displayed 
opposite regulation between the cell line-hybrid pairs. For example stathmin (Gagne, 
Gagne et al. 2005), a conserved cytosolic phosphoprotein that regulates microtubule 
dynamics,  was  down-regulated  (-2.05  fold)  in  the  TOV-112D  hybrid  pool,  but  up-
regulated  (3.03  fold)  in  the  TOV-21G  hybrid  pool.  WD-repeat  protein  1  displayed 
significant  up-regulation  in  the  TOV-112D  hybrid  pool  (3.83  fold)  and  down-
regulation in the TOV-21G hybrid pool (-3.94 fold).  T-complex protein 1 (epsilon 
subunit) was identified in two protein spots. Expression was significantly up-regulated 
for one hybrid pool and significantly down-regulated for the other hybrid pool in one 
spot and vice-versa in the other spot suggesting differential PTMs. Hsp70 and hsp27 
were down-regulated in the TOV-112D hybrid pool but displayed up-regulation in the 
TOV-21G hybrid pool. The phospholipid and Ca
2+-binding protein annexin A1 was 
down-regulated (-2.25 fold) in the TOV-112D hybrid pool and conversely up-regulated 
(2.75 fold) in the TOV-21G hybrid pool. The phosphoprotein ezrin, a member of the 
ezrin/radixin/moesin family of membrane-actin cross-linking proteins that transduces 
signals by growth factors to the cytoskeleton was up-regulated (2.17 fold) in the TOV-  106 
112D hybrid pool. In contrast, its expression was moderately down-regulated (-1.31 
fold) in the TOV-21G hybrid pool. Galectin-1, a secreted protein was significantly up-
regulated in the TOV-112D hybrid pool (4.93 fold) and significantly down-regulated (-
4.32)  in  the  TOV-21G  hybrid  pool.  Valosine-containing  protein  (VCP)  was 
significantly up-regulated (4.62 fold) in the TOV-21G hybrid pool and down-regulated 
(-1.69  fold)  in  the  TOV-112D  hybrid  pool.  VCP  is  a  member  of  the  ATPase 
superfamily associated with a variety of cellular activities. Peroxiredoxin 2, part of the 
antioxidant  family  of  thioredoxin-dependent  peroxidases,  was  potently  up-regulated 
(5.71 fold) in the TOV-112D hybrid pool, but down-regulated (-4.75 fold) in the TOV-
21G hybrid pool compared to their respective parental cell lines. Finally, the largest 
contrast in expression observed between the cell models was aldehyde dehydrogenase 
1A1.  Significant  down-regulation  by  -24.65  fold  was  observed  in  the  TOV-112D 
hybrid pool and conversely an up-regulation of 15.01 fold was observed in the TOV-
21G  hybrid  pool.  These  data  suggest  considerable  heterogeneity  between  the  cell 
models, which may reflect their different origins; TOV-112D from clear cell and TOV-
21G from endometrioid carcinoma. It also shows that these proteins are not involved in 
the observed tumour suppression displayed by the Ch18 MMCT hybrid clones. 
 
Other proteins of interest; were growth factor receptor bound-2 (Grb2) (significantly 
up-regulated 3.21 fold in the TOV-21G hybrid pool), an adaptor protein responsible for 
recruitment of Ras and the activation of the mitogen-activated protein kinase (MAPK) 
cascade in response to growth factor receptor activation (see Introduction) and Ras-  107 
related protein (Rab2A) (up-regulated in the TOV-21G hybrid pool), which is required 
for protein transport from the endoplasmic reticulum to the Golgi complex.  
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Spot No. Name IPI No.
HGNC 
Symbol Chr Av. Ratio T-test Av. Ratio T-test pI (gel) Mw (gel) pI (pred) Mw (pred) Score %Cov Molecular and Bilological Function Localisation
1483 ACETYL-COA ACETYLTRANSFERASE, 
CYTOSOLIC
IPI00291419 ACAT2 6 -2.4 0.00013 1.43 0.29 7.65 43338 6.47 41838 141 71 Lipid metabolism. 2 acetyl-CoA = CoA + acetoacetyl-CoA. Cytoplasmic
1357 ADENOSYLHOMOCYSTEINASE IPI00012007 AHCY 20 -1.9 0.021 4.97 0.00017 6.84 47275 5.92 48255 200 54 Adenosylhomocysteine is a competitive inhibitor of S- adenosyl-L-methionine-dependent 
methyl transferase reactions; therefore adenosylhomocysteinase may play a key role in 
the control of methylations via regulation of the intracellular concentration of 
adenosylhomocysteine.
Cytoplasmic
1184 ALDEHYDE DEHYDROGENASE 1A1  IPI00218914 ALDH1A1 9 -24.65 0.0015 15.01 2.60E-06 7.55 52770 6.3 55454 174 55 Binds free retinal and cellular retinol-binding protein- bound retinal. Can convert/oxidize 
retinaldehyde to retinoic acid (By similarity).
Cytoplasmic
1694 ANNEXIN A1 IPI00218918 ANXA1 9 -2.25 0.00071 2.75 0.00018 7.14 37126 6.57 38918 78 55 Calcium/phospholipid-binding protein which promotes membrane fusion. Involved in 
exocytosis and regulates phospholipase A2 activity. Binds from two to four calcium ions 
with high affinity.
Plasma Membrane
1805 ANNEXIN A3 IPI00024095 ANXA3 4 7.44 0.0034 -5.29 0.0097 5.7 33645 5.63 36524 192 74 Inhibitor of phospholipase A2, also possesses anti- coagulant properties. Also cleaves 
the cyclic bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate
Cytoplasm
779 ATP-DEPENDENT DNA HELICASE II, 70 KDA 
SUBUNIT; KU70
IPI00465430 XRCC6 22 -7.93 0.016 -5.05 0.016 7.3 64008 6.23 70114 88 41 Has a role in chromosome translocation.  Involved in DNA nonhomologous end joining 
(NHEJ) required for double-strand break repair and V(D)J recombination.
Nuclear
605 ATP-DEPENDENT DNA HELICASE II, 80 KDA 
SUBUNIT; KU80
IPI00220834 XRCC5 2 1.6 0.095 -2.88 0.0026 5.75 68234 5.55 83222 67 24 Chromosome translocation Nuclear
1856 CATHEPSIN D PRECURSOR IPI00011229 CTSD 11 2.81 0.00017 -2.06 0.0014 5.76 32421 6.1 45037 74 42 Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of 
several diseases such as breast cancer and possibly Alzheimer's disease.
Lysosomal
2156 COFILIN 1 (NON-MUSCLE)  IPI00012011 CFL1 11 3.1 1.70E-05 1.69 0.00066 7.07 16718 8.22 18719 89 81 Controls reversibly actin polymerization and depolymerization in a pH-sensitive manner. It 
has the ability to bind G- and F-actin in a 1:1 ratio of cofilin to actin. It is the major 
component of intranuclear and cytoplasmic actin rods.
Intranuclear and cytoplasmic; almost 
completely in nucleus in cells exposed to 
heat shock or 10% dimethyl sulfoxide
1003 D-3-PHOSPHOGLYCERATE 
DEHYDROGENASE.
IPI00011200 PHGDH 1 -1.6 0.00031 2.66 9.20E-05 7.59 57564 6.29 57356 91 40 Serine biosynthesis; first step. 3-phosphoglycerate + NAD(+) = 3- 
phosphohydroxypyruvate + NADH.
Cytoplasmic
2103 DJ-1; PARK7 IPI00298547 PARK7 1 -1.18 0.031 3.22 3.40E-05 6.92 19490 6.33 20063 160 78 Acts as positive regulator of androgen receptor- dependent transcription.  Nuclear and cytoplasmic
1422 DNAJ HOMOLOG SUBFAMILY B MEMBER 11 
PRECURSOR
IPI00008454 DNAJB11 3 -1.46 0.12 2.59 0.0012 6.87 45033 5.81 40774 79 41 Protein folding - endoplasmic reticulum -  chaperone activity Endoplasmic reticulum lumen
1937 ENDOPLASMIC RETICULUM PROTEIN ERP29 
PRECURSOR
IPI00024911 ERP29 12 -1.46 0.00074 3.42 0.00024 6.87 30027 6.77 29032 57 52 Plays an important role in the processing of secretory proteins within the endoplasmic 
reticulum (ER), possibly by participating to the folding of proteins in the ER. Does not 
seem to be a disulfide isomerase. 
Endoplasmic reticulum lumen
1258 ENOLASE ALPHA IPI00465248 ENO1 1 1.04 0.75 2.12 9.80E-05 7.18 50784 6.99 47350 82 49 Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various 
processes such as growth control, hypoxia tolerance and allergic resonses. May also 
function in the intravascular and pericellular fibrinolytic system due to its ability to serve 
as a receptor and activator of plasminogen on the cell surface of several cell-types such 
as leukocytes and neurones.
Cytoplasmic
1250 ENOLASE ALPHA IPI00465248 ENO1 1 1.78 0.00017 1.25 0.11 7.77 50914 7.57 47405 184 64 Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various 
processes such as growth control, hypoxia tolerance and allergic resonses. May also 
function in the intravascular and pericellular fibrinolytic system due to its ability to serve 
as a receptor and activator of plasminogen on the cell surface of several cell-types such 
as leukocytes and neurones.
Cytoplasmic
1254 ENOLASE ALPHA IPI00465248 ENO1 1 2.21 0.0012 1.15 0.34 7.11 50784 7.57 47405 90 45 Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various 
processes such as growth control, hypoxia tolerance and allergic resonses. May also 
function in the intravascular and pericellular fibrinolytic system due to its ability to serve 
as a receptor and activator of plasminogen on the cell surface of several cell-types such 
as leukocytes and neurones.
Cytoplasmic
1187 EUKARYOTIC TRANSLATION ELONGATION 
FACTOR 1 GAMMA 
IPI00000875 EEF1G 11 -1.61 0.029 3.98 8.90E-05 7.28 52501 6.25 50429 210 61 Probably plays a role in anchoring the complex to other cellular components. Cytoplasm
1873 EXOSOME COMPLEX EXONUCLEASE RRP41 IPI00218310 EXOSC4 8 -19.71 3.80E-05 -10.13 0.00078 7.07 32009 6.14 27905 56 43 Component of the exosome 3'->5' exoribonuclease complex. Required for the 
3'processing of the 7S pre-RNA to the mature 5.8S rRNA. Has a 3'-5' exonuclease 
activity.
Cytoplasm. Nucleus; nucleolus
559 EZRIN IPI00479359 VIL2 6 2.17 0.0022 -1.31 0.13 6.85 69378 5.94 69313 122 48 Probably involved in connections of major cytoskeletal structures to the plasma 
membrane.
Microvillar peripheral membrane protein 
(cytoplasmic side)
1980 F-ACTIN CAPPING PROTEIN BETA SUBUNIT  IPI00218782 CAPZB 1 1.05 0.18 3.22 0.0014 4.84 27176 5.69 30952 129 61 F-actin capping proteins bind in a Ca(2+)-independent manner to the fast growing ends of 
actin filaments (barbed end) thereby blocking the exchange of subunits at these ends.
Cytoskeleton
1055 FASCIN 1  IPI00163187 FSCN1 7 1.88 8.00E-05 -2.67 0.00013 8 56182 6.83 55729 120 54 Organizes filamentous actin into bundles with a minimum of 4.1:1 actin/fascin ratio. 
Probably involved in the assembly of actin filament bundles present in microspikes, 
membrane ruffles, and stress fibers.
Cytoskeleton
1972 FIZZY-RELATED PROTEIN HOMOLOG, SPLICE 
ISOFORM 1
IPI00383919 FZR1 19 2.51 0.0004 2.91 2.60E-05 5.11 27952 9.4 55544 54 27 Regulates ubiquitin ligase activity of the anaphase promoting complex/cyclosome 
(APC/C) and may confer substrate specifity upon the complex. The APC/C-Cdh1 dimeric 
complex is activated during anaphase and telophase and remains active in degrading 
substrates until onset of the next S phase.
Nuclear (isoform 2) and cytoplasmic 
(isoform 3)
1348 FUMARYLACETOACETASE IPI00031708 FAH 15 1.3 0.0034 -3.83 2.40E-06 7.72 47275 6.46 46743 82 51 Hydrolase activity 4-fumarylacetoacetate + H(2)O = acetoacetate + fumarate. Cytoplasm
2230 GALECTIN-1 IPI00219219 LGALS1 22 4.93 3.20E-05 -4.32 0.0016 4.67 12190 5.34 15048 96 95 May regulate cell apoptosis and cell differentiation. Binds beta-galactoside. Binds CD45, 
CD3 and CD4. Inhibits CD45 protein phosphatase activity and therefore the 
dephosphorylation of Lyn kinase.
Extracellular+nucleus+cytoplasm+plasma 
membrane
1141 GLUTAMATE DEHYDROGENASE 1, 
MITOCHONDRIAL PRECURSOR
IPI00016801 GLUD1 10 1.88 0.0012 -2.46 0.0024 8.13 54068 7.66 61701 133 48 May be involved in learning and memory reactions by increasing the turnover of the 
excitatory neurotransmitter glutamate (By similarity).
Mitochondrial matrix
112D hybrid pool / 
112D parental
21G hybrid pool / 21G 
parental  109 
726 GLYCEROL-3-PHOSPHATE 
DEHYDROGENASE, MITOCHONDRIAL 
PRECURSOR
IPI00017895 GPD2 2 2.17 0.00075 -1.51 0.00016 7.71 65331 6.98 81277 84 31 Oxidoreductase activity, Sn-glycerol 3-phosphate + acceptor = glycerone phosphate + 
reduced acceptor.
Mitochondrial
2064 GROWTH FACTOR RECEPTOR-BOUND 
PROTEIN 2; GRB2
IPI00021327  GRB2 17 -1.02 0.83 3.21 3.20E-05 6.38 21867 5.89 25304 93 64 Associates with activated EGF and PDGF receptors via SH2 domain. GRB2 also 
associates to other cellular Tyr-phosphorylated proteins such as IRS1, SHC and LNK; 
Binds to and translocates the guanine nucleotide exchange factors SOS (By similarity).
Cytoplasmic
852 HEAT SHOCK COGNATE 71 KDA PROTEIN, 
SPLICE ISOFORM 1
IPI00003865 HSPA8 11 -1.12 0.055 3.44 5.60E-05 5.16 61995 5.37 71082 [1339] [49] Chaperone. Isoform 2 may function as an endogenous inhibitory regulator of HSC70 by 
competing the cochaperones.
Translocates to  nuclei, upon heat shock
865 HEAT SHOCK COGNATE 71 KDA PROTEIN, 
SPLICE ISOFORM 1
IPI00003865/IPI0
0037070
HSPA8 11 -1.05 0.5 2.31 5.80E-05 5.05 61836 5.37 71082 189 57 Chaperone. Isoform 2 may function as an endogenous inhibitory regulator of HSC70 by 
competing the cochaperones.
Translocates to  nuclei, upon heat shock
937 HEAT SHOCK COGNATE 71 KDA PROTEIN, 
SPLICE ISOFORM 1
IPI00003865/IPI0
0037070
HSPA8 11 -1.02 0.98 2.42 0.0024 5.22 59206 5.37 71082 89 43 Chaperone. Isoform 2 may function as an endogenous inhibitory regulator of HSC70 by 
competing the cochaperones.
Translocates to  nuclei, upon heat shock
997 HEAT SHOCK PROTEIN 60, MITOCHONDRIAL 
PRECURSOR
IPI00472102 HSPD1 2 -1.02 0.69 4.15 1.20E-05 5 57343 5.7 61346 210 67 Mitochondrial protein import and macromolecular assembly. May also prevent misfolding 
and promote the refolding and proper assembly of unfolded polypeptides generated 
under stress conditions in the mitochondrial matrix.
Mitochondrial matrix
1006 HEAT SHOCK PROTEIN 60, MITOCHONDRIAL 
PRECURSOR
IPI00472102 HSPD1 2 1.01 0.99 3.06 0.0014 4.88 57490 5.7 61346 186 65 Implicated in mitochondrial protein import and macromolecular assembly.  May also 
prevent misfolding and promote the refolding and proper assembly of unfolded 
polypeptides generated under stress conditions in the mitochondrial matrix.
Mitochondrial matrix
882 HEAT SHOCK PROTEIN 70KDA 1 IPI00304925 HSPA1A 6 -1.71 0.022 6.3 0.00085 5.39 61207 5.48 70280 161 49 In cooperation with other chaperones, Hsp70s stabilize preexistent proteins against 
aggregation and mediate  folding of newly translated polypeptides in the cytosol as well 
as within organelles.
Cytoplasmic
2026 HEAT-SHOCK PROTEIN BETA-1; HSP27 IPI00025512 HSPB1 7 -1.69 0.0036 5.33 0.0009 6.62 24099 5.98 22826 62 50 Involved in stress resistance and actin organization. Cytoplasmic in interphase cells. Colocalizes 
with mitotic spindles. Translocates to 
nucleus during heat shock
2118 HEME BINDING PROTEIN 1 IPI00148063 HEBP1 12 -1.43 0.0048 3.28 2.10E-05 5.36 18661 5.71 21198 80 82 Heme binding Secreted
1166 HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN H
IPI00026230 HNRPH2 X -1.61 4.90E-05 2.52 0.0068 6.54 52973 5.89 49517 99 52 This protein is a component of the heterogenous nuclear ribonucleoprotein (hnRNP) 
complexes which provide the substrate for the processing events that pre-mRNAs 
undergo before becoming functional, translatable mRNAs in the cytoplasm. Binds 
poly(RG).
Nuclear; nucleoplasm
917 HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN K, SPLICE ISOFORM 2
IPI00216746 HNRPK 9 -1.26 0.14 2.65 8.40E-05 4.91 60121 5.19 51281 182 64 One of the major pre-mRNA-binding proteins. Binds tenaciously to poly(C) sequences. 
Likely to play a role in the nuclear metabolism of hnRNAs.
Cytoplasmic and nuclear; nucleoplasm.
1301 ISOCITRATE DEHYDROGENASE [NADP] 
CYTOPLASMIC
IPI00027223 IDH1 2 -1.31 0.011 2.27 0.0011 7.86 49187 6.53 46915 139 64 Isocitrate + NADP(+) = 2-oxoglutarate + CO(2) + NADPH. Cytoplasmic and peroxisomal
2089 LACTOYLGLUTATHIONE LYASE. IPI00220766 GLO1 6 -1.81 2.00E-05 2.81 4.60E-05 4.54 20487 5.24 20934 98 72 Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, 
to S-lactoylglutathione.
Cytoplasmic
822 LAMIN A/C, SPLICE ISOFORM 2 IPI00216952 LMNA 1 2.48 7.70E-05 -1.31 0.059 7.89 62712 6.4 65153 [225] [22] Structural component of nuclear envelope and may also interact with chromatin Nuclear
1273 LUPUS LA PROTEIN IPI00009032 SSB 2 -1.53 0.038 2.37 0.006 7.51 50203 6.68 46979 102 50 Plays a role in the transcription of RNA polymerase III most probably as a transcription 
termination factor.
Nuclear (Probable)
1258 LUPUS LA PROTEIN IPI00009032 SSB 2 1.04 0.75 2.12 9.80E-05 7.18 50784 6.68 46979 155 61 Plays a role in the transcription of RNA polymerase III most probably as a transcription 
termination factor.
Nuclear (Probable)
940 MYO-INOSITOL 1-PHOSPHATE SYNTHASE A1. IPI00301189 19 5.91 0.00045 -2.37 0.01 5.41 59206 5.44 61528 98 46 Inositol-3-phosphate synthase activity Cytoplasmic
1376 ORNITHINE AMINOTRANSFERASE, 
MITOCHONDRIAL PRECURSOR
IPI00022334 OAT 10 -1.43 0.047 -2.07 0.002 6.98 46318 6.57 48846 101 48 Transferase activity. L-ornithine + a 2-oxo acid = L-glutamate 5- semialdehyde + an L-
amino acid.
Mitochondrial matrix
1688 PDZ AND LIM DOMAIN PROTEIN 1; ELFIN IPI00010414 PDLIM1 10 2.36 0.00056 -2.27 0.0032 7.81 37317 6.56 36505 124 63 Protein binding - response to oxidative stress  Cytoplasmic
2141 PEROXIREDOXIN 2 IPI00027350 PRDX2 19 5.71 0.00014 -4.25 0.00012 5.49 17394 5.66 22049 109 63 Electron transporter activity-antioxidant activity-oxidoreductase activity  Cytoplasmic
726 PHENYLALANYL-TRNA SYNTHETASE BETA 
CHAIN
IPI00300074 FARSLB 2 2.17 0.00075 -1.51 0.00016 7.71 65331 6.4 66715 58 26 Ligase activity, ATP + L-phenylalanine + tRNA(Phe) = AMP + diphosphate + L-
phenylalanyl-tRNA(Phe).
Cytoplasmic (By similarity)
1134 PRE-B CELL ENHANCING FACTOR 
PRECURSOR
IPI00018873 PBEF1 7 2.02 0.0042 -2.21 0.0012 8.07 54694 6.69 55772 79 37 It is the rate limiting component in the mammalian NAD biosynthesis pathway (By 
similarity).  Nicotinamide D-ribonucleotide + diphosphate = nicotinamide + 5-phospho-
alpha-D-ribose 1-diphosphate.
Secreted
1359 PROLIFERATION-ASSOCIATED PROTEIN 2G4 IPI00299000 PA2G4 12 -1.1 0.39 2.48 0.0012 7.2 46914 6.13 44101 167 73 Hydrolase activity Cytoplasm. Nucleus; nucleolus.
1846 PROTEASOME ACTIVATOR COMPLEX 
SUBUNIT 1
IPI00030154 PSME1 14 2.03 5.90E-05 -1.81 0.00077 5.94 32462 5.78 28876 92 61 Proteasome activator complex subunit 1 (Proteasome activator 28-alpha subunit) 
(PA28alpha) (PA28a) (Activator of multicatalytic protease subunit 1) (11S regulator 
complex alpha subunit) (REG-alpha) (Interferon gamma up-regulated I-5111 protein) 
(IGUP I-5111).
Cytoplasmic
1100 PROTEIN DISULFIDE-ISOMERASE A3 
PRECURSOR
IPI00025252 PDIA3 15 -1.12 0.0035 2.71 4.30E-05 5.97 55610 5.98 57146 241 58 Electron transporter activity/isomerase activity/hydrolase activity. Catalyzes the 
rearrangement of -S-S- bonds in proteins.
Endoplasmic reticulum lumen (By similarity)
1068 PROTEIN DISULFIDE-ISOMERASE A3 
PRECURSOR
IPI00025252 PDIA3 15 1.09 0.2 2.01 0.0033 5.75 55753 5.98 57146 [58] [8] Electron transporter activity/isomerase activity/hydrolase activity. Catalyzes the 
rearrangement of -S-S- bonds in proteins.
Endoplasmic reticulum lumen (By similarity)
1147 PRP19/PSO4 HOMOLOG. IPI00004968 PRPF19 11 -2.08 0.00068 1.57 0.057 7.28 53930 6.14 55603 62 34 Plays a role in DNA double-strand break (DSB) repair.  Acts as a structural component of 
the nuclear framework. May also serve as a support for spliceosome binding and activity.
Nucleoplasmic in interphase cells
1802 PURINE NUCLEOSIDE PHOSPHORYLASE IPI00017672 NP 14 -2.79 7.00E-05 -1.03 0.76 7.49 34035 6.71 32758 57 52 Transferase activity Cytoplasmic
2103 RAS-RELATED PROTEIN RAB-2A IPI00031169 RAB2 8 -1.18 0.031 3.22 3.40E-05 6.92 19490 6.08 23702 71 64 Required for protein transport from the endoplasmic reticulum to the Golgi complex. Intermediate compartment between ER and 
Golgi apparatus
1104 RUVB-LIKE 1 IPI00021187 RUVBL1 3 -1.29 0.038 2.59 4.80E-06 7.38 55327 6.02 50538 100 59 Single-stranded DNA-stimulated ATPase and ATP- dependent DNA helicase (3' to 5'). 
Component of NuA4 histone acetyltransferase complex involved in transcriptional 
activation associated with oncogene mediated growth induction, tumor suppressor 
mediated growth arrest and replicative senescence, apoptosis, and DNA repair.
Nuclear
 
   110 
801 SERUM ALBUMIN PRECURSOR IPI00022434 ALB 4 2.15 5.60E-05 -1.89 1.50E-05 6 68000 5.92 71317 [108] [7] Regulation of the colloidal osmotic pressure of blood.good binding capacity for water, 
Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs.
Secreted
803 SERUM ALBUMIN PRECURSOR IPI00022434 ALB 4 3.16 0.00021 -1.94 1.40E-05 6.22 63682 5.92 71317 [63] [7] regulation of the colloidal osmotic pressure of blood.good binding capacity for water, 
Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs.
Secreted
779 SIMILAR TO ATP-DEPENDENT DNA HELICASE 
II, 70 KDA SUBUNIT; KU70
IPI00412259 XRCC6 X -7.93 0.016 -5.05 0.016 7.3 64008 7.31 65656 52 34 Has a role in chromosome translocation.  Involved in DNA nonhomologous end joining 
(NHEJ) required for double-strand break repair and V(D)J recombination.
Nuclear
1134 SIMILAR TO PRE-B CELL ENHANCING 
FACTOR
IPI00472879 PEBF 10 2.02 0.0042 -2.21 0.0012 8.07 54694 7.72 53773 64 31 It is the rate limiting component in the mammalian NAD biosynthesis pathway (By 
similarity).  Nicotinamide D-ribonucleotide + diphosphate = nicotinamide + 5-phospho-
alpha-D-ribose 1-diphosphate.
Secreted
2159 STATHMIN  IPI00479997 STMN1 1 -2.05 0.00028 3.03 0.00028 5.31 16527 5.76 17326 51 48 Involved in the regulation of the microtubule (MT) filament system by destabilizing 
microtubules. It prevents assembly and promotes disassembly of microtubules.
Cytoplasmic
814 STRESS-70 PROTEIN, MITOCHONDRIAL 
PRECURSOR; GRP75
IPI00007765 HSPA9B 5 -1.63 7.40E-05 3.45 4.60E-05 5.41 62873 6.04 74093 142 53 Implicated in the control of cell proliferation and cellular aging. May also act as a 
chaperone.
Mitochondrial
1037 STRESS-INDUCED-PHOSPHOPROTEIN 1 IPI00013894   STIP1 11 1.17 0.024 2.45 3.70E-06 7.42 56978 6.4 63227 125 50 Mediates the association of the molecular chaperones HSC70 and HSP90 (HSPCA and 
HSPCB).
Nuclear and cytoplasmic (By similarity)
1061 T-COMPLEX PROTEIN 1, BETA SUBUNIT IPI00297779 CCT2 12 -1.08 0.18 2.43 0.0015 7.07 56182 5.91 59929 265 70 Molecular chaperone; assist the folding of proteins upon ATP hydrolysis. Known to play a 
role, in vitro, in the folding of actin and tubulin.
Cytoplasmic
949 T-COMPLEX PROTEIN 1, EPSILON SUBUNIT IPI00010720 CCT5 5 -5.19 0.00012 6.85 3.30E-06 5.57 59130 5.45 60089 182 61 Molecular chaperone; assist the folding of proteins upon ATP hydrolysis. Known to play a 
role, in vitro, in the folding of actin and tubulin.
Cytoplasmic
940 T-COMPLEX PROTEIN 1, EPSILON SUBUNIT IPI00010720  CCT5 5 5.91 0.00045 -2.37 0.01 5.41 59206 5.45 60089 85 47 Molecular chaperone; assist the folding of proteins upon ATP hydrolysis. Known to play a 
role, in vitro, in the folding of actin and tubulin.
Cytoplasmic
2226 THIOREDOXIN  IPI00216298 TXN 9 1.24 0.12 3.27 0.00011 4.4 15000 4.82 12015 49 78 Participates in various redox reactions through the reversible oxidation of its active center 
dithiol to a disulfide and catalyzes dithiol-disulfide exchange reactions.
Cytoplasmic
471 TRANSITIONAL ENDOPLASMIC RETICULUM 
ATPASE; VALOSIN-CONTAINING PROTEIN
IPI00022774 VCP 9 -1.69 8.60E-05 4.62 7.50E-05 4.91 71540 5.14 89950 331 74 Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly 
after mitosis. Involved in the formation of the transitional endoplasmic reticulum (tER).
Nuclear and cytoplasmic
1285 TRANSLATION ELONGATION FACTOR TU, 
MITOCHONDRIAL 
IPI00027107 TUFM 16 -1.13 0.04 2.52 1.50E-05 7.78 49692 7.26 50185 168 54 This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of 
ribosomes during protein biosynthesis.
Mitochondrial
1932 TRIOSEPHOSPHATE ISOMERASE 1 IPI00465028 TPI1 12 1.92 0.00017 1.38 0.0049 8 28000 6.45 26910 142 76 Plays an important role in several metabolic pathways.D-glyceraldehyde 3-phosphate = 
glycerone phosphate.
Cytoplasmic
1935 TRIOSEPHOSPHATE ISOMERASE 1 IPI00465028 TPI1 12 2.66 0.0013 1.24 0.13 7.05 30027 6.45 26910 121 80 Plays an important role in several metabolic pathways.D-glyceraldehyde 3-phosphate = 
glycerone phosphate.
Cytoplasmic
1780 TROPOMYOSIN 4 . IPI00010779 TPM4 19 1.23 0.36 2.46 0.0078 4.21 34694 4.67 28619 94 52 Binds to actin filaments in muscle and nonmuscle cells. Plays a central role, in 
association with the troponin complex, in the calcium dependent regulation of vertebrate 
striated muscle contraction.
Cytoplasmic
1807 TROPOMYOSIN ALPHA 3 CHAIN, SPLICE 
ISOFORM 2
IPI00218319 TPM3 1 1.45 0.0014 2.3 0.0014 4.3 30000 4.75 29243 157 72 Binds to actin filaments in muscle and nonmuscle cells Cytoplasmic
1988 UBIQUITIN CARBOXYL-TERMINAL 
HYDROLASE ISOZYME L1
IPI00018352 UCHL1 4 -7.76 1.80E-07 8.37 0.0011 5.29 26456 5.33 25151 54 53 Ubiquitin-protein hydrolase involved both in the processing of ubiquitin precursors and of 
ubiquinated proteins. This enzyme is a thiol protease that recognizes and hydrolyzes a 
peptide bond at the C-terminal glycine of ubiquitin. Also binds to free monoubiquitin and 
may prevent its degradation in lysosomes. The homodimer may have ATP-independent 
ubiquitin ligase activity.
Cytoplasmic
1300 VIMENTIN IPI00418471 VIM 10 -3.93 0.0011 1.73 0.00091 4.42 49313 5.09 53604 237 72 Class-III intermediate filaments found in various non-epithelial cells, especially 
mesenchymal cells.
Cytoplasm
1333 VIMENTIN  IPI00418471 VIM 10 -5.45 0.00021 1.58 0.013 4.27 48191 5.09 53604 172 61 Class-III intermediate filaments found in various non-epithelial cells, especially 
mesenchymal cells.
Cytoplasm
821 WD-REPEAT PROTEIN 1, SPLICE ISOFORM 2 IPI00216256 WDR1 4 3.83 9.80E-05 -3.94 0.0007 7.52 62632 6.41 58593 225 68 Induces disassembly of actin filaments in conjunction with ADF/cofilin family proteins (By 
similarity).
Cytoplasmic  
 
Table 3.2 Differentially expressed proteins identified from a comparison between the two MMCT hybrid cell line pools and 
their respective parental cell lines. Protein features that were matched across all gels with a fold change ≥ 2 fold where p ≤ 0.05 
were identified. Ratios are shown with T-test P values for the TOV-112D hybrid pool/TOV-112D parental and the TOV-21G hybrid 
pool/TOV-21G  parental.  Orange  shading  indicates  a  ≥2-fold  increase  in  expression  and  green  indicates  a  ≥  2-fold  decrease  in 
expression. Yellow shading indicates multiple identifications from a single gel spot. Protein identification by LC-MS/MS is indicated 
in the ‘Score’ column by square brackets, all other identifications were performed by MALDI-TOF MS peptide mass finger printing. 
The identifications were scored according to algorithms that take into account mass accuracy and peptide coverage. The search criteria 
used allowed +/- 50 ppm mass error and up to 2 missed cleavages. The identified proteins were also verified by comparison of their 
theoretical molecular weights and pIs with gel position on the master gel.   111 
In summary there were a few proteins that displayed concordant changes in expression in 
both  cell  models.  Notable  among  these  was  cofilin,  a  protein  responsible  for  rapid 
recycling  of  the  actin  cytoskeleton  associated  with  membrane  ruffling,  motility  and 
cytokinesis. It is also required for controlled changes in cell shape, organelle and ion 
transport and receptor-mediated responses to external stimuli (Bailly and Jones 2003). 
Cofilin  has  been  reported  as  a  potential  marker  of  ovarian  cancer  associated  with 
proliferation and differentiation (Martoglio, Tom et al. 2000).  
 
Despite  the  obvious  heterogeneity  between  the  cell  models  many  of  the  proteins 
identified have been implicated in human cancers. Annexin A1 and A3 belong to the 
annexin family of calcium-dependent phospholipid binding proteins that are involved in a 
diverse  range  of  cellular  functions  that  include  cell  division,  apoptosis,  vesicle 
trafficking,  calcium  signalling  and  growth  regulation.  Differential  expression  of  the 
annexins has been commonly found in a host of human cancers (Sinha, Hutter et al. 1998; 
Xia, Hu et al. 2002; Garcia Pedrero, Fernandez et al. 2004; Pedrero, Fernandez et al. 
2005; Wang, Wu et al. 2006; Xue, Teng et al. 2007; Inokuchi, Lau et al. 2009). Aldehyde 
dehydrogenase  1A1  (ADH1A1)  displayed  the  most  extreme  change  in  expression 
between the cell models. This protein belongs to the aldehyde dehydrogenase family of 
proteins which are involved in the conversion of aldehydes to their corresponding acids 
through  NAD(P)
+-dependent  reactions.  Recently,  ADH1A1  was  reported  to  strongly 
promote  cell  invasion  in  pancreatic  cancer  cell  lines  (Walsh,  Dowling  et  al.  2008). 
Adenosylhomocysteinase is an important regulator of methylation and it is known that 
expression of  some  tumour  suppressor  genes  can be  blocked  by  methylation  of  their   112 
promoter regions (Garinis, Patrinos et al. 2002; Kloor and Osswald 2004; Esteller 2005; 
Christoph,  Kempkensteffen  et  al.  2006;  Ha  and  Califano  2006;  Soufir,  Queille  et  al. 
2007). GRB2 overexpression has been reported in human breast, bladder and prostate 
cancer (Daly, Binder et al. 1994; Watanabe, Shinohara et al. 2000; Dankort, Maslikowski 
et al. 2001; Gril, Vidal et al. 2007). Galectin-1 may regulate apoptosis, cell proliferation 
and  cell  differentiation  and  has  been  identified  as  a  counter  receptor  for  the  ovarian 
cancer  antigen,  CA125  (Seelenmeyer,  Wegehingel  et  al.  2003).  T-complex  protein  1 
epsilon subunit is a cytosolic chaperonin and its over-expression has been observed in 
colon cancer cells (Coghlin, Carpenter et al. 2006). This protein was identified from two 
protein spots, each displaying contrasting expression between the two cell models. This 
may be attributed to a post-translational modification on one of the isoforms. However, 
one spot contains another protein, myo-inostitol 1-phosphatase synthase A1, which may 
reflect the change in expression. Gel features containing multiple protein identifications 
are a drawback of 2D-DIGE since it is difficult to know which protein is responsible for 
the change in signal. Few chromosome 18 gene products were also found. This is likely 
to reflect the complexity of the proteome versus the genome and the measurement of 
secondary  effects  of  tumour  suppression  effected  through  chromosome  18  gene 
expression,  the  products  of  which  were  not  detected  or  identified  due  to  their  low 
abundance or poor resolution on 2D gels. 
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3.2 2D-DIGE analysis of Parent:Single Hybrid clones 
The  lack  of  common  trends  between  the  two  cell  line  systems  and  large  changes  in 
abundance recorded in the previous experiment raised concerns that variation between 
individual clones within each pool had biased the results. To further examine this, a direct 
comparison by 2D-DIGE was applied to each parental cell line and two hybrids from 
each pool. The hybrid cell lines were chosen based on their potent tumour suppression in 
nude mice. Hybrid cell lines 18-D-22, 18-D-23  and 18-G-5, 18-G-1.26 were selected 
from hybrid pool ‘A’ and ‘B’ respectively. The samples were labelled and run in the 
same manner as before in two experiments. 2D gel images were curated, matched and 
statistical analysis carried out and protein features displaying reproducible changes were 
selected. This time, protein features displaying a change in average abundance ≥ 1.5 fold 
(n=3,  p  value  <0.05)  were  selected  for  identification  as  fewer  changes  overall  were 
observed.  
 
3.2.1 Identification of differentially expressed proteins in 
single clone comparisons 
In the first experiment, the parental cell lines were compared to the hybrid clones 18-D-
22  and  18-G-5.  A  total  of  2088  protein  spots  were  detected  and  matched.  Direct 
comparison  of  the  TOV-112D  and  18-D-22  cell  lysates  resulted  in  a  total  of  28 
differentially expressed protein spots with 19 up-regulated and 9 down-regulated. Direct 
comparison between the TOV-21G and 18-G-5 cell lysates resulted in a total of 8 spots   114 
changing, of which 5 were up-regulated and 3 down-regulated. In the second experiment 
the parental cell lines were compared to the hybrid clones 18-D-23 and 18-G-1.26. A 
total of 2089 protein features were detected. The direct comparison of the TOV-112D and 
18-D-23 cell lysates resulted in a total of 28 differentially expressed protein spots with 11 
up-regulated and 17 down-regulated. Direct comparison between the TOV-21G and 18-
G-1.26 cell lysates resulted in a total of 214 protein spots changing with 78 up-regulated 
and  136  down-regulated.  Again,  there  was  little  overlap  in  differential  expression 
between  the  two  cell  models  with  only  1  common  feature  displaying  contrasting 
expression. The analysis of the two cell models were treated separately from this point 
on. The protein features displaying a change in abundance ≥ 1.5 fold (n=3, p value ≤ 
0.05)  were  selected. The  spots were  matched  to a  CCB stained  gel  image  and spots 
excised and digested with trypsin for identification by mass spectrometry.  A total of 30 
spots were picked in the first experiment. Of these, 28 were identified by LC-MS/MS 
with high confidence (Fig 3.2 and Table 3.3A). A total of 189 spots were picked in the 
second experiment and of these, 137 were identified by LC-MS/MS with a high degree of 
confidence (Fig 3.3 and Table 3.3B).  
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Figure 3.2 Annotated master gel image of identified proteins in the first single hybrid clone: parental comparison experiment. 
The  gel  pieces  were  digested  with  trypsin  and  MS/MS  peak  lists  were  compared  against  theoretically  expected  tryptic  peptide 
fragment masses in the NCBI and IPI databases using the Mascot search engine including +2 and +3 peptide charge, and a mass 
tolerance of ±50ppm. The identifications were accepted when at least two peptide sequences matched an entry with MOWSE scores 
above the p=0.05 threshold value. The identified proteins were also verified by comparison of their theoretical molecular weights and 
pIs with gel position on the master gel. 
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Figure 3.3 Representative 2D gel image of differential protein expression in TOV-
112D cell line and its hybrid cell line 18-D-23. 150µg of total cell lysate from TOV-
112D and 18-D-23 were labelled with Cy3 and Cy5 respectively, mixed and loaded with 
an equal amount of internal standard labelled with Cy2. This superimposed image was 
created in Adobe Photoshop and shows TOV-112D in red and 18-D-22 in blue 
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Master No. Name IPI No. Gene Symbol Chr. Av. Ratio T-test
Av. 
Ratio T-test pI (gel) Mw (gel) pI (pred) Mw (pred) Score % Cov Peptides Matched Function  Localisation
511  No ID 1.31 0.43 -2.17 0.021 5 95000
653  No ID -1.52 0.032 1.53 0.064 6.63 85427
1029  No ID 1.51 0.00037 -1.11 0.65 6.43 61762
1345  No ID 1.5 0.023 -1.39 0.021 4.46 44307
1492  Unpickable -2.67 0.032 1 0.96 6.25 38078
1497  Unpickable -1.53 0.0046 -1.11 0.31 6.39 37710
1910  Unpickable 1.96 0.006 -1.03 0.76 4.35 18308
1919  Unpickable 1.29 0.28 1.9 0.023 5.79 18026
1959  Unpickable 1.61 0.11 1.8 0.018 4.34 15857
1230 Adenosylhomocysteinase IPI00012007 AHCY 20 1.52 0.017 1.19 0.024 6.07 50367 5.92 48124 779 40 21 Control of S-adenosyl-L-methionine-dependent methylation 
via regulation of adenosylhomocysteine concentrations
Cytoplasm
1042 Aldehyde dehydrogenase family 7 
member A1
IPI00221234 ALDH7A1 5 1.74 0.037 1.05 0.72 6.77 61046 6.24 55714 659 34 19 Oxidoreductase activity. An aldehyde + NAD(+) + H(2)O = 
an acid + NADH.
Cytoplasm
1505 Annexin A1 IPI00218918 ANXA1 9 -2.83 0.0059 -1.02 0.75 6.56 37418 6.64 38787 1329 74 53 Inflammatory response, phospholipase A2 inhibitor activity, 
calcium-dependent phospholipid binding
Cytoplasm
1542 Annexin A1 IPI00218918 ANXA1 9 -3.05 0.0043 -1.15 0.051 6.8 40000 6.64 38787 1329 74 53 Inflammatory response, phospholipase A2 inhibitor activity, 
calcium-dependent phospholipid binding
Cytoplasm
1573 Annexin A1 IPI00218918 ANXA1 9 -1.06 0.68 1.59 0.0051 4.68 34353 6.64 38787 258 20 11 Inflammatory response, phospholipase A2 inhibitor activity, 
calcium-dependent phospholipid binding
Cytoplasm
1562 Annexin A2 IPI00455315 ANXA2 15 1.67 0.0026 1.09 0.17 7.11 35095 7.56 38677 1511 71 50 Cytoskeletal protein binding, calcium-dependent 
phospholipid binding, phospholipase inhibitor activity, 
skeletal development
Cytoplasm
1584 Annexin A2 IPI00455315 ANXA2 15 1.68 0.0022 1.06 0.45 7.11 33889 7.56 38677 1511 71 50 Cytoskeletal protein binding, calcium-dependent 
phospholipid binding, phospholipase inhibitor activity, 
skeletal development
Cytoplasm
1835 Annexin A2 IPI00455315 ANXA2 15 1.62 0.0099 1.29 0.23 4.64 21721 7.56 38677 871 59 22 Cytoskeletal protein binding, calcium-dependent 
phospholipid binding, phospholipase inhibitor activity, 
skeletal development
Cytoplasm
1003 Aspartyl-tRNA synthetase IPI00216951 DARS 2 -1.54 0.0033 1.31 0.052 6.53 62973 6.11 57499 [124] 37 21 Belongs to the class-II aminoacyl-tRNA synthetase family. Cytoplasm
1835 Calpain, small subunit 1 IPI00025084 CAPNS1 19 1.62 0.0099 1.29 0.23 4.64 21721 5.82 34050 545 45 19 Calcium-regulated thiol-protease. Proteolysis of substrates 
involved in cytoskeletal remodelling and signal transduction
Cytoplasm; PM on calcium 
binding
2036 Calpain, small subunit 1 IPI00025084 CAPNS1 19 1.78 0.043 1.01 0.93 6.57 9776 5.05 28453 [62] 57 12 Calcium-regulated thiol-protease. Proteolysis of substrates 
involved in cytoskeletal remodelling and signal transduction
Cytoplasm; PM on calcium 
binding
2026 Cofilin-1 IPI00012011 CFL1 11 1.87 0.018 -1.09 0.56 6 10000 8.26 18588 515 72 19 Actin binding protein. Controls reversible actin 
polymerization. Major component of intranuclear and 
cytoplasmic actin rods
Intranuclear and cytoplasmic
1990 Cytochrome b5 outer mitochondrial 
membrane isoform precursor
IPI00303954 CYB5B 16 2.53 0.026 1.31 0.24 4.45 14003 4.88 16798 217 62 7 Electron carrier for several membrane bound oxygenases Mitochondrial outer 
membrane
1304 Cytoplasmic antiproteinase 3; 
SerpinB9
IPI00032139 SERPINB9 6 1.64 0.041 -1.36 0.014 5.43 47056 5.61 43004 459 28 12 Serine endopeptidase inhibitor activity. Tumour antigen Cytoplasm
1844 Eukaryotic translation initiation factor 
4E
IPI00027485 EIF4E 4 1.86 0.0058 1.41 0.43 5.66 21386 5.79 25310 251 30 6 RNA binding. Protein biosynthesis Cytoplasm
1781 Nicotinamide N-methyltransferase IPI00027681 NNMT 11 1.74 0.017 -1.12 0.54 5.14 23476 5.56 30011 345 31 10 Nicotinamide N-methyltransferase activity Cytoplasm
1953 Peroxiredoxin 2, isoform b IPI00027350 PRDX2 19 1.51 0.033 1 0.97 5.25 16199 6.13 16036 92 78 17 Protection from redox stress Cytoplasm
1838 Phosphoribosyl transferase domain 
containing 1 (PRTFDC1), similar to 
hypoxanthine phosphoribosyl 
transferase
IPI00024644 PRTFDC1 10 1.51 0.022 1.02 0.91 5.59 21637 5.76 25828 257 37 9 Nucleoside metabolism. Phosphoribosyl transferase 
activity
Cytoplasm
800 Prolyl 4-hydroxylase alpha-1 subunit 
precursor, splice isoform 2
IPI00218682 P4HA1 10 1.11 0.65 -1.68 0.042 5.69 75295 5.7 61214 809 38 23 Catalyzes the posttranslational formation of 4- 
hydroxyproline in -Xaa-Pro-Gly- sequences in collagens 
and other proteins.
ER lumen
845 Protein disulfide-isomerase 
precursor
IPI00010796 P4HB 17 1.53 0.024 -1.29 0.13 4.52 70895 4.76 57480 1515 55 45 Catalyzes the rearrangement of -S-S- bonds in proteins. ER lumen
959 Retinal dehydrogenase 1 IPI00218914 ALDH1A1 9 -1.34 0.026 1.55 0.024 6.5 64584 6.29 55323 212 12 6 Binds free retinal and retinol-binding protein-bound retinal. 
Can oxidize retinaldehyde to retinoic acid
Cytoplasm
985 Retinal dehydrogenase 1 IPI00218914  ALDH1A1 9 -2.63 0.0037 -1.2 0.36 6.57 63588 6.29 55323 771 54 25 Binds free retinal and retinol-binding protein-bound retinal. 
Can oxidize retinaldehyde to retinoic acid
Cytoplasm
1830 Rho GDP-dissociation inhibitor 1 IPI00003815 ARHGDIA 17 1.08 0.29 -1.52 0.00065 4.69 21805 5.02 23250 403 51 14 GTPase activator activity. RhoGDP-dissociation inhibitor 
activity. Rho protein signal transduction.
Cytoplasm
18-G-5 clone/21G 
parental 
18-D-22 clone/112D 
parental 
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980 Splicing factor 45 IPI00176706 RBM17 10 -1.42 0.38 1.52 0.04 5.6 60000 5.76 45162 141 14 5 Involved in the regulation of alternative splicing and the 
utilization of cryptic splice sites.
Nuclear
1573 Thioredoxin-like protein 1 IPI00305692 TXNL1 18 -1.06 0.68 1.59 0.0051 4.68 34353 4.84 32499 329 44 11 Signal transduction, electron transporter activity, apoptosis, 
transport, thiol-disulfide exchange activity
Cytoplasm
2015 Transcription factor BTF3, isoform 1 IPI00221035 BTF3 5 -1.55 0.023 1.23 0.33 7.02 11092 9.41 22211 116 24 5 Transcription regulator activity Nuclear
1577 Tumor protein p53 inducible protein 
3 (PIG3)
IPI00472656 TP53I3 2 1.67 0.0097 1.21 0.2 6.85 34553 7.05 34601 569 45 14 Oxidoreductase activity. Gene contains a microsatellite 
polymorphism that may be associated with cancer 
susceptibility
Cytoplasmic
959 Vacuolar sorting protein 4b IPI00182728 VPS4B 18 -1.34 0.026 1.55 0.024 6.5 64584 6.75 49443 625 45 20 Intracellular protein transport Cytoplasmic and prevacuolar 
endosomes
1162 Vimentin IPI00418471 VIM 10 3.5 0.021 -2 0.21 4.57 53597 5.06 53545 [65] 37 21 Class-III intermediate filament protein. Structural 
constituent of cytoskeleton found in non-epithelial cells
Cytoplasm
1248 Vimentin IPI00418471 VIM 10 1.78 0.002 -1.2 0.016 4.6 50000 5.06 53545 892 46 25 Class-III intermediate filament protein. Structural 
constituent of cytoskeleton found in non-epithelial cells
Cytoplasm  
Table 3.3A Proteins differentially expressed in the two epithelial ovarian cancer cell models identified by LC-MS/MS and 
MALDI-TOF MS PMF. Protein  features that  were matched across all  gels with a fold change ≥ 1.5 fold where p  ≤ 0.05 are 
identified. Ratios are shown for 18-D-22 vs. TOV-112D parental and 18-G-5 clone vs. TOV-21G parental. Orange shading indicates 
an increase in expression and green indicates a decrease. Yellow shading indicates multiple identifications from a single gel spot. 
Protein identifications were made by database searching of peptide ion fragments from LC-MS/MS or by MALDI-TOF MS PMF, the 
latter indicated by [ ] in the ‘Score’ column. The identifications were scored according to algorithms that take into account mass 
accuracy and peptide coverage. The search criteria used allowed +/- 50 ppm mass error and up to 2 missed cleavages. The identified 
proteins were also partly verified by comparison of their theoretical molecular weights and pIs with gel position on the master gel. 
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Master No. Protein Name HGNC IPI Chr.
Av. 
Ratio T-test
Av. 
Ratio T-test
Gel 
Mwt Gel pI
Pred 
Mwt
Pred 
pI Score %Cov
No. of 
Pep's Function Localisation
1731 14-3-3 protein zeta/delta YWHAZ  IPI00021263  8 1.3 0.13 1.72 0.022 27190 4.52 27899 4.73 114 12 3 Adapter protein implicated in the regulation of a 
large spectrum of both general and specialized 
signaling pathway. Binds to a large number of 
partners, usually by recognition of a 
phosphoserine or phosphothreonine motif. Binding 
generally results in the modulation of the activity of 
the binding partner.
Cytoplasm. Melanosome
1163 26S protease regulatory 
subunit 6B, isoform 1
PSMC4 IPI00020042 19 1.02 0.87 -1.89 0.0019 58218 5.08 47451 5.09 [231] 54 26 The 26S protease is involved in the ATP-
dependent degradation of ubiquitinated proteins. 
The regulatory (or ATPase) complex confers ATP 
dependency and substrate specificity to the 26S 
complex.
Cytoplasm. Nucleus
876 60 kDa heat shock 
protein, mitochondrial 
precursor
HSPD1 IPI00784154 2 1.06 0.5 -2.54 0.0025 72203 5.41 61187 5.7 1314 49 29 Implicated in mitochondrial protein import and 
macromolecular assembly. May facilitate the 
correct folding of imported proteins. May also 
prevent misfolding and promote the refolding and 
proper assembly of unfolded polypeptides 
generated under stress conditions in the 
mitochondrial matrix.
Mitochondrion; mitochondrial 
matrix
1496 60S acidic ribosomal 
protein P0
RPLP0 IPI00008530 12 1.4 0.26 2.14 0.0085 39335 6.45 34423 5.71 62 6 1 Ribosomal protein P0 is the functional equivalent 
of E.coli protein L10.
Cytoplasm
1289 Actin, aortic smooth 
muscle
ACTA2 IPI00008603 10 1.13 0.14 1.61 0.016 51207 6.14 42381 5.23 181 12 4 Actins are highly conserved proteins that are 
involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells.
Cytoplasm
1157 Actin, cytoplasmic 1 ACTB IPI00021439 7 1.13 0.48 -1.71 0.022 58635 5.53 42052 5.29 203 10 4 Actins are highly conserved proteins that are 
involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells.
Cytoplasm
1270 Actin, cytoplasmic 1 ACTB IPI00021439 7 1.07 0.77 1.97 0.0031 51500 5.82 42052 5.29 881 44 19 Actins are highly conserved proteins that are 
involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells.
Cytoplasm
1287 Actin, cytoplasmic 1 ACTB IPI00021439 7 1.12 0.031 1.65 0.00066 51281 6.03 42052 5.29 565 32 11 Actins are highly conserved proteins that are 
involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells.
Cytoplasm
1296 Actin, cytoplasmic 1 ACTB IPI00021439 7 -1.03 0.83 1.52 0.031 50555 5.11 42052 5.29 591 26 13 Actins are highly conserved proteins that are 
involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells.
Cytoplasm
1297 Actin, cytoplasmic 1 ACTB IPI00021439 7 1 0.97 1.83 0.00062 50627 5.25 42052 5.29 539 23 12 Actins are highly conserved proteins that are 
involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells.
Cytoplasm
1308 Actin, cytoplasmic 1 ACTB IPI00021439 7 1.05 0.59 1.73 0.042 49697 5.45 42052 5.29 861 36 22 Actins are highly conserved proteins that are 
involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells.
Cytoplasm
1894 Adenine 
phosphoribosyltransferas
e
APRT  IPI00218693 16 1.19 0.0014 -1.65 0.008 19983 5.13 19766 5.78 109 11 2 Catalyzes a salvage reaction resulting in the 
formation of AMP, that is energically less costly 
than de novo synthesis.
Cytoplasm
1309 Adenosine kinase, short 
isoform
ADK IPI00234368 10 -1.11 0.04 1.71 0.0027 50053 8.12 39078 6.23 [91] 32 11 ATP dependent phosphorylation of adenosine and 
other related nucleoside analogs to 
monophosphate derivatives. Serves as a potential 
regulator of concentrations of extracellular 
adenosine and intracellular adenine nucleotides.
Cytoplasm
1489 AIP AH receptor-
interacting protein
AIP IPI00010460 11 -1.83 0.0012 -1.19 0.25 39504 7.84 38096 6.09 216 14 4 May play a positive role in AHR-mediated 
(aromatic hydrocarbon receptor) signaling, 
possibly by influencing its receptivity for ligand 
and/or its nuclear targeting.
Cytoplasm
18D23/112D 18G1.26/21G
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861 Alpha-internexin INA IPI00001453 10 1.26 0.61 -2.33 0.0034 72616 5.61 55528 5.34 [96] 30 19 Class-IV neuronal intermediate filament able to 
self-assemble. Involved in the morphogenesis of 
neurons. May form an independent structural 
network without involvement of other 
neurofilaments or may cooperate with NF-L to 
form the filamentous backbone to which NF-M and 
NF-H attach to form the cross-bridges.
Cytoplasm
1494 Annexin A1 ANXA1 IPI00218918 9 -2.37 0.00064 -1.07 0.61 39448 8.07 38918 6.57 764 45 12 Calcium/phospholipid-binding protein which 
promotes membrane fusion and is involved in 
exocytosis. This protein regulates phospholipase 
A2 activity. It seems to bind from two to four 
calcium ions with high affinity.
Cytoplasm
1592 Annexin A3 ANXA3 IPI00024095 4 1.09 0.63 1.67 0.038 34796 6.12 36524 5.63 319 18 4 Inhibitor of phospholipase A2, also possesses anti- 
coagulant properties. Also cleaves the cyclic bond 
of inositol 1,2-cyclic phosphate to form inositol 1-
phosphate.
Cytoplasm
1599 Annexin A4 protein ANXA4  IPI00555692  2 1.09 0.13 -2.38 0.0053 34109 6.32 33759 5.64 237 19 6 Calcium ion binding Cytoplasm
959 Calreticulin precursor CALR IPI00020599 19 -1.12 0.096 -1.65 0.0012 68201 4.22 48283 4.29 162 12 11 Molecular calcium binding chaperone promoting 
folding, oligomeric assembly and quality control in 
the ER via the calreticulin/calnexin cycle. This 
lectin interacts transiently with almost all of the 
monoglucosylated glycoproteins that are 
synthesized in the ER. Interacts with the DNA-
binding domain of NR3C1 and mediates its 
nuclear export.
Endoplasmic reticulum; 
endoplasmic reticulum 
lumen. Cytoplasm; cytosol. 
Secreted protein; 
extracellular space; 
extracellular matrix. Cell 
surface.
1006 Calreticulin precursor CALR IPI00020599  19 -1.14 0.028 -2.06 0.00036 66001 4.22 48283 4.29 687 23 15 Molecular calcium binding chaperone promoting 
folding, oligomeric assembly and quality control in 
the ER via the calreticulin/calnexin cycle. This 
lectin interacts transiently with almost all of the 
monoglucosylated glycoproteins that are 
synthesized in the ER. Interacts with the DNA-
binding domain of NR3C1 and mediates its 
nuclear export.
Endoplasmic reticulum; 
endoplasmic reticulum 
lumen. Cytoplasm; cytosol. 
Secreted protein; 
extracellular space; 
extracellular matrix. Cell 
surface.
1979 Cofilin-1 CFL1  IPI00012011  11 1.15 0.4 -2.35 0.02 15372 3.95 18719 8.22 299 37 6 Controls reversibly actin polymerization and 
depolymerization in a pH-sensitive manner. It has 
the ability to bind G- and F-actin in a 1:1 ratio of 
cofilin to actin. It is the major component of 
intranuclear and cytoplasmic actin rods.
Nucleus. Cytoplasm. 
2000 Cofilin-1 CFL1 IPI00012011 11 1.39 0.00022 -1.63 8.30E-05 14499 7.52 18719 8.22 143 15 2 Controls reversibly actin polymerization and 
depolymerization in a pH-sensitive manner. It has 
the ability to bind G- and F-actin in a 1:1 ratio of 
cofilin to actin. It is the major component of 
intranuclear and cytoplasmic actin rods.
Nucleus. Cytoplasm. 
1890 Cytidylate kinase CMPK  IPI00219953 1 1.49 0.004 -1.74 0.0017 22000 6.2 26180 8.17 196 15 10 Catalyzes specific phosphoryl transfer from ATP to 
UMP and CMP.
Nucleus. Cytoplasm. 
Note=Mainly nuclear.
2002 Destrin DSTN  IPI00473014 20 1.03 0.42 -3.4 1.20E-05 14335 6.52 18950 8.06 222 19 4 Actin-depolymerizing protein. Severs actin 
filaments (F- actin) and binds to actin monomers 
(G-actin). Acts in a pH- independent manner.
Cytoplasm
2011 Destrin DSTN  IPI00473014 20 1.66 0.0055 -1.02 0.96 13000 8 18950 8.06 78 44 12 Actin-depolymerizing protein. Severs actin 
filaments (F- actin) and binds to actin monomers 
(G-actin). Acts in a pH- independent manner.
Cytoplasm
1599 DnaJ homolog subfamily 
C member 9
DNAJC9/M
RPS16
IPI00154975 10 1.09 0.13 -2.38 0.0053 34109 6.32 30062 5.58 127 11 3 Chaperone activity. Cytoplasm
   121 
1128 Dynactin 2 DCTN2 IPI00220503 12 1.11 0.32 -1.62 0.024 59902 5.16 44906 5.06 138 4 3 Modulates cytoplasmic dynein binding to an 
organelle, and plays a role in prometaphase 
chromosome alignment and spindle organization 
during mitosis.
Cytoplasm. Membrane; 
peripheral membrane 
protein.
1702 Elongation factor 1-beta EEF1B2 IPI00178440  2 1.08 0.092 -1.78 0.0015 28541 4.31 24788 4.5 94 18 9 EF-1-beta and EF-1-delta stimulate the exchange 
of GDP bound to EF-1-alpha to GTP.
Nucleus
1758 Endoplasmic reticulum 
protein ERp29 precursor
ERP29  IPI00024911 12 -1.31 9.70E-05 -1.67 1.20E-05 26313 7.32 29032 6.77 176 11 3 Does not seem to be a disulfide isomerase. Plays 
an important role in the processing of secretory 
proteins within the ER, possibly by participating in 
the folding of proteins in the ER.
Endoplasmic reticulum; 
endoplasmic reticulum 
lumen. 
1759 Endoplasmic reticulum 
protein ERp29 precursor
ERP29  IPI00024911 12 -1.62 0.00025 -1.65 0.0016 26351 6.48 29032 6.77 126 14 3 Does not seem to be a disulfide isomerase. Plays 
an important role in the processing of secretory 
proteins within the ER, possibly by participating in 
the folding of proteins in the ER.
Endoplasmic reticulum; 
endoplasmic reticulum 
lumen. 
1768 Enoyl-CoA hydratase, 
mitochondrial precursor
ECHS1  IPI00024993 10 1.06 0.0024 -1.55 0.00011 25793 7.04 31823 8.34 496 40 9 Straight-chain enoyl-CoA thioesters from C4 up to 
at least C16 are processed, although with 
decreasing catalytic rate.
Mitochondrion; mitochondrial 
matrix.
2017 Eukaryotic translation 
initiation factor 5A-1, 
isoform 2
EIF5A  IPI00376005 17 1.07 0.11 -5.4 2.60E-06 13368 6.38 20442 6.52 207 21 4 The precise role of eIF-5A in protein biosynthesis 
is not known but it functions by promoting the 
formation of the first peptide bond.
Nucleus
1635 F-actin capping protein 
subunit beta, , isoform 1 
CAPZB IPI00026185  1 1.09 0.27 1.54 0.0081 32172 6.14 31616 5.36 344 21 7 F-actin capping proteins bind in a Ca(2+)-
independent manner to the fast growing ends of 
actin filaments (barbed end) thereby blocking the 
exchange of subunits at these ends. Unlike other 
capping proteins (such as gelsolin and severin), 
these proteins do not sever actin filaments.
Cytoplasm
1068 Fascin FSCN1 IPI00163187 7 1.21 0.12 1.97 0.0016 63057 8.41 55123 6.84 176 6 4 Organizes filamentous actin into bundles with a 
minimum of 4.1:1 actin/fascin ratio. Probably 
involved in the assembly of actin filament bundles 
present in microspikes, membrane ruffles, and 
stress fibers.
Cytoplasm
1848 FLJ25678, highly similar 
to purine nucleoside P
NP IPI00017672  14 1.2 0.12 -1.93 0.00063 22270 7.13 32758 6.71 146 13 3 Belongs to the PNP/MTAP phosphorylase family. Cytoplasm
428 Full-length cDNA clone 
CS0CAP007YF18 of 
Thymus of Homo sapiens
HSP90AA1 IPI00796844 14 1.02 0.91 1.63 0.0019 95074 5.75 49669 5.33 [85] 28 15 Molecular chaperone. Has ATPase activity (By 
similarity).
Cytoplasm (By similarity).
1304 Fumarylacetoacetase FAH IPI00031708 15 1.11 0.12 1.75 0.0045 49910 8.34 46743 6.46 [64] 23 11 Amino-acid degradation; L-phenylalanine 
degradation; acetoacetate and fumarate from L-
phenylalanine: step 6 [final step].
Cytoplasm
1067 Glutamate 
dehydrogenase 1
GLUD1 IPI00016801 10 1.23 0.011 1.57 0.00045 63418 8.79 61701 7.66 [98] 35 19 Belongs to the Glu/Leu/Phe/Val dehydrogenases 
family
Mitochondrion; mitochondrial 
matrix.
1090 Glutathione synthetase GSS IPI00010706 20 1.18 0.068 1.5 9.70E-05 62253 6.13 52523 5.67 [141] 34 22 Sulfur metabolism; glutathione biosynthesis; 
glutathione from L-cysteine and L-glutamate: step 
2 [final step].
Cytoplasm
837 Heat shock protein 60 
kDa , mitochondrial 
precursor
HSPD1 IPI00784154 2 1.11 0.55 -2.16 0.01 74080 5.42 61187 5.7 177 52 25 Implicated in mitochondrial protein import and 
macromolecular assembly. May facilitate the 
correct folding of imported proteins. May also 
prevent misfolding and promote the refolding and 
proper assembly of unfolded polypeptides 
generated under stress conditions in the 
mitochondrial matrix.
Mitochondrion; mitochondrial 
matrix.
 
   122 
839 Heat shock protein 60 
kDa, mitochondrial 
precursor
HSPD1 IPI00784154 2 1.32 0.45 -1.8 0.0013 74292 5.29 61187 5.7 1403 42 23 Implicated in mitochondrial protein import and 
macromolecular assembly. May facilitate the 
correct folding of imported proteins. May also 
prevent misfolding and promote the refolding and 
proper assembly of unfolded polypeptides 
generated under stress conditions in the 
mitochondrial matrix.
Mitochondrion; mitochondrial 
matrix.
1772 Heat-shock protein beta-
1
HSPB1  IPI00025512 7 1.72 0.00049 2.65 0.00014 25501 6.01 22826 5.98 324 30 6 Involved in stress resistance and actin 
organization.
Cytoplasm. Nucleus. 
Cytoplasmic in interphase 
cells. Colocalizes with mitotic 
spindles in mitotic cells. 
Translocates to the nucleus 
during heat shock.
1467 Hepatoma-derived growth 
factor
HDGF IPI00020956 1 -1.02 0.61 -3.06 0.024 40705 4.56 26886 4.7 [76] 37 10 Heparin-binding protein, with mitogenic activity for 
fibroblasts.
Cytoplasm
1364 Heterogeneous nuclear 
ribonucleoprotein A/B, 
isoform 2
HNRPAB IPI00334587  5 -1.04 0.18 -1.63 0.011 45688 8.17 36059 6.49 240 13 4 Binds single-stranded RNA. Has a high affinity for 
G- rich and U-rich regions of hnRNA. Also binds to 
APOB mRNA transcripts around the RNA editing 
site.
Nucleus
1346 Heterogeneous nuclear 
ribonucleoprotein D0, 
isoform 1
HNRPD IPI00028888 4 -1 0.96 -1.77 0.0026 46942 8.91 38581 7.62 446 22 8 Binds with high affinity to RNA molecules that 
contain AU-rich elements (AREs) found within the 
3'-UTR of many proto- oncogenes and cytokine 
mRNAs. Also binds to double- and single- 
stranded DNA sequences in a specific manner 
and functions a transcription factor.
Nucleus.Component of 
ribonucleosomes.
1346 Heterogeneous nuclear 
ribonucleoprotein D0, 
isoform 3
HNRPD IPI00220684 4 -1 0.96 -1.77 0.0026 46942 8.91 32985 8.23 82 33 8 Binds with high affinity to RNA molecules that 
contain AU-rich elements (AREs) found within the 
3-prime untranslated regions of many 
protooncogenes and cytokine mRNAs. Also binds 
to double- and single-stranded DNA sequences in 
a specific manner and functions a transcription 
factor.
Nucleus
1524 Heterogeneous nuclear 
ribonucleoprotein D-like, 
isoform 3
HNRPDL IPI00045498 4 1.16 0.0011 -2.26 0.00031 38339 8.4 27346 8.76 98 10 2 Acts as a transcriptional regulator. Promotes 
transcription repression. Promotes transcription 
activation in differentiated myotubes (By similarity). 
Binds to double- and single-stranded DNA 
sequences. Binds to the transcription suppressor 
CATR sequence of the COX5B promoter (By 
similarity). Binds with high affinity to RNA 
molecules that contain AU-rich elements (AREs) 
found within the 3'-UTR of many proto-oncogenes 
and cytokine mRNAs.
Nucleus. Cytoplasm.
1111 Heterogeneous nuclear 
ribonucleoprotein H1
HNRPH1 IPI00013881 5 1.02 0.79 -1.83 0.038 61023 6.98 49484 5.89 [110] 42 21 Involved in the splicing process and participates in 
early heat shock-induced splicing arrest. Due to 
their great structural variations the different 
isoforms may possess different functions in the 
splicing reaction.
Nucleus
1524 Heterogeneous nuclear 
ribonucleoprotein H3, 
isoform 1
HNRPH3 IPI00013877 10 1.16 0.0011 -2.26 0.00031 38339 8.4 36960 6.37 81 9 2 Involved in the splicing process and participates in 
early heat shock-induced splicing arrest. Due to 
their great structural variations the different 
isoforms may possess different functions in the 
splicing reaction.
Nucleus
866 Heterogeneous nuclear 
ribonucleoprotein K
HNRPK IPI00647717 9 1.18 0.43 -1.95 0.042 72513 5.31 42009 5.43 638 32 13 One of the major pre-mRNA-binding proteins. 
Binds tenaciously to poly(C) sequences. Likely to 
play a role in the nuclear metabolism of hnRNAs, 
particularly for pre-mRNAs that contain cytidine-
rich sequences. Can also bind poly(C) single- 
stranded DNA (By similarity).
Nucleus
624 HSPA5 protein HSPA5 IPI00003362 9 1.05 0.81 -2.83 0.0022 86659 4.85 72492 5.07 [145] 40 24 Probably plays a role in facilitating the assembly of 
multimeric protein complexes inside the ER.
Endoplasmic reticulum; 
endoplasmic reticulum 
lumen.
969 HSPA5 protein HSPA5 IPI00003362  9 1.42 0.34 -2.42 0.022 68007 5.85 72492 5.07 821 29 14 Probably plays a role in facilitating the assembly of 
multimeric protein complexes inside the ER.
Endoplasmic reticulum; 
endoplasmic reticulum 
lumen.
635 HSPA5 protein HSPA5 IPI00003362  9 -1.18 0.2 -2.57 0.016 86043 4.95 72492 5.07 [151] 40 32 Probably plays a role in facilitating the assembly of 
multimeric protein complexes inside the ER.
Endoplasmic reticulum; 
endoplasmic reticulum 
lumen.    123 
1270 Hypothetical protein 
LOC345651
IPI00003269 5 1.07 0.77 1.97 0.0031 51500 5.82 42318 5.39 [224] 15 11 Unknown Cytoplasm
1287 Hypothetical protein 
LOC345651
IPI00003269 5 1.12 0.031 1.65 0.00066 51281 6.03 42318 5.39 [235] 17 13 Unknown Cytoplasm
1408 Isocitrate dehydrogenase 
[NAD] subunit alpha, 
isoform 2
IDH3A IPI00607898 15 -1.1 0.25 -3.06 0.0015 43278 6.7 34940 6.02 [90] 30 11 Isocitrate + NAD(+) = 2-oxoglutarate + CO(2) + 
NADH.
Mitochondrion.
1061 Keratin, type II 
cytoskeletal 8
KRT8 IPI00793917 12 1 0.94 1.86 0.011 63147 6.29 26765 4.66 [91] 48 12 Intermediate filament protein Cytoplasm
294 KIAA1187 protein MAP7D1 IPI00645814 1 -1.56 0.037 -1.26 0.2 101518 6.45 88958 10.06 [72] 21 19 Hypothetical protein DKFZp761F19121 
(Fragment).
Cytoplasm
1496 Lactate dehydrogenase B 
chain
LDHB IPI00219217 12 1.4 0.26 2.14 0.0085 39335 6.45 36900 5.71 101 10 3 Anaerobic glycolysis; final step.S)-lactate + 
NAD(+) = pyruvate + NADH. 
Cytoplasm
1119 Lupus La protein SSB IPI00009032 2 1.09 0.28 -1.92 0.015 60676 8.05 46979 6.68 [67] 9 12 La protein plays a role in the transcription of RNA 
polymerase III. It is most probably a transcription 
termination factor. Binds to the 3' termini of 
virtually all nascent polymerase III transcripts. It is 
associated with precursor forms of RNA 
polymerase III transcripts including tRNA and 
4.5S, 5S, 7S, and 7-2 RNAs.
Nucleus (Probable).
1121 Lupus La protein SSB IPI00009032 2 1.02 0.83 -2.85 0.0021 60590 7.65 46979 6.68 [115] 47 25 La protein plays a role in the transcription of RNA 
polymerase III. It is most probably a transcription 
termination factor. Binds to the 3' termini of 
virtually all nascent polymerase III transcripts. It is 
associated with precursor forms of RNA 
polymerase III transcripts including tRNA and 
4.5S, 5S, 7S, and 7-2 RNAs.
Nucleus (Probable).
1353 Macrophage capping 
protein
CAPG IPI00027341 2 1.1 0.87 -2.24 0.00027 46146 7.01 38779 5.88 77 28 13 Calcium-sensitive protein which reversibly blocks 
the barbed ends of actin filaments but does not 
sever preformed actin filaments. May play an 
important role in macrophage function. May play a 
role in regulating cytoplasmic and/or nuclear 
structures through potential interactions with actin. 
May bind DNA.
Cytoplasm. Nucleus. 
1770 Membrane-associated 
progesterone receptor 
component 2
PGRMC2  IPI00005202 4 1.15 0.19 3.49 0.00012 29000 4.3 26211 5.2 105 7 1 Membrane-associated progesterone receptor 
component 2 (Progesterone membrane-binding 
protein) (Steroid receptor protein DG6).
Cytoplasm. Memebrane.
1659 Nuclear protein Hcc-1 CIP29 IPI00014938  12 1.01 0.81 -3.22 0.00091 30737 7.73 23713 6.1 400 32 8 May have nucleic acid binding capability that may 
participate in important transcriptional or 
translational control of cell growth, metabolism and 
carcinogenesis.
Nucleus
1426 Nucleophosmin, isoform 
2
NPM1 IPI00220740 5 -1.05 0.51 -4.7 0.0045 42605 5.35 29617 4.47 101 6 3 Associated with nucleolar ribonucleoprotein 
structures and bind single-stranded nucleic acids. 
It may function in the assembly and/or transport of 
ribosome.
Nucleus
1443 Nucleophosmin, isoform 
2
NPM1 IPI00220740 5 1.15 0.21 -2.6 0.0017 41942 5.83 29617 4.47 86 5 2 Associated with nucleolar ribonucleoprotein 
structures and bind single-stranded nucleic acids. 
It may function in the assembly and/or transport of 
ribosome.
Nucleus
1960 Parathymosin PTMS IPI00550020 12 2.21 0.00022 1.31 0.21 16674 4.56 11523 4.14 59 10 1 Parathymosin may mediate immune function by 
blocking the effect of prothymosin alpha which 
confers resistance to certain opportunistic 
infections.
Cytoplasm
1484 PDZ and LIM domain 
protein 1
PDLIM1 IPI00010414 10 -1.09 0.59 -2.5 0.00083 39448 8.43 36505 6.56 [119] 45 14 Cytoskeletal protein that may act as an adapter 
that brings other proteins (like kinases) to the 
cytoskeleton.
Cytoplasm, Cytoplasm; 
cytoskeleton (By similarity). 
Associates with actin stress 
fibers (By similarity)    124 
1890 Peroxiredoxin-2 PRDX2  IPI00027350 19 1.49 0.004 -1.74 0.0017 22000 6.2 22049 5.66 369 31 7 Involved in redox regulation of the cell. Reduces 
peroxides with reducing equivalents provided 
through the thioredoxin system. It is not able to 
receive electrons from glutaredoxin. May play an 
important role in eliminating peroxides generated 
during metabolism. Might participate in the 
signaling cascades of growth factors and tumor 
necrosis factor-alpha by regulating the intracellular 
concentrations of H(2)O(2).
Cytoplasm
1797 Peroxiredoxin-6 PRDX6  IPI00220301  1 1.26 0.039 -2.14 0.00022 24854 7.79 25133 6 410 38 8 Involved in redox regulation of the cell. Can reduce 
H(2)O(2) and short chain organic, fatty acid, and 
phospholipid hydroperoxides. May play a role in 
the regulation of phospholipid turnover as well as 
in protection against oxidative injury.
Cytoplasm, Lysosome, 
Cytoplasmic vesicle (By 
similarity).
748 Phenylalaninyl-tRNA 
synthetase beta chain
FARSB IPI00300074 2 1.22 0.14 -1.91 0.033 79667 8.51 66715 6.4 [71] 23 13 ATP + L-phenylalanine + tRNA(Phe) = AMP + 
diphosphate + L-phenylalanyl-tRNA(Phe).
Cytoplasm (by simularity)
1694 Prohibitin PHB  IPI00017334  17 1.27 0.011 1.5 0.0025 28868 5.82 29843 5.57 273 18 5 Prohibitin inhibits DNA synthesis. It has a role in 
regulating proliferation. As yet it is unclear if the 
protein or the mRNA exhibits this effect. May play 
a role in regulating mitochondrial respiration 
activity and in aging.
Mitochondrion; mitochondrial 
inner membrane (By 
similarity).
1695 Prohibitin PHB  IPI00017334 17 1.06 0.55 -2.44 0.00023 28951 6.37 29843 5.57 126 55 5 Prohibitin inhibits DNA synthesis. It has a role in 
regulating proliferation. As yet it is unclear if the 
protein or the mRNA exhibits this effect. May play 
a role in regulating mitochondrial respiration 
activity and in aging.
Mitochondrion; mitochondrial 
inner membrane (By 
similarity).
1609 Proliferating cell nuclear 
antigen
PCNA IPI00021700 20 1.24 0.054 1.85 0.0055 33387 4.45 29092 4.57 497 42 11 This protein is an auxiliary protein of DNA 
polymerase delta and is involved in the control of 
eukaryotic DNA replication by increasing the 
polymerase's processibility during elongation of 
the leading strand.
Nucleus
1657 Proteasome subunit 
alpha type 1, short 
isoform
PSMA1  IPI00016832 11 1.16 0.046 1.55 0.0079 30693 7.95 29822 6.15 207 22 5 Ubiquitin- and ATP-dependent proteasomal 
degradation
Cytoplasm. Nucleus.
1840 Proteasome subunit 
alpha type 2
PSMA2  IPI00219622 7 1.15 0.083 1.6 0.0092 22719 8.7 25996 6.92 180 17 4 Ubiquitin- and ATP-dependent proteasomal 
degradation
Cytoplasm. Nucleus.
1770 Proteasome subunit 
alpha type 5
PSMA5  IPI00291922 1 1.15 0.19 3.49 0.00012 29000 4.3 26565 4.74 219 26 5 Ubiquitin- and ATP-dependent proteasomal 
degradation
Cytoplasm. Nucleus.
953 Protein disulfide-
isomerase A3 precursor
PDIA3 IPI00025252 15 -1.05 0.67 -1.76 0.00077 68493 6.49 57146 5.98 98 35 10 Catalyzes the rearrangement of -S-S- bonds in 
proteins.
Endoplasmic reticulum; 
endoplasmic reticulum lumen 
(By similarity).
909 Protein disulfide-
isomerase precursor
P4HB IPI00010796 17 -1.1 0.11 -2.2 0.0021 70074 4.52 57480 4.76 113 24 10 This multifunctional protein catalyzes the 
formation, breakage and rearrangement of 
disulfide bonds.
Endoplasmic reticulum 
lumen. Melanosome. May 
also be secreted or 
associated with  plasma 
membrane
926 Protein disulphide-
isomerase precursor
P4HB IPI00010796 17 -1.05 0.49 -3.68 5.70E-06 69576 4.7 57480 4.76 [163] 42 26 This multifunctional protein catalyzes the 
formation, breakage and rearrangement of 
disulfide bonds.
Endoplasmic reticulum 
lumen. Melanosome. May 
also be secreted or 
associated with  plasma 
membrane
939 Protein disulphide-
isomerase precursor
P4HB IPI00010796 17 -1.29 0.26 -2.27 0.022 69477 6.21 57146 5.98 70 6 2 This multifunctional protein catalyzes the 
formation, breakage and rearrangement of 
disulfide bonds.
Endoplasmic reticulum 
lumen. Melanosome. May 
also be secreted or 
associated with  plasma 
membrane    125 
957 Protein disulphide-
isomerase precursor
P4HB IPI00010796 17 -1.16 0.00086 -2.04 3.50E-05 68396 6.42 57146 5.98 [102] 37 28 This multifunctional protein catalyzes the 
formation, breakage and rearrangement of 
disulfide bonds.
Endoplasmic reticulum 
lumen. Melanosome. May 
also be secreted or 
associated with  plasma 
membrane
1872 Protein DJ-1 PARK7  IPI00298547 1 1.08 0.28 -2.63 0.0002 21338 7.39 20050 6.33 279 32 6 Acts as a positive regulator of androgen receptor- 
dependent transcription. May function as a redox-
sensitive chaperone and as a sensor for oxidative 
stress. Prevents aggregation of SNCA. Protects 
neurons against oxidative stress and cell death. 
Plays a role in fertilization. Has no proteolytic 
activity. Has cell-growth promoting activity and 
transforming activity.
Nucleus. Cytoplasm. 
Associated with mitochondria 
in some cells, particularly 
after oxidative stress. 
Detected in tau inclusions in 
brains from 
neurodegenerative disease 
patients.
1029 Retinal dehydrogenase 1 ALDH1A1 IPI00218914 9 -2.04 0.0068 -1.01 0.93 65159 8.1 55323 6.29 [144] 31 11 Binds free retinal and cellular retinol-binding 
protein- bound retinal. Can convert/oxidize 
retinaldehyde to retinoic acid (By similarity).
Cytoplasm
1577 Ribose-phosphate 
pyrophosphokinase I
PRPS1 IPI00219616 X 1.08 0.54 -1.52 0.014 35956 8.73 35194 6.56 84 12 2 ATP + D-ribose 5-phosphate = AMP + 5-phospho- 
alpha-D-ribose 1-diphosphate.
Cytoplasm
1372 RNA-binding protein 4, 
isoform 1
RBM4 IPI00003704 11 1.17 0.12 -1.77 0.047 45493 8.36 40688 6.61 102 35 3 May play a role in alternative splice site selection 
during pre-mRNA processing.
Nucleus. Nucleus; nucleolus. 
Cytoplasm. Note=May 
undergo continuous 
nucleocytoplasmic shuttling.
1929 RNA-binding protein 8A,  
isoform 2
RBM8A IPI00216659  1 1.1 0.36 -3.96 6.20E-05 18241 5.2 19805 5.64    10 12 Part of a post-splicing multiprotein complex 
involved in both mRNA nuclear export and mRNA 
surveillance. Involved in nonsense-mediated 
decay (NMD) of mRNAs containing premature 
stop codons. Associates preferentially with 
mRNAs produced by splicing. Does not interact 
with pre-mRNAs, introns, or mRNAs produced 
from intronless cDNAs. Associates with both 
nuclear mRNAs and newly exported cytoplasmic 
mRNAs. Complex with MAGOH is a component of 
the nonsense mediated decay (NMD) pathway.
Cytoplasm. Nucleus.
1089 RuvB-like2 RUVBL2 IPI00009104 19 -1.03 0.62 1.68 0.013 62253 5.93 51165 5.49 64 31 14 Possesses single-stranded DNA-stimulated 
ATPase and ATP- dependent DNA helicase (5' to 
3') activity. Component of the NuA4 histone 
acetyltransferase complex which is involved in 
transcriptional activation of select genes principally 
by acetylation of nucleosomal histone H4 and 
H2A. This modification may both alter nucleosome 
- DNA interactions and promote interaction of the 
modified histones with other proteins which 
positively regulate transcription. This complex may 
be required for the activation of transcriptional 
programs associated with oncogene and proto-
oncogene mediated growth induction, tumor 
suppressor mediated growth arrest and replicative 
senescence, apoptosis, and DNA repair.
Nucleus; nuclear matrix. 
Nucleus; nucleoplasm. 
Cytoplasm. Membrane.
1057 Selenium binding protein 
1
SELENBP
1
IPI00745729 1 1.05 0.76 1.56 0.032 63690 7.23 53598 6.03 [132] 36 15 Selenium-binding protein which may be involved in 
the sensing of reactive xenobiotics in the 
cytoplasm. May be involved in intra-Golgi protein 
transport (By similarity).
Nucleus. Cytoplasm, cytosol. 
Cytoplasm; Peripheral 
membrane protein (By 
similarity).
1314 Septin-2 Sep-02 IPI00014177 2 1.32 0.077 1.65 0.0076 49133 7.71 41689 6.15 340 18 5 Involved in cytokinesis (Potential). Cytoplasm
1394 Serine-threonine kinase 
receptor-associated 
protein
STRAP IPI00294536 12 1.17 0.077 1.75 0.015 44277 4.99 38756 4.98 231 18 20 The SMN complex plays an essential role in 
spliceosomal snRNP assembly in the cytoplasm 
and is required for pre-mRNA splicing in the 
nucleus. STRAP may play a role in the cellular 
distribution of the SMN complex.
Cytoplasm. Nucleus.
   126 
1157 Similar to Polyprotein DNAJC14 IPI00783777 12 1.13 0.48 -1.71 0.022 23916 5.69 61 27 10 Regulation of transport of the dopamine D1 
receptor by a new membrane-associated ER 
protein.
Cytoplasm
1942 Sorcin SRI IPI00027175  7 1.24 0.054 -3.36 7.30E-05 17577 5.08 21947 5.32 108 22 9 This protein has been shown to bind calcium with 
high affinity.
Cytoplasm
877 Splicing factor U2AF 65 
kDa subunit
U2AF2 IPI00031556 19 -1.01 0.95 -1.55 0.04 71690 7.23 53809 9.19 66 20 4 Necessary for the splicing of pre-mRNA. Binds to 
the polypyrimidine tract of introns early during 
spliceosome assembly. Required for the export of 
mRNA out of the nucleus, even if the mRNA is 
encoded by an intron-less gene.
Nucleus
2011 Stathmin STMN1  IPI00479997 1 1.66 0.0055 -1.02 0.96 13000 8 17292 5.76 254 44 6 Involved in the regulation of the microtubule (MT) 
filament system by destabilizing microtubules. 
Prevents assembly and promotes disassembly of 
microtubules.
Cytoplasm
2017 Stathmin 1 variant 
(Fragment)
STMN1  IPI00744618  1 1.07 0.11 -5.4 2.60E-06 13368 6.38 15264 8.47 123 26 9 Involved in the regulation of the microtubule (MT) 
filament system by destabilizing microtubules. 
Prevents assembly and promotes disassembly of 
microtubules.
Cytoplasm
661 Stress-70 protein, 
mitochondrial precursor
HSPA9 IPI00007765 5 -1.27 0.0024 -1.82 0.00032 84825 5.84 73920 5.87 [221] 50 41 Implicated in the control of cell proliferation and 
cellular aging. May also act as a chaperone.
Mitochondrion.
1465 SUGT1 32 kDa protein SUGT1 IPI00009149 13 1.16 0.12 -2 0.038 40589 5.01 32347 5.28 140 11 2 Involved in kinetochore function and required for the G1/S and G2/M transitions (by simularity) Nucleus.
2000 Superoxide dismutase 1 SOD1  IPI00218733 21 1.39 0.00022 -1.63 8.30E-05 14499 7.52 16340 5.87 195 16 2 Important antioxidant catalyzes the dismutation of 
superoxide into oxygen and hydrogen peroxide.
Cytoplasm.
1879 Thioredoxin-dependent 
peroxide reductase
PRDX3 IPI00024919 10 1.21 0.38 -1.54 0.014 20946 4.9 28017 7.67 267 28 33 Involved in redox regulation of the cell. Protects 
radical-sensitive enzymes from oxidative damage 
by a radical- generating system. Acts 
synergistically with MAP3K13 to regulate the 
activation of NF-kappa-B in the cytosol.
Mitochondrion.
1878 Thioredoxin-dependent 
peroxide reductase
PRDX3  IPI00024919 10 -1.02 0.75 -1.73 0.00043 21006 7.26 28017 7.67 324 27 6 Involved in redox regulation of the cell. Protects 
radical-sensitive enzymes from oxidative damage 
by a radical- generating system. Acts 
synergistically with MAP3K13 to regulate the 
activation of NF-kappa-B in the cytosol.
Mitochondrion.
1778 Triosephosphate 
isomerase 1 variant
TPI1  IPI00465028 12 1.28 0.046 -1.75 5.40E-05 25283 8.16 31057 5.65 457 35 8 Glycolytic pathway Cytoplasm
1809 Triosephosphate 
isomerase 1 variant
TPI1  IPI00465028 12 -1.17 0.28 -1.55 0.04 24121 7.39 31057 5.65 423 34 7 Glycolytic pathway Cytoplasm
1638 Tropomyosin alpha-4 
chain,  isoform 1
TPM4  IPI00010779 19 1.17 0.011 -2.05 0.00044 31807 4.64 28619 4.67 357 18 7 Implicated in stabilizing cytoskeleton actin 
filaments.
Cytoplasm
1412 Tropomyosin isoform TPM1 IPI00018853 15 1.26 0.07 -2.16 0.041 43155 4.65 28517 4.89 132 11 3 Implicated in stabilizing cytoskeleton actin 
filaments.
Cytoplasm
1040 Tubulin 46 kDa protein TUBA1B IPI00792677 12 1.32 0.24 1.69 0.027 64054 5.39 46797 4.96 [89] 36 12 Constituent of microtubules Cytoplasm
1057 Tubulin 46 kDa protein TUBA1B IPI00792677 12 1.05 0.76 1.56 0.032 63690 7.23 46797 4.96 [73] 29 11 Constituent of microtubules Cytoplasm
1030 Tubulin alpha-3 chain TUBA1A IPI00180675  12 1.07 0.84 1.6 0.01 64881 5.56 50788 4.94 385 25 8 Major constituent of microtubules Cytoplasm
1627 Tubulin folding cofactor B TBCB  IPI00293126  19 1.06 0.41 -2.11 0.02 31989 4.91 27594 5.06 345 26 6 Binds to alpha-tubulin folding intermediates after 
their interaction with cytosolic chaperonin in the 
pathway leading from newly synthesized tubulin to 
properly folded heterodimer. Involved in regulation 
of tubulin heterodimer dissociation. May function 
as a negative regulator of axonal growth.
Cytoplasm
1083 Tubulin, beta polypeptide TUBB IPI00645452 6 -1.17 0.39 1.62 0.011 62342 5.8 48135 4.7 [91] 27 15 Major constituent of microtubules Cytoplasm
1125 Tubulin, beta polypeptide TUBB IPI00645452 6 1.15 0.41 1.6 0.033 58000 5 48135 4.7 120 33 14 Major constituent of microtubules Cytoplasm
1372 Twinfilin-2 TWF2 IPI00550917 3 1.17 0.12 -1.77 0.047 45493 8.36 39751 6.37 162 9 5 Actin-binding protein involved in motile and 
morphological processes. Inhibits actin 
polymerization, likely by sequestering G-actin. By 
capping the barbed ends of filaments, it also 
regulates motility. Seems to play an important role 
in clathrin-mediated endocytosis and distribution of 
endocytic organelles (By similarity).
Cytoplasm. Cytoplasm; 
perinuclear region. 
Note=Perinuclear and G-
actin-rich cortical actin 
structures sublocalization.
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2021 Ubiquitin-conjugating 
enzyme E2 N
UBE2N  IPI00003949 12 1.06 0.4 -1.89 0.003 13000 5.2 17184 6.13 157 26 4 Mediates transcriptional activation of target genes. 
Plays a role in the control of progress through the 
cell cycle and differentiation. Plays a role in the 
error-free DNA repair pathway and contributes to 
the survival of cells after DNA damage.
Cytoplasm
1835 Ubiquitin-conjugating 
enzyme E2-25 kDa, 
isoform 1
HIP2  IPI00021370 4 -1.52 0.013 1.94 0.00015 22947 5.23 22507 5.33 290 30 6 Catalyzes the covalent attachment of ubiquitin to 
other proteins. Mediates the selective degradation 
of short-lived and abnormal proteins. Ubiquitinates 
huntingtin. May mediate foam cell formation by the 
suppression of apoptosis of lipid-bearing 
macrophages through ubiquitination and 
subsequence degradation of p53.
Cytoplasm (By similarity).
1017 UV excision repair protein 
RAD23 homolog B
RAD23B IPI00008223 9 1.56 0.013 1.38 0.084 65252 4.73 43202 4.79 69 20 6 Plays a central role both in proteosomal 
degradation of misfolded proteins and DNA repair. 
Central component of a complex required to 
couple deglycosylation and proteasome-mediated 
degradation of misfolded proteins in the 
endoplasmic reticulum that are retrotranslocated in 
the cytosol. Involved in DNA excision repair by 
stabilizing XPC protein. May play a part in DNA 
damage recognition and/or in altering chromatin 
structure to allow access by damage-processing 
enzymes.
Nucleus. Cytoplasm (By 
similarity).
570 Villin 2 (Ezrin) VIL2 IPI00746388 6 1.02 0.65 -1.55 0.0038 89420 7.51 69816 5.94 [284] 45 42 Probably involved in connections of major 
cytoskeletal structures to the plasma membrane.
Membrane
727 Vimentin VIM IPI00418471 10 -1.03 0.48 -1.54 0.0043 80811 6.07 53545 5.06 [105] 36 20 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
786 Vimentin VIM IPI00418471 10 1.45 0.041 -2.48 0.00091 76768 5.18 53545 5.06 181 22 32 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
821 Vimentin VIM IPI00418471 10 1.11 0.85 -2.56 0.0085 74930 5.63 53545 5.06 [208] 59 36 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
837 Vimentin VIM IPI00418471  10 1.11 0.55 -2.16 0.01 74080 5.42 53676 5.06 114 38 16 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
839 Vimentin VIM IPI00418471 10 1.32 0.45 -1.8 0.0013 74292 5.29 53676 5.06 803 32 17 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
851 Vimentin VIM IPI00418471 10 -1.15 0.64 -1.94 0.046 73449 4.93 53676 5.06 165 8 4 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
857 Vimentin VIM IPI00418471  10 1.23 0.27 -2.07 0.0037 73659 5.18 53545 5.06 105 14 16 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
861 Vimentin VIM IPI00418471 10 1.26 0.61 -2.33 0.0034 72616 5.61 53676 5.06 303 74 23 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
866 Vimentin VIM IPI00418471 10 1.18 0.43 -1.95 0.042 72513 5.31 53676 5.06 296 14 6 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
903 Vimentin VIM IPI00418471 10 1.67 0.0025 -1.52 0.16 70374 5.18 53676 5.06 576 27 13 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
924 Vimentin VIM IPI00418471 10 -1.04 0.74 -1.76 0.043 69675 5.84 53676 5.06 864 35 17 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
927 Vimentin VIM IPI00418471 10 1.14 0.63 -1.68 0.0083 69774 5.59 53545 5.06 [94] 28 20 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
1093 Vimentin VIM IPI00418471 10 -1.04 0.5 1.57 0.023 61988 5.21 53545 5.06 146 47 24 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
1137 Vimentin VIM IPI00418471 10 1.2 0.4 2.28 0.022 58551 4.65 53676 5.06 578 21 11 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
   128 
 
969 Vimentin 50 kDa protein VIM IPI00827679 10 1.42 0.34 -2.42 0.022 68007 5.85 49680 5.19 [111] 34 28 Vimentins are class-III intermediate filaments 
found in various non-epithelial cells
Cytoplasm
560 Vinculin isoform  VCL IPI00291175 10 1.02 0.92 -1.65 0.0053 89931 7.15 117220 5.83 [106] 24 26 Involved in cell adhesion. May be involved in 
attachment of actin-based microfilaments to the 
plasma membrane.
Cytoplasm, cytoskeleton.
213 Vinculin isoform meta-
VCL
VCL IPI00307162 10 1.29 0.064 -1.77 4.10E-05 106712 7.16 124292 5.5 97 5 2 Involved in cell adhesion. May be involved in 
attachment of actin-based microfilaments to the 
plasma membrane.
Cytoplasm, cytoskeleton.
1858 Von Hippel-Lindau 
binding protein 1
VBP1  IPI00334159 X -1.21 0.083 -2.26 0.011 21799 7.51 26690 9.1 123 12 3 Binds specifically to cytosolic chaperonin (c-CPN) 
and transfers target proteins to it. Binds to nascent 
polypeptide chain and promotes folding in an 
environment in which there are many competing 
pathways for nonnative proteins.
Cytoplasm. Nucleus.
 
 
Table 3.3B Differentially expressed proteins identified from a comparison between the whole cell lysates of hybrid clones 18-D-
23 and 18-G-1.26 and their respective parental cell lines. Protein features that were matched across all gels with a fold-change 
≥1.5-fold  where  p≤  0.05  are  identified.  Orange  shading  indicates  an  increase  in  expression  and  green  indicates  a  decrease  in 
expression. Yellow shading indicates a protein feature with two distinct protein identifications. Protein identifications were made by 
database searching of peptide ion fragments from LC-MS/MS or by MALDI-TOF MS PMF, the latter indicated by [ ] in the ‘Score’ 
column. The identifications were scored according to algorithms that take into account mass accuracy and peptide coverage. The 
search criteria used allowed +/- 50 ppm mass error and up to 2 missed cleavages. The identified proteins were partly verified by 
comparison of their theoretical molecular weights and pIs with gel position on the master gel. 
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The analysis of single hybrids in the first experiment showed that the overall differential 
expression was greatly reduced and the changes in abundance were significantly less; the 
largest change in protein abundance detected was 3.5-fold for an isoform of vimentin. 
Unlike  with  the  analysis  of  the  pools,  there  were  no  opposing  expression  changes 
identified between the two cell models and all of the changes were unique to one cell 
model or the other when using an average ≥ 1.5-fold (p <0.05, n=3) threshold. Notably, 
one gene product of Ch18 was identified (thioredoxin-like protein 1; up-regulated in 18-
G-5).  A  number  of  the  proteins  identified  in  this  analysis  were  also  observed  in  the 
previous 2D-DIGE analysis of the hybrid pools, although their changes in abundance 
were not equivalent between the two experiments (Table 3.4). For example, annexin A1 
was down-regulated in the TOV-112D hybrid pool and the single 18-D-22 clone (-2.25 
and –2.83 fold, respectively) and cofillin was up-regulated in the TOV-112D hybrid pool 
and  in  the  18-G-5  clone  (+3.1  and  +1.87  fold  respectively).  However, 
adenosylhomocysteinase which was significantly up-regulated (+4.97 fold) in the TOV-
21G pool and down-regulated (-1.9 fold) in the TOV-112D pool was moderately, but 
significantly, up-regulated in both the single 18-G-5 and 18-D-22 hybrid clones (+1.19 
and  +1.52  fold,  respectively).  This  difference  is  not  likely  to  be  a  product  of  poor 
reproducibility  of  the  technique  since  2D-DIGE  has  been  proved  to  be  a  highly 
reproducible method (Gharbi, Gaffney et al. 2002) and is most likely to be accounted for 
by the heterogeneity of the clones. Proteins of interest included eukaryotic translation 
initiation  factor  4E  (EIF4E)  and  PIG3  which  were  up-regulated  (1.86  and  1.67  fold 
respectively)  in  the 18-D-22/parental  comparison  as  was peroxiredoxin  2  (1.51  fold), 
whilst  basic  transcription  factor  BTF3  isoform  1  was  down-regulated  (-1.55  fold).  In   130 
contrast, thioredoxin-like protein 1 displayed a significant increase in expression (1.59 
fold)  in the  18-G-5  hybrid  clone,  although  annexin  A1  was  also  identified  from  this 
protein spot with an equally high significance score. Notably, there were less similarities 
between the TOV-21G hybrid pool and the single 18-G-5 clone than in the other cell 
models, suggesting greater clonal variation in the clear cell model. 
 
As  previously  observed  there  were  few  proteins  identified  showing  the  same 
directionality  of  altered  expression  in  both  parent:hybrid  cell  models.  This  was  also 
evident  in  the  second  analysis  of  hybrid  clones  18-D-23  and  18-G-1.26,  where  only 
endoplasmic  reticulum  protein  ERp29  precursor  displayed  a  decrease  in  average 
abundance in both hybrid cell lines, whilst heat-shock protein beta 1 (Hsp27) was up-
regulated in both the 18-D-23 and 18-G-1.26 cell lines (Table 3.3B). In contrast to the 
previous  comparison, only two  proteins displayed  opposite  regulation  in the  two  cell 
models.  These  were  ubiquitin-conjugating  enzyme  E2-25  kDa  isoform  1  which  was 
down-regulated (-1.52 fold) in the 18-D-23 hybrid cell line and up-regulated (1.94 fold) 
in the 18-G-1.26 hybrid cell line, and an isoform of the intermediate filament protein 
vimentin, which was up-regulated in the 18-D-23 hybrid (1.67 fold) and down-regulated 
(-1.52 fold) in the 18-G-1.26 hybrid versus their parental cell lines. Of the 15 isoforms of 
vimentin identified, all except two were significantly down-regulated in the 18-G-1.26 
hybrid cell line. Vimentin is known to be multiply phosphorylated and subject to protease 
cleavage, so these differential changes may be caused by PTMs. 
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 In the comparison of the hybrid cell line 18-D-23 and its parental cell line TOV-112D, a 
total of 12 protein isoforms were identified from 11 protein features (Fig 3.3). Some of 
these  changes  were  also  observed  in  the  18-D-22  vs  TOV-112D  comparison.  These 
included annexin A1 (down-regulated over two-fold in the 18-D-23 and 18-D-22 clones); 
retinol dehydrogenase 1 (down-regulated over two-fold in both clones) and a matched 
isoform of vimentin which was up-regulated by 1.67 fold in the 18-D-23 hybrid cell line 
and by 1.78 fold in the 18-D-22 hybrid cell line.  
 
The comparison between the hybrid cell line 18-G1.26 and its parent cell line TOV-21G 
resulted in a total of 136 protein identifications from 123 distinct protein features. Of 
these,  91  displayed  significant  down-regulation  and  34  displayed  significant  up-
regulation.  Eukaryotic  translation  initiation  factor  5A-1  isoform  2  (EIF-5A2)  and  a 
fragment  of  stathmin  1  variant  were  identified  from  a  gel  feature  which  was  down-
regulated the most (5.4 fold).  Stathmin was seen previously as being significantly up-
regulated in the TOV-21G/hybrid pool. At this stage it is difficult to know whether the 
change  observed  is  from  EIF5A  or  stathmin,  particularly  since  the  predicted  and 
measured pI’s and MW’s are not concordant for the stathmin and EIF5A identifications, 
respectively. This highlights a drawback of 2D-DIGE, but also implicates the detection of 
differential post-translational modifications. The most up-regulated protein feature also 
gave  two  different  protein identifications.  Membrane-associated  progesterone  receptor 
component 2 and proteasome subunit alpha type 5 were identified from a protein feature 
being up-regulated 3.49 fold. Both proteins have a similar Mw and pI.  
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Several proteins were identified from multiple gel features, calreticulin precursor was 
identified in 2 protein spots. Expression was significantly down-regulated in the 18-G-
1.26/parental  comparison  (-1.65  and  -2.06  fold).  However,  expression  was  only 
marginally  down-regulated  in  only  one  of  the  gel  spots  of  the  18-D-23/parental 
comparison. Calreticulin precursor is a calcium-binding chaperone promoting folding, 
oligomeric assembly and quality control in the ER via the calreticulin/calnexin cycle. 
Another protein identified twice and significantly down-regulated (-4.7 and -2.6 fold) in 
the  18-G-1.26/parental  comparison  was  nucleophosmin.    This  abundant  and  highly 
conserved phosphoprotein shuttles between the nucleus and cytoplasm and is involved in 
ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell 
proliferation and regulation of tumor suppressors TP53/p53 and ARF. Prohibitin was also 
identified in two gel spots and expression was shown to be significantly up-and down-
regulated in each in the 18-G-1.26/parental comparison. A post-translational modification 
is the likely cause for contrasting expression for a protein found in two closely located 
gel-spots. 
 
Other proteins of interest included proliferating cell nuclear antigen (PCNA) which was 
significantly up-regulated (1.85 fold) in the 18-G-1.26/parental comparison and protein 
DJ-1,  which  was  found  to  be  significantly  down-regulated  (-2.63  fold)  in  the  18-G-
1.26/parental  comparison.  Of  the  identifications,  several  were  proteins  with  structural 
functions. These included the actin binders cofilin, F-actin capping protein, macrophage 
capping protein, twinfilin 2, destrin, fascin, PDLIM1, ezrin, dynactin and septin. F-actin 
capping  protein  and  fascin  were  up-regulated  in  the  hybrid  clone  18-G-1.26  whilst   133 
macrophage capping protein displayed down-regulation (-2.24 fold) in the same hybrid 
clone.  Destrin  was  identified  from  two  closely  located  protein  spots.  These  spots 
displayed  differential  regulation  in  the  two  hybrid  clones  under  analysis.  Although 
abundant proteins, these changes suggest changes to the actin skeleton in response to 
tumour suppression. Finally, von Hippel-Lindau binding protein 1 (VBP1) was identified 
and  displayed  down-regulation  in  hybrid  clone  18-G-1.26.  VBP1  binds  Von  Hippel-
Lindau, a well known tumour suppressor protein and chaperones it to the nucleus or 
cytoplasm. 
 
3.2.2 Common protein identifications and expression 
changes 
A number of proteins were identified as common to all three experiments described in 
this chapter, including annexin Al, cofilin-1, peroxiredoxin 2, vimentin, PDI and ERp29 
(Table 3.4). Annexin A1 displayed down-regulation (-2.25 fold) in the TOV-112D hybrid 
pool  and  up-regulation  (2.28  fold)  in  the  TOV-21G  hybrid  pool.  In  accordance,  two 
isoforms were down-regulated in the 18-D-22 and 18-D-23 hybrid clones and a single 
isoform was up-regulated in the 18-G-5 hybrid clone. Cofilin displayed concordant up-
regulation (3.1, 1.69  and 1.87 fold, respectively)  in both hybrid pools and the single 
hybrid clone 18-D-22, whilst being down-regulated (-2.35 fold) in the hybrid clone 18-G-
1.26. Peroxiredoxin 2 displayed down-regulation (-4.25 fold) in the TOV-112D hybrid 
pool  and  up-regulation  (5.71  fold)  in  the  TOV-21G  hybrid  pool,  whilst  being  up-
regulated (1.51 and 1.49 fold, respectively) in the hybrid clones 18-D-22 and 18-D-23   134 
and down-regulated (-1.74 fold) in the hybrid clone 18-G-1.26. Vimentin was down-
regulated (-2 and -1.94 fold, respectively) in the 18-G-5 and 18-G-1.26 hybrid clones, 
two isoforms of ERp29 displayed down-regulation in the hybrid clones 18-D-23 and 18-
G-1.26 and adenosylhomocysteinase displayed up-regulation in the hybrid clones 18-D-
22 and 18-G-5, whilst PDI showed no common changes in expression. 
 
The  lack  of  common  changes  in  both  clones  of  both  cell  lines  makes  selection  of 
candidates for further testing very difficult and reveals the extensive variation between 
the cell models.    135 
A .Data from pools
Av. Ratio T-test Av. Ratio T-test
Adenosylhomocysteinase -1.9 0.021 4.97 0.00017
Annexin A1 -2.25 0.00071 2.75 0.00018
Cofilin-1 3.1 1.70E-05 1.69 0.00066
Peroxiredoxin 2 -4.25 0.00012 5.71 0.00014
Vimentin -3.93 0.0011 1.73 0.00091
Vimentin -1.84 7.80E-05 5.38 0.00029
Vimentin -5.45 0.00021 1.58 0.013
Protein disulphide-isomerase -1.12 0.0035 2.71 0.000043
ERp29 -1.46 0.00074 3.42 0.00024
B. Data from single clones
Av. Ratio T-test Av. Ratio T-test Av. Ratio T-test Av. Ratio T-test
Adenosylhomocysteinase 1.52 0.017 1.19 0.024
Annexin A1 -2.83 0.0059 -2.37 0.00064 -1.02 0.75 -1.07 0.61
Annexin A1 -3.05 0.0043 -1.15 0.051
Annexin A1 -1.06 0.68 1.59 0.0051
Cofilin-1 1.87 0.018 1.15 0.4 -1.09 0.56 -2.35 0.02
Peroxiredoxin 2 1.51 0.033 1.49 0.004 1 0.97 -1.74 0.0017
Vimentin 3.5 0.021 -1.15 0.64 -2 0.21 -1.94 0.046
Vimentin 1.78 0.002 1.14 0.63 -1.2 0.016 -1.68 0.0083
Protein disulphide-isomerase -1.29 0.13 1.53 0.024 -1.1 0.11 -2.2 0.0021
ERp29 -1.31 0.000097 -1.67 1.2E-05
ERp29 -1.62 0.00025 -1.65 0.0016
18-G-1.26/21G
21G hybrid pool / 
18-G-5/21G  18-D-22 /112D  18-D-23/112D
112D hybrid pool / 
 
 
Table  3.4  Comparison  of  protein  expression  for  identified  proteins  seen  in  the 
pooled hybrid and single hybrid 2D-DIGE experiments. Table A. shows changes in 
protein abundance for the pools of hybrids compared with the parent cell lines. Table B. 
shows  changes  in  protein  abundance  for  proteins  identified  in  the  two  hybrids  pairs 
versus parental comparison. Red = up-regulated (>1.5 fold). Green = down-regulated (>-
1.5 fold). 
 
 
3.2.2 Conclusions 
In summary, the whole cell lysate analysis of the single hybrid clones highlights the issue 
of clonal variation. In the case of the 18-G-5 and 18-G-1.26 cell lines the variation is 
dramatic; the 18-G-5/parental comparison resulted in 8 spots changing  and the 18-G-  136 
1.26/parental comparison resulted in 214 spots changing. Both comparisons were made 
under  the  same  stringent  experimental  and  statistical  criteria.  The  18-D-23/parental 
comparison more closely correlated with the 18-D-22/parental comparison, with the total 
number  of  spots  changing  being  28  for  each  and  more  overlap  was  observed  in  the 
proteins identified. For example, annexin A1, retinol dehydrogenase and vimentin were 
identified as displaying the same direction of altered expression when compared with the 
TOV-112D  parental  line.  Weight  could  be  attached  to  the  significance  of  these 
identifications in light of the clonal variation discussed above. The region of chromosome 
18 successfully inserted into each hybrid has clearly affected the proteomic expression 
signature displayed by each hybrid in a cell model. The aCGH analysis of the TOV-112D 
hybrid clones indicated that both hybrids acquired a small region comprising ~10 Mb 
spanning 18p11.21-18q11.2, whereas analysis of the TOV-21G hybrid clones revealed 
almost complete transfer in both hybrid clones (Chapter 1).  This would help to account 
for the proteomic variation between the cell models and also provide a more focused 
approach to uncovering the tumour suppressor gene signatures in each cell model. 
 
A  number  of  proteins  identified  as  differentially  expressed  have  been  previously 
implicated in tumourigenisis. For example, in the first analysis EIF4E was identified as 
an up-regulated protein in the 18-D-22 clone. This protein is involved in RNA binding 
and protein synthesis. It has been implicated in malignancy since increased mRNA levels 
have been reported in carcinomas of the bladder, head and neck, liver, colon and breast 
(Kerekatte, Smiley et al. 1995; Anthony, Carter et al. 1996; Li, Liu et al. 1997; Nathan, 
Franklin et al. 1999; Rosenwald, Chen et al. 1999; Crew, Fuggle et al. 2000; DeFatta,   137 
Nathan et al. 2000; Haydon, Googe et al. 2000; Graff, Konicek et al. 2009) and EIF4E 
over-expression preferentially increases the expression of a number of oncogenes (De 
Benedetti and Harris 1999; Nathan, Franklin et al. 1999; Mamane, Petroulakis et al. 2004; 
Graff, Konicek et al. 2008; Konicek, Dumstorf et al. 2008). Its increased expression in 
one  of  the  suppressed  cell  lines  would  however  argue  that  EIF4E  is  not  universally 
involved in promoting oncogenesis. Another protein, BTF3, forms a stable complex with 
RNA polymerase IIB and is required for transcriptional initiation. It has been found to be 
over-expressed  in  glioblastoma  multiforme,  sporadic  colorectal  cancer  and  pancreatic 
ductal adenocarcinoma. In the latter, BTF3 is involved in the regulation of genes involved 
in tumourigenesis (Kusumawidjaja, Kayed et al. 2007). Here, its down-regulation may 
promote the suppressed tumourigenic phenotype of the 18-D-22 clone versus its parental 
cell line. The antioxidant enzymes, peroxiredoxin 2, 3 and 6 and thioredoxin-like protein, 
were found to be differentially expressed. These enzymes regulate cellular redox state 
and protect against protein, lipid and DNA oxidation that can modulate cell proliferation 
and apoptosis and also speculated to be important in tumour development and invasion. 
The link between redox state and cancer is unclear. Whilst tumours adapt to hypoxic 
conditions by up-regulating angiogenesis and switching to anaerobic glycolysis (Warburg 
effect), oxidants may also up-regulate oncogenic mutation of DNA. Although clear roles 
for these antioxidant enzymes in tumour suppression are not apparent, it appears that 
redox balance in the hybrid clones is perturbed. Another protein involved in response to 
oxidative stress and irradiation was PIG3; up-regulated in 18-D-22. It is induced by the 
tumour suppressor p53 and is thought to be involved in p53 mediated cell death (Flatt, 
Polyak et al. 2000). These data implicate p53 in the suppressed phenotype of this clone.    138 
Endoplasmic reticulum protein ERp29 displayed significant down-regulation in hybrid 
clones of both cell models.  Levels of this protein have been found to be elevated in 
cancerous  cells  compared  to  normal  cells  (Cheretis,  Dietrich  et  al.  2006).  Prohibitin 
(PHB) expression was also down-regulated in the hybrid clone 18-G-1.26. PHB is an 
evolutionarily  conserved  gene  that  is  ubiquitously  expressed  and  is  thought  to  be  a 
negative  regulator  of  cell  proliferation  (Mishra,  Murphy  et  al.  2006).  More  recent 
research has shown that PHB interacts with p53 in vivo and in vitro,  increasing p53 
mediated transcription by enhancing its recruitment to promoters (Fusaro, Dasgupta et al. 
2003).  Also,  PHB  has  been  shown  to  interact  with  all  of  the  Rb  family  of  tumour 
suppressor proteins to negatively regulate cell proliferation (Wang, Nath et al. 1999). Its 
down-regulation in the model studied here would suggest that it does not play a role in 
suppressing tumourigenic phenotype in this system. PCNA acts as a subunit of DNA 
polymerase delta  and thus associated with DNA replication. Its involvement in DNA 
replication  and  excision  repair  after  sub-lethal  damage  has  been  reported  (Umar, 
Buermeyer et al. 1996; Essers, Theil et al. 2005; Masih, Kunnev et al. 2008). PCNA has 
been  shown  to  be  a  valuable  prognostic  and  diagnostic  marker  in  some  cancers  (al-
Sheneber, Shibata et al. 1993; Mayer, Takimoto et al. 1993; Basolo, Pinchera et al. 1994; 
Inagaki, Ebisuno et al. 1997), including ovarian cancer (Thomas, Nasim et al. 1995). The 
elevated levels of PCNA observed in the 18-G-1.26 hybrid clone are surprising given its 
role in proliferation and the fact this clone grew more slowly than the parental cell line. 
Protein DJ-1 was originally identified as an oncogenic product that is able to transform 
cells weakly on its own and more strongly in combination with Ras (Nagakubo, Taira et 
al. 1997). Protein DJ-1 prevents cell death through its anti-oxidative activities and it has   139 
been suggested that this provides a survival advantage in cancer cells (Taira, Saito et al. 
2004; Kim, Peters et al. 2005; Davidson, Hadar et al. 2008). Its expression was down-
regulated  in  the  18-G-1.26  clone,  which  would  appear  to  reflect  the  tumourigenic 
suppression displayed by this cell line. Actin is necessary for a large number of cellular 
processes  including  cell  division,  cell  migration,  polarized  growth,  secretion  and 
endocytosis. Finally, actin dynamics are tightly controlled by a number of actin binding 
proteins that interact with actin filaments and/or monomeric actin. De-regulation of actin-
organization forms a critical element of the oncogenic and invasive potential of cancer 
cells. The actin binding proteins ezrin and fascin, for example, have been implicated in a 
host of  cancers  (Grothey,  Hashizume  et  al.  2000;  Martin,  Harrison  et  al.  2003).  The 
observed de-regulated expression of these proteins and other actin-binders in the hybrid 
clones suggest that changes to the actin cytoskeleton are functionally important in tumour 
suppression.  
 
In conclusion, the analysis of protein changes associated with tumour suppression in the 
EOC Ch18 MMCT cell models has resulted in the identification of gene signatures of 
neoplastic suppression, but the picture is extremely complex and hampered by clonal 
variation. Despite this, it has provided numerous interesting findings that could be taken 
forward for validation, functional studies and investigations of biomarker potential in 
tumour tissue samples or sera from ovarian cancer cases and controls.    
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Chapter 4  2D-DIGE analysis of the secreted 
proteome of Ch18 MMCT models 
Introduction 
Many  genetic  alterations  selected  during  malignant  transformation  disrupt  signalling 
networks, resulting in the release of tumour cells from normal growth constraints or the 
establishment of new signalling pathways that confer growth and survival advantages on 
cancer cells. This is often facilitated by the improper expression of secreted proteins or 
their receptors. The study of secreted and cell surface proteins is regarded as the most 
promising  area  for  biomarker  discovery.  This  chapter  concentrates  on  differential 
expression profiling of secreted proteins in the chromosome 18 MMCT epithelial ovarian 
cancer cell models using 2D-DIGE. 
 
The diagnostic potential ascribed to serum and plasma is reflected in the huge efforts put 
into  their  characterisation  worldwide  such  as  the  HUPO  Plasma  Proteome  Project 
(http://www.hupo.org/research/hppp/). Multiple approaches to discover putative tumour 
biomarkers within the plasma or serum of cancer patients have been reported (Welsh, 
Sapinoso et al. 2003; Zhang, Bast et al. 2004; Ahmed, Oliva et al. 2005; Rai, Gelfand et 
al.  2005;  Volmer,  Stuhler  et  al.  2005;  Wu,  Chien  et  al.  2005;  Lin,  Lin  et  al.  2006). 
However, the complexity and the huge dynamic range of expression of the plasma and 
serum proteomes present a challenge for their analyses. Additionally, proteins derived   141 
from tumours and present in the circulation are expected to be of low abundance and 
attempts  to  identify  tumour  markers in  blood  has  largely  resulted  in  the  detection  of 
changes in abundant serum proteins and immune-response proteins which lack specificity 
for  disease  detection.  Working  with  tumour  tissues  or  cell  models  to  find  secreted 
candidate markers is a promising alternative approach. 
 
The  release  of  proteins  from tumour  cells occurs  as  a  result of  a  number  of  diverse 
mechanisms.  Classical  secretion  is  the  most  obvious  mode  of  protein  release  and  is 
expected to be relevant for proteins such as extracellular matrix molecules, proteases and 
protease inhibitors, as well as growth factors and cytokines. There is also the release of 
membrane proteins through proteolytic shedding of ectodomains or through cleavage of 
phospholipid membrane anchors. Exosomal release of proteins is a further mechanism by 
which  cells  may  release  proteins  into  the  extracellular  environment.  Exosomes  are 
membrane-coated  vesicles  derived  from  multivesicular  bodies  in  the  late  endosomal 
compartment  which  fuse  with  the  plasma  membrane  to  expel  their  protein  content. 
Proteins  may  also  be  released  from  cells  due  to  apoptosis  and  necrosis  or  through 
physical disruption during handling. 
 
4.1 Proteomic analysis of secreted proteins 
To investigate the ‘secretome’ of proteins released in vitro, from ovarian cancer cell lines 
and their Ch18 MMCT hybrids, cells were grown in standard medium with 15% fetal calf 
serum  until  reaching  a  confluence  of  80%.  Cells  were  then  washed  to  remove   142 
contaminating serum proteins and were then cultured for 24 h in serum-free medium. The 
serum free media was then replenished and harvested after a further 24 h as conditioned 
media  for  analysis.  The  media  was  concentrated  and  then  desalted  using  Millipore 
Centriplus devices, dried down and then resuspended in 2D lysis buffer. The secreted 
proteins were first assessed on a 1D gel (Fig 4.1) and then the cell culture was scaled up 
for 2D-DIGE analyses. 
 
 
 
 
 
 
 
 
Figure 4.1 CCB-stained 1D gel of the secretome of the epithelial ovarian cancer cell 
lines. Proteins from conditioned media (10 µg), total cell lysate (TCL; 10 µg) and fetal 
calf serum (10 µg) were loaded for comparison of the extracted secretome of the two 
parental cell lines TOV-112D and TOV-21G and the hybrid cell lines 18-D-22 and 18-G-
5. 
 
This  preliminary  analysis  showed  the  efficiency  of  secreted  protein  extraction  from 
conditioned  media  before  scaling  up  preparation  for  2D-DIGE,  but  also  suggested 
considerable contamination from serum proteins, particularly BSA. For 2D-DIGE, two 
experiments were run, each using media from four 15 cm tissue culture dishes per cell 
230
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line.  In  the  first  experiment  10  ml  of  media  was  used  per  dish.  This  made  sample 
desalting  and  concentration  quite  time  consuming.  The  yield  of  protein  was  only 
sufficient to load a total of 60 µg per gel (20 µg per sample). This gave rise to problems 
in identification due to low abundance. A second experiment used 5 ml of media per dish 
reducing the sample processing time and allowing the number of culture dishes to be 
doubled  to  improve  protein  yield.  Samples  from  each  parent  and  hybrid  pair  were 
labelled with Cy3 or Cy5 in triplicate. A pool of samples was also prepared as an internal 
standard  and  labelled  with  Cy2  to  be  run  on  all  six  gels.  Samples  were  mixed 
appropriately  and  proteins  separated  by  2D  electrophoresis.  The  gels  from  both 
experiments  were curated and  analysed  in the  BVA  module  of  Decyder  (Fig  4.2)  as 
described in Materials and Methods. 
 
 
 
 
 
 
Figure  4.2  Master  gel  images  for  the  two  separate  2D-DIGE  ‘secretome’ 
experiments.  (A)  In  the  first  experiment  the  amount  of  secreted  protein  harvested 
allowed a maximum load of 60  g of labelled secreted protein to be run on each gel. The 
label was increased to 8 pmol/ g of protein. (B) The experiment was repeated starting 
with more conditioned media. The total load per gel was 300  g. Labelling was carried 
out at the usual 4 pmol of Cydye per 1  g of protein. The superimposed images shown 
were created in Adobe Photoshop to show differentially expressed proteins in red and 
blue. 
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In  the  second  experiment,  differentially  expressed  proteins  within  each  parent/hybrid 
comparison which displayed a change in average abundance of ≥ 2-fold (n=3, p value 
<0.05) were selected. The 18-D-22/TOV-112D comparison resulted in a total of 38 spots 
displaying differential expression. Of these, 23 were up-regulated and 15 down-regulated. 
The 18-G-5/TOV-21G comparison resulted in a total of 90 spots displaying differential 
expression. Of these 43 were up-regulated and 47 down-regulated (Fig 4.3). 
 
 
 
 
 
 
 
 
 Figure  4.3  Differentially  expressed  proteins  for  parent/hybrid  comparisons.  (A) 
Example image of 18-D-22/TOV-112D comparison. (B) Example image of 18-G-5/TOV-
21G comparison. Up-regulated spots are in red and down-regulated spots are in blue. 
Images  were  merged  using  Adobe  Photoshop.  1654  common  protein  features  were 
identified using Decyder software. 
   
 
 
 
A. B.  145 
4.2 Identification of differentially expressed secreted 
proteins 
In the second experiment, 43 of the 128 differentially expressed spots were identified by 
MALDI-TOF MS and/or LC-MS/MS. These represented 29 distinct gene products (Table 
2.4). A large proportion of the proteins identified were cellular proteins, derived from the 
cytoplasm,  nucleus,  cytoskeleton,  endoplasmic  reticulum  and  mitochondrial  matrix  of 
cells. However, nine distinct gene products were identified as classically secreted proteins 
and were differentially expressed proteins not identified previously in our laboratory. The 
large proportion of proteins identified as cellular proteins may be present due to non-
specific release through cell rupture and apoptosis. However, these proteins could also be 
released into the media from membrane vesicles such as exosomes or micro-particles. 
Around half of the proteins labelled with the fluorescent Cy dyes were also not visible by 
CCB staining and so were not picked. Whilst these are likely to be of low abundance, 
some secreted glycoproteins may be poorly detected by CCB due to their glycosylation 
(Zacharius, Zell et al. 1969). The scarcity of bovine proteins identified in the secretome 
underlines the effectiveness of the protocol of minimizing media contaminants. However, 
a later experiment revealed how ineffective washing of cells during sample preparation 
can result in significant and differential BSA contamination (see later). 
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18D22/112D 18G5/21G
Master No. Name IPI
HGNC 
Symbol Chr. Av. Ratio T-test Av. Ratio T-test pI Mw
pI 
(pred)
Mw 
(pred) Score  Cov% Peptides  Function Location
840 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 ACAT2 6 -1.12 0.16 -2.22 3.80E-05 7.15 72254 6.47 41838 164 45 12 Belongs to the thiolase family. Cellular
916 Annexin A1 IPI00218918 ANXA1 9 1.15 0.1 -2.03 0.0011 7.06 65687 6.64 38787 101 44 9 Calcium/phospholipid-binding protein which promotes 
membrane fusion and is involved in exocytosis. This 
protein regulates phospholipase A2 activity.
Cellular
941 Annexin A1 IPI00218918 ANXA1 9 1.17 0.033 -3.02 0.00029 6.7 63230 6.64 38787 139 49 12 Calcium/phospholipid-binding protein which promotes 
membrane fusion and is involved in exocytosis. This 
protein regulates phospholipase A2 activity.
Cellular
1110 Annexin A1 IPI00218918 ANXA1 9 -1.24 0.026 -2.58 0.00029 8.21 48526 6.64 38787 108 37 9 Calcium/phospholipid-binding protein which promotes 
membrane fusion and is involved in exocytosis. This 
protein regulates phospholipase A2 activity.
Cellular
1099 Carboxy-propeptide of alpha 1 (III) procollagen IPI00021033 COL3A1 2 -2.36 8.30E-06 -1.55 0.0094 5.12 49460 5.34 27904 189 51 20 Collagen type III occurs in most soft connective tissues 
along with type I collagen.
Secreted
1629 Chromosome 6 open reading frame 115 
(predicted)
IPI00374316 C6orf115 6 1.1 0.33 -2.06 0.00023 5.85 6902 5.86 9108 75 46 5
1470 Cofilin, non-muscle isoform IPI00012011 CFL1 11 2.5 7.00E-06 -2.74 3.60E-06 6.68 16341 8.26 18588 76 38 6 It is the major component of intranuclear and cytoplasmic 
actin rods.
Cellular
1605 Galectin-1 IPI00219219 LGALS1 22 -1.28 0.19 -2.58 3.10E-05 4.5 6000 5.34 14917 123 66 8 Lactose-binding lectin 1 Secreted
443 Glucose-6-phosphate dehydrogenase IPI00289800 G6PD X 1.53 0.0011 -2.21 0.00018 7.2 108959 6.44 59553 132 25 12 Produces pentose sugars for nucleic acid synthesis and 
main producer of NADPH reducing power.
Cellular
1381 Heterogeneous nuclear ribonucleoprotein A1 IPI00797148 HNRNPA1 12 2.45 0.00022 1.03 0.81 8.1 27923 8.38 22316 107 45 9 Involved in the packaging of pre-mRNA into 
hnRNP particles
Nucleus/ Cytoplasm
981 Insulin-like growth factor binding protein 2 
precursor
IPI00297284 IGFBP2 2 1.29 0.058 2.12 2.80E-05 7.16 60352 7.48 36198 178 45 15 IGF-binding proteins prolong the half-life of the IGFs and 
have been shown to either inhibit or stimulate the growth 
promoting effects of the IGFs on cell culture. They alter 
the interaction of IGFs with their cell surface receptors.
Secreted
1089 Insulin-like growth factor binding protein 2 
precursor
IPI00297284 IGFBP2 2 -2.96 6.90E-06 -1.19 0.27 7.38 50411 7.48 36198 78 21 7 IGF-binding proteins prolong the half-life of the IGFs and 
have been shown to either inhibit or stimulate the growth 
promoting effects of the IGFs on cell culture. They alter 
the interaction of IGFs with their cell surface receptors.
Secreted
1169 Insulin-like growth factor binding protein 2 
precursor
IPI00297284 IGFBP2 2 -1.56 0.00026 2.24 5.60E-05 7.3 50000 7.48 36198 86 28 6 IGF-binding proteins prolong the half-life of the IGFs and 
have been shown to either inhibit or stimulate the growth 
promoting effects of the IGFs on cell culture. They alter 
the interaction of IGFs with their cell surface receptors.
Secreted
962 Insulin-like growth factor binding protein 7 
precursor
IPI00016915 IGFBP7 4 -1.29 0.26 3.52 4.10E-06 7.29 62564 8.25 30138 116 45 12 Binds IGF-I and IGF-II with a relatively low affinity. 
Stimulates prostacyclin (PGI2) production.
Secreted
991 Insulin-like growth factor binding protein 7 
precursor
IPI00016915 IGFBP7 4 1.36 0.14 3.13 0.00025 7.67 60097 8.25 30138 105 47 11 Binds IGF-I and IGF-II with a relatively low affinity. 
Stimulates prostacyclin (PGI2) production.
Secreted
1108 Insulin-like growth factor binding protein 7 
precursor
IPI00016915 IGFBP7 4 -1.17 0.15 2.23 0.00044 4.18 48321 8.25 30138 72 27 6 Binds IGF-I and IGF-II with a relatively low affinity. 
Stimulates prostacyclin (PGI2) production.
Secreted
1043 Insulin-like growth factor binding protein 7 
precursor
IPI00016915 IGFBP7 4 1.46 0.015 2.12 0.00032 8.24 56279 8.25 30138 [107] 14 3 Binds IGF-I and IGF-II with a relatively low affinity. 
Stimulates prostacyclin (PGI2) production.
Secreted
1030 Insulin-like growth factor binding protein 7 
precursor (IGFBP-7) 
IPI00016915 IGFBP7 4 -1.05 0.54 4.35 3.40E-06 7.7 56878 8.25 30138 117 52 13 Binds IGF-I and IGF-II with a relatively low affinity. 
Stimulates prostacyclin (PGI2) production.
Secreted
1033 Insulin-like growth factor binding protein 7 
precursor (IGFBP-7) (IBP-7)
IPI00016915 IGFBP7 4 1.81 0.001 3.54 8.80E-07 7.94 56758 8.25 30138 183 56 14 Binds IGF-I and IGF-II with a relatively low affinity. 
Stimulates prostacyclin (PGI2) production.
Secreted
787 Leukocyte elastase inhibitor IPI00027444 SERPINB1 6 1.91 0.21 -2.16 0.00019 6.34 75699 5.9 42829 100 28 9 Regulates the activity of the neutrophil proteases 
elastase, cathepsin G and proteinase-3.
Secreted
193 Lumican precursor IPI00020986 LUM 12 2.57 0.00019 1.01 0.9 4.6 128798 6.16 38747 129 32 10 Belongs to the small leucine-rich proteoglycan (SLRP) 
family. Class II subfamily
Secreted
1381 Peroxiredoxin 1 IPI00640741 PRDX1 1 2.45 0.00022 1.03 0.81 8.1 27923 6.41 19135 78 32 6 An antioxidant. Has a protective role in cells.
1393 Peroxiredoxin 1 IPI00000874 PRDX1 1 2.84 1.50E-05 -1.1 0.11 8.44 26652 8.27 22324 145 41 11 Involved in redox regulation of the cell. Cellular
1402 Peroxiredoxin 1 IPI00000874 PRDX1 1 -1.15 0.0032 -2.27 6.70E-05 7.97 26315 8.27 22324 165 71 14 Involved in redox regulation of the cell. Cellular
1234 Phosphoglycerate mutase 2 IPI00218570 PGAM2 7 -1.75 0.0023 -3.96 1.30E-06 6.81 37241 9 28788 [96] 8 3 Interconversion of 3- and 2-phosphoglycerate with 2,3- 
bisphosphoglycerate as the primer of the reaction.
Cellular
624 Pigment epithelium-derived factor precursor IPI00006114 SERPINF1 17 -3.05 1.40E-05 2.61 0.00039 5.46 93156 5.97 46484 124 28 12 Belongs to the serpin family. Secreted
846 Placental thrombin inhibitor IPI00514598 SERPINB6 6 1.21 0.084 -2.45 0.00017 5.02 71796 5.18 42904 105 28 8 Inhibits thrombin. Cellular
1222 Platelet-activating factor acetylhydrolase IB beta 
subunit
IPI00026546 PAFAH1B2 11 1.07 0.49 -3.99 4.60E-06 5.6 38362 5.57 25724 74 33 7 Platelet-activating factor acetylhydrolase IB beta subunit Cytoplasm
1361 Prolactin precursor (PRL) IPI00000871 PRL 6 2.28 0.00013 -1.5 0.0074 6.97 28946 6.5 26258 166 73 19 Belongs to the somatotropin/prolactin family. Secreted
121 Protein disulfide-isomerase A3 precursor IPI00025252 PDIA3 15 -1 0.95 2.12 1.40E-05 7.65 138413 5.98 57146 79 30 17 Belongs to the protein disulfide isomerase family. Endoplasmic reticulum 
lumen
425 Protein disulfide-isomerase A3 precursor IPI00025252 PDIA3 15 -1.05 0.38 2.95 7.00E-05 5.76 110586 5.98 57146 134 30 17 Belongs to the protein disulfide isomerase family. Endoplasmic reticulum 
lumen  
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607 Protein disulfide-isomerase A6 precursor IPI00644989 PDIA6 2 1.1 0.39 2.22 2.30E-05 4.71 94347 4.95 48490 67 18 7 Catalyzes the rearrangement of -S-S- bonds in proteins. Endoplasmic reticulum; 
endoplasmic reticulum 
lumen (By similarity)
1451 Vimentin IPI00418471 VIM 10 -2.86 0.00014 2.04 0.0097 4.22 20410 5.06 53545 [149] 8 4 Vimentins are class-III intermediate filaments Cellular
1282 Splice Isoform 2 of Triosephosphate isomerase IPI00451401 TPI1 12 1.72 0.0057 -2.61 0.00016 7.78 34581 8.5 27320 81 39 7 Metabolic pathways. Cellular
1282 Splice Isoform A2 of Heterogeneous nuclear 
ribonucleoproteins A2/B1
IPI00414696  HNRPA2B1 7 1.72 0.0057 -2.61 0.00016 7.78 34581 8.67 36041 72 25 8 Involved with pre-mRNA processing. Forms complexes 
(ribonucleosomes) with at least 20 other different hnRNP 
and heterogeneous nuclear RNA in the nucleous.
Nucleus. Component of 
ribonucleosomes.
1142 Splice Isoform Short of Proteasome subunit 
alpha type 1
IPI00016832 PSMA1 11 -1.3 0.11 3.25 0.00052 6.89 45443 6.15 29822 92 29 7 Involved in an ATP/ubiquitin-dependent non-lysosomal 
proteolytic pathway.
Cytoplasmic and 
nuclear
786 Stathmin IPI00479997 STMN1 1 1.09 0.24 2.18 0.00028 6.98 76020 5.77 17161 124 51 9 It prevents assembly and promotes disassembly of 
microtubules.
Cellular
1492 Stathmin IPI00479997 STMN1 1 1.26 0.012 -2.19 8.40E-05 5.5 20000 5.77 17161 [73] 10 2 It prevents assembly and promotes disassembly of 
microtubules.
Cellular
1169 Tissue inhibitor of metalloproteinase 1 IPI00642739 TIMP1 X -1.56 0.00026 2.24 5.60E-05 7.3 50000 8.4 16560 88 52 6 Tissue inhibitor of metalloproteinase 1 (Erythroid 
potentiating activity, collagenase inhibitor).
Secreted
1199 Tissue inhibitor of metalloproteinase 1 IPI00642739 TIMP1 X -2.36 0.003 1.3 0.047 7.92 40362 8.4 16560 86 65 8 Tissue inhibitor of metalloproteinase 1 (Erythroid 
potentiating activity, collagenase inhibitor).
Secreted
454 Tryptophanyl-tRNA synthetase IPI00295400 WARS 14 1.26 0.011 -2.42 4.50E-05 6.3 107811 5.83 53474 80 24 11 Belongs to the class-I aminoacyl-tRNA synthetase family. Cellular
539 Tubulin beta-2 chain IPI00011654 TUBB 6 -1.08 0.97 2.57 0.00014 4.56 100535 4.78 50095 118 41 19 Tubulin is the major constituent of microtubules. Cellular
1335 Ubiquitin carboxyl-terminal hydrolase isozyme 
L1
IPI00018352 UCHL1 4 1.22 0.072 2.9 0.00024 5.24 31041 5.33 25151 121 47 12 Ubiquitin-protein hydrolase involved both in the 
processing of ubiquitin precursors and of ubiquitinated 
proteins.
Cytoplasm
 
 
 
Table 4.1 Differentially expressed proteins in the secretome of the EOC cell models 18-D-22/TOV-112D and 18-G-5/TOV-21G 
identified by mass spectrometry. Protein features that were matched across all gels with a fold change ≥ 2 fold where p ≤ 0.05 were 
identified by MS. Orange shading indicates an increase in expression in the hybrid clone verses parent and green indicates a decrease. 
Yellow shading indicates multiple identifications from a single gel spot. Protein identifications were made by database searching of 
peptide ion fragments from LC-MS/MS or by MALDI-TOF MS PMF (indicated by [ ] in the ‘Score’ column). The identifications 
were scored according to algorithms that take into account mass accuracy and peptide coverage. The search criteria used allowed +/- 
50 ppm mass error and up to 2 missed cleavages. The identified proteins were partially verified by comparison of their theoretical 
molecular weights and pIs with gel position on the master gel. 
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Multiple isoforms of insulin-like growth factor-binding protein 2 (IGFBP2) and insulin-
like  growth  factor  binding protein  7  (IGFBP7)  were  identified (Grimberg  and  Cohen 
2000;  Zumkeller  2001).  Of  these  secreted  proteins,  the  former  appears  to  stimulate 
cellular proliferation (Lee, Mircean et al. 2005; Chakrabarty and Kondratick 2006) and 
the latter inhibits proliferation by binding IGF1, IGF2 and insulin (Oh, Nagalla et al. 
1996;  Yamanaka,  Wilson  et  al.  1997).  Two  isoforms  of  IGFBP2  were  identified 
displaying down-regulation of expression in the 18-D-22 cell line. Conversely, one of 
these isoforms and a third were significantly elevated in the 18-G-5 hybrid clone (Fig 
4.3). IGFBP2 has been previously found to be overexpressed in malignant ovarian tissues 
and in the serum and cystic fluid of ovarian cancer patients (Wang, Rosen et al. 2006) 
and appears to increase the invasive capability of ovarian cancer cells (Lee, Mircean et al. 
2005; Wang, Rosen et al. 2006). Its expression level also seems to positively correlate 
with levels of the EOC serum marker CA125, and it is also overexpressed in a variety of 
other cancers (Quinn, Treston et al. 1996). Six isoforms of IGFBP7 were significantly up-
regulated in the 18-G-5 cell line. IGFBP7 expression is down regulated in several types 
of  cancer,  and  restoration  of  expression  induces  cellular  senescence  or  apoptosis 
(Swisshelm, Ryan et al. 1995; Lopez-Bermejo, Buckway et al. 2000; Landberg, Ostlund 
et al. 2001; Mutaguchi, Yasumoto et al. 2003). The nature of the identified isoforms is 
unclear but may represent glycosylated or splice variant forms, including a very acidic 
form (Fig 4.4).  
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Figure 4.4 Change in protein expression of IGFBP2 and IGFBP7 isoforms. (A) Table 
displaying the fold-change in  expression for the protein isoforms in each cell model. 
Orange indicates an increase and green a decrease in expression over 2-fold. (B) Gel 
image displaying each protein isoform of IGFBP2 and IGFBP7. 
 
 
Galectin-1 was down-regulated in both hybrid clones compared to their parental lines 
(Fig  4.5A).  Galectin-1  is  a  carbohydrate-binding  protein  and  a  component  of  the 
extracellular matrix thought to be involved in cell adhesion, cell proliferation and tumour 
progression. It has been reported that ovarian cancer antigen CA125 is a counter receptor 
for  galectin-1,  binding  specifically  to  human  galectin  with  high  efficiency  in  vitro 
(Seelenmeyer,  Wegehingel  et  al.  2003).  Pigment  epithelium-derived  factor  precursor 
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981  Insulin-like growth factor binding protein 2 precursor  1.29 0.058  2.12 2.80E-05
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1169  Insulin-like growth factor binding protein 2 precursor  -1.56  0.00026  2.24 5.60E-05
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981 
1089 
1169 
40kDa
55kDa  962 
991 
1030 
1043 
1108
1033 
18-D-22/112D  18-G-5/21G
Master No. Name  Av. Ratio  T-test  Av. Ratio T-test 
981    1.29 0.058  2.12 2.80E-05
1089  Insulin-like growth factor binding protein 2 precursor  -2.96  6.90E-06 -1.19 0.27 
1169  Insulin-like growth factor binding protein 2 precursor  -1.56  0.00026  2.24 5.60E-05
962  Insulin-like growth factor binding protein 7 precursor  -1.29  0.26  3.52 4.10E-06
991  Insulin-like growth factor binding protein 7 precursor  1.36  0.14  3.13 0.00025 
1108  Insulin-like growth factor binding protein 7 precursor  -1.17  0.15  2.23 0.00044 
1043  Insulin-like growth factor binding protein 7 precursor  1.46  0.015  2.12 0.00032 
1030  Insulin-like growth factor binding protein 7 precursor  -1.05  0.54  4.35 3.40E-06
1033  Insulin-like growth factor binding protein 7 precursor  1.81  0.001  3.54 8.80E-07
981 
1089 
1169   150 
displayed a contrasting expression in the two cell line models (Fig 4.5B). Expression was 
significantly down-regulated (-3.05 fold) in the 18-D-22 cell line and up-regulated (2.61 
fold) in the 18-G5 hybrid cell line. Pigment epithelium-derived factor has been shown to 
be a potent inhibitor of angiogenesis (Cheung,  Au et al. 2006). Two isoforms of the 
protein  tissue  inhibitor  metalloproteinase  1  (TIMP1)  were  identified  which  both 
displayed opposite changes in expression in the two cell models (Fig 4.5C/D) (Table 4.1). 
The  family  of  tissue  inhibitors  of  metalloproteinases  (TIMPs)  inhibit  various  matrix 
metalloproteinase (MMP) activities (Nelson, Fingleton et al. 2000) which are thought to 
be  important  for  the  creation  and  maintenance  of  a  microenvironment  that  facilitates 
growth and angiogenesis of tumours. TIMP1 is reported to induce proliferation, promote 
angiogenesis and regulate apoptosis (Ikenaka, Yoshiji et al. 2003) (Reed, Koike et al. 
2003). Finally, the hormone prolactin, which has been used in a multiplexed biomarker 
panel  for  ovarian  cancer  detection  (Mor,  Visintin  et  al.  2005)  was  found  to  be  up-
regulated (2.28 fold) in the 18-D-22 hybrid (Fig 4.5E). 
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Figure 4.5 DeCyder analysis of differential protein expression in the 18-G-5/21G 
and  18-D-22/112D  cell  line  comparisons  for  several  of  the  identified  secreted 
proteins.  Graphical  representations  for  selected  proteins  are  shown  as  average 
standardised  abundance  (i.e.  abundance  versus  the  Cy2-labelled  standard)  for  each 
condition  with triplicate  measurements.  Where  multiple  isoforms  were  identified spot 
numbers are indicated in brackets. 
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4.3 2D-DIGE comparison of secreted proteins from two 
hybrid clones and parental cell lines  
A 9 gel experiment was next undertaken involving a comparison between the two parent 
cell  lines  and  both  Ch18  hybrid  clones  displaying  the  most  potent  tumourigenic 
suppression (see  Introduction, section). Secreted proteins were prepared as previously 
described from 8 x 15 cm plates using 5 ml media/plate. A total of 1779 distinct protein 
features were matched across the gels using Decyder image analysis software (Fig 4.6). 
 
 
 
 
 
 
 
 
Figure  4.6  Representative  superimposed  gel  images  for  parental:hybrid 
comparisons of secreted protein. 100 µg of secreted protein from each cell line was 
labelled in triplicate with either Cy3 or Cy5. The internal standard was created from a 
pool of all the cell lines and labelled with Cy2. (A) Example gel of 18-D22/TOV-112D 
comparison. The hybrid clone cell line is represented by blue and the parent cell line by 
red. (B) Example gel of 18-G1.26/TOV-21G comparison. The hybrid clone cell line is 
represented by blue and the parental cell line by red. 
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The comparison between the TOV-112D parental cell line and the 18-D-22 and 18-D-23 
hybrid cell lines resulted in 122 and 63 protein features displaying significant differential 
expression, respectively (≥2 fold change; n=3; p≤0.05). For the comparison between the 
TOV-21G parental cell line and the 18-G-5 and 18-G-1.26 hybrid cell lines, 348 and 23 
protein features displayed significant differential expression at the same threshold cut-
offs. These protein spots were selected for picking and matched to a CCB stained gel 
image  and  spots  excised  and  digested  with  trypsin  for  identification  by  mass 
spectrometry.  A  total  of  384  spots  were  picked,  and  of  these,  160  yielded  confident 
identifications by LC-MS/MS using the same stringent criteria to search the NCBI and 
IPI databases.  
 
Inspection  of  the  gel  images  and  identification  of  protein  spots  revealed  a  higher 
abundance of bovine serum albumin (BSA) and other serum proteins in the conditioned 
media from the 18-G-5 cells compared to the other cell lines (Fig 4.7).  
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  A. B. A. B.
 
  
Figure 4.7 Gel images displaying higher abundance of bovine serum proteins in 18-
G-5  cells.  (A)  Displays  18-G-1.26  secreted  proteins  (B)  Displays  18-G-5  secreted 
proteins.  The  spots  from  the  regions  in  red  were  identified  as  BSA  and  bovine 
serotranferrin. 
 
 
This is most probably attributed to retention of serum proteins by the 18-G-5 cells at the 
washing and media swap stage during cell culture. The higher abundance of BSA and 
other serum  proteins  in  this fraction  led to  a  reduction  in  endogenous  protein  in  the 
sample and is likely to have resulted in the much larger number of differences displayed 
by the 18-G-5 clone versus its parent in the analysis. Importantly, the levels of these 
serum proteins in the other cell lines were not altered and so the differentially expressed 
proteins identified could be used for data interpretation. This did not occur in the previous 
experiments,  but  highlights  the  difficulty  in  preparing secreted protein  fractions  from 
cells in culture. It is not sufficient to starve the cells and replenish with serum free media 
for  collection  in  all  cases.  Different  cell  types  may  have  higher  affinity  for 
binding/retaining serum proteins, thus making it more difficult to wash unwanted media   155 
proteins from their surface. To differentiate proteins released into the media from cells 
protein  and  constituents  of  the  serum  utilized  for  culture,  one  can  grow  cells  in  the 
presence  of  [
13C]-labelled  lysine  and  use  the  mass  shift  to  differentiate cellular  from 
serum-derived proteins (Faca, Ventura et al. 2008). Application iof heavy labellling in 
this study would prove too expensive given the number of cell lines under study and the 
scale of cell culture required for sufficient ‘secreted’ protein for 2D-DIGE analysis. 
 
The experiment was thus repeated with more stringent washing. Image analysis revealed 
a total of 262 spots displaying a change in average abundance of ≥ 2 fold. These spots 
were picked from two Sypro-Ruby-stained gels, giving greater sensitivity. Identifications 
were made by LC-MS/MS on an LTQ Orbitrap XL linked to an Ultimate3000 nano-LC 
system (Table 4.2). The MS/MS peak lists were compared against theoretically expected 
tryptic  peptide  fragment  masses  in  the  IPI  database  submitted  by  the  Mascot  search 
engine including +2 and +3 peptide charge, mass tolerance of ± 30 ppm and a fragment 
mass tolerance of 0.1 Da. As before, identifications were accepted when at least two 
peptide sequences matched an entry with MOWSE scores above the p=0.05 homology 
threshold value. 
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4.3.1 Identification of differentially expressed proteins 
from two hybrid clones and parental cell lines 
 The  direct  comparison  of  the  18-D-22/TOV-112D  secretome  resulted  in  228 
differentially expressed protein spots, with 136 up-regulated and 82 down-regulated. For 
the 18-D-23/TOV-112D comparison, 143 were found to be differentially expressed with 
124  up-regulated  and  18  down-regulated.  The  comparison  between  18-G-5/TOV-21G 
resulted in 32 differentially expressed spots with 7 up-regulated and 25 down-regulated. 
Finally,  the  18-G-1.26/TOV-21G  comparison  resulted  in  75  differentially  expressed 
protein spots with 37 up-regulated and 38 down-regulated.  
 
The number of differentially expressed spots was greater for each hybrid clone:parental 
comparison in this experiment compared to the previous, with the exception of the hybrid 
clone 18-G-5 where contamination in the previous experiment resulted in an exaggerated 
expression profile. However, the relative numbers changing between each comparison are 
comparable. This seems to be in contrast with the WCL analysis where the hybrid clones 
18-G-5 and 18-G-1.26 displayed the greatest numbers of differentially expressed spots  
while the hybrid clones 18-D-22 and 23 displayed relatively few changes (see section 
3.2.2).  Additionally,  the  hybrid  pairs  in  the  secreted  analysis  displayed  greater 
concordance in expression changes than that observed in the WCL analysis where only 
isoforms of two proteins, ALDH1A1 and LDHB, showed concordant expression in both 
hybrids and both cell models. 
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No gene products for chromosome 18 were reported. A good proportion (52%) of the 
identified  proteins  are  known  to  be  secreted  and  of  these,  IGFBP2,  lumican, 
PEDGF/SERPINF1, prolactin, procollagen (III) and TIMP1 were previously identified as 
differentially expressed in the single hybrid clone versus parent comparison (section 4.2). 
It should be noted however that comparison of expression profiles between experiments 
is difficult because of the presence of multiple isoforms of each of the identified proteins 
and are hard to match.  A number of secreted proteins not seen previously were  also 
identified.  These  included  apolipoprotein  E,  glucagon  and  IGFBP6.  ApoE1  was 
significantly up-regulated in the 18-D-22/parental (2.99 fold) and 18-D-23/parental (3.54 
fold)  comparisons.  This  secreted  protein  mediates  the  binding,  internalization  and 
catabolism of lipoprotein particles. Functions seemingly unrelated to lipid transport have 
been reported for ApoE1 including the promotion of proliferation and survival in ovarian 
cancer cells (Chen, Pohl et al. 2005). IGFBP6 was also significantly up-regulated in the 
18-D-22 (5.41 fold) and 18-D-23 (3.82 fold) hybrids compared to the parental TOV-
112D cell line. In contrast, its expression was moderately down-regulated in both hybrid 
clones of the TOV-21G cell model. IGFBP6 is a member of the family of insulin-like 
growth factor binding proteins that regulate the functions of insulin-like growth factors 
which are important in cell survival and tumourigenesis (LeRoith and Roberts 2003). 
Three  isoforms  of  glucagon,  a  hormone  involved  in  carbohydrate  metabolism,  were 
identified, two displaying concordant up-regulation in the 18-D-22 and 18-D-23 cell lines 
and significant down-regulation in the 18-G-5 and 18-G-1.26 cell lines, whilst a third 
isoform displayed down-regulation in the 18-D-22 and 18-D-23 cell lines. Glycolytic 
rates are usually increased in cancer  cells, the  observed down-regulation of  glucagon   158 
secreted by the hybrid clones may be a consequence of the suppression of tumourigenic 
phenotype  in  these  cell  models.  There  were  also  differentially  expressed  proteins 
identified  from  the  WCL  analysis  including  ANXA1,  ERp29,  EIF5A,  DLD,  FSCN1, 
GRB2,  LDHB,  PDIA3,  PRDX6,  ALDH1A1  and  UCHL1  where  there  was  general 
agreement  in  direction  of  altered  expression.  For  example,  ERp29  was  again  down-
regulated in the hybrid clones. This ER protein is involved in the processing of secretory 
proteins within the endoplasmic reticulum. It has been suggested that in the context of 
carcinogenesis, ERp29 facilitates secretion of proteins that mediate cross-talk between 
cancer  cells  and  surrounding  fibroblasts  to  confer  a  growth  advantage  (Mkrtchian, 
Baryshev  et  al.  2008).  Thus,  its  down-regulation  may  participate  in  the  observed 
suppression  of  neoplastic  phenotype  in  these  cell  models.  Two  isoforms  of  lactate 
dehydrogenase  B  were  identified.  One  isoform  was  conspicuous  in  that  it  displayed 
significant down-regulation in each of the hybrid clones of both cell models. However, 
the other isoform displayed moderate up-regulation in the 18-D-22 and 18-D-23 hybrid 
cell lines, but down-regulation in the 18-G-5 and 18-G-1.26 hybrid cell lines. This protein 
catalyses the reversible transformation of pyruvate to lactate, having a principal role in 
anaerobic cellular metabolism. It has been shown to be up-regulated in gynaecological 
malignancies  and  correlated  with  tumour  grade  (Simaga,  Osmak  et  al.  2005; 
Koukourakis, Kontomanolis et al. 2008).   
 
A number of isoforms of lumican were identified and all isoforms were significantly up-
regulated in the 18-D-22 and 18-D-23 hybrid clones, but moderately down-regulated in 
the 18-G-5 and 18-G-1.26 hybrid clones versus their parental cell lines. Lumican belongs   159 
to the family of small leucine rich repeat proteoglycans which constitute an important 
fraction of non-collagenous extracellular matrix proteins. Altered expression of lumican 
has  been  reported  in  a  variety  of  cancers  including  breast,  pancreatic  and  colorectal 
cancer (Vuillermoz, Khoruzhenko et al. 2004; Nikitovic, Katonis et al. 2008). Prolactin 
was  again  found  to  be  significantly  up-regulated  (5.99  fold)  in  the  18-D-22/parental 
comparisons and in the 18-D-23/parental comparison (4.37 fold). Expression in the other 
hybrid  cell  lines  was  moderately  down-regulated  (<2  fold)  compared  to  the  parental 
TOV-21G  cell  line.  Prolactin  acts  primarily  in  the  mammary  gland  by  promoting 
lactation. It has been shown to be linked to proliferation and survival in breast neoplasms 
(Manni, Wright et al. 1986) and to inhibit apoptosis in ovarian carcinoma (Asai-Sato, 
Nagashima et al. 2005).  Also of note, were four isoforms of collagen alpha-1 (III) chain 
(COL3A1)  displaying  differential  expression  in the 18-D-22  and  18-D-23  hybrid  cell 
lines. The different isoforms may arise as a result of differential glycosylation. It is likely 
that  the  most  basic  isoform,  which  was  down-regulated  compared  to  the  other  up-
regulated  forms,  has  a  lower  content  of  sialic  acids  and  therefore  different  pI.  The 
COL3A1  gene  produces  the  components  of  type  III  collagen,  where  copies  of  this 
filament  combine  to  make  a  molecule  of  type  III  procollagen.  These  triple  stranded 
molecules are processed by enzymes outside the cell to remove protein segments from 
their ends. Once processed, they arrange themselves into long fibrils that become cross-
linked providing strength and support around the cell.  Levels of COL3A1 have been 
found to increase with the degree of malignancy in serous ovarian carcinomas (Tapper, 
Kettunen et al. 2001).  
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18D22/122D 18D23/112D 18G5/21G 18G126/21G
Master No. Protein Name HGNC IPI Chr. Av. Ratio T-test Av. Ratio T-test Av. Ratio T-test Av. Ratio T-test Gel pI Gel Mw Pred pI Pred Mwt Score % Cov Function Localisation
1318 3,2-trans-enoyl-CoA 
isomerase, mitochondrial 
(Isoform 1 )
DCI IPI00300567  16 -2.21 0.0012 -2.44 0.00012 -1.14 0.18 -1.2 0.037 6.45 28776 8.8 33080 118 8 Able to isomerize both 3-cis and 3-trans double 
bonds into the 2-trans form in a range of enoyl-
CoA species.
Mitochondrion matrix.
1095 Annexin A1 ANXA1 IPI00218918 9 -4.57 0.00096 -5.16 0.00011 -1.11 0.55 1.3 0.64 8.44 38898 6.57 38918 574 35 Calcium/phospholipid-binding protein which 
promotes membrane fusion and is involved in 
exocytosis. This protein regulates phospholipase 
A2 activity. It seems to bind from two to four 
calcium ions with high affinity.
Cytoplasm
1061 Apolipoprotein E APOE IPI00021842 19 2.99 0.0081 3.54 0.0014 1.06 0.69 1.15 0.34 5.38 40028 5.65 36246 330 25 Mediates the binding, internalization, and 
catabolism of lipoprotein particles. It can serve as 
a ligand for the LDL (apo B/E) receptor and for 
the specific apo-E receptor (chylomicron remnant) 
of hepatic tissues.
Secreted
371 Collagen alpha-1(III) chain 
(Isoform 1) 
COL3A1 IPI00021033  2 5.46 1.60E-06 3.63 0.00016 -1.28 0.33 1 0.84 4.17 73039 6.21 139733 63 1 Collagen type III occurs in most soft connective 
tissues along with type I collagen.
Secreted, extracellular 
space, extracellular matrix
512 Collagen alpha-1(III) chain 
(Isoform 1) 
COL3A1 IPI00021033  2 -3.97 6.10E-05 -2.4 0.04 -1.49 0.15 -1.43 0.00059 8.99 67117 6.21 139733 639 10 Collagen type III occurs in most soft connective 
tissues along with type I collagen.
Secreted, extracellular 
space, extracellular matrix
1076 Collagen alpha-1(III) chain 
(Isoform 1) 
COL3A1 IPI00021033  2 5.41 0.0047 3.82 0.0095 -1.32 0.0053 -1.68 0.0016 5.79 39432 6.21 139733 1289 7 Collagen type III occurs in most soft connective 
tissues along with type I collagen.
Secreted, extracellular 
space, extracellular matrix 
1156 Collagen alpha-1(III) chain 
(Isoform 1) 
COL3A1 IPI00021033  2 10.58 2.10E-05 6.2 5.00E-05 -1.41 0.0016 -1.68 0.00039 7.23 35598 6.21 139733 646 6 Collagen type III occurs in most soft connective 
tissues along with type I collagen.
Secreted, extracellular 
space, extracellular matrix 
594 Dihydrolipoyl 
dehydrogenase, 
mitochondrial
DLD IPI00015911 7 -3.52 7.70E-05 -1.85 0.0016 1.47 0.039 1.81 0.0026 9.06 63554 7.59 54686 464 19 Lipoamide dehydrogenase is a component of the 
glycine cleavage system as well as of the alpha-
ketoacid dehydrogenase complexes.
Mitochondrial matrix
1318 Endoplasmic reticulum 
protein ERp29
ERP29 IPI00024911 12 -2.21 0.0012 -2.44 0.00012 -1.14 0.18 -1.2 0.037 6.45 28776 6.77 29032 112 29 Does not seem to be a disulfide isomerase. Plays 
an important role in the processing of secretory 
proteins within the ER, possibly by participating in 
the folding of proteins in the ER.
Endoplasmic reticulum 
lumen.
767 Enolase (Isoform alpha-
enolase)
ENO1 IPI00465248 1 8.48 0.00027 5.15 0.00042 -1.34 0.0071 -1.82 0.00033 8.25 55528 7.01 47481 293 21 Multifunctional enzyme that, as well as its role in 
glycolysis, plays a part in various processes such 
as growth control, hypoxia tolerance and allergic 
responses. May also function in the intravascular 
and pericellular fibrinolytic system due to its ability 
to serve as a receptor and activator of 
plasminogen on the cell surface of several cell-
types such as leukocytes and neurons.
Cytoplasm
1684 Eukaryotic translation 
initiation factor 5A-1 
(Isoform 2) 
EIF5A IPI00376005 17 -1.15 0.4 1.31 0.042 -2.14 0.0012 -1.89 0.0037 4.86 13244 6.52 20442 426 41  Promotes the formation of the first peptide bond. Nucleus
641 Fascin FSCN1 IPI00163187 7 3.52 0.00013 2.2 3.80E-05 -1.18 0.058 -1.64 0.0039 6.01 61676 6.84 55123 246 23 Organizes filamentous actin into bundles with a 
minimum of 4.1:1 actin/fascin ratio.
Cytoplasm
990 Fructose-bisphosphate 
aldolase A
ALDOA IPI00465439 16 -3.16 0.00019 -1.86 0.00053 1.04 0.69 1.63 0.0016 10.27 44279 8.3 39851 1297 50 D-fructose 1,6-bisphosphate = glycerone 
phosphate + D-glyceraldehyde 3-phosphate.
Cytoplasm
991 Fructose-bisphosphate 
aldolase A
ALDOA IPI00465439 16 -3.39 0.00018 -1.97 0.0012 1.09 0.47 1.73 0.00066 10.43 44279 8.3 39851 732 37 D-fructose 1,6-bisphosphate = glycerone 
phosphate + D-glyceraldehyde 3-phosphate.
Cytoplasm
1710 Glucagon GCG IPI00306140 2 3.16 0.00074 3.29 0.00029 -8.14 2.50E-05 -9.13 0.00018 5.76 12941 5.84 20896 116 22 Glucagon plays a key role in glucose metabolism 
and homeostasis.
Secreted
1712 Glucagon GCG IPI00306140 2 3.61 0.00055 3.76 6.30E-05 -8.21 0.00022 -9.23 0.00028 5.28 12906 5.84 20896 1791 67 Glucagon plays a key role in glucose metabolism 
and homeostasis.
Secreted
1779 Glucagon GCG IPI00306140 2 -2.86 0.00011 -1.98 0.00094 -1 0.99 1.08 0.49 8.57 11446 5.84 20896 741 44 Glucagon plays a key role in glucose metabolism 
and homeostasis.
Secreted
1192 Glucosamine-6-phosphate 
isomerase 1
GNPDA1 IPI00009305 5 4.29 0.00031 2.75 0.001 -1.31 0.0063 -1.51 0.002 7.68 33986 6.42 32819 180 27 Seems to trigger calcium oscillations in 
mammalian eggs. These oscillations serve as the 
essential trigger for egg activation and early 
development of the embryo.
Cytoplasm
963 Glutaredoxin-3 GLRX3 IPI00008552 10 3.87 0.00081 2.45 0.0014 -1.16 0.31 -1.6 0.0029 5.2 45071 5.31 37693 91 8 May play a role in regulating the function of the 
thioredoxin system.
Cytoplasm, cell cortex. 
Under the plasma 
membrane. After PMA 
stimulation.
1267 Glutathione transferase 
omega-1
GSTO1 IPI00019755 10 -2.87 0.00075 -1.64 0.0026 -1.34 0.17 1.5 0.095 6.49 30765 6.23 27833 625 43 Exhibits glutathione-dependent thiol transferase 
and dehydroascorbate reductase activities.
Secreted
1412 Growth factor receptor-
bound protein 2 (Isoform 1)
GRB2 IPI00021327 17 3.7 0.0016 2.53 0.0042 -1.45 0.0056 -1.48 0.0012 6.88 25314 5.89 25304 66 15 Isoform GRB3-3 does not bind to phosphorylated 
epidermal growth factor receptor (EGFR) but 
inhibits EGF-induced transactivation of a RAS-
responsive element. Isoform GRB3-3 acts as a 
dominant negative protein over GRB2 and by 
suppressing proliferative signals, may trigger 
active programmed cell death.
Golgi apparatus (By 
similarity).
499 heat shock protein 60 kDa, 
mitochondrial
HSPD1 IPI00784154 2 6.42 0.00011 4.06 0.00035 -1.74 0.00095 -1.57 0.0065 5.01 67669 5.7 61187 92 8 Implicated in mitochondrial protein import and 
macromolecular assembly. May facilitate the 
correct folding of imported proteins. May also 
prevent misfolding and promote the refolding and 
proper assembly of unfolded polypeptides 
generated under stress conditions in the 
mitochondrial matrix.
Mitochondrial matrix.  161 
1558 HNRPA2B1 protein HNRNPA2B1IPI00386854 7 -4.44 0.00046 -3.69 0.00073 1.07 0.68 -1.41 0.24 9.19 18984 4.79 28451 455 34
1157 Insulin-like growth factor-
binding protein 2
IGFBP2 IPI00297284 2 -1.3 0.048 1.19 0.14 -4.21 4.20E-05 -4.93 0.00011 5.42 35696 7.48 36198 375 30 IGF-binding proteins prolong the half-life of the 
IGFs and have been shown to either inhibit or 
stimulate the growth promoting effects of the IGFs 
on cell culture. They alter the interaction of IGFs 
with their cell surface receptors.
Secreted
1076 Insulin-like growth factor-
binding protein 6
IGFBP6 IPI00029235  12 5.41 0.0047 3.82 0.0095 -1.32 0.0053 -1.68 0.0016 5.79 39432 8.15 26219 162 9 IGF-binding proteins prolong the half-life of the 
IGFs and have been shown to either inhibit or 
stimulate the growth promoting effects of the IGFs 
on cell culture. They alter the interaction of IGFs 
with their cell surface receptors.
Secreted
626 L-lactate dehydrogenase B 
chain
LDHB IPI00219217 12 -2.29 0.00074 -2.31 0.0008 -3.77 0.0063 -3.43 0.0074 8.14 62183 5.71 36900 688 31 S)-lactate + NAD(+) = pyruvate + NADH. Cytoplasm
743 L-lactate dehydrogenase B 
chain
LDHB IPI00219217 12 1.98 0.00059 1.83 0.0016 -2.68 0.0055 -2 0.0034 6.27 56753 5.71 36900 170 14 S)-lactate + NAD(+) = pyruvate + NADH. Cytoplasm
307 Lumican LUM IPI00020986 12 3.82 3.80E-05 2.29 1.10E-05 -1.26 0.018 -2.21 4.60E-05 8.34 75882 6.16 38747 375 18 Binds to laminin Secreted, extracellular 
space, extracellular matrix
373 Lumican LUM IPI00020986 12 5.57 0.0027 3.53 0.01 -1.21 0.41 -1.55 0.18 4.45 72741 6.16 38747 155 14 Binds to laminin Secreted, extracellular 
space, extracellular matrix
470 Lumican LUM IPI00020986 12 10.5 4.60E-05 6.58 0.00019 -1.74 0.00011 -1.52 0.0052 4.46 68411 6.16 38747 135 16 Binds to laminin Secreted, extracellular 
space, extracellular matrix
472 Lumican LUM IPI00020986 12 10.05 8.60E-05 6.59 0.00014 -1.76 1.60E-05 -1.61 0.00021 4.56 68225 6.16 38747 181 25 Binds to laminin Secreted, extracellular 
space, extracellular matrix
473 Lumican LUM IPI00020986 12 17.27 0.00013 10.42 0.00025 -1.71 0.00022 -1.61 0.0014 4.67 68132 6.16 38747 47 2 Binds to laminin Secreted, extracellular 
space, extracellular matrix
499 Lumican LUM IPI00020986 12 6.42 0.00011 4.06 0.00035 -1.74 0.00095 -1.57 0.0065 5.01 67669 6.16 38747 157 15 Binds to laminin Secreted, extracellular 
space, extracellular matrix
543 Lumican LUM IPI00020986 12 6.35 0.00068 3.8 0.00072 -1.3 0.0042 -1.6 0.012 4.62 65401 6.16 38747 182 13 Binds to laminin Secreted, extracellular 
space, extracellular matrix
1045 N(G)-dimethylarginine 
dimethylaminohydrolase 1
DDAH1 IPI00220342 1 3.07 0.00045 2.59 0.00067 -1.31 0.046 -1.58 0.0055 5.81 40689 5.53 31444 607 44 Hydrolyzes N(G),N(G)-dimethyl-L-arginine 
(ADMA) and N(G)-monomethyl-L-arginine (MMA) 
which act as inhibitors of NOS. Has therefore a 
role in nitric oxide generation.
Cytoplasm
543 Nucleobindin-1 NUCB1 IPI00295542 19 6.35 0.00068 3.8 0.00072 -1.3 0.0042 -1.6 0.012 4.62 65401 5.15 53846 672 35 Major calcium-binding protein of the Golgi. May 
have a role in calcium homeostasis (By similarity).
Golgi apparatus, cis-Golgi 
network membrane; 
Peripheral membrane 
protein; Lumenal side. 
1329 Peroxiredoxin-6 PRDX6 IPI00220301  1 3 0.0007 2.19 0.0028 -1.33 0.16 -1.31 0.14 8.5 28503 6 25133 979 63 Involved in redox regulation of the cell. Can 
reduce H(2)O(2) and short chain organic, fatty 
acid, and phospholipid hydroperoxides. May play 
a role in the regulation of phospholipid turnover as 
well as in protection against oxidative injury.
Cytoplasm
743 Pigment epithelium-derived 
factor
SERPINF1 IPI00006114 17 1.98 0.00059 1.83 0.0016 -2.68 0.0055 -2 0.0034 6.27 56753 5.97 46484 285 16 Neurotrophic protein; induces extensive neuronal 
differentiation in retinoblastoma cells. Potent 
inhibitor of angiogenesis. It exhibits no serine 
protease inhibitory activity.
Secreted
753 Pigment epithelium-derived 
factor
SERPINF1 IPI00006114 17 -3.41 7.40E-05 -2.77 0.00032 1.04 0.85 1.38 0.059 8.46 56521 5.97 46484 142 16 Neurotrophic protein; induces extensive neuronal 
differentiation in retinoblastoma cells. Potent 
inhibitor of angiogenesis. It exhibits no serine 
protease inhibitory activity.
Secreted
1409 Prolactin PRL IPI00000871 6 5.99 0.00037 4.37 0.00057 -1.47 0.012 -1.62 0.0033 6.4 25418 6.5 26329 489 36 Belongs to the somatotropin/prolactin family. Secreted
1283 Proteasome subunit alpha 
type-4
PSMA4 IPI00299155 15 -2.68 0.00069 -1.71 0.0019 -1.24 0.15 1.02 0.85 9.69 29897 7.57 29750 334 25 The proteasome is a multicatalytic proteinase 
complex which is characterized by its ability to 
cleave peptides with Arg, Phe, Tyr, Leu, and Glu 
adjacent to the leaving group at neutral or slightly 
basic pH. The proteasome has an ATP-
dependent proteolytic activity.
Cytoplasm. Nucleus.
1329 Proteasome subunit alpha 
type-6
PSMA6 IPI00029623 14 3 0.0007 2.19 0.0028 -1.33 0.16 -1.31 0.14 8.5 28503 6.34 27838 418 20 The proteasome is a multicatalytic proteinase 
complex which is characterized by its ability to 
cleave peptides with Arg, Phe, Tyr, Leu, and Glu 
adjacent to the leaving group at neutral or slightly 
basic pH. The proteasome has an ATP-
dependent proteolytic activity.
Cytoplasm. Nucleus.
1412 Proteasome subunit beta 
type-4
PSMB4 IPI00555956 1 3.7 0.0016 2.53 0.0042 -1.45 0.0056 -1.48 0.0012 6.88 25314 5.89 25304 66 15 The proteasome is a multicatalytic proteinase 
complex which is characterized by its ability to 
cleave peptides with Arg, Phe, Tyr, Leu, and Glu 
adjacent to the leaving group at neutral or slightly 
basic pH. The proteasome has an ATP-
dependent proteolytic activity.
Cytoplasm. Nucleus.
474 Protein disulfide-isomerase 
A3
PDIA3 IPI00025252  15 20.22 0.00066 12.3 0.0013 -1.72 2.00E-06 -1.59 0.0019 4.83 68225 5.98 57146 1742 31 Catalyzes the rearrangement of -S-S- bonds in 
proteins.
Endoplasmic reticulum 
lumen
575 Protein disulfide-isomerase 
A3
PDIA3 IPI00025252  15 4.65 0.0028 2.93 0.00013 -1.59 0.078 -1.99 0.0015 6.82 64251 5.98 57146 323 20 Catalyzes the rearrangement of -S-S- bonds in 
proteins.
Endoplasmic reticulum 
lumen
584 Protein disulfide-isomerase 
A3
PDIA3 IPI00025252  15 -3.06 8.30E-05 -2.76 4.20E-05 -1.06 0.44 -1.2 0.033 6.4 63902 5.98 57146 2272 42 Catalyzes the rearrangement of -S-S- bonds in 
proteins.
Endoplasmic reticulum 
lumen
497 Pyruvate kinase isozymes 
M1/M2 (Isoform M2)
PKM2 IPI00479186 15 -1.5 0.099 1.16 0.34 2 0.0023 3.8 4.50E-06 9.83 67301 7.96 58470 178 24 Glycolytic enzyme that catalyzes the transfer of a 
phosphoryl group from phosphoenolpyruvate to 
ADP, generating ATP.
Cytoplasm
631 Retinal dehydrogenase 1 ALDH1A1 IPI00218914 9 -3.87 0.00056 -2.38 0.0023 1.09 0.73 1.5 0.19 8.8 62352 6.3 55454 768 36 Binds free retinal and cellular retinol-binding 
protein- bound retinal. Can convert/oxidize 
retinaldehyde to retinoic acid (By similarity).
Cytoplasm  162 
645 Retinal dehydrogenase 1 ALDH1A1 IPI00218914 9 -4.62 8.00E-06 -3.07 8.30E-05 -4.92 0.012 -10.15 3.70E-05 8.48 61844 6.3 55454 267 20 Binds free retinal and cellular retinol-binding 
protein- bound retinal. Can convert/oxidize 
retinaldehyde to retinoic acid (By similarity).
Cytoplasm
717 Retinal dehydrogenase 1 ALDH1A1 IPI00218914 9 2.29 0.011 1.94 0.018 -2.47 0.00012 -1.92 0.0026 5.85 57297 6.3 55454 986 55 Binds free retinal and cellular retinol-binding 
protein- bound retinal. Can convert/oxidize 
retinaldehyde to retinoic acid (By similarity).
Cytoplasm
1283 RSU1 Ras suppressor 
protein 1
RSU1 IPI00017256 10 -2.68 0.00069 -1.71 0.0019 -1.24 0.15 1.02 0.85 9.69 29897 8.57 31521 51 12 Potentially plays a role in the Ras signal 
transduction pathway. Capable of suppressing v-
Ras transformation in vitro.
Cytoplasm
1684 SMT3 suppressor of mif two 
3 homolog 2 isoform b 
precursor
SMT3 IPI00140827 X -1.15 0.4 1.31 0.042 -2.14 0.0012 -1.89 0.0037 4.86 13244 5.32 10889 380 27 Involved in a variety of cellular processes, such as 
nuclear transport, transcriptional regulation, 
apoptosis, and protein stability. It is not active until 
the last two amino acids of the carboxy-terminus 
have been cleaved off.
Cytoplasm
1680 Superoxide dismutase [Cu-
Zn]
SOD1 IPI00218733  21 2.6 0.00097 2.5 0.00018 -5.36 7.30E-05 -5.54 0.00092 6.58 13299 5.7 16154 854 35 Destroys radicals which are normally produced 
within the cells and which are toxic to biological 
systems.
Cytoplasm
444 T-complex protein 1 subunit 
alpha
TCP1 IPI00290566 6 6.76 0.001 3.63 0.0045 -1.46 0.011 -1.91 0.0019 6.91 70207 5.8 60819 70 4 Molecular chaperone; assists the folding of 
proteins upon ATP hydrolysis. Known to play a 
role, in vitro, in the folding of actin and tubulin.
Cytoplasm
1283 TIMP1 Metalloproteinase 
inhibitor 1
TIMP1 IPI00032292 X -2.68 0.00069 -1.71 0.0019 -1.24 0.15 1.02 0.85 9.69 29897 8.46 23840 74 13 Complexes with metalloproteinases (such as 
collagenases) and irreversibly inactivates them. 
Also mediates erythropoiesis in vitro; but, unlike IL-
3, it is species-specific, stimulating the growth and 
differentiation of only human and murine erythroid 
progenitors. Known to act on MMP-1, MMP-2, 
MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-
11, MMP-12, MMP-13 and MMP-16. Does not act 
on MMP-14.
Secreted
1217 Tropomyosin alpha-4 chain 
(Isoform 1)
TPM4 IPI00010779  19 -2.25 0.00082 -1.9 0.0064 1.32 0.28 1.38 0.034 4.32 32846 4.67 28619 1915 52 Binds to actin filaments in muscle and non-
muscle cells. Plays a central role, in association 
with the troponin complex, in the calcium 
dependent regulation of vertebrate striated 
muscle contraction. Smooth muscle contraction is 
regulated by interaction with caldesmon. In non-
muscle cells is implicated in stabilizing 
cytoskeleton actin filaments.
Cytoplasm
1401 Ubiquitin carboxyl-terminal 
hydrolase isozyme L1
UCHL1 IPI00018352 4 -1.6 0.017 1.11 0.24 -2.27 0.0091 -3.5 0.0013 5.57 25837 5.33 25151 1103 62 Ubiquitin-protein hydrolase involved both in the 
processing of ubiquitin precursors and of 
ubiquitinated proteins. This enzyme is a thiol 
protease that recognizes and hydrolyzes a 
peptide bond at the C-terminal glycine of ubiquitin. 
Also binds to free monoubiquitin and may prevent 
its degradation in lysosomes. The homodimer 
may have ATP-independent ubiquitin ligase 
Cytoplasm
1318 Uncharacterized protein 
ENSP00000348237
IPI00453476 12 -2.21 0.0012 -2.44 0.00012 -1.14 0.18 -1.2 0.037 6.45 28776 6.67 29003 278 19 Belongs to the phosphoglycerate mutase family. Cytoplasm
1076 Vesicular integral-
membrane protein VIP36
LMAN2 IPI00009950 5 5.41 0.0047 3.82 0.0095 -1.32 0.0053 -1.68 0.0016 5.79 39432 6.46 40545 80 5 Plays a role as an intracellular lectin in the early 
secretory pathway. Interacts with N-acetyl-D-
galactosamine and high-mannose type glycans 
and may also bind to O-linked glycans. Involved in 
the transport and sorting of glycoproteins carrying 
high mannose-type glycans (By similarity).
Membrane
611 Xaa-Pro dipeptidase PEPD IPI00257882  19 3.89 0.00013 2.35 5.20E-05 -1.37 0.01 -1.86 0.0024 6.53 62267 5.64 55311 92 5 Splits dipeptides with a prolyl or hydroxyprolyl 
residue in the C-terminal position. Plays an 
important role in collagen metabolism because 
the high level of iminoacids in collagen.
Cytoplasm
1614 Xaa-Pro dipeptidase PEPD IPI00257882  19 -3 0.00034 -2.05 0.00072 1.29 0.14 1.13 0.19 6.52 14852 5.64 55311 47 9 Splits dipeptides with a prolyl or hydroxyprolyl 
residue in the C-terminal position. Plays an 
important role in collagen metabolism because 
the high level of iminoacids in collagen.
Cytoplasm
Table 4.2 Differentially expressed proteins in the secretome of the EOC cell models identified by mass spectrometry. Protein 
features that were matched across all gels with a fold change ≥ 2 fold where p ≤ 0.05 were identified by LC-MS/MS. Orange shading 
indicates an increase in expression and green indicates a decrease. Protein identifications were made by database searching of peptide 
ion fragments from LC-MS/MS generated peak lists. The search criteria used allowed +/- 30 ppm peptide mass error and up to 2 
missed cleavages. The identified proteins were verified by comparison of their theoretical molecular weights and pIs with gel position 
on the master gel.   163 
4.4 Conclusions 
To  answer  one  of  the  aims  of  this  research,  a  method  was  developed  to  isolate  the 
secreted  proteome  of  cells  in  culture.  Cells  were  grown  in  standard  medium  until 
reaching a confluence of 80%. These were then washed extensively to remove residual-
serum proteins and were then cultured in serum-free medium before being harvested and 
cleared  of  dead  and  detached  cells.  A  combination  of  ultrafiltration  and  subsequent 
desalting  on  columns  resulted  in  a  secreted  protein  extract  amenable  to  2D-DIGE 
analysis. In the analysis of conditioned medium, as expected, a proportion of classically 
secreted  proteins  were  identified,  however,  there  was  some  overlap  with  the  WCL 
analyses as described earlier. Notable among the classically secreted proteins identified 
were the insulin-like growth factor binding proteins. These have a regulatory role in the 
insulin-like  growth  factor  signalling  system  that  is  important  in  the  growth  and 
development of cells and thought to be particularly prominent in tumourigenesis (Lee, 
Mircean et al. 2005; Chakrabarty and Kondratick 2006). Of these, much work has been 
published on elevated levels of IGFBP2 in ovarian cancer and its value as a prognostic 
marker (Baron-Hay, Boyle et al. 2004). In this study, the less well characterised IGFBP6 
and IGFBP7 were also identified as differentially expressed in the models of neoplastic 
suppression.  The  obvious  importance  of  this  family  of  proteins  in  tumourigenesis 
necessitates further understanding of the role that these two IGFBPs play. Their value as 
markers of neoplastic suppression cannot be ignored. Another secreted protein, pigment 
epithelium-derived factor precursor (PEDF), was identified as differentially expressed in 
both  analyses  and  is  reported  to  be  involved  in  ovarian  cancer  development  and   164 
progression (Phillips, Ziegler et al. 1996). Its role in growth inhibition and apoptosis and 
observed decrease in expression in transformed cells has implicated PEDF as a potential 
tumour suppressor gene in ovarian cancers (Cheung, Au et al. 2006). Two isoforms were 
identified in one experiment, one displaying down-regulation in one hybrid pair and up-
regulation in the other hybrid pair, whilst the second displayed the opposite. The secreted 
protein, galectin-1, identified as differentially expressed in one of the hybrid cell lines has 
been shown to interact specifically with CA125. A study has proposed a link between the 
expression  of  CA125  by  tumour  cells  with  the  increased  cell-surface  expression  of 
galectin-1  and  further  postulates  a  functional  role  for  CA125  as  a  cargo  protein. 
Undoubtedly,  this  emphasizes  the  potential  of  galectin-1  as  a  marker  of  neoplastic 
suppression  in  these  models.  Unfortunately,  galectin-1  was  only  identified  as 
differentially expressed in one hybrid cell-line; however, this does not mean expression is 
not  altered  in  the  other  cell  model.  It  is  possible  that  the  protein  was  differentially 
expressed but its identification was missed. Of the other secreted proteins identified as 
differentially expressed, all have been implicated in tumourigenesis, and roles in ovarian 
cancer have been suggested in the literature. These proteins include apolipoprotein E, 
involved  in  proliferation  in  ovarian  cancer  cells  (Chen,  Pohl  et  al.  2005);  prolactin, 
involved in the inhibition of apoptosis in ovarian cancer (Asai-Sato, Nagashima et al. 
2005); lactate dehydrogenase, found to be up-regulated in  gynaecological malignancy 
(Yuce, Baykal et al. 2001); and TIMP1 and lumican, both of which have been implicated 
in  the  proliferation  of  cancer  cells  (Ping  Lu,  Ishiwata  et  al.  2002;  Nakopoulou, 
Giannopoulou et al. 2003). Future work would be to assess the value of these candidate 
markers in the serum of women diagnosed with malignant ovarian cancer, benign disease   165 
and  matched  healthy  controls  from  the  UKOPS  (United  Kingdom  Ovarian  Cancer 
Population Study) using immunoassays. 
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Chapter 5 Profiling of models of OC tumour 
suppression by 2D-LC-MS/MS with Tandem Mass 
Tags for Quantitation 
Introduction 
It has been over 30 years since O’Farrell introduced 2-dimensional polyacrylamide gel 
electrophoresis. Much improvement has been made to this technique over the years by 
researchers. However, 2DE still has limitations because it poorly resolves specific classes 
of proteins, such as very large and very small proteins, basic proteins and hydrophobic 
proteins.  Considering  the  important  functions  these  classes  of  proteins  might  have 
receptors, signal transducers and transporters etc) it is important that these proteins were 
not excluded in this study. Thus, although 2DE remains a standard tool for proteome 
research, improvements in chromatography-based separation linked to automated MS/MS 
have paved the way for new and exciting quantitative MS-based techniques. 
 
Gel-free  approaches  have  addressed  the  challenges  presented  by  complex  protein 
mixtures.  In  its  simplest  form,  a  complex  mixture  of  proteins  would  be  digested  to 
peptides and separated over a gradient profile by charge and/or hydrophobic interactions 
and  eluted  peptides  introduced  to  the  mass  spectrometer  for  automatic  precursor  ion 
detection and subsequent fragmentation carried out in a data dependent fashion for the   167 
duration of the experiment. For complex mixtures one dimensional separation of peptides 
does  not  provide  the  necessary  separating  power  to  enable  the  mass  spectrometer  to 
process the hundreds of thousands of peptide species. Consequently, peptides derived 
from the low abundance protein components from within a complex mixture are often 
completely missed in the analysis. To address this challenge, multi-dimensional peptide 
separations  have  been  developed  coupling  orthogonal  separation  methods  to  better 
resolve  these  complex  mixtures  and  to  increase  the  ability  to  detect  low  abundance 
protein components. The first chromatographic step is usually strong cation exchange, 
and the second is reversed-phase high performance liquid chromatography (HPLC) (Fig 
5.1).  This  2D  method  has  demonstrated  its  ability  to  overcome  the  limitations  of 
membrane protein analysis in 2DE separations, and significantly increases the proteomic 
coverage by allowing previously undetected low-abundance proteins to be identified in 
complex  mixtures  (Blonder,  Chan  et  al.  2006).  However,  this  technology  does  not 
provide  quantitative  information  on  its  own  and  a  number  of  MS-based  quantitative 
methods exist that can be employed (Fig 5.1). These include label-free quantification 
including spectral counting and a variety of stable isotope labelling strategies which are 
explained in more detail in Chapter 1.5.1. 
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Figure 5.1  Quantitative  MS-based  labelling  strategies  coupled  to  2D-LC-MS/MS. 
This figure shows SILAC labelling at the cellular level; ICAT labelling at the protein 
level; O
16-O
18 labelling at proteolytic digestion; and isobaric mass tagging (e.g. TMT; 
iTRAQ)  at  the  peptide  level.  Label-free  quantitation  can  be  carried  out  but  requires 
multiple replicate runs for experimental robustness. 
 
 
In  this  study,  the  recently  commercialized  TMT  strategy  was  chosen  for  relative 
quantification  of  the  EOC  cell  models  by  peptide  2D-LC.  As  described  in  the 
introduction, TMT labelling involves the tryptic digestion of samples prior to labelling, 
then pooling the labelled digests for 2D-LC separation coupled to MS/MS analysis (Fig 
5.2). This strategy was applied to a WCL, secreted, crude membrane and surface labelled 
fraction as a complimentary approach to the 2D-DIGE profiling. The major aim was to 
identify proteins whose expressions were altered between each parental cell line and its 
pair of hybrid clones.  
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Figure 5.2 TMT labelling strategy. Protein was extracted from cells in culture. Amine-
based buffers and salts were removed by precipitation and samples denatured, reduced 
and alkylated, before trypsin digestion. Samples were labelled with 6-plex TMT labels 
appropriately,  combined,  separated  by  SCX  in  the  first  dimension  and  RP 
chromatography in  the  second  dimension  before  introduction  to  a  mass spectrometer. 
Reporter ion intensities in the MS/MS spectra were used to determine relative peptide and 
protein abundances.      
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5.1.2 2D-LC-MS/MS 
2D-LC  had  not  previously  been  attempted  in  the  laboratory  and  so  set-up  and 
optimisation was necessary. As described earlier, to achieve  adequate resolution with 
complex mixtures of peptides, a combination of SCX and RP-HPLC can be employed. In 
this study a Polysulfoethyl SCX column (1 mm I.D x 15 cm, 5 µm, 300 Å) was used in 
the  first  dimension  attached  to  the  loading  valve  of  an  Ultimate  3000  HPLC  system 
(Dionex). The column was chosen to be compatible with an off-line 2D-LC workflow to 
be performed entirely on the Ultimate 3000. The column is designed to work optimally 
within the flow rates (<100 µl/min) available on the loading pump of an Ultimate 3000. 
The differentially labelled digest mixture was separated using a salt gradient at pH 2-3, 
where carboxyl groups have lost their negative charge and nearly all peptides have a net 
positive charge. It is thought that approximately 65 % of peptides in a typical complex 
tryptic digest have a net charge of + 2 due to the basic N-terminus and the Lys or Arg at 
the C-terminus. Peptide digests were acidified (pH 2-3) with FA prior to separation over  
a gradient of 5-55% mobile phase B (95%/5% water/ACN v/v, 5 mM NaH2PO4 buffer pH 
3.0, 1M NaCl) as recommended by the column manufacturer. The SCX column has a 
higher binding capacity (60 µg) than the RP column (3 µg) allowing more sample to be 
loaded and at a higher flow rate (50 µL/min). This versatility reduced chromatographic 
separation times and improved detection of low abundance proteins in complex mixtures. 
The gradient length and fraction number collected was optimised by RP-MS/MS analysis 
in the absence of a UV detector. A separation time of 30 min with fractions collected 
every 3 min after injection was found to be optimal (Fig 5.3).    171 
 
 
 
 
 
 
 
Figure 5.3 LC-MS/MS analysis of 10 SCX fractions. SCX fractions were collected 
every 3 min over a 30 min gradient of 5-55% mobile phase B. Fractions were dried down, 
Ziptipped, resuspended in 0.1% FA and injected for RP-LC-MS/MS analysis over a 60 
min  gradient.  Spectra were processed using  Proteome  Discoverer and the  IPI Human 
database interrogated using the Mascot search algorithm to identify peptide sequences. 
Fraction 5 yielded fewer peptides because of incomplete injection. ~6000 unique peptides 
were identified in this run. 
 
 
The second dimension  was carried out by RP-HPLC, in an  automated fashion on an 
Ultimate 3000 HPLC (Dionex) linked to an LTQ-Orbitrap XL (Thermo  Fisher) mass 
spectrometer  with  a  PicoView  ESI  source.  Each  SCX  fraction  was  dried  down  in  a 
speedvac and desalted using Ziptips (see chapter 2.16), before resuspending in mobile 
phase A and injection. Separation was carried out on a C18 Pepmap column (75 µM x 
150mm, 3 µm, 100 Å) with a linear gradient of 5-50% solvent B (20%/80% water/ACN 
v/v + 0.1% FA) over 90-120 min depending on sample complexity; the WCL fraction 
was separated over 120 minutes and the secreted, crude membrane and surface labelled 
fractions were separated over 90 minutes. 
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5.1.3 TMT-MS/MS 
The TMT technology relies on accurate detection of low mass ‘reporter ions’ in MS/MS 
scans which are generated by fragmentation of the peptide tags. Mass spectrometers such 
as quadrupoles and TOF instruments have the capability of detecting low m/z fragment 
ions whereas for ion traps, detection is relatively poor. The MS platform used was an 
LTQ Orbitrap XL. This features a collision cell in which fragmentation is performed 
using  higher  energy  collisional  dissociation  (HCD).  This  fragmentation  technique 
produces rich ‘triple-quad like’ fragmentation patterns including fragments in the low m/z 
mass range. Ions fragmented by HCD in this extra octapole collision cell are returned to a 
C-trap and detected in the Orbitrap mass analyser. This provides very high mass accuracy 
and  resolution  of  the  reporter  ions  but at  the  possible  expense  of  under  sampling  of 
precursor ions due to the longer MS/MS scan time.  
 
The Orbitrap was operated using Xcalibur software and parameters were optimized for 
acquisition of high quality spectra for quantification and identification of TMT-tagged 
peptides. TMT-tagged peptides were detected in the Orbitrap at 60,000 resolution at m/z 
400. A maximal ion accumulation of 1 x 10
6 ions in the Orbitrap was determined to be 
preferable with 1 second selected for all scan modes and automatic gain control selected 
to  prevent  over  filling  of  the  ion  trap.  A  single  microscan  was  deemed  sufficient  to 
produce high quality spectra whilst keeping the cycle time down.  Fragmentation was 
optimal with HCD normalized collision energy set at 40%. Product ions were detected in 
the Orbitrap at a resolution of 7500. This resulted in prominent reporter fragment ions   173 
and good sequence spectra from fragmented ions across the chromatographic separation. 
Ion detection in the Orbitrap alone increases the cycle time and so between three and five 
HCD spectra were acquired in a data dependent manner following each full scan in order 
to  identify  as  many  novel  peptides  with  quantitative  information  as  possible.  Data 
dependent settings and lock masses were set as described in Chapter 2. Mascot 2.2 and 
Proteome  Discoverer  were  then  used  for  protein  identification  by  searching  the  IPI 
human database. In each program, searches were carried out using carbamidomethylation 
of cysteine residues set as a fixed modification. In addition, TMT modification of peptide 
N-termini and lysine residues were set as fixed modifications. Methionine oxidation and 
N-terminal acetylation were set as variable modifications. A decoy database was searched 
under the same parameters to estimate a FDR. A peptide mass tolerance of 10 ppm and a 
fragment mass tolerance of 0.1 Da were selected for confident peptide matching. 
 
5.2.1 Quantitative TMT profiling of the WCL 
For the quantitative evaluation of protein expression profiles of the WCL of cell models 
of ovarian cancer neoplastic suppression, protein from each cell line was harvested and 
purified by acetone precipitation as described. 100 µg of each sample was denatured, 
reduced, alkylated, digested with trypsin and labelled appropriately with TMT labels (Fig 
5.2). The labelled samples were combined and dried down in a speedvac. The sample was 
resuspended in SCX mobile phase A and acidified to pH 2.5. Approximately 50 µg of 
sample was injected onto a Polysulfoethyl SCX column for separation. 10 fractions were 
collected,  dried  down  in  a  speedvac  and  desalted  with  Ziptips  according  to  the   174 
manufacturer’s protocol. Each sample was further dried down and resuspended in 7 µl of 
0.1 % formic acid (FA) and subjected to RP-LC-MS/MS. Each .Raw file produced in 
Xcalibur software (Thermo) was transferred to Mascot Daemon for processing by Mascot 
Distiller,  where  peak  detection  was  carried  out  and  datasets  combined  for  Mudpit 
analysis, before searching against the IPI human database. The search parameters were 
set as described in Materials and Methods (Chapter 2). Search result filters were selected 
as follows; only “Mudpit scored” peptides with a score >20 and equal to or above the 
Mascot homology at a significance threshold of p<0.05 were included and single peptide 
identifications required a score equal to or above the Mascot identity threshold. MudPIT 
protein scoring is a more stringent scoring algorithm used for searches with more than 
1000 spectra. It is determined from the excess of ions score over the homology threshold 
for each query plus the average of the thresholds used added to the score. In addition, for 
a given protein or peptide sequence the highest scoring and highest ranking respectively 
are highlighted in a Mascot report. This ensures that when a peptide belongs to another 
protein  the  most  likely  assignment  is  given  preference.  Quantitative  information, 
calculated from reporter ion intensities, was only accepted for peptides with scores equal 
to or above the Mascot homology score and the median value was taken to compare 
protein ratios (Fig 5.4). Proteins with a ratio above 2 or below 0.5 in each comparison 
(127/126, 128/126, 130/129 and 131/129) were considered to be significantly different 
changes in expression. 
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Figure 5.4 Representative annotated spectra and reporter ion intensities for three 
peptide  sequence  identifications  from  Annexin  A1.  A1)  Annotated  spectrum  for 
sequence:  GVDEATIIDILTK,  identified  with  Mascot;  ion  score  75.68,  Exp  Value: 
7.20E-07. A2) Reporter ion intensities for sequence: GVDEATIIDILTK, reporter tag 126 
was labelled to TOV-112D; tag 127 labelled to 18-D-22; tag 128 labelled to 18-D-23; tag 
129 labelled to TOV-21G; tag 130 labelled to 18-G-5 and tag 131 labelled to 18-G-1.26. 
B1)  Annotated  spectrum  for  sequence:  SEDFGVNEDLADSDAR,  identified  with 
Mascot; ion score 80.28, Exp Value: 6.80E-08. B2) Reporter ion intensities for sequence: 
SEDFGVNEDLADSDAR.  C1).    Annotated  spectrum  for  sequence: 
GTDVNVFNTILTTR, identified with Mascot; ion score 50.72, Exp Value 0.00029. C2) 
Reporter  ion  intensities  for  sequence:  GTDVNVFNTILTTR.  Annexin  A1  displayed 
significant down-regulation in the hybrid clones 18-D-22 (median ratio 0.42) and 18-D-
23 (median ratio 0.44) compared to the parent cell line TOV-112D. Reporter ions are 
boxed in red on the spectra. Data were generated using Proteome Discoverer. 
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5.2.2 Identification of differentially expressed WCL 
proteins 
A  total  of  946  unique  protein  identifications  were  made  from  2499  unique  peptide 
matches using Mascot (Appendix 1A) .Of these, only 21 proteins were identified using a 
single, high-scoring peptide. The decoy database search resulted in 196 matches with a 
score equal to or above the Mascot peptide identity threshold compared to 4924 matches 
in the target database. For a peptide score equal to or above the homology threshold the 
decoy search resulted in 266 matches compared to 5435 matches in the target database 
resulting in a false discovery rate of 3.98% and 4.89% respectively which are considered 
acceptable for published data. The distribution of charge states of identified peptides was 
94% +2, with only 6% of peptides displaying a charge state of +3. Database searches 
with the TMT modifications deselected determined the TMT labelling efficiency. The 
level of labelling was found to be in excess of 99% of peptides matches. The 2D-LC 
approach has proven to be competent at detecting proteins previously under-represented 
in the 2D-DIGE analysis. High and low molecular weight proteins; including spectrin 
beta chain (316 kDa) and thymosin beta-4-like protein 3 (7 kDa) respectively, and highly 
basic proteins, including histones and ribosomal proteins, were identified. 
 
A total of 65 proteins were differentially expressed > 2 fold between a parental cell line 
and its corresponding hybrid clone. 36 proteins were found to be up-regulated and 2 
down-regulated in the 18-D-22/TOV-112D comparison; 9 proteins were up-regulated and 
3 down-regulated in the 18-D-23/TOV-112D comparison; 8 proteins were up-regulated   177 
and  3 down-regulated  in  the  18-G-5/TOV-21G  comparison  and  2  up-regulated and 3 
down-regulated in the 18-G-1.26/TOV-21G comparison. A total of 11 proteins displayed 
concordant expression changes (> 2 fold) in both hybrids compared to its parental cell 
line and these are shown in Table 5.1. The greatest change in expression was observed for 
Cytochrome b5 outer mitochondrial membrane precursor. Expression was changing 4.2 
fold in the hybrid clone 18-D-22 and 3.7 fold in the hybrid clone 18-D-23.  
 
Name 127/126 N SD 128/126 N SD 130/129 N SD 131/129 N SD
 Annexin A1 0.416 32 NN 0.441 32 NN 0.787 30 NN 1.24 30 1.127
Cytochrome b5 outer mitochondrial 
membrane precursor
4.2 5 1.328 3.704 5 1.276 1.228 4 1.233 1.19 5 1.214
Caldesmon 1 2.983 2 1.007 2.021 2 1.031 1.274 2 1.196 0.859 2 1.041
Oxidation resistance protein 1 2.864 2 1.964 2.1 2 1.775 0.81 2 1.131 0.713 2 1.002
DNA-(apurinic or apyrimidinic site) lyase 2.524 2 1.347 2.117 2 1.347 0.983 2 1.377 0.877 2 1.099
PURINE NUCLEOSIDE P 2.505 2.284 1.31 1.295
Integral membrane protein GPR177 1 8.26 3.349 0.964 0.792
DNA polymerase epsilon subunit 4 2.213 2.489 0.885 0
60S ribosomal protein L23a  1.197 2 1.011 0.92 2 1.036 2.709 2 3.617 2.304 2 3.304
Four and a half LIM domains 1 variant 0.686 0.42 2.765 2.26  
 
Table  5.1  Proteins  displaying  concordant  expression  changes  in  a  hybrid  pair 
compared  to  its  parent  cell  line.  Protein  abundance  is  measured  by  peptide  ratio. 
Significant up-regulation (>2 fold) is displayed in bold red and down-regulation (<0.5 
fold) is displayed in bold blue. The reporter ions 127 and 128 are labelled to 18-D-22 and 
18-D-23 and compared to the parental, TOV-112D, which is labelled with 126. Reporter 
ion 130 and 131 were labelled to 18-G-5 and 18-G-1.26 respectively, and each were 
compared to the parental TOV-21G, labelled with 129. Identifications in italic type were 
from a single peptide only. (‘N’ represents the number of labelled peptides (>1) used for 
ratio calculation, ‘SD’ is the geometric standard deviation of the peptide ratios for a given 
protein and ‘NN’ indicates the presence of a peptide ratio outside a normal distribution). 
Data were generated using Mascot with quantitation tool box. 
 
Annexin A1 was the only concordantly expressed protein which was down-regulated by 
>2-fold in the 18-D-22 and 18-D-23 cell lines, compared to parental cell line TOV-112D. 
This protein was also identified in the 2D-DIGE analysis where its expression was also 
down-regulated  in  the  pooled  experiment  and  single  hybrid  clone  comparisons.   178 
Cytochrome b5 outer mitochondrial membrane precursor an electron carrier for several 
membrane  bound  oxygenases  (Borgese,  D'Arrigo  et  al.  1993)  was  significantly  up-
regulated  in  the  hybrid  cell  lines  18-D-22  and  18-D-23  by  ratios  of  4.2  and  3.7 
respectively. Caldesmon, an actin and myosin binding protein was up-regulated in hybrid 
cell  lines  18-D-22  and  18-D-23  by  ratios  of  2.98  and  2.02,  respectively.  Oxidative 
resistance protein 1 is involved in protection from oxidative damage (Volkert, Elliott et 
al. 2000). This protein was up-regulated in the 18-D-22 and 18-D-23 hybrid cell lines by 
ratios of 2.86 and 2.1, respectively. DNA-(apurinic or apyrimidinic site) lyase (APE) was 
up-regulated in the 18-D-22 and 18-D-23 hybrid cell lines by ratios of 2.52 and 2.12, 
respectively. This protein repairs DNA damage and may have a role in protecting against 
lethal mutations. Purine nucleoside phosphorylase (PNP) was up-regulated in the 18-D-
22  and  18-D-23  hybrid  cell  lines  by  ratios  of  2.51  and  2.28,  respectively.  The  60S 
ribosomal  protein  L23a  was the  only  concordantly  regulated  protein  identified  in  the 
TOV-21G model and was up-regulated in the 18-G-5 and 18-G-1.26 cell lines by ratios of 
2.71 and 2.3, respectively. Several other proteins displaying concordant expression in one 
of the cell models were identified using only a single, but highly significant peptide and 
should not be ignored. These included, PNP, integral membrane protein GPR1771, DNA 
polymerase  epsilon 4  and four and a half  LIM domains 1 variant.  Whilst no protein 
changes were identified that were common to both cell models, numerous changes were 
identified that were  also found in the 2D-DIGE analysis. Proteins included vimentin, 
annexin  A1  (above),  retinol  dehydrogenase  1,  laminin  A/C,  COL3A1,  galectin-1  and 
ezrin. Generally there was agreement in the direction of altered expression between the 
experiments. For example, multiple isoforms of vimentin were identified from 2D-DIGE   179 
gels with differing expression levels. The first single clone analysis of WCL by 2D-DIGE 
identified up-regulation of different vimentin isoforms in the 18-D-22 & 18-D-23 hybrid 
clones which is supported by the similar up-regulation of vimentin in this TMT analysis. 
However,  the  specific  isoform  of  vimentin  in  the  two  analyses  cannot  be  matched, 
highlighting  the  drawback  of  peptide-based  analysis.  Two  isoforms  of  annexin  A1 
displayed  down-regulation  of  expression  in  hybrid  cell  lines  18-D-22  and  18-D-23 
compared to the parental cell line TOV-112D in the 2D-DIGE analysis of WCL. These 
findings  are  supported  by  the  TMT  analysis  which  identified  annexin  A1  as  down-
regulated  -2.38  and  -2.27  fold  in  hybrid  clones  18-D-22  and  18-D-23,  respectively. 
However, retinol dehydrogenase 1 did not display concordant expression between the two 
proteomic approaches. The TMT analysis of WCL identified up-regulation 2.2 fold in the 
hybrid clone 18-D-22, whereas the 2D-DIGE analysis identified down-regulation of an 
isoform  by  2.63  fold  and  2.04  fold  in  the  hybrid  clones  18-D-22  and  18-D-23, 
respectively. Galectin-1 was identified up-regulated 2.11 fold in hybrid clone 18-D-22 in 
the TMT analysis of WCL. This was previously identified in the 2D-DIGE analysis of the 
pooled hybrid clones displaying significant up-regulation of 4.93 fold in the TOV-112D 
which  is  consistent  with  the  findings  in  this  TMT  analysis.  Another  differentially 
expressed protein also identified in the 2D-DIGE analysis of the pooled hybrid clones 
was purine nucleoside phosphorylase. The TMT analysis identified a single high scoring 
peptide displaying up-regulation in the hybrid clone 18-D-22 of 2.5 fold and the hybrid 
clone 18-D-23 of 2.3 fold. The 2D-DIGE analysis displayed contrasting down-regulation 
-2.79 fold in the TOV-112D hybrid clone pool. This possibly reflects the problems when 
dealing with pooled analyses discussed in Chapter 3.   180 
5.3 Quantitative TMT profiling of secreted protein 
TMT labelling combined with the 2D-LC-MS/MS strategy was applied to the secreted 
proteome  of  the  cell  models  under  study.  The  isolation  of  the  secreted  fraction  was 
carried out in the same way as for the 2D-DIGE analysis (Chapter 2.4), although the 
extraction from conditioned medium was scaled down to reduce time. As a result, 25 µg 
of secreted protein from each cell line was recovered and labelled with the appropriate 
TMT tag before 2D-LC-MS/MS. The SCX step was carried out in exactly the same way 
as described earlier with 10 fractions collected over a gradient of 30 minutes. The RP 
gradient was reduced to 90 min to match the reduced complexity of the SCX fractions. 
Orbitrap raw data files were processed by Mascot distiller before merging and searching 
against the  IPI human  database. The search parameters were set as described earlier. 
Proteins were considered if the median value of the expression ratios for filtered peptides 
from that protein was >2 or <0.5 in the hybrid versus parental comparisons (and were 
significant, lying within a 95 % confidence interval). 
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5.3.1 Identification of differentially expressed secreted 
proteins 
Analysis of the secreted fraction revealed a total of 223 unique protein identifications 
from 657 unique peptide matches (Appendix 1B). Of these, 45 proteins were identified by 
a single, high scoring peptide match. 76 proteins were differentially expressed > 2 fold in 
one  or  more  of  the  hybrid  clones  and  parental  comparisons.  The  peptide  charge 
distribution  favoured  +2  peptides  making  up  72.5%  of  peptide  matches.  26.6%  of 
peptides matches were +3 charged and the remainder +4. The labelling efficiency was 
found to be > 99% by searching the target database without the TMT mass modification 
addition. The decoy database search resulted in 229 peptide matches with a score equal to 
or above the Mascot peptide identity threshold compared to 1583 in the target database. 
For matches with a peptide score equal to or above the homology threshold the decoy 
database search resulted in 369 matches compared to 2178 matches in the target database, 
giving false discovery rates of 14.5 % and 16.9 %, respectively. These false discovery 
rates are quite high and not representative of the rates achieved for the analysis of the 
whole cell and membrane fractions (see later). This may have occurred since the data set 
comprised a relatively high number of repeat sequence identifications from a few highly 
abundant proteins. Bovine serum albumin peptides made up a large proportion of the 
peptide  matches.  A  total  of  489  peptide  matches  were  identified  from  mass  spectra, 
however,  this  represented  only  8%  of  the  total  coverage.  Many  of  the  protein 
identifications came from a single peptide sequence observed repeated times which is 
common to MudPIT experiments analysing complex samples such as these. Additional   182 
contaminants  from  the  medium  that  were  identified  included  alpha  feto-protein, 
transferrin, growth-inhibiting protein 12 and serotransferrin. In addition, the incidence of 
6-8 amino-acid peptide identifications were greater than observed for the WCL results, 
possibly  because  of  a  greater  prevalence  of  lysine  and  arginine  residues  in  secreted 
proteins. To conduct a decoy database search in Mascot, a random sequence of equal 
length is automatically generated and tested under the same search and filter parameters. 
Thus the combined effect of multiple repeats and shorter peptide sequence could result in 
the misrepresentation of decoy  matches in the data set. To achieve a  FDR < 5% for 
peptide  matches  with  a  score  equal  to  or  above  the  threshold  for  homology  the 
significance threshold would have to be changed from 0.05 to 0.0099. At this level the 
number of unique proteins identified was reduced to 156 from 223 with the majority of 
the single peptide identifications from the previous search being excluded. Indeed, only 
15 proteins were identified by a single high scoring unique peptide in this search. A 
comparison  of  protein  identifications  with  gene  ontology  databases  resulted  in 
extracellular region, extracellular space and proteinaceous extracellular matrix proteins 
comprising  26%  of  the  proteins  identified  (Fig  5.5).  Furthermore,  cell  surface  and 
membrane protein made up 8% of cellular proteins identified. 
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Figure  5.5  Cellular  location  of  identified  proteins  in  the  secreted  fraction 
determined from gene ontology databases. Some proteins represented multiple cellular 
components. The high number of ‘unknown’ assignments may again reflect the need for 
more thorough updating of gene ontology databases. 
 
At the relaxed significance threshold, the comparison between the hybrid clone 18-D-22 
and  parent  cell  line  TOV-112D,  resulted  in  19  up-regulated  and  14  down-regulated 
proteins. The comparison between hybrid clone 18-D-23 and parent cell line TOV-112D 
resulted  in  26  up-regulated  and  14  down-regulated  proteins.  In  the  other  cell  model, 
comparison of hybrid clone 18-G-5 and parent cell line TOV-21G resulted in 20 up-
regulated and 9 down-regulated proteins and for hybrid clone 18-G-1.26, 8 proteins were 
up-regulated and 54 down-regulated compared to its parent cell line TOV-21G. Of these, 
only calreticulin displayed concordant change in expression of >2 fold in both hybrids of 
both cell models and 7 displayed concordant expression > 1.5 fold. 18 proteins displayed 
>2 fold concordant changes in expression within a cell model (Table 5.2).  
   184 
Name 127/126 N SD 128/126 N SD 130/129 N SD 131/129 N SD
Butyrophilin-like protein 
3
3.049 1 --- 2.646 1 --- 2.874 1 --- 3.171 1 ---
Stromelysin-2 2.957 6 1.342 2.782 6 1.286 2.157 5 1.723 1.521 4 1.205
SECIS binding protein 2 1.839 16 1.108 2.352 16 NN 1.997 16 1.277 2.11 16 1.283
Midasin 1.856 11 1.139 2.327 11 1.089 2.168 2 1.045 2.203 2 1.268
TMEFF1 1.585 3 1.299 2.036 3 1.131 2.438 2 3.53 2.48 2 2.759
Creatine kinase M-type 3.75 3 1.09 4.54 3 1.034 --- 0 --- --- 0 ---
Peptidyl-prolyl cis-trans 
isomerase B
4.19 2 1.23 2.762 2 1.117 1.337 2 1.012 0.568 2 1.191
C3 Complement C3 
(Fragment)
2.407 12 1.601 3.179 13 1.539 1.208 10 1.325 1.038 10 NN
Calreticulin 0.412 5 1.597 0.303 2 1.417 0.314 3 1.523 0.145 3 NN
Calreticulin (Fragment) 0.333 2 1.243 0.266 2 1.18 0.291 2 1.048 0.147 2 1.079
Follistatin-related 
protein 1
0.335 7 2.16 0.513 8 2.195 0.483 9 NN 0.328 8 1.206
Reelin 1.554 4 1.119 1.34 4 1.313 0.443 5 NN 0.289 4 1.124
Histone H2B type 1-L 1.164 5 1.349 0.836 5 1.356 0.495 5 1.055 0.427 5 1.059
Heat shock protein, 
mitochondrial
0.933 6 1.388 0.824 6 1.423 0.393 8 1.101 0.323 8 1.278
Collagen alpha-1(XII) 
chain
0.879 1 --- 1.332 1 --- 0.426 1 --- 0.302
Serglycin 1.376 1 --- 1.198 1 --- 0.389 1 --- 0.184
Collagen alpha-1(III) 
chain
0.398 12 1.909 0.276 11 1.496 1.023 6 2.068 0.967 5 1.542
Insulin-like growth factor-
binding protein 2
0.264 2 1.382 0.487 2 1.399 --- 1 --- 0.57 2 2.4
 
 
Table  5.2  Secreted  proteins  displaying  concordant  expression  changes  across  all 
hybrid clones or in a hybrid pair compared to their parent cell line. Protein changes 
are shown as peptide reporter ion ratios for peptides matching that protein. Significant 
up-regulation >2 fold is displayed in bold red and down-regulation is displayed in bold 
blue. The reporter ions 127 and 128 were labelled to 18-D-22 and 18-D-23 and compared 
to their parental (TOV-112D), which was labelled with 126. Reporter ions 130 and 131 
were labelled to 18-G-5 and 18-G-1.26 respectively, and each were compared to their 
parental (TOV-21G), labelled with 127. Identifications in italic type were from a single 
peptide only. ‘N’ represents the number of labelled peptides used, ‘SD’ the geometric 
standard  deviation  of  the  peptide  ratios  for  a  given  protein  and  ‘NN’  indicates  the 
presence of a peptide ratio outside a normal distribution. Proteins in red type displayed 
concordant expression changes in both cell models. Data were generated using Mascot 
with quantitation tool box. 
 
Butyrophilin-like protein 3 displayed up-regulation > 2 fold in all four hybrid clones 
compared to their parental cell lines, although this membrane protein involved in lipid 
metabolism was identified by only a single high scoring peptide match. Stromelysin-2, a   185 
secreted  matrix-metalloproteinase  (MMP10),  displayed  >2  fold  up-regulation  in  all 
hybrid clone/parental comparisons except in the 18-G-1.26 hybrid clone compared to its 
parental cell line TOV-21G (1.52 fold). SECIS binding protein displayed up-regulation in 
all the hybrid clones. Expression was only marginally under the 2-fold cut-off in the 18-
D-22 hybrid clone (1.86 fold) parent comparison. Midasin displayed up-regulation in all 
hybrid clones with only 18-D-22 expression just below the 2-fold level. This protein has 
been implicated as a chaperone involved in the assembly/disassembly of macromolecular 
complexes in the nucleus. Tomoregulin-1 (TMEFF1) displayed up-regulation over 2-fold 
in  all  but  the  18-D-22  hybrid  clone  when  compared  to  the  parental  cell  lines.  This 
transmembrane protein with EGF-like and one follistatin-like domain is speculated to be 
involved  in  growth  factor  signalling  (Eib,  Holling  et  al.  2000).  TMEFF1  has  been 
reported  as  a  tumour  suppressor  gene  in  brain  cancers  (Gery,  Yin  et  al.  2003).  Up-
regulation in the hybrid clones may promote the suppressed tumourigenic phenotype in 
these clones versus the parental cell lines. Calreticulin and a fragment of calreticulin were 
both  identified  as  displaying  significant  down-regulation  in  all  four  hybrid  clones 
compared to their parental cell lines. The fragment is distinguished by a unique peptide 
(sequence:  EPAVYFK).  Calreticulin  is  an  ER  and  cytoplasmic  protein  involved  in 
calcium binding and was identified in the 2D-DIGE analysis of WCL of the hybrid clones 
18-D-22  and  18-G-1.26  where  its  expression  was  also  found  to  be  down-regulated. 
Follistatin-related  protein  1  (FRP)  displayed significant  down-regulation  in  all  hybrid 
clones except 18-D-23 with a change in expression of 0.51-fold (Fig 5.6). This secreted 
protein  is  predicted  to  modulate  the  action  of  TGFß  superfamily  members  on  cell 
proliferation and differentiation. Reelin displayed down-regulation in hybrid clones 18-  186 
G-5 (0.44 fold) and 18-G-1.26 (0.29 fold) compared to parental cell line TOV-21G. This 
secreted protein is involved in modulating cell adhesion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Representative annotated spectra and reporter ion intensities for three 
peptide sequence  identifications  from  Follistatin-related  protein  1.  A1)  Annotated 
spectrum  for  sequence:  LDSSEFLK  identified  in  Mascot;  ion  score  45.8,  Exp  Value 
0.00081.  A2)  Reporter  ion  intensities  for  peptide  sequence:  LDSSEFLK.  Tag  126  is 
labelled to TOV-112D, tag 127 to 18-D-22, tag 128 to 18-D-23, tag 129 to TOV-21G, tag 
130  to  18-G-5  and  tag  131  to  18-G-1.26.  B1)  Annotated  spectrum  for  sequence: 
LSFQEFLK identified in Mascot; ion score 45.89, Exp Value 0.00074. B2) Reporter ion 
intensities for sequence: LSFQEFLK. C1) Annotated spectrum for sequence: YVQELQK 
identified in Mascot; ion score 34.45, Exp Value 0.014. C2) Reporter ion intensities for 
sequence: YVQELQK. Follistatin-related protein 1 displayed significant down-regulation 
in both hybrid clone pair. Data were generated using Proteome Discoverer. 
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Two secreted proteins displaying down-regulation in hybrid clones 18-D-22 and 18-D-23 
were collagen alpha-1 (III) chain (COL3A) and IGFBP2. Four isoforms of COL3A were 
identified in the 2D-DIGE analysis, three of which displayed significant up-regulation 
and  the  fourth  down-regulation  in  hybrid  cell lines  18-D-22  and  18-D-23.  The  TMT 
result correlates with the fourth isoform identified in the 2D-DIGE analysis.  A number of 
isoforms  of  IGFBP2  were  identified  in  the  2D-DIGE  analyses  of  secreted  proteins. 
Expression  of  all  were  down-regulated  in  hybrid  clones  18-D-22  and  18-G-1.26 
compared to their respective parental cell lines. Contrasting up and down-regulation was 
observed in hybrid clone 18-G-5 and no significant change was observed in hybrid clone 
18-D-23.  The  TMT  analysis  identified  down-regulation  in  hybrid  clone  18-D-22 
correlating with the expression change observed in the 2D-DIGE analysis. 
 
A number of other secreted and non-secreted proteins that were identified as changing > 
2 fold in at least one hybrid clone in the TMT analysis were also identified in the 2D-
DIGE experiments.  These  included  lactate deydrogenase,  lumican,  IGFBP7,  glucagon 
and TIMP1. For example, three isoforms of glucagon were identified in the 2D-DIGE 
analysis, two of which displayed significant up-regulation in the hybrid clones 18-D-22 
and  18-D-23  and  down-regulation  in  hybrid  clones  18-G-5  and  18-G-1.26.  The  third 
isoform  displayed  moderate  down-regulation  in  hybrid  clones  18-D-22  and  18-D-23, 
possibly suggesting a post-translational modification. The TMT analysis indicated down-
regulation of glucagon in the hybrid clone 18-D-22 (0.47 fold), correlating only with the 
expression change displayed by the third isoform in the 2D-DIGE analysis, this again 
highlights  one  of  the  drawbacks  of  peptide  analysis  where  information  on  isoform   188 
distribution  is  lacking.  Finally,  TIMP1  was  identified  in  two  separate  2D-DIGE 
experiments displaying down-regulation -2.68 and -2.36 fold in the hybrid clone 18-D-
22. This correlates strongly with the change in expression -2.19 fold observed in the TMT 
analysis in the same hybrid clone. 
 
5.4 Quantitative TMT profiling of membrane protein 
The  plasma  membrane  is  a  cellular  compartment  that  provides  a  physical  boundary 
between the cell and its environment. Membrane proteins are integral components of the 
plasma membrane and positioned at the interface between the cell and the surrounding 
environment. These proteins are involved in key biological function, such as cell-to-cell 
recognition,  adhesion  and  the  transport  of  ions  and  solutes.  In  addition,  they  act  as 
receptors for relaying diverse intracellular and extracellular signals. Defining the surface 
membrane  proteome  is  key  to  understanding  the  role  of  membrane  proteins  in  these 
fundamental biological processes and the development of cancer (Santoni, Molloy et al. 
2000). For example, levels of the type I EGF transmembrane protein receptor are elevated 
in  50%  of  ovarian  cancers,  which  is  associated  with  poor  prognosis.  Importantly, 
membrane proteins are particularly under-represented in conventional proteomic analyses 
using 2D, owing to their low abundance and hydrophobicity, although they are predicted 
to represent ~30% of the human genome. 
 
In  order  to  examine  the  expression  changes  of  membrane  proteins  in  the  tumour 
suppression models, a crude membrane fractionation was prepared from cells in culture   189 
(Chapter 2.5). Cells were harvested in a hypotonic lysis buffer, homogenised and the 
nuclear  fraction  cleared  before  ultracentrifugation  at  100,000xg  for  1  hour.  The 
membrane-enriched  fraction  was  suspended  in  RIPA  buffer  and  the  protein  content 
determined by BCA assay. 100 µg of protein from each cell line was precipitated in ice-
cold  acetone  overnight  for  digestion  and  subsequent  TMT  labelling  before  2D-LC-
MS/MS analysis as described earlier. 
 
5.4.1 Identification of differentially expressed membrane 
proteins   
 A  total  of  432  unique  protein  identifications  were  made  from  1392  unique  peptide 
matches (Appendix 1C). Of these, 82 proteins were identified by a single, high scoring 
peptide match. 101 proteins were differentially expressed > 2 fold. The decoy database 
search resulted in 76 matches with a score equal to or above the Mascot peptide identity 
threshold compared to 2053 matches against the target database; a false discovery rate of 
3.7%. For matches with a peptide score equal to or above the homology threshold the 
decoy database search resulted in 140 matches compared to 2681 matches against the 
target database which resulted in a false discovery rate of 5.22%. The distribution of 
charge state among the peptides identified was 62% +2 and 36% +3 with the remainder 
+4. Peptide labelling with the TMT tags was in excess of 99%. A comparison of protein 
identifications  with  gene ontology  databases resulted  in 11%  of  the crude  membrane 
preparation proteins identified as bona fide membrane protein (Fig 5.7). There was poor 
depletion of nuclear, chromosome and cytoplasmic localised proteins, which made up a   190 
significant proportion (70%) of the crude membrane fraction. Thus Ultra-centrifugation 
on  its  own  is  not  sufficient  for  the  recovery  of  membrane  proteins  and  a  more 
sophisticated approach including sucrose density gradients may reduce the contamination 
from non-membrane proteins (see below).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Cellular location of identified proteins in the crude membrane fraction 
determined from gene ontology databases. Some proteins represented multiple cellular 
components. The high number of ‘unknown’ assignments may again reflect the need for 
more thorough management and updating of gene ontology databases.   
 
As  with  the  previous  TMT  analyses,  quantitative  information  was  only  accepted  for 
peptides with scores equal to or above the Mascot homology score and the median value 
calculated from peptides matching a particular protein to compare protein ratios. Peptides 
displaying a change in expression >2-fold or <0.5-fold were considered as displaying 
differential expression. In hybrid clone 18-D-22, 10 proteins were up-regulated and 16 
down-regulated compared to parental cell line TOV-112D; in the hybrid clone 18-D-23, 
20 proteins were up-regulated and 7 down-regulated compared to parental cell line TOV-
112D;  in  hybrid  clone  18-G-5,  1  protein  was  up-regulated  and  12  down-regulated 
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compared to the parental cell line TOV-21G; and in hybrid clone 18-G-1.26, no proteins 
were observed up-regulated, whereas 64 were down-regulated compared to parental cell 
line TOV-21G. In total, 14 proteins displayed differential expression of >2-fold in a pair 
of hybrid clones when compared to their parental cell line (Table 5.3). 
 
 
Name 127/126 N SD 128/126 N SD 130/129 N SD 131/129 N SD
Heat shock protein 90kDa alpha 0.453 31 1.4 0.375 29 1.4 0.953 32 NN 1.427 32 NN
Endoplasmin 0.491 15 1.3 0.349 15 NN 0.799 14 1.1 1.241 15 1.3
HLA-B associated transcript 1 0.27 2 1.1 0.365 2 1.1 0.798 2 1.2 0.796 2 1.2
T-complex protein 1 subunit beta 0.417 0.48 0.695 0.936
Prolyl 3-hydroxylase 3 2.079 3 1.2 2.355 3 NN 0.636 3 1.2 1.502 3 NN
Vimentin 2.438 32 NN 4.624 32 1.4 0.601 29 1.6 0.416 26 1.5
Protein tyrosine phosphatase-like 
protein 
2.13 2 1 2.918 2 1.2 0.302 2 1.1 --- 1 ---
Cytochrome b5 outer mitochondrial 
membrane precursor
5.509 2 1.1 6.665 2 1.3 0.205 2 1 0.157 2 1.2
Voltage-dependent anion-selective 
channel protein 3 
2.051 3 1.2 1.505 3 1.2 0.447 3 1.5 0.207 3 1.5
Nucleolin 0.866 8 1.3 1.759 8 NN 0.438 9 NN 0.384 9 NN
Prohibitin 1.212 4 1.1 1.83 4 1.2 0.406 4 1.1 0.267 4 1.2
Prohibitin-2 1.26 1.86 0.298 0.196
Translocase 2 1.165 1.383 0.462 0.343
Phosphatidylinositide phosphatase 
SAC1
1.635 1.665 0.392 0.302
 
Table  5.3  Proteins  from  a  crude  membrane  extraction  displaying  concordant 
expression  >2-fold  in  a  hybrid  pair  compared  to  their  parent  cell  line.  Protein 
abundance change is measured by median peptide ratio. Up-regulation is displayed in 
bold red and down-regulation is displayed in bold blue. The reporter ions 127 and 128 
were labelled to 18-D-22 and 18-D-23, respectively and compared to the parental, TOV-
112D, which was labelled with 126. Reporter ions 130 and 131 were labelled to 18-G-5 
and 18-G-1.26 respectively, and each were compared to the parental, TOV-21G, labelled 
with 129. Identifications in italic type were from a single peptide only. ‘N’ represents the 
number  of  labelled  peptides  used  for  median  protein  ratio  calculation  and  ‘SD’  the 
geometric standard deviation of the peptide ratios for a given protein. If there was no 
reporter  ion  information,  dashes  are  displayed.  If  a  peptide  ratio  appeared  outside  a 
normal  distribution  (not  normal)  ‘NN’  is  displayed.  Proteins  in  red  type  displayed 
concordant expression in both clones of a cell model. 
 
None of the proteins identified displayed a concordant change in expression in both cell 
models.  The  hybrid  pair,  18-D-22  and  18-D-23  displayed  down-regulation  of  four   192 
proteins; heat shock protein 90kDa alpha, endoplasmin, HLA-B associated transcript 1 
and  T-complex  protein  1  subunit  beta.  Heat  shock  protein  90  alpha  is  a  molecular 
chaperone  found  in  the  cytoplasm  and  is  involved  in  mediating  stress  responses  and 
importantly  in  promoting  the  active  conformation  of  signalling  proteins  (Yonehara, 
Minami  et  al.  1996;  Liang  and  MacRae  1997).  Endoplasmin  is  also  a  molecular 
chaperone that functions in the processing of secreted proteins and is localised in the 
lumen  of  the  endoplasmic  reticulum.  HLA-B  associated  transcript  1  is  a  membrane 
protein involved in the presentation of foreign antigens to the immune system. T-complex 
protein 1β is a molecular chaperone located in the cytoplasm which is involved in protein 
folding  including  actin  and  tubulin  complex  assembly.  Prolyl  3-hydroxylase  3  (an 
oxidoreducatase found in the endoplasmic reticulum), was up-regulated in hybrid clones 
18-D-22  and  18-D-23,  three  other  proteins  displayed  up-regulation  of  expression  in 
hybrid clones 18-D-22 and 18-D-23, but also displayed contrasting expression in one or 
both hybrids of the other cell model. Vimentin, up-regulated in hybrid clones 18-D-22 
and 18-D-23 but down-regulated in 18-G-1.26, was identified previously in the 2D-DIGE 
analysis of WCL where its expression was also up-regulated in clones 18-D-22 and 18-D-
23.  Protein  tyrosine  phosphatase-like  protein  (PTPLAD1)  displayed  up-regulation  in 
hybrid  clones  18-D-22  and  18-D-23,  but  down-regulation  in  hybrid  clone  18-G-5.  
PTPLAD1  is  a  membrane  protein  involved  in  Rac-1-mediated  modulation  of  gene 
expression (Courilleau, Chastre et al. 2000). Cytochrome b5 outer membrane precursor 
(CYB5B)  displayed  significant  up-regulation  in  hybrid  clones  18-D-22  and  18-D-23 
(5.51- and 6.67-fold, respectively), but was down-regulated 0.21- and 0.16-fold in the 18-
G-5 and 18-G-1.26 clones. CYB5B is a mitochondrial membrane bound hemoprotein and   193 
was also observed to be up-regulated in the 18-D-22 and 18-D-23 clones in the TMT 
analysis of WCL. 
 
Finally,  6  proteins  were  identified  displaying  down-regulation  in  both  of  the  hybrid 
clones 18-G-5 and 18-G-1.26 compared to their parental cell line TOV-21G and were 
mostly mitochondrial membrane proteins. These were voltage-dependent anion-selective 
channel  protein  3,  nucleolin,  prohibitin,  prohibitin-2,  translocase  2  and 
phosphatidylinositide phosphatase SAC 1 (SACM1L). Voltage-dependent anion-selective 
channel  protein  3  displayed  up-regulation  in  the  single  hybrid  clone  18-D-22  and 
contrasting down-regulation in hybrid clones 18-G-5 and 18-G-1.26. This protein forms a 
channel through the mitochondrial membrane that allows diffusion of small hydrophilic 
molecules. Nucleolin is a multifunctional protein thought to be involved in pre-rRNA 
transcription, ribosome assembly and transcriptional elongation. As mentioned previously 
prohibitin has a role in down-regulating proliferation and is located in the mitochondrial 
inner membrane. Prohibitin was previously identified in the 2D-DIGE analysis of WCL 
where two undefined isoforms displayed contrasting expression changes in hybrid cell 
line  18-G-1.26  (Chapter  3).  Prohibitin-2  is  also  located  on  the  mitochondrial  inner 
membrane and acts as a mediator of transcriptional repression. Translocase 2 catalyses 
the exchange of ADP and ATP across the mitochondrial inner membrane. SACM1L is 
localised  in  the  ER  membrane  and  functions  in  vesicular  trafficking  through  its 
hydrolysis of PI lipids (Kiss, Kedra et al. 2001).    194 
5.4.2 Profiling of the cell surface proteome of EOC cell 
models 
In order to better ‘probe’ membrane proteins, a strategy was devised for the enrichment 
of cell surface proteins (Fig 5.8). Live cells in culture were biotinylated using sulfo-NHS-
SS-biotin for 30 min at 37 
°C. The labelling is based on the reaction of primary amines in 
cell membrane proteins with the labelling reagent at pH 8. The biotinylation reagent is 
water soluble, but membrane impermeable and is therefore expected to only label cell 
surface  and  extracellular  proteins  which  are  then  purified  using  immobilised  avidin 
(Zhao, Zhang et al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.8  Cell  surface  protein  labelling  and  enrichment  strategy.  A.  Chemical 
structure  of  Sulfo-NHS-SS-Biotin  [sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-
dithiopropionate]. B. Labelling method. Cells are washed with PBS to remove serum 
proteins then labelled for 30 min. The reaction is quenched and the cells gently harvested 
into a 50 ml falcon tube and washed with TBS before lysis. Biotinylated proteins are 
captured on streptavidin, washed then eluted in sample buffer with reductant (DDT) at 95 
°C for 5 min. 
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Firstly, in order to test the enrichment strategy, a 1D gel was loaded with total cell lysate 
(TCL), the depleted fraction and the eluant (enriched labelled protein) from two different 
elution steps (Figure 5.9).    
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Enrichment of cell surface proteins. CCB stained gel image of 10µg of TCL 
and depleted fraction and 1/20 of eluates 1 & 2. E1 was from an incubation with 400 µL 
of Sample Buffer (SB) containing DTT for 60 minutes at room temperature. E2 was a 
subsequent incubation with SB and DTT, but with heating at 95 ºC for 5 minutes.  
 
This preliminary analysis showed that there were distinct protein features not present in 
the TCL or depleted lanes, however, a proportion appeared to match. The second elution 
step (E2) showed that material could still be eluted from the beads, suggesting that the 
first  elution  was  not  complete.  Boiling  on  the  beads  is  preferable  for  complete 
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detachment of biotinylated protein from the avidin substrate. Elution, by cleavage of the 
disulphide  bond,  in  the  presence  of  DTT  was  only  found  to  yield  poor  recovery  of 
proteins and so elution was carried out in the presence of sample buffer also, although 
this created complications for TMT-labelling (see below). The gel lane was cut into 60 
bands of approximately 2 mm each and diced into smaller pieces. The protein bands were 
digested with trypsin and analysed by LC-MS/MS as described in Materials and Methods 
(Chapter 2). 
 
In total, 281 proteins were identified in the streptavidin-enriched sample from TOV-21G 
cells. Firstly, there was a significant number of non-membrane proteins detected. Of the 
proteins identified only 15% are classified as membrane proteins and two of the proteins 
were chromosome 18 gene products. The high proportion of non-membrane proteins may 
be attributed to experimental procedure and non-specific binding. Cellular material from 
dying cells may also be labelled and enriched. The label maybe internalised to a small 
degree  during  labelling,  accounting  for  the  recovery  of  abundant  housekeeping 
cytoplasmic  proteins.  However,  some  of  these  non-membrane  proteins  may  infact  be 
targeted  to  the  cell  surface  by  as  yet  unexplained  mechanisms.  Previous  research 
employing surface labelling by biotinylation and enrichment with streptavidin has shown 
similar proportions of non-membrane proteins amongst the total identified (Shin, Wang et 
al. 2003). For example, heat shock proteins (HSPs) have been found that do not encode 
transmembrane  domains  or  signal  sequences  within  their  genomic  structures.  It  is 
uncertain how these proteins are targeted to the cell surface, but it is unlikely that they 
utilize the classical secretory pathway from the ER via the golgi to the plasma membrane   197 
(Multhoff and Hightower 1996). Labelling on ice was thus implemented from this point 
on to slow down possible label internalization and labelled cells were first fractionated 
into a crude membrane-enriched sample by hypotonic lysis and centrifugation to reduce 
possible non-specific binding of intracellular proteins to the streptavidin beads. 
 
This technique for profiling of the cell surface proteome was then adapted for quantitative 
analysis of expression in the EOC models. This involved the use of TMT labels as before, 
although  the  enriched  fractions  from  each  cell  line  were  run  onto  the  top  of  a  20% 
polyacrylamide gel as a discrete band, fixed, stained and excised prior to digestion with 
trypsin and TMT labelling. This was introduced as a clean-up step because the surface 
fractions were better eluted in sample buffer rather than DTT alone as hoped. The digests 
were  TMT  labelled  and  separated  into  ten  fractions  by  SCX  for  identification  and 
quantification by RPLC-MS/MS (see Chapter 5.1).  
 
5.4.3 Identification of differentially expressed surface 
labelled proteins 
A total of only 93 unique protein identifications were made from 147 unique peptide 
matches. The decoy database search resulted in 10 matches with a score equal to or above 
the  Mascot  peptide  identity  threshold  compared  to  146  matches  against  the  target 
database; a false discovery rate of 6.8%. For matches with a peptide score equal to or 
above  the  homology  threshold  the  decoy  database  search  resulted  in  55  matches   198 
compared to 247 matches against the target database which resulted in a false discovery 
rate  of  22.3%.  The  charge  distribution  among  the  identified  peptides  was  43.8%  +2, 
52.1% +3 and 4.2 % +4. The proportion of TMT-labelled peptides was 7.7% with none 
changing significantly, calculated by database searching with and without TMT-6plex 
modifications. Database searching without TMT-6plex (N-term/K) modifications resulted 
in 441 proteins identified from 1418 unique peptide matches. The decoy database search 
resulted  in  75  matches  with  a  score  equal  to  or  above  the  Mascot  peptide  identity 
threshold compared to 1342 matches against the target database; a false discovery rate of 
5.6%. For matches with a peptide score equal to or above the homology threshold the 
decoy database search resulted in 125 matches compared to 1869 matches against the 
target database which resulted in a false discovery rate of 6.7%. The charge distribution 
among the matched peptides was 76.1% +2, 23.5 % +3 and 0.34% +4. 
 
Thus despite careful preparation of the surface-labelled protein digests, TMT labelling 
had not been successful. The method required an equal amount of surface labelled lysate 
from each cell line to be captured on streptavidin beads. After washing, captured protein 
was eluted in sample buffer and DTT and loaded onto a gel. This may have introduced 
contaminants  which  reduced  the  TMT-labelling.  In  addition  a  Speedvac  was  used  to 
concentrate the sample prior to TMT labelling and results in heating of the sample over 
prolonged periods and was difficult to resolubilise. It is possible that freeze drying would 
have improved the TMT labelling although, unfortunately, a freeze dryer was unavailable 
at the time of the experiment and there was insufficient time on the project to repeat and 
optimize the experiment.    199 
5.5 Conclusions 
The  TMT-6plex  labelling  approach  allowed  the  simultaneous  relative  quantitation  of 
proteins  from  extracts  of  the  six  cell  lines  under  study,  which  included  whole  cell, 
secreted and crude-membrane fractions. This application was optimised on an Orbitrap 
XL  resulting  in  sensitive  and  accurate  protein  identification  with  quantification. 
Importantly, the application of 2D-LC with TMT labelling has addressed the fundamental 
limitations  of  the  2D-DIGE  method  for  detecting  proteins  of  low-abundance,  poor 
solubility,  very  small  or  large  size  and  extreme  pIs  that  were  previously  under-
represented in the earlier analyses. Unfortunately the application of surface labelling with 
2D-LC MS/MS in combination with TMT was unsuccessful. Adjustments to the protein 
extract  preparation  prior  to  labelling  would  certainly  improve  the  TMT  labelling. 
However, due to time constraints the experiments could not be repeated in this study. The 
protein identifications were useful in assessing the performance of the surface labelling 
strategy.   
   
A total of 1601 proteins identifications with quantitative information were obtained by 
2D-LC with TMT labelling from the whole cell, secreted and crude membrane fractions, 
with 242 differentially expressed proteins (> 2-fold) found between at least one parental 
cell line and its corresponding hybrid clone. Functional classification of the differentially 
expressed proteins using gene ontology databases showed that the majority were involved 
with cell differentiation (11%), followed by multi-cellular organismal development (9%) 
and cell death (7%) (Fig 5.10). Cellular differentiation is important for dividing cells to   200 
achieve a set of structural and functional characteristics specific to a tissue. This process 
appears to be controlled by a combination of genetics and external stimuli, whilst the 
organisation of differentiated cells is maintained by proteins involved in multicellular 
organismal development. The processes of cellular differentiation and organization are 
key  to  understanding  mechanisms  of  cellular  transformation  where  failure  in  these 
processes can lead to abnormal growth and division of cells. Proteins that are involved in 
cell death are vitally important in maintaining quality control and repair mechanisms by 
elimination of unwanted genetically damaged cells. Evasion of apoptosis is a hallmark of 
cancer.  Despite  these  functional  classifications,  many  of  the  identified  differentially 
expressed proteins have unknown biological functions, and it is tempting to speculate 
these as having roles in tumour promotion or suppression  
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Figure  5.10  Biological  function  based  on  gene  ontology  databases  of  proteins 
identified displaying differential expression > 2 fold in at least a single hybrid clone. 
Individual  proteins  may  have  multiple  functions  assigned.  The  high  proportion  of 
assignments as ‘unknown’ possibly reflects the need for databases to be managed and 
updated more thoroughly as functional data is generated.   
 
 
As seen in the 2D-DIGE analyses there was little overlap between the cell models in 
terms of protein changes identified. Again this possibly reflects the different molecular 
atiologies of endometrioid versus clear cell carcinomas from which the two parental cell 
lines were derived. Additionally, few proteins displayed concordant expression within a 
hybrid pair due to the possible clonal variation described earlier. Those proteins whose 
expression was concordant across both cell models or at least within a hybrid pair were 
considered to be the most interesting as potential biomarkers of neoplastic suppression 
and possibly functionally involved in tumour suppression.  
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A single protein, annexin A1, displayed concordant down-regulation (> 2 fold) in the 18-
D-22 and 18-D-23 cell lines, compared to parental cell line TOV-112D in the whole cell 
lysate analysis. Annexin A1, a protein involved in cell differentiation, is a calcium and 
phospholipid  binding  protein  with  roles  in  maintenance  of  the  cytoskeleton  and 
extracellular matrix integrity, but may have other cellular functions and has been linked 
with reduced cell proliferation through regulation of the ERK/MAPK signalling pathway 
(Alldridge and Bryant 2003). Expression of annexin A1 has been observed to be down-
regulated in head and neck, prostate, oesophagus and gastric cancer (Paweletz, Ornstein 
et al. 2000; Xia, Hu et al. 2002; Garcia Pedrero, Fernandez et al. 2004; Inokuchi, Lau et 
al.  2009),  but  up-regulated  in  pituitary,  pancreatic,  breast  and  hepatocellular  cancer 
(Masaki, Tokuda et al. 1996; Pencil and Toth 1998; Bai, Ni et al. 2004; Mulla, Christian 
et  al.  2004).  The  up-regulation  of  annexin  A1  seems  to  occur  predominantly  in 
hormonally regulated cancers (Zhao, Hashiguchi et al. 2002). Annexin A1 was down-
regulated in the hybrid clones used in this study and this was observed in both the 2D-
DIGE and 2D-LC-MS/MS with TMT labelling analyses. Thus, it is tempting to speculate 
that annexin A1 may normally promote OC progression, and that it is down-regulated in 
the hybrid clones as a consequence of neoplastic suppression. Another protein identified 
in  the  whole  cell  lysate  involved  in  cell  differentiation,  is  galectin-1,  a  ubiquitously 
expressed  protein  (Camby,  Le  Mercier  et  al.  2006).  Galectin-1  lacks  a  recognisable 
secretion signal sequence and does not pass through the ER/Golgi pathway and so must 
be secreted by another as yet undetermined process. In tumour development, galectin-1 
has been shown to interact with the oncogene H-RAS and contributes to its membrane 
anchorage and transforming capacity (Paz, Haklai et al. 2001). Furthermore, galectin-1   203 
has been shown to promote cell growth, cell adhesion and cell migration (Yang and Liu 
2003;  Rabinovich  2005).  Interestingly,  while  the  endogenously  expressed  protein  is 
implicated as a growth-promoting factor, exogenously added galectin-1 was shown to 
inhibit neuroblastoma cell proliferation (Kopitz, von Reitzenstein et al. 2001). Galectin-1 
was previously identified as down-regulated in clone 18-G-5 by 2D-DIGE analysis of 
secreted protein. This result would seem to correlate with the suppressed tumourigenic 
phenotype exhibited by  this hybrid clone. However, analysis by 2D-LC-MS/MS  with 
TMT quantification identified a significant up-regulation of galectin-1 in the hybrid clone 
18-D-22 with a limited change observed in the other hybrid clones. It must be noted that 
the origin of the extract is different for this comparison.  
 
Among the whole cell lysate proteins functionally classified as involved in cell motility 
was caldesmon. Cell motility is important in cancer cells as migration is critical in tumour 
invasion and metastasis. Caldesmon is an actin and tropomyosin binding protein that has 
been shown to be a potent repressor of podosome/invadopodium and cell invasion in 
cancer cell lines (Yoshio, Morita et al. 2007). The up-regulation of this protein in the 
hybrid  clones  18-D-22  and  18-D-23  may  reflect  the  suppression  of  tumourigenic 
phenotype in these clones as evidenced by their relatively poor growth in soft agar. 
 
The  fractionation  of  secreted  proteins  from  conditioned  medium  was  examined 
previously  by  2D-DIGE  analysis  with  some  success.  For  the  same  fraction,  2D-LC-
MS/MS approach would be expected to identify an overlapping set of secreted proteins 
plus others, potentially of lower abundance or not amenable to 2DE analysis. The cellular   204 
location of identified proteins were determined from gene ontology databases (Fig 5.5). 
The success of the fractionation technique was highlighted by the numbers of proteins 
assigned to the extracellular region, extracellular space and proteinaceous extracellular 
matrix  representing  26%  of  the  cellular  protein  identified.  In  addition,  8%  of 
identifications were assigned to membrane and cell surface proteins. These classes of 
proteins would be considered good candidate serum markers. 
 
The  secreted  fraction  yielded  a  significantly  increased  response in  protein expression 
changes  compared  to  the  WCL  fraction  with  some  proteins  displaying  concordant 
expression across both cell models. Calreticulin (CRT) and a fragment of CRT, displayed 
significant  down-regulation  of  expression  in  both  cell  models.  This  calcium  binding 
protein has a high capacity for buffering Ca
2+ and behaves as a Ca
2+ signalling regulator. 
It is located most abundantly in the lumen of the ER and can be presented at the surface 
of cells where it is thought to induce an immunogenic response (Chaput, De Botton et al. 
2007;  Obeid,  Tesniere  et  al.  2007;  Obeid,  Tesniere  et  al.  2007);  an  association  with 
ERp57 at the surface of cells has been identified as a signal for phagocytosis (Johnson, 
Michalak et al. 2001). CRT fragments have also been found in the serum of patients with 
pancreatic cancer (Hong, Misek et al. 2004). The decrease in CRT expression observed in 
all the hybrid clones under analysis may reflect that these cells have been rescued from a 
state of lethality by incorporation of chromosome 18 and its tumor suppressive effect. It 
has also been shown that tumour cells treated with anthracyclins expose CRT on their cell 
surface, which marks them for removal by the immune system (Obeid, Tesniere et al. 
2007).    205 
Another protein displaying significant down-regulation was follistatin-related protein 1 
(FRP),  also  known  as  FSTL1  and  TSC-36.  This  is  an  extracellular  glycoprotein 
containing  a  follistatin-like  sequence  containing  10  conserved  cysteine  residues. 
Follistatin is a specific inhibitor of the biosynthesis and secretion of pituitary follicle 
stimulating  hormone.  FRP  may  regulate  the  action  of  some  growth  factors  in  cell 
proliferation and differentiation. Expression has been shown to be increased by TGFβ1, a 
potent  inhibitor  of  cell  growth  (Shibanuma,  Mashimo  et  al.  1993).  Furthermore,  it 
appears to play a role in the altered phenotype of transformed cells, including negative 
regulation of their growth (Liu, Wang et al. 2006; Chan, Ngan et al. 2009). Levels of FRP 
are  also  decreased  in  V-ras  transformed  NTH3T3  (DT)  fibroblastic  cells  (Mashimo, 
Maniwa et al. 1997). Moreover, when FRP was transfected into a NSCLC cell line, the 
transfectants  displayed  decreased  growth  rate  and  a  change  in  cell  morphology 
(Sumitomo,  Kurisaki  et  al.  2000)  and  in  the  ovarian  cancer  cell  line  Ovca420  and 
endometrial cancer cell line AN3CA, cell migration and invasive capability were reduced 
(Chan,  Ngan  et  al.  2009).  It  has  also  been  shown  to  inhibit  the  invasiveness  of  rat 
fibroblasts transformed with v-fos (Johnston, Spence et al. 2000). Clearly, FRP has a 
tumour  suppressive  effect  on  a  spectrum  of  cancer  cell  types.  The  down-regulation 
displayed in the hybrid cell lines compared to their parental cells does not indicate a 
suppressive role in the OC models used here. The down-regulation of expression could 
possibly  reflect  the hybrid  cells  return  to more  normal  cell  growth  and  proliferation, 
therefore FRP is not causative to the suppressed phenotype. 
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The secreted protein, stromelysin-2 (MMP10), displayed significant up-regulation in all 
but one of the hybrid clones under analysis. This protein is one of a family of 24 matrix-
metalloproteinases (MMPs) that degrade the protein constituents of the connective tissue 
thereby  facilitating  invasion.  MMP  activity  is  tightly  controlled  by  transcriptional 
activation of tissue inhibitors of metalloproteinases (TIMPs). MMP10 activity has been 
implicated  in  carcinogenesis  and  its  over-expression  has  been  observed  in  NSCLC 
compared to normal lung tissues (Gill, Kirwan et al. 2004; Zhang, Zhu et al. 2007), in 
human bladder transitional cell carcinoma (Seargent, Loadman et al. 2005), renal cell 
carcinoma (Miyata, Iwata et al. 2007) and lymphoid tumours (Van Themsche, Alain et al. 
2004). Furthermore, MMP10 along with MMP9 have been shown to confer protection 
from PKC/p53-mediated apoptosis in human colon adenocarcinoma cell lines (Meyer, 
Vollmer et al. 2005). However, it is becoming apparent that MMPs also play a critical 
role in physiological processes such as  regulation of the  growth factors, chemokines, 
cytokines  and  cell  surface  adhesion  receptors  and  proteoglycans  involved  in  cell 
communication. The dys-regulation of these molecules may promote carcinogenesis. It 
would appear that MMP10 may also play a role in neoplastic suppression, as evidenced 
by its up-regulation in the OC cell models used here. 
 
The  membrane  protein,  protein  tyrosine  phosphatase-like  protein  (PTPLAD1),  was 
identified from the crude membrane extract displaying concordant changes in the TOV-
112D cell model. PTPLAD1 is involved in RAC-1 signalling leading to the modulation of 
gene  expression  (Courilleau,  Chastre  et  al.  2000).  The  observed  up-regulation  of  this 
protein in the 18-D-22 and 18-D-23 hybrid cell lines may reflect an inhibitory control   207 
over cell proliferation, differentiation and transformation through apoptosis in which this 
poorly characterised protein may play a role.  
 
Another protein identified in the crude membrane extract displaying a significant change 
in  expression  was  nucleolin,  an  abundant  RNA-  and  protein-binding  protein  that  is 
ubiquitously expressed.  In the nucleus it controls DNA and RNA metabolism. In the 
cytoplasm it chaperones protein into the nucleus and also regulates mRNA activity. On 
the cell surface it can serve as an attachment protein for several ligands (Storck, Shukla et 
al.  2007).  The  ligands  of  nucleolin  have  been  found  to  play  an  important  role  in 
tumourigenesis  and  angiogenesis.  Nucleolin  binds  to  laminin-1  that  induces 
differentiation of cells (Turck, Lefebvre et al. 2006) and hepatocyte growth factor that 
regulates angiogenesis and the invasion and growth of cancer cells (Tate, Isotani et al. 
2006). Surface levels of nucleolin have been reported to be increased in cells stimulated 
with  VEGF  (Huang,  Shi  et  al. 2006)  and  it  has been  identified  as an  ErbB  receptor 
interactor in breast cancer cells (Di Segni, Farin et al. 2008) It is also reported to reduce 
levels of the tumour suppressor protein p53 by inhibiting translation of the p53 mRNA 
(Takagi, Absalon et al. 2005). The down-regulation of expression of nucleolin observed 
in the hybrid cell lines 18-G-5 and 18-G-1.26 could reduce the potential of the cells to 
respond  to  growth  ligands  and/or  promote  p53  expression  and  thus  suppresses  their 
tumourigenic phenotype. 
 
Another ubiquitously expressed protein displaying reduced expression in one of the cell 
models was prohibitin. Studies have shown that overexpression of prohibitin promotes   208 
cell survival in ovarian cancer cells by inhibiting the cell cycle and blocking apoptosis 
whilst silencing has the opposite effect (Gregory-Bass, Olatinwo et al. 2008). The down-
regulation of its expression observed in the hybrid cell lines 18-G-5 and 18-G1.26 may 
thus contribute to the reduced transformed phenotype of these cells.  
 
Finally,  heat  shock  protein  90α  (HSP90A)  was  identified  as  displaying  a  significant 
reduction in expression in the TOV-112D cell model. This molecular chaperone regulates 
protein interactions by facilitating normal protein folding and its expression in cells under 
stress is an adaptive response to promote cell survival (Zhao, Hashiguchi et al. 2002). In 
cancer cells, the ability to prevail over stressful environments is vital for their survival 
and their ability to tolerate mutations in critical signalling molecules that would otherwise 
be lethal ((Isaacs, Xu et al. 2003; Neckers 2007; Tsutsumi, Beebe et al. 2009). HSP90 
performs  these  twin  roles  through  interaction  with  key  protein  kinase  signalling 
molecules  and  its  potential  as  a  target  for  anti-cancer  agents  has  been  realised  (e.g. 
17AAG  (Maloney,  Clarke  et  al.  2007)  currently  on  trial).  The  down-regulation  of 
expression of HSP90A in the hybrid clones 18-D-22 and 18-D-23 is likely to reflect the 
tumourigenic  suppression  observed  in  these  hybrid  clones  compared  to  their  parental 
cancer cell line and as such may make a useful marker in OC. 
 
It  has  not  been  possible  to  comment  on  all  the  proteins  found  to  be  differentially 
expressed,  but  these may  well  have  roles  in  generating the  tumourigenic  suppression 
phenotype. However, it is difficult to assess from this work which of these changes are 
causative and which are a consequence. This will require further functional studies.    209 
 
Chapter 6 Validation of protein changes observed 
by proteomic profiling 
Introduction 
The  differential  expression  of  protein  candidates identified  by  2D-DIGE and 2D-LC-
MS/MS + TMT analysis were further validated in the TOV-112D and TOV-21G models 
by  immunoblotting  where  antibodies  were  available.  Additional  clones  were  also 
examined, as were revertant cell lines, where the normal Ch18 material has been lost, and 
a  panel  of  ovarian  cancers  and  NOSE  cell  lines.  Candidates  were  selected  based  on 
expression profile and putative role in cancer. Furthermore, the potential of one candidate 
(MMP10) as a biomarker was assessed by measuring the level of this protein in serum 
from cases of malignant and benign OC and healthy controls. Finally, to further assess if 
any of the candidates were linked to aberrant growth factor signalling, the activation of 
downstream signalling was assessed in the cell models following EGF treatment. 
 
6.1 Validation by immunoblotting 
Tumour protein p53-inducible gene 3 (PIG3) expression was up-regulated in hybrid clone 
18-D-22 and 18-G-5 in the 2D-DIGE analysis of whole cell lysates (Fig 6.1A). In western 
blot analysis the PIG3 signal was elevated in hybrid clone 18-G-5 and slightly less so in 
hybrid clone 18-G-1.26 compared to the parental cell line TOV-21G (Fig 6.2A). Notable,   210 
PIG3 expression was also elevated in the other 18-G-clones, and importantly reverted in 
revertant clones where normal Ch18 material transferred into TOV-21G has been lost due 
to  removal  of  the  antibiotic  selection.  The  elevated  signal  in  hybrid  clone  18-G-5 
compared to its parental cell line TOV-21G was thus in agreement with the 2D-DIGE 
data. Its consistent behaviour in the other clones, reduced expression in the revertants and 
p53-inducible nature support its functional role as a tumour suppressor in this model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6.1  DeCyder  analysis  of  differential  protein  expression.  Graphical 
representations for selected proteins are shown as average standardized abundance (i.e. 
abundance  versus  the  Cy2-labelled  standard)  for  each  condition  with  triplicate 
measurements. Isoforms of PEDF are distinguished by spot number in brackets. 
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Figure 6.2 Western Blot analyses of A. Models of EOC tumour suppression and 
revertants, and B. OC cell lines and normal ovarian surface epithelium cell lines. 
Equal amounts of protein extract were loaded onto a 12% SDS-PAGE gel and processed 
for western blotting with the indicated antibodies. Highlighted in red are the cell lines 
used for proteomic screening in this study. Clones 18-D-22R3, R5 and 18-G-5R4,R5 are 
revertants of the 18-D-22 and 18-G-5 hybrid clones, where normal Ch18 material has 
been lost. 
 
 
PDZ and LIM domain protein 1 (PDLIM1), a cytoskeletal protein, was found to be down-
regulated in hybrid clone 18-G-1.26 in the 2D-DIGE analysis of the whole cell lysate (Fig 
6.1B). Levels were fairly consistent for all cell lines in the western blot analysis except in 
hybrid  clone  18-G-5  where  it  was  up-regulated  and  revertant  18-D-22-R3,  where  no 
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signal was detected (Fig 6.2A). The differentially expressed protein spot identified as 
PDLIM1 in the 2D-DIGE analysis could represent a specific isoform, while western blot 
analysis detected total PDLIM1 protein and may explain the difference in results between 
the two methods. 
 
 Fascin 1 organises actin filaments, this protein was up-regulated in hybrid clone 18-G-
1.26 (Fig 6.1C) and is consistent with the robust signal in the western blot analysis (Fig 
6.2A). Expression of fascin 1 was also elevated in all of the TOV-21G hybrid clones 
compared to their parental cell line, although this expression change appeared not to be 
reverted by loss of Ch18 material. In the other cell model, signals were elevated in hybrid 
clone  18-D-22,  although,  this  was  not  observed  in  the  2D-DIGE  analysis,  where  as 
expression in clone 18-D-23 was.  
 
Prohibitin, a regulator of proliferation was identified in the 2D-DIGE and TMT analyses 
as being down-regulated in hybrid clones 18-G-1.26 (Fig 6.1D) and 18-G-5. Surprisingly, 
the  western  blot  analysis  displayed  strong  signals  for  all  revertant  cell  lines  tested, 
although its expression appeared to be down-regulated in 18-G-1.26 versus its parental 
(Fig 6.2A). Expression of prohibitin has obviously been altered further by the removal of 
incorporated chromosome 18 in these cells.  
 
The  2D-DIGE  analysis  of  secreted  proteins  identified  prolactin  and  PEDF  as 
differentially expressed proteins. Prolactin, a hormone belonging to the somatotrophin   213 
family, displayed up-regulation in hybrid clones 18-D-22 and 18-D-23 (Fig 6.1E). This 
was consistent with the western blot analysis, where signals were elevated in these two 
cell  lines  compared  to  the  parental,  TOV-112D  (Fig  6.2A).  The  revertant  cell  lines 
behaved as would be expected and exhibited a similar signal to their parental cell lines. In 
the other cell model, levels were also elevated in all hybrid clones, though this was not 
detected in the 2D-DIGE analysis where the prolactin isoform was moderately decreased 
in the two TOV-21G hybrid clones examined. Three isoforms of the neurotrophic protein, 
pigment epithelium-derived factor (PEDF), were identified by 2D-DIGE/MS displaying 
contrasting expression possibly due to the presence of different PTMs. The up-regulation 
of expression in hybrid clone 18-G-5 observed in gel spot 624 (Fig 6.1F) is consistent 
with the increased signal detected by western blot analysis in this cell line. Notably, its 
expression  was  reduced  in  the  revertants,  adding  weight  to  its  choice  as  a  candidate 
biomarker for further characterization. 
 
Fascin 1 and PDLIM1 were differentially expressed in the 2D-DIGE analysis of whole 
cell lysate. Antibodies for these were used to probe the whole cell lysates of a panel of 
OC cell lines and normal ovarian surface epithelium (NOSE) cell lines (Fig 6.2B). Fascin 
1 expression fluctuated between very low signal to robust signal in the OC cell lines. 
Levels in the two NOSE cell lines examined were elevated in comparison to the TOV-
112D and TOV-21G cancer cell lines. Whilst this suggests fascin may play a role in 
tumour suppression, its down-regulation is not a general feature in all ovarian cancers. 
PDLIM1 displayed a more consistent level of expression in the OC cell lines, while the 
signal was conspicuously absent in the two NOSE cell lines. This suggests that PDLIM1   214 
may be generally elevated in ovarian cancers, and thus may play a role in promoting 
tumourigenic phenotype.  
 
Unfortunately, not all the promising candidates could be validated by immunoblotting 
because some antibodies that were tested proved to be non-specific or resulted in no 
signal at the correct molecular weight or antibodies could not be found against them. 
These included IGFBP7, galectin-1, TIMP1 and FRP. 
 
6.2 Validation by ELISA 
A commercially available ELISA kit has been developed for MMP10, therefore the level 
of this secreted protein was examined in serum as a potential biomarker of EOC. Serum 
samples collected from women diagnosed with malignant ovarian cancer, benign disease 
and  matched  healthy  controls  from  the  UKOPS  (United  Kingdom  Ovarian  Cancer 
Population Study) were tested using this MMP10 immunoassay for validation. Serum 
samples  from  43  malignant,  22  benign  and  22  healthy  controls  were  examined.  The 
ovarian  cancer  serum  samples  came  from  a  representative  selection  of  histological 
subtypes and were split by stage resulting in 24 stage I + II and 19 stage III + IV cases. 
The MMP10 immunoassay (Quantikine) is a sandwich enzyme immunoassay carried out 
in a 96 well plate format as described in Chapter 2. Levels of MMP10 were marginally 
elevated  in  the  ovarian  cancer  cases.  A  stage  wise  comparison  showed  a  significant 
elevation of MMP10 (p=0.041) in stage III + IV versus healthy whilst none of the other 
comparisons were statistically significant (Figure 6.3).    215 
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Figure  6.3  Serum  levels  of  MMP10  in  malignant  and  benign  cases  of  OC  and 
healthy controls. Bars indicate median and upper and lower quartiles. 
 
The up-regulation of MMP10 in the hybrid clones found in the TMT analysis suggested a 
potential role of this protein as a tumour suppressor. However, the contrasting expression 
in the immunoassay suggests an alternative role. MMP10 would not be valuable as an 
early detection biomarker for OC, however, elevated levels in stage III + IV OC cases 
were  significantly  different  to healthy  controls,  indicating  it as  a  potential  prognostic 
marker. Thus functional characterisation of this protein should be considered, as well as 
further testing in larger cohorts, of ovarian cancer cases and controls with correlation to 
follow-up clinical data. 
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6.3 Examination of EGF-dependent signalling  
Cellular proliferation is a tightly regulated process carried out by a complex inter-play of 
growth factors, growth factor receptors and signalling components. The role of growth 
factor  driven  signalling  has  been  recognized  for  a  long  time  as  important  in  the 
pathogenesis of human cancer. Many proto-oncogenes code for proteins that are involved 
in intracellular signal transduction. For instance, the epidermal growth factor receptor 
(EGFR) family has a critical role in the pathogenesis and progression of many cancers. 
EGFR is a glycoprotein and tyrosine kinase that is expressed on the cell surface and it 
functions as a receptor for a family of ligands including EGF. It is involved in regulating 
cellular  proliferation,  survival,  migration  and  differentiation.  Approximately  50%  of 
ovarian cancers have elevated levels of EGFR which is associated with a poor prognosis 
(Nicholson, Gee et al. 2001; Yarden 2001). Akt and Erk are downstream targets of EGFR 
that form part of  a survival and  mitogen activated protein  kinase (MAPK) signalling 
cascade, respectively. Phosphorylation and activation of these kinases drives proliferation 
and survival, and signalling through these kinases has been intricately linked with the 
pathogenesis  of  human  cancer  (Hanahan  and  Weinberg  2000;  Deb,  Su  et  al.  2001; 
Vivanco  and  Sawyers  2002).  Akt,  a  component  of  the  PI3K  signalling  pathway,  is 
activated  in  response  to  receptor-driven  PIP3  production  that  drives  Akt  membrane 
recruitment  through  binding  to  its  pleckstrin  homology  domain,  and  activating 
phosphorylation at Thr308 and Ser473. The Erk (MAPK) signalling cascade is activated 
downstream of numerous tyrosine kinase receptors in response to ligand binding and Ras 
activation and regulates many cellular processes, including proliferation and survival.   217 
The expression and activation of these proteins in the parental and hybrid cell lines was 
examined  by  western  blotting  to  ascertain  the  level  of  disruption  to  these  signalling 
pathways, if any. The EOC cell lines were starved of serum and then stimulated with 
EGF and cells harvested at different time points. Protein concentration was measured and 
equal  amounts  of  sample  were  separated  by  1D  SDS-PAGE  and  transferred  onto 
membranes.  The  effect  of  EGF  stimulation  was  analysed  by  western  blotting  with 
antibodies against Akt and Erk and their phosphorylated activated forms. The membranes 
were probed with the phospho-specific antibodies and then reprobed with the respective 
pan antibody. Epidermal growth factor receptor (EGFR) levels were also examined (Fig 
6.4).  
 
Anti-EGFR immunoblotting revealed virtually no signal in the TOV-112D cell line or its 
Ch18 MMCT hybrids 18-D-22 and 18-D-23, suggesting that this cell line expresses low 
levels of the receptor (Fig 6.4). In comparison, EGFR was detected at a much higher level 
in the TOV-21G and 18-G-1.26 cell lines, but less so in clone 18-G-5. This data suggests 
that EGFR may be over-expressed in this cancer cell line, and its expression lowered in at 
least  one  Ch18  MMCT  clone,  possibly  explaining  its  suppressed  tumourigenic 
phenotype.  Upon  stimulation  with  EGF,  EGFR  expression  declined  over  time  in  the 
TOV-21G  cell  line  consistent  with  ligand-induced  receptor  internalisation  and 
degradation as reported in many cell systems (Oksvold, Huitfeldt et al. 2002). However, 
in  the  18-G-1.26  cell  line,  EGFR  expression  was  less  dependent  on  EGF  ligand 
triggering.  
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Figure 6.4 Response of parental EOC cell lines and their Ch 18 MMCT hybrids to 
EGF stimulation. Serum starved cells were harvested at 0, 5, 30 and 240 minutes after 
stimulation  with  10  nM  EGF.  Targets  are  EGFR;  a cell surface  receptor  involved  in 
regulating cellular growth and differentiation, Akt and Erk; proteins that form part of a 
survival and MAPK signalling cascade respectively. Their phosphorylated forms drive 
proliferation and survival and have been linked with pathogenesis in human cancer. 
 
The phosphorylation and activation of Akt was relatively unresponsive to EGF in both 
cell models, although it was constitutively elevated in the TOV-21G parental and derived 
hybrid cells, but less so in the 18-G-5 clone. The levels of total Akt remained constant 
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over the time course, but were higher in TOV-112D cells and its hybrid clones. Erk1/2 
phosphorylation  was  rapidly  and  transiently  activated  by  EGF  in  all  cases,  but  was 
noticeably abrogated in hybrid clone 18-D-22. Total Erk1/2 levels remained unchanged 
with the mobility shift due to phosphorylation, clearly visible in one set of blots. 
 
The fact that Erk was phosphorylated in the TOV-112D cells indicated that EGFR is 
indeed expressed in these cells, albeit at lower levels that the TOV-21G cells. It is clear 
from  this  preliminary  data  that  the  parental  cell  lines  appear  to  have  diverse  and 
potentially disrupted signalling pathways. This may be expected in cell lines derived from 
tumours. For example, the apparent constitutive activation of Akt in the TOV-21G cells 
suggests  deregulated  PI3K  signalling.  This  important  signalling  pathway  has  been 
reported to be activated in ~30% of all ovarian cancers and 45% of endometrioid and 
clear  cell  subtypes  due  to  mutation  and  activation  of  PI3K  itself  or  loss  of the  lipid 
phosphatase and tumour suppressor gene PTEN (Kurose, Zhou et al. 2001; Vivanco and 
Sawyers 2002). The hybrids also appeared to show some differences from their parental 
cell lines in both receptor levels and their response to EGF stimulation, suggesting that 
genes  on  Chromosome  18  may  have  the  capacity  to  suppress  these  pathways.  The 
alterations in the activation of these pathways may result in some of the observed protein 
changes deleted using the proteomic profiling technologies reported herein. These would 
occur through regulated transcription or protein turnover and it will be interesting to test 
this level of regulation using specific kinase inhibitors of Akt and ERK signalling, as well 
as to test the effect of acute EGF stimulation on the expression of candidate proteins. This 
however is beyond the scope of this study.   220 
6.4 Conclusions 
A  number  of  proteins  have  been  validated  by  immunoblotting.  Candidates  whose 
expression was found to be reverted in the revertant cell lines are especially promising. 
However,  the  effect  of  clonal  variation  is  a  problem  when  interpreting  findings. 
Validation of more candidates has been hampered by reagent availability and lack of 
specificity of antibodies that were tested. MMP10 was found to be a marker in serum that 
could  significantly  discriminate  between  healthy  and  late  stage  ovarian  cancer  cases. 
Although not consistent with the TMT profiling data, where MMP10 was up-regulated in 
the Ch18 MMCT hybrids, this serum data is interesting and warrants further validation 
and needs to be repeated on a larger sample cohort. In addition, further candidates from 
the  proteomic  profiling  should  be  tested  in  this  manner  to  establish  if  they  have 
biomarker potential.  
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Chapter 7 Discussion 
Identifying molecular markers of disease may provide novel approaches to screening and 
diagnosis  and  could  enable  targeted  treatment  and/or  lead  to  the  design  of  novel 
therapies. The biological and molecular basis of epithelial ovarian tumour development 
remains poorly understood. The development of models of tumour suppression in EOC 
cell lines offers an alternative method for identifying potential markers for ovarian cancer 
and for understanding the molecular mechanisms of tumourigenesis. 
 
The focus of this study has been the investigation of the protein expression profiles of 
two  parental  EOC  cell  lines  and  their  MMCT  Chromosome  18  hybrid  cell  lines  to 
identify protein signatures of neoplastic suppression. The insertion of whole or partial 
normal  chromosomal  material  into  a  cell  has  the  potential  for  far  reaching  effects 
throughout the cell. In order to identify as many components of the complex biological 
processes occurring within these cell models, a large scale proteomic investigation was 
preferred. To achieve this, a combination of cellular fractionation, quantitative 2D-DIGE, 
affinity chromatography and 2D-LC-MS/MS were employed to examine the whole cell, 
secreted, membranous and cell surface proteomes. 
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The  first  approach  was  based  on  a  differential  two-dimensional  gel  electrophoresis 
pattern  analysis  between  protein  samples.  This  technique  gives  additional  molecular 
information such as isoelectric point and molecular weight alterations arising from PTMs, 
providing further insight into possible protein activities. The drawbacks of this method 
included  limited  analysis  of  low-abundance,  high  molecular  weight  and  hydrophobic 
proteins, and also time consuming and labour-intensive manipulation of gels. The second 
approach was a gel-free mass spectrometry-based peptide analysis technique that used 
isobaric  amino-group-specific  mass  tags  to  compare  the  peptide  intensities  between 
samples to infer quantitative values for the proteins from which they are derived. This 
method is advantageous in that it can be completely automated and there is reduced bias 
against low-abundance proteins. The disadvantages include a bias towards high molecular 
weight proteins, lack of protein mass or pI information and hence loss of information 
about specific isoforms and reduced through-put due to extended analysis times. 
 
In  a  comparison  of  the  two  proteomic  platforms,  nearly  400  protein  changes  were 
identified in the whole cell and secreted fractions of the two cell models by 2D-DIGE, 
while over a 1000 proteins were identified and quantified in the TMT analyses resulting 
in  ~250  protein  changes  being  identified.  A  typical  pH  3-10  NL  gel  is  capable  of 
resolving over 2000 protein isoforms, a number comparable (until recently) with non-gel 
2D-LC-MS/MS  approaches.  2D-LC-MS/MS  is  still  improving  in  terms  of  the 
identification of  greater numbers and lower abundance proteins from a single sample 
(Nagele, Vollmer et al. 2004). With these advances, the use of isobaric tags has become 
increasingly popular for protein quantification between multiple samples. While 2D-LC-  223 
MS/MS  techniques  identify  as  many  peptides  as  possible  before  the  quantitative 
information  can  be  determined,  2D-DIGE  has  the  advantage  that  only  significantly 
altered protein isoforms are selected for identification. Although labour intensive, image 
analysis software such as DeCyder, quickly identifies protein spots that are differentially 
expressed above a determined threshold for picking and identification by MS. The need 
for  more  convoluted  HPLC  and  MS  identification  and  analysis  is  negated.  The 
quantitative  information  in  gel-free  platforms  is  only  ‘unlocked’  once  complicated 
analysis of MS data has been performed. For this reason, there is a lot of redundancy in 
the data-sets produced. Due to the large number of proteins identified, more stringent 
approaches for selecting proteins of interest must be employed. In the present study, the 
list  of  protein  identifications  was  extensive  (see  Appendix)  and  so  only  proteins 
displaying a change of expression in both hybrid clones of at least one cell model were 
reported in the results sections. 
  
Using  the  gel-based  platform,  protein  products  from  a  single  gene  were  identified  in 
multiple distinct protein spots. For example, IGFBP7 was identified by 2D-DIGE/MS as 
6 differentially expressed isoforms. As noted in Chapter 4, these isoforms may represent 
glycosylated  and/or splice  variant forms, including  a  very  acidic  form.  Although  this 
gives us information on the chemistry of certain isoforms and their abundance, it also 
poses  challenges  for  quantitation.  For  example,  IGFBP2,  identified  in  the  same 
experiment, displayed 3 distinct isoforms. These isoforms behaved differently in each cell 
line comparison. Interpretation of these kinds of features must be carefully undertaken. It 
should not be assumed that it is possible to determine overall protein regulation when it is   224 
represented by a number of different protein isoforms. This was less problematic in the 
gel-free platform with TMT labelling, where quantitation is assessed at the peptide level, 
although isoform-specific information is usually lost. Another feature of 2D-DIGE that 
affects interpretation of differential expression is the co-migration of proteins. For co-
migrated  proteins,  DeCyder  is  not  robust  enough  to  identify  unambiguously  the 
boundaries of each protein form, so assignment of the altered protein is not possible. In 
the present study, multiple cases of 2 and 3 unique protein identifications were observed 
in a single spot. 2D-DIGE quantitation works best where a proteome has been resolved to 
the extent that a single spot will represent one protein. This can be done by introducing 
fractionation steps to reduce the complexity of the sample before 2D-separation. The use 
of different pH gradients in the first dimension and gradient gels in the second dimension 
could also be used to improve separation, although this would be labour intensive and 
costly.  In  the  present  study  the  use  of  both  gel-based  and  2D-LC-MS/MS  platforms 
together was complimentary and generated a large dynamic spectrum of protein changes 
with putative roles in neoplastic suppression. Indeed, there was little overlap between the 
two  approaches,  although  importantly,  those  proteins  identified  by  both  approaches 
generally displayed concordant changes in expression level. Those protein changes that 
did not, could be explained by differential PTMs exhibited by multiple isoforms. 
 
Preliminary experiments examined whole cell lysates of parental cell lines versus hybrid 
pools  using  2D-DIGE.  Five  hybrid  clones  derived  from  each  parental  cell  line  were 
chosen for their potent suppression of tumourigenicity in vitro and in vivo. This was 
considered to be the best way to analyse a large number of hybrids without incurring the   225 
high  costs  of  running  many  2D-DIGE  gels.  The  results  showed  that  there  was  little 
overlap between the cell models with many proteins being oppositely regulated and all 
but one being a chromosome 18 gene product. The lack of overlap in protein expression 
between the two cell models may reflect the fact that the cell lines are derived from 
endometrioid and clear cell ovarian carcinomas respectively, which presumably display 
different  molecular  aetiologies.  However,  the  differences  will  also  reflect  the 
considerable clonal variation that was apparent. Following on from this, a single hybrid 
clone from each pool was selected for direct comparison with its parental cell line under 
the same experimental conditions. The number of protein spots displaying a significant 
change  in  expression  was  reduced.  This  difference  compared  to  the  pooled  analysis 
indeed reflects the heterogeneity of the hybrid cells selected for each pool. Despite this, 
common changes were identified across the two experiments and between the two cell 
models. Two further hybrid clones from each pool were then selected for comparison in 
the same way. These also displayed potent suppression of tumourigenic phenotype in 
vitro and in vivo and further candidate proteins involved in suppression were identified.  
 
Microsatellite repeat analysis and CGH array analysis showed a ~10 Mb region had been 
transferred in the TOV-112D hybrid cell lines. The proteomic signatures of these hybrid 
clones were relatively equivalent, as would be expected. A full copy of chromosome 18 
was transferred into the TOV-21G hybrid cell lines. The proteomic signatures of these 
hybrid clones were vastly different from the TOV-112D clones and could be attributed to 
the difference in Ch18 incorporation. In addition, CGH array also identified other gross 
differences in the chromosomal material (Chapter 1). Particularly, the TOV-112D hybrid   226 
clones  had  additional  genetic  changes including  deletion of  chromosome  8q  and  part 
deletion of chromosome 9q in both hybrids, and deletion of the majority of chromosome 
12q in hybrid clone 18-D-23. The TOV-21G hybrid clones revealed almost complete 
transfer  of  Ch18  without  other  gross  changes.  These  changes  may  also  explain  the 
observed  differences  between  the  hybrid  clones  of  each  cell  model.  Despite  broad 
coverage of the genome, few chromosome 18 gene products were identified as being 
differentially expressed. Thus, a proportion of the expression changes measured must be 
secondary effects of Ch18 insertion, where Ch18-encoded genes regulate the expression 
of  genes  on  other  chromosomes.  This  reveals  the  complexity  of  gene  and  protein 
regulation in this system.  
 
Functional  classification  by  gene  ontology  database  searching  revealed  that  the  most 
represented  classes  of  proteins  were  structural  proteins  involved  in  maintaining  and 
modulating the cytoskeleton and ECM. Stress response and chaperone proteins were also 
highly represented. This is perhaps not surprising as many of these are abundant cellular 
components. Structural proteins and cytoskeletal regulators identified included; vimentin, 
collagen, fascin, PDLIM1, F-actin capping protein, twinfillin-2, cofilin, actin and tubulin. 
The  rearrangement  of  extracellular  matrix  proteins  and  cytoskeletal  microfilaments 
induces major cellular morphological alterations in transformed cells (Yamazaki, Kurisu 
et al. 2005). The action of actin cross-linking, severing and polymerisation factors serves 
to  potentiate  the  invasiveness  of  tumour  cells.  The  differential  expression  of  these 
cytoskeletal  and  associated  proteins  would  be  expected  to  confer  the  distinct  growth 
characteristics observed in the parental cell lines and the Ch18 hybrids on soft agar and in   227 
nude mice (Dafou, Ramus et al. 2009). Whilst actin and tubulin were up-regulated in 
hybrid  clone  18-G-1.26,  the  other  structural  proteins  were  generally  down-regulated, 
suggesting  these  proteins  may  participate  in  the  observed  suppression  of  neoplastic 
phenotype in this cell line.  In future, it will be necessary to test the function of these 
proteins in affecting cell morphology, cell migration and invasion by targeted knockdown 
of their expression. 
 
Oxidative stress is primarily a result of the generation of reactive oxygen species (ROS) 
in  the  mitochondrion  during  production  of  adenosine  triphosphate.  ROS  in  cells 
profoundly  affects  numerous  critical  cellular  functions  and  the  absence  of  efficient 
cellular detoxification mechanisms which remove these ROS may contribute to cancer 
and  other  diseases.  ROS  are  thought  to  be  tumourigenic  because  of  their  ability  to 
damage  DNA  and  initiate  tumour  development  through  mutagenesis.  ROS  may  also 
increase cell proliferation, survival and cellular migration and it is now accepted that 
certain  ROS  such  as  H2O2  are  signalling  intermediates  that  provide  a  permissive 
environment  for  receptor  tyrosine  kinase  signalling  (Finkel  2000;  Rhee,  Kang  et  al. 
2005). ROS, however, can induce senescence and cell death and so may also function in 
tumour  suppression.  Proteins  associated  with  regulating  the  redox  status  of  the  cell 
include  superoxide  dismutases,  thioredoxins,  peroxiredoxins,  glutaredoxins  and 
glutathione transferases. This class of proteins were highly represented in the present 
study,  displaying  differential  expression  between  the  parent  and  hybrid  cell  lines. 
However,  their  regulation  was  somewhat  varied  between  the  cell  models  making  it 
difficult  to  draw  conclusions  about  the  redox  status  of  cells  in  relation  to  neoplastic   228 
suppression. The adaptation of tumour cells to hypoxia and acidification of the tumour 
micro-environment  is  also  known  to  promote  their  survival  over  normal  cells.  When 
tumour  cells  experience  stressful  conditions  such  as  oxygen  deprivation,  the 
accumulation of mis-folded proteins can induce the over-expression of chaperones such 
as  heat-shock  proteins.  Heat  shock  proteins  (HSP)  are  expressed  at  high  levels  in  a 
variety  of  tumours  (Calderwood,  Khaleque  et  al.  2006).  In  the  majority  of  cancers, 
increased levels of HSP is attributed to mutation of the tumour suppressor p53, which 
releases  the  transcriptional  repression  of  HSP  genes  (Lee,  Montebello  et  al.  1994; 
Gandour-Edwards, Trock et al. 1998). The observed differential expression of HSPs and 
other  chaperones  in  ovarian  cancer  cell  models  again  cannot  be  linked  to  a  specific 
cellular  effect  owing  to  the  heterogeneity  of  the  effects,  although  many  of  the 
chaperone/HSPs were down-regulated in clone 18-G-1.26, which was the most different 
of the clones examined in terms of its proteomic profile. 
 
 A strategy was developed to analyse secreted proteins from cells grown in culture. This 
was  successful  with  the  identification  of  numerous  differentially  expressed  secreted 
proteins  by 2D-DIGE/MS  and  2D-LC-MS/MS  with  TMT  labelling.  Secreted  proteins 
identified  by  both  technologies  displayed  consistent  regulation  (e.g.  IGFBP2)  giving 
increased confidence in the results. It is immediately apparent that the analysis of the 
secretome  has  identified  a  number  of  proteins  involved  in  tumourigenesis  that  have 
already been characterised to some extent as diagnostic or prognostic markers of cancer. 
Among these were IGFBP2, IGFBP7, PEDF, prolactin, lactate dehydrogenase, lumican, 
TIMP1 and galectin-1. It is encouraging that these proteins were identified in the models   229 
of neoplastic suppression used in this study. In addition, the secreted protein MMP10 
identified  by  2D-LC  with  TMT,  displayed  promise  as  a  potential  biomarker.  These 
identifications  highlight  the  effectiveness  of  fractionation  combined  with  two 
complimentry  proteomic  platforms  to  probe  deeper  into  the  proteome  in  search  of 
suitable  diagnostic  and/or  prognostic  markers  of  OC.  Future  work  will  involve 
confirming these changes in the cell models used herein, and then testing their expression 
in tissue or serum samples from ovarian cancer cases and healthy controls, as was done 
for MMP10. Indeed MMP10 could significantly discriminate between healthy and late 
stage OC cases and may therefore have potential as a prognostic marker rather than a 
diagnostic  marker.  Further  to  this,  and  for  poorly  characterised  gene  products,  their 
functions could be tested by knocking down their expression using RNAi and assessing 
the effect this has on proliferation, growth on soft agar and invasion. 
 
The development of a membrane enrichment strategy combined with TMT labelling for 
quantification requires further work. The suitability of 2D-LC with TMT labelling for the 
analysis of membrane protein fractions is evidenced by the identification of surface and 
membrane  proteins  in  this  study,  however  problems  were  encountered  at  the  TMT-
labelling stage and further optimization work is required.   
 
7.5 Future prospects 
The  proteomic  analysis  of neoplastic suppression  presented  here  represents a  starting 
point for the selection of candidate proteins to be assessed for their potential as future   230 
biomarkers of ovarian cancer. Further validation of differentially expressed proteins by 
quantitative immunochemistry in normal ovarian and cancer cell lines and in the serum 
from malignant and benign cases of ovarian cancer and healthy controls is necessary. 
While,  their  value  as  markers  is  evaluated,  functional  characterisation  studies  would 
improve our understanding of the mechanisms of neoplastic suppression. Gene silencing 
to  alter  the  expression  of  specific  gene  products  of  interest,  using  double  stranded 
interfering RNAs (Downward 2004), could be  usefully  applied in this  model system. 
Additionally, candidate proteins could be over expressed in the parental cell lines using 
transfected  constructs  which  overexpress  the  target  proteins  to  assess  their  roles  in 
suppressing tumourigenic phenotype. A combination of soft agar colony forming, MTT 
proliferation,  transwell  migration/invasion  assays  and tumour  formation  in  nude  mice 
assays would improve our understanding of the role of these candidates in ovarian cancer 
biology.  
 
A shortlist of 20 candidate proteins has been selected for further study based on the 
expression  profiling  performed  in  this  study.  Protein  identifications  that  displayed 
concordant expression in a hybrid pair in either the 2D-DIGE and/or 2D-LC-MS/MS 
analysis were considered. Despite heterogeneity between the cell models and the clonal 
variation between the hybrid clones, calreticulin, MMP10 and follistatin-related protein 
displayed concordant expression in both cell models and represent the most promising 
candidates. In addition, proteins from novel genes and those that were secreted or surface 
proteins  were  considered  more desirable  as  potential  biomarkers.  Example  candidates 
include;  galectin-1,  TIMP1,  pigment  epithelium-derived  factor  precursor,  IGFBP2,   231 
IGFBP7,  prolactin,  tomoregulin-1  and  procollagen  (III).  Finally,  their  functional 
importance and links to cancer in the literature were also considered, for example PIG3, 
annexin A1 and prohibitin are examples with strong links to cancer progression, whilst 
prolactin has been previously used in a biomarker panel for the detection of early stage 
ovarian cancer (Visintin, Feng et al. 2008) and shown to transform NOSE cells (Levina, 
Nolen et al. 2009). 
 
7.6 Conclusions 
Understanding the biology of ovarian cancer is limited because little is known about the 
processes  governing  neoplastic  transformation  and  suppression.  Differential  protein 
expression  analysis  of  cell  models  of  neoplastic  suppression  using  a  combination  of 
complimentry proteomic techniques has identified a number of proteins of interest with 
regard  to  their  potential  in  mediating  tumourigenic  suppression  or  being  altered  as  a 
consequence  of  suppression.  As  such  they  represent  candidate  biomarkers  of  ovarian 
cancer. This has been possible despite the problems associated with the complexity of the 
model systems used due to the fact that the cell types were derived from endometrioid 
and clear cell carcinomas with different molecular aetiologies and the effects of clonal 
variation.  
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